Back Matter (PDF)

Abbott, J, 910(ab) Ailman, KC, 2067 Arsenault, A, 875(ab) Barness, B, 837(ab) Benard, iF, 1003(ab) Abdel-Dayem, HM, 1396, Al-Mohannadi, 5, 2014, Asahina, M, 917(ab) Barnett, CA, 938(ab) Bender, H, 942(ab), 1002(ab) 2014, 843(ab), 867(ab) 867(ab) Asano, T, 333 Barnhart, CS, 951(ab) Bendriem,B, 2020,843(ab), Abdel-Nabi,HH, 14, Alpert, NM, 908(ab), Ascoop, CAPL, 1727 Barrett, HH, 851(ab), 882(ab), 883(ab), 888(ab), 959(ab), l000(ab) 924(ab) Ashida, K, 246 879(ab), 891(ab), 1002(ab) 943(ab) Abe, K, lOl9(ab) Altehoefer, C, 886(ab) Ashmore, RF, 995(ab) Barrett, iS, 959(ab) Ben-Haim, S, 1486 Abe, S, 10l9(ab) Aithouse, L, 972(ab) Assis, RVC, 995(ab) Barrio, JR. 633, 1472 Benhali, H, 101l(ab) Abel,W, 117 A1-Tikriti, MS, 848(ab), Atkins, HI, 305 Barron, Bi, 968(ab), Ben-Harush, M, 1699 Abi-Dargham, A, 91 1(ab) 945(ab) Atkins,HL, 1717 l047(ab) Benjamin, C, 855(ab), Abraham, V, 832(ab) Altman, K!, 1725 Atkinson,ER, 423 Bartelsmeier,A, 906(ab) 866(ab) Abramovici,J, 1005(ab) Altmann,A, 1982,lOl9(ab) Atkinson,JB, 826(ab) Bartenstein, P, 915(ab) Benjamin, RS, 858(ab), Abrams,Mi, 710,9l0(ab) A1-Zaabi, KS, 978(ab) Aubert, B, 1006(ab) Barthelemy,E, 956(ab) 992(ab) Abrams,P0, 1099 Amano, M, 1008(ab) Austin, MC, 877(ab), Bartlett, B, 1024(ab) Benkert, 0, 887(ab) Aburano, T, 2024, 957(ab), Amarenco,P, 858(ab) 930(ab) Bartolozzi, C, 954(ab) Bennett, DV, 849(ab) 1020(ab) Ambrose,KR, 1028(ab) Avet, P. 1269 Barton, D, 846(ab) Bennett, LR, 827(ab), Acharya, AS, 986(ab) Ambrosetti,P, 1766 Awad,I, 970(ab) Barton,H, 2222 l043(ab) Achong,DM, 256 Aminian, A, 102l(ab) Axworthy, DB, 880(ab), Barzen, 0, 902(ab), 971(ab), Benoliel, i, 1846 Acito, P, 9l5(ab) Amino, 5, 1019(ab) 909(ab), 9l0(ab), 934(ab) 997(ab), 1018(ab) Bensel, K, 835(ab) Ackerman, RF, 1819 Amis, ES, 1042(ab) Basile, F, 866(ab) Benvenuti,C, 471 Ackermann, RF, 908(ab) Ammann, W, 157 Babaian, Ri, lOOl(ab) Basmadjian, GP, 98l(ab) Berding, G, 972(ab) Adachi, I, 1023(ab) Ampil, FL, 1047(ab) Babich, J, 924(ab), 935(ab) Basoglu, T, 906(ab) Berg, 80, 918(ab) Adams,HR, 945(ab) Amstutz, HP, 231 Babich, JW, 2154, 9l0(ab), Bassano, DA, 150, 90l(ab) Berger,HJ, 144 Adams, M, 974(ab) Anderson, Cl, 558, 1685, 996(ab), 1024(ab) Bassingthwaighte,JB, 581 Berger, KL, 1579, 858(ab), Adatepe, MH, 263 837(ab) Bacharach, SL, 1209, 2058, Bataille, 0, 832(ab) l003(ab), 1007(ab), Adelstein, Si, 384 Anderson, JA, l003(ab), 2226,88l(ab), 938(ab) Batchelor, S, 1041(ab) l009(ab) Aden, MD, 1132, 894(ab) lOlO(ab) Badger, C, 960(ab) Bateman,TM, 876(ab), Berger, MR. 1982, 966(ab), Adler, A, 997(ab), 1044(ab) Anderson,PJ, 2090 Badger,CC, 863(ab), 987(ab) 951(ab) l019(ab) Adriaens,Pi, 551, 1032(ab) Anderson, R, 927(ab) Bading,JR, 1373 BattiSti,C, 1859 Bergh, JR. 1039(ab) Affleck, D, 88 l(ab) Anderson, T, 839(ab) Bae, R, 926(ab) Baudhuin, T, 825(ab), Bergmann, SR. 836(ab), Afriyie,M, 973(ab) Anderson, U, 990(ab) Baer,L, 906(ab) 837(ab), 875(ab) 837(ab), 855(ab), 884(ab), Aftab,N, 2154 Andersson, L, 1654, 954(ab) Bagdades, E, 1022(ab) Baudoux, M, 1337 1426(le) Aggarwal, S, 1548 Andreassian, B, 835(ab) Bahrassa, FS, l047(ab) Bauer, A, 865(ab), 993(ab) Berk, MR. 1556 Agid,Y, 1481,10l9(ab) Andre-Fouet, X, 953(ab) Baidoo, KE, 899(ab), Baum,RP, 853(ab),904(ab), Berkovic,SF, 930(ab) Agostini, D, 471 Andrews, D, 964(ab) 921(ab), l032(ab) 9l2(ab) Berkovitz,DM, N25(10) Ahn, CS, 964(ab) Andrich, MP, 852(ab), Bailey, DL, 90l(ab) Baxter,KG, l039(ab), Berkowitz, KA, 512 Ahonen, A, 1255 976(ab) Baird, AE, 877(ab) 1046(ab) Berlangieri,SU, l047(ab) Aigner, TO, 1383, 945(ab), Angelberger, P. 108 Bakir, MA, 2154 Bayhan, H, 464(le), 866(ab) Berlin, JA, 858(ab), 873(ab) 965(ab) Anker, JP, 903(ab) Bakker, WH, 652, 955(ab), Bayouth, JE, 941(ab) Berman,DS, 1509,854(ab), Akamune,A, 893(ab), Ansari, A, 844(ab) 903(ab), 914(ab) Bazin,JP,101l(ab) 876(ab),91l(ab) 933(ab), 972(ab) Ansari, MS, 847(ab) Baldock,C, 104I(ab) Beanlands, R, 684, 826(ab), BernÃ¢,L, 840(ab), 845(ab), Akansel, G, 21 10, 868(ab) Antar, MA, 928(ab), Baldwin,R, 896(ab) 865(ab), 882(ab) 895(ab), 994(ab) Akiba, A, 1005(ab) 970(ab), 1040(ab), Baldwin, RM, 1836, 1964, Beatty, 50, 953(ab) Bernard, HF, 955(ab) Akiba, H, 958(ab) 1041(ab) 848(ab),911(ab),945(ab) Beauchamp, HT, 900(ab) Bernstein, ID, 863(ab), Akoun, 0, 81 Antich, PP, 974(ab), 990(ab), BalÃ©riaux,D, 868(ab) Beaumier, P, 934(ab) 941(ab), 960(ab), 987(ab) Aktolun, C, 464(le) 1003(ab), l010(ab) Ballinger, iR, 970(ab) Beaumier, PL, 394, 880(ab), Berrah, H, 843(ab), 888(ab) Alagona,P, Jr, 1723(le) Antico, VF, 2094 Balon,HR, 1393,898(ab) 909(ab),910(ab),l028(ab) Berridge,MS,885(ab), Alamos, F, 838(ab) Antman, KH, 1594 Balseiro, i, 2059(le) Bebin, M, 971(ab) 984(ab) Alavi, A, 269, 590, 751, Antoine,J-M, 956(ab) Baiter,HS, 1949 Beck,P, 972(ab) Berry, i, 2067 1964, 2036, 848(ab), Antonino,A, 2222 Ban, T, 886(ab) Becker, DP, 867(ab) Bertoni, iM, 1047(ab) 849(ab),857(ab),858(ab), Antonucci, F, 895(ab) Banaszczyk,M, 921(ab) Becker, JA, 1005(ab), Bertrand,A, 906(ab), 896(ab), 897(ab), 898(ab), Aoki,5, 844(ab),966(ab) Bander, N, 913(ab) 1043(ab) 956(ab) 902(ab), 929(ab), 940(ab), Aoshima, S, 6 Bando, M, lOl6(ab) Becker, W, 903(ab), 1428(le) Besnard, i-C, 981(ab) 954(ab),965(ab),992(ab), Aotsuka, A, 917(ab) Bankole, A, 849(ab) Beckers,C, 73 Besozzi, MC, 885(ab), 999(ab), l012(ab), Appelbaum,FR, 863(ab), Banks, WR, 830(ab), Bede,ii, 1914(le) 93l(ab), 983(ab) 1013(ab),1588(le) 94l(ab), 960(ab), 987(ab) 975(ab), 983(ab) Beetz, R, 1021(ab) Besser,GM, 1121, 914(ab) AlbarÃ¨de,P, 409 Appelbaum,JW, 1099 Banzo, I, 955(ab) Behrenbeck, T, 2080 BessiÃ¨res,M, 906(ab) Albeit, R, 900(ab) Appledorn,R, 956(ab) Barbaras, L, 947(ab) Beierwaltes,WH, 2116 Bettinardi, V, 973(ab) Alderson, P0, 570, 1042(ab) Arai, H, 10l9(ab) Barbarics, E, 1033(ab) Beilin, I, 886(ab) Beuscart, R, 947(ab) Alexander, GE, 940(ab) Araki, N, 1029(ab) Barbaro, NM, 967(ab) Bekdik, C, 319 Bex, M, 832(ab) Alexander, M, 873(ab), Araki,Y, 95l(ab) Barber, HB, 851(ab), Belinka, BA ir, 988(ab) Bhadkamkar, VA, 858(ab), 874(ab) Aras,T, 1027(ab) 879(ab),1002(ab) Bellande, E, 989(ab), lOOl(ab) Alexoff,DL, 853(ab) Araujo,LI, 1669 Barber, R, 983(ab) l034(ab) Bhatia, K, 1994 Aliabadi,P, 643 Archer,CM, 850(ab) Barbet, J, 9l2(ab), 1000(ab) Bellen,J, 1283 Bhargava, KK, 919(ab), Alioth, C, 833(ab) Archer, 5, 423 Barbour,MM, 95l(ab) BelIer,GA, 668, 1732, 986(ab) Alkire, AL, 974(ab) Areeda, J, 876(ab) Bares, R, 100l(ab) 864(ab) Bhattacharva, 5, 938(ab) Allada, V, 977(ab) Argenyi, E, 1917(le) Barkan,AL, 1608,834(ab) Bellina, CR, 1020(ab) Bianchi, R, 1020(ab) Allen,EW,98l(ab), Aric,I, l041(ab) Barker,WW, 1459 Bellinger, MF, 923(ab), Bianco, iA, l586(le) 1034(ab) Arimizu,N, 324 Barkovich, AJ, 967(ab) 977(ab) Biaslo, Y, 854(ab) Allen,LF, 23 Anlkan, 0, 1027(ab) Barlow, CF. 838(ab) Belliveau,iW, 867(ab) Bice,AN, 771,864(ab), Allenberg,JR. 907(ab) Arntz, IE, 936(ab) Barnes, D, 950(ab) Bellon, EM, 1044(ab) 872(ab), 889(ab), Allie, D, 1269 Aronen, Hi, 867(ab) Barnes, WE, 2214 Belzberg,AS, 1468 l005(ab), 125l(le),

AuthorIndexâ€¢1992 2251 Bidaut

1429(le) Boles Ponto, LL, 1008(ab), Breithardt, G, 915(ab) Burke,TS, 1390 Carson, GC, l047(ab) Bidaut, LM, 868(ab) l027(ab) Breitz, HB, 1099 Burkholder, D, 979(ab) Carson, RE, 2103, 881(ab), Biedler, JL, 1373 Bolzati, C, 850(ab) Bremner, ID, 911(ab) Burn, PR, 998(ab) 945(ab), 10l0(ab) Biegel, J, 878(ab) Bomanji,J, 1121,904(ab), Brennan, KM, 884(ab) Burns,HD, 900(ab) Carstens, MC, 992(ab) Biegon, A, 890(ab) 9l4(ab), 924(ab) Brenner, N, 900(ab) Burrows, L, 949(ab) Cartner, T, 874(ab) Biemer, E, 859(ab) Bond,HW, 885(ab) Bresnahan,DR Jr, 951(ab) Buscombe,JR, 903(ab) Carton, EG, 239 Bierman,R, 435 Boni, G, 1020(ab) Bride, B, 526, 839(ab), Bushe,H, 958(ab) Cartwright, PC, 873(ab) Biersack, H-i, 526, 839(ab), Boniface, G, 853(ab) 844(ab), 9l4(ab), 995(ab) Bushman, Mi, 989(ab), Carvalho, PA, 181, 1516, 844(ab), 914(ab), 972(ab), Bonilla, JJ, 955(ab) Britell,C, l035(ab) l033(ab), 1024(ab) 970(ab) 995(ab), 1028(ab) Bonino, C, 999(ab) Britton,KE, 1121,904(ab), Bushnell,DL, 2214 Casara, D, 1478 Bigard, M-A, 956(ab) Bonnet,AM, 1481,l019(ab) 914(ab), 924(ab) Busnardo,B, 1478 Casciari, JJ, 2202, l010(ab) Biggs, T, 676 Bonow,RO,815, 1209, Broadhurst, P, 938(ab) BussiÃ©re-Lapalus,F, 1846 Casey, ME, 86l(ab), 1430(le) Bigner,DD, 1535,881(ab), 2226, 2057(le), 88 l(ab), Brodack, i, 1025(ab) Butchko, G, 912(ab) Casey, Mi, 829(ab) 934(ab) 938(ab) BrOdaCk,JW, 850(ab), Butler, cs, 964(ab) Cashman, P, 938(ab) Bihi, H, 839(ab) Bonte, F, 992(ab) 937(ab),980(ab) Butler, RE, 1014(ab) Casi, M, 863(ab) Bilchik, T, 269 Bonte, Fi, 826(ab) Brodie,JD, 192,287, 1720, Butler, SP, 1029(ab), Cassel, D, 916(ab), 952(ab) Billings, J, 870(ab), 890(ab), Booker, FS, 850(ab) 847(ab) 1252(le) Castaigne,A, 471, 896(ab) 963(ab),989(ab) Borbely,K, 1931 Broich, K, 870(ab), 898(ab), Buxton,DB,865(ab), Castaneda, AR, 838(ab), Billingsley,JL, 2052 Borchert,R, 830(ab), 972(ab) 945(ab), 1425(le) 930(ab) Biniakiewicz,D, 993(ab) 975(ab),983(ab) Brooks, CE, 950(ab) Bylund, DB, 861(ab) Castelli, L, 892(ab), 918(ab), Binon, J-P, 1337 Bordlee, RP, 1857 Brooks,KM, 921(ab) Byrne, CL, 843(ab) 999(ab) Birnbaum, BA, 960(ab) Borer, iS, 2057(le), 845(ab) Bmoks,RA, 1931 Cattaruzzi, E, 895(ab) Cabahug, C, 1015(ab), BischofDelaloye, A, 1756, Borges-Neto, S, 825(ab) Broquet, PE, 1766 Cavagnaro, CF, 956(ab) 1028(ab) 903(ab), 956(ab) Borkon, AM, 95 l(ab) Brotchi, J, 868(ab) Cave,V, 186,2086,854(ab), Cacheris, W, 974(ab) Bischoff@H, 828(ab), Borm, iiJ, 917(ab) Brouillet, E, 973(ab) 866(ab), 952(ab) Cacini, W, 2190 1045(ab) Bormans, G, 937(ab) Broussard, W, 985(ab) Cerar, A, 587 Brown,DW, 1750 Cahill, N, l9N(le) Bishop, HA, 1040(ab) Bormans, GM, 551 Caillat-Vigneron,N, 913(ab) Ceriani,R,912(ab) Brown,J, 848(ab) Bisson, G, 855(ab), 866(ab) Borst, MM, 2138 Cain,JW, 838(ab) Ceriani, RI, 1530 Bjorn, MJ, 1099 Bosworth, M, 974(ab) Brown,JA, 985(ab) Cerino,M, 951(ab) Calay,R, 1337 Bjornson, B, 1758 Bottino,B, 1028(ab) Brown,JK, 1881, 901(ab) Cerletty, JM, 869(ab) Caldwell, JH, 102, 2144, Bottlaender,M, 883(ab), Brown,MA, 884(ab) Cerqueira, MD, 202, 763, Black,HR, 2045,906(ab) 2202 Black, KL, 867(ab) 973(ab) Brown,MD, 885(ab) 1324,1493,1642,866(ab), Calenoff, E, 934(ab), 936(ab) Botvithck, EH, 1444, Brown,ML, 1613,923(ab) 939(ab) Black,PMcL,844(ab), calikoglu, T, 319 896(ab), 910(ab), 935(ab), Bmwn, MT. 966(ab) 1018(ab) Callahan, AP, 9l0(ab), Cerrito, M, 959(ab) Bladin,PF, 930(ab) 994(ab) Brown, RS, 841(ab), 893(ab), 1023(ab),1028(ab) CÃªsaro,P, 858(ab) Blaha, WH, 1017(ab) Boucher, Y, 1801, 894(ab) 102l(ab) Callahan, RI, 819, 845(ab), Cestaro, V, 1046(ab) Blahd,W, 967(ab) BÃ³udreau,Ri, 873(ab) Brown,SJ, 2017,835(ab), 925(ab), 1024(ab), Chabriat, H, 1481, 1019(ab) Blair,DR, 101l(ab), Bouillon, R, 832(ab) 1049(ab) 1028(ab) Chabris, CF, 908(ab) lOl8(ab) Boulabdour,H, 919(ab) Brown,T, 949(ab) Caine, DB, 964(ab) Chaiken, L, 829(ab) Blanche, 5, 976(ab) Bourekas, EC, 1553 Brownell, AL, 946(ab) Caluser, C, 867(ab) Chaillout,JJ, 1003(ab) Blanchot, C, 913(ab) Bourgeois, P, 1427(le) Brownell, GL, 946(ab) Camargo, EE, 1216, Chaiwanarat, T, 924(ab) Blank,EW, 1530 Bourguignon, M, 696, Bruchelt, G, 859(ab) 1004(ab) Chalmers, N, 872(ab) Blankenship, D, 993(ab) 896(ab), 1019(ab) Bran, A, 868(ab) Camera, L, 842(ab), Chalon,S, 98I(ab) Blankespoor, SC, 1881, Bourguignon, MH, 471, Brunetti,A, 834(ab) 1001(ab) Chaly, T, 923(ab), 1027(ab) 901(ab) 1481, 843(ab), 888(ab), Brunken,R, 882(ab) Camici, P0, 1353 Chamberlain,Mi, 516 Blanksma, pic 870(ab) 896(ab), 947(ab) Brunken,RC, 1628,856(ab), Cammilleri, 5, 990(ab) Chamovitz,DL, 2055 Blaser,K, 231 Bourne, D, 981(ab) 857(ab), 945(ab), 977(ab) Campim, R, 846(ab) Chan, A, 836(ab), 865(ab) Blatchford,G, 975(ab) Bove,E, 68 Bruns,C, 652 Camrud, AR, 845(ab) Chan, H-W, 14 BlIucnstein, P, 231 Boven, E, 2000 Bubeck, B, 629(Ie) Cancro, R, 287 Chan, K, 833(ab) Blaufox, MD, 175, 739, Bowen, WD, 981(ab) Buchbinder, B, 867(ab) Caner, B, 319 Chan, SY, 836(ab), 856(ab), 1723, 907(ab) Bowman, BM, 975(ab) Buchbinder, SF, 842(ab), Cann,CE, 1881, 901(ab) 857(ab), 1009(ab) Blend, Mi, 853(ab) Bowsher,JE, 879(ab), 926(ab) Cantos, E, 1046(ab) Chan, YW, 920(ab) Blickman, JG, 2249 961(ab) Buchegger, F, 903(ab) Cao,Q, 905(ab) Chandarlapaty, SCK, Blokiand, JAK, 1406 Boyd,Si, 1029(ab) Buchsbaum, DJ, l029(ab) Cao,11, 892(ab) 1045(ab) Blomqvist, G, 908(ab) Braat, 5, 874(ab), 875(ab) Buchwald, AB, 845(ab) Capelli, L, 68 Chang, Ci, 985(ab) Bloomfield, PM, 1669, Braat, SH, 874(ab) Buckley,KR, 922(ab) CaIaccni,T, 1014(ab) Chang, L, 839(ab), 977(ab) 91 1(ab), 994(ab), 1008(ab) Bracken, RB, 937(ab) Buczala, S, 832(ab) CaracÃ´,C, 892(ab), 918(ab), Chang, P1, 993(ab) Blower, PJ, 469(Ie) Brady, LW, 942(ab) Budihna,NV,587 999(ab) Chan& 5L@1012(ab) Blum,R,912(ab) Brady, T, 867(ab) Budinger, TF, 2133, 862(ab), Caraher, 3, 994(ab) Chang, W, 852(ab) Blumenthal, RD. 958(ab), Braegelmann, F, 845(ab) 884(ab), 9l5(ab), 939(ab) Caraher,JM,1243,881(ab) Chao, BH, 981(ab) l000(ab) Brandau, W, 920(ab) Bud, U, 102,886(ab), Carey, D, 865(ab) Chaovapong, W, 2006, Blumhardt, R, 984(ab) Brandt, J, 848(ab) l00l(ab) Carey, JE, 423 880(ab) BOck,iC, 971(ab) Branscheid, D, 828(ab) Bugaj, JE, 979(ab) Caride,VJ, 1712,913(ab) Chapnick,J, 960(ab) Bockisch, A, 887(ab), Brass,LM, 878(ab) Buijs,WCAM, 1113 Carisen, 3, 251 Chapuis, A, 1003(ab) 102l(ab) Brasseur, P, 1337 Buist,MR. 2000 Carlson, KE, 558 Charkes, ND, 1780 Boelrijk, A, 921(ab) Braun, A, 2103 Bulteau, C, 977(ab) Carpenter, RC, 873(ab) Charney, DS, 1964, 848(ab), Boerman, OA, 958(ab) Braun, J, lOOl(ab) Bunker,C, 1301 Carpi, A, 954(ab) 91 l(ab), 945(ab) Bohdiewicz,PJ, 898(ab) Brechbiel, MW, 842(ab), Bunko, H, 441, 1200, Carrasquillo, JA, 842(ab), Charron, M, 923(ab), Boisson, N, 1006(ab) lOOl(ab), 103l(ab) 875(ab) 986(ab), 1001(ab) 977(ab), 996(ab), 997(ab) Bok, BD, 380, 835(ab), Breeman,A, 1727 Bunting, RW, 1028(ab) Carretta, R, 939(ab) Chartrand, R, 1550 1251(le) Breeman, WAP, 652, Buonanno, F5, 908(ab) Carril, JM, 955(ab) Chatal, JF, 9l2(ab), 943(ab), Bol,A, 837(ab),875(ab), 955(ab) Buonocore,E, 885(ab), CarriÃ´,I, 2249, 840(ab), 985(ab),1030(ab) 884(ab) Breen, 5, 1005(ab) 923(ab) 845(ab), 895(ab), 994(ab) Chatteijee, K, 896(ab) Boles, MA, 2214, 1041(ab) Breen,SL, 1316 Burg,MM,939(ab) Carroll, RG, 498, 2249(le) Chatteijee, S. 830(ab)

2252 The Journal of Nudear Med@ane Dewan

Chatziioannou, A, 86l(ab) Christian, iT, 2080 1041(ab), l048(ab), Czemin, J, 856(ab) DeKock, M, 905(ab) Chaudhuri, Tic 1035(ab) Christman, DR, 192 1586(le) Czernin, I, 836(ab) Delaage, M, 912(ab), Chavali, RV, 839(ab), Chrumpradit, 5, 890(ab) Cooke, CD, 876(ab), 927(ab) Czernin, J, 1628, 856(ab), l000(ab) 1005(ab), 1018(ab), Chu, LS, 10l2(ab) Cooper,DL, 913(ab) 857(ab), 865(ab), 1009(ab) de la Fourniere, L, 981(ab) 1043(ab) Chu, TS, 865(ab) Cooper, iA, 59, 1566, DeLaney, ML, 969(ab) Chen, BC, 613 Chua, T, 854(ab), 91 l(ab) 932(ab) DaCosta, M, 969(ab) DeLaPaz, R, 867(ab) Chen, B-5, 282 Chun, SB,986(ab) Cooper,M, 829(ab),982(ab), DaCosta, MC, 969(ab) DeLaPena, R, l014(ab) Chen, C, 848(ab), 964(ab) Chung,D-G, 55 101l(ab), 10l2(ab), Dadparvar, 5, 2017, 835(ab), Delbeke, D, 826(ab) Chen, CL, 955(ab) Chung,JK, 877(ab),892(ab), 10l8(ab), 10l9(ab) 1049(ab) Delcourt, E, 1337 Chen, C-T, 783, 947(ab), 905(ab) Cooper, MD, 947(ab), Dae, MW, 1444, 896(ab), deLearie,L, 974(ab) 949(ab), 962(ab), Chung, Y-H, 919(ab) 949(ab) 910(ab), 935(ab), 994(ab) de Leon, F, l043(ab) 1012(ab), 1019(ab) Ciarmiello, A, 68 Cooper, R, 868(ab) Daemen,RIG, 373 Delforge, J, 882(ab), 883(ab), Chen, CY, 955(ab) Cmi, R, 900(ab) Cooper, 5, 964(ab) Daghighian, F, 2020 888(ab),896(ab),943(ab) Chen, DCP, 844(ab), 937(ab) Cinotti, L, 953(ab), 101l(ab) Coote,D, 868(ab) Dahlberg, ST, 1783, 846(ab), Delgado-Escucta, AV, Chen, EQ, 888(ab) Claessens, RAMi, 388, 1113, Coppens,A, 875(ab) 864(ab) lOl7(ab) Dahlbom,M,633,1191, Chen, F, 934(ab), 936(ab) 1330,903(ab),920(ab), Coppola,N, 68 Della Vittoria, G, 9l5(ab) Chen, GH, 997(ab) 936(ab), 950(ab), 1031(ab) Corbett, iR, 927(ab), 990(ab) 828(ab), 862(ab), l045(ab) Del Rio, P. 999(ab) Chen, GTY, 1005(ab), Clark,CM, 157 Cordes, M, 922(ab), 964(ab), Dai, WL, 996(ab) del Rosario, RB, 860(ab) Dailey,RW, 1789 1043(ab) Clarke, LP, 161, 889(ab) 971(ab),l018(ab) Del Vecchio, 5, 1848 Chen, K, 944(ab) Clarke, SEM, 469(Ie) Cordon Cardo, C, 1002(ab) Dahymple,G, 978(ab) De Marco, T, 1444, 896(ab) Damasio, H, 1008(ab) Chen, LS, 1132, 894(ab) Clavo, A, 841(ab) Cordovilla, JJ, 955(ab) Demirel, D, 464(Ie) Dambro, Ti, 1701 Chen, MN, 986(ab) aeeland, R, 924(ab) Corlija, M, 851(ab), 988(ab), Demonceau,G, 480 Damjanov, A, 85l(ab) Chen, MT. 1034(ab) Clerc, J, 2162 1032(ab),1048(ab) DeNardo, GL, 1030, Danchin, N, 906(ab) Chen, U, 829(ab), 867(ab) Cleto, EM, Jr. 435 Conic, RA, 2061 862(ab), 863(ab), 926(ab), Dannals, RF, 847(ab), Chen, WL, 1033(ab) Qe@nhen@,B, 1032(ab) Corona, JF, 287 927(ab), 94l(ab), 982(ab), 848(ab), 860(ab), 883(ab), Chen, YK, 1034(ab) Clinthorne,NH, 831(ab), Correia, JA, 620, 924(ab) 103l(ab) 885(ab), 929(ab), 964(ab), Cheng,H, 87l(ab) 842(ab), 878(ab) Corrigan,GE, 1042(ab) DeNardo, 5, 9l2(ab) 968(ab) Cheres, A, 2017 Cload, P, 875(ab) Corrigan, P, 1620, 948(ab) DeNardo, Si, 862(ab), Danos, P, 972(ab) Cherqui, D, 919(ab) Qoninger, K, 876(ab) Corstens,FHM, 388,1113, 863(ab),927(ab),941(ab), Dao, NH, 1039(ab) Cherrick,I, 914(ab) aonu@,JH,907(ab) 1330,1958,903(ab), 982(ab), 1030(ab), Darbee, J, 835(ab) Chemer, F, 906(ab) Coade, G, 939(ab) 920(ab), 936(ab), 950(ab), Darcourt,i, 1846 1031(ab) Cherry, SC, 1045(ab) Coakley, AJ, 313 1031(ab),N16(4) DeNardo, SL, 926(ab) Darras, J-C, 409 Cherry, SR. 595, 862(ab), Cody,R, 1020(ab) Cosgrove,R, 97l(ab) Denays,R, 485 DaSilva, IN, 983(ab) Costa, DC, 1014(ab) Dence, c:s, 724, 925(ab), 879(ab), 922(ab), l0l0(ab) Coenen,HH, 2138 DaSilva, iN, 86l(ab), Costello, J, 838(ab), 930(ab) Chetanneau, A, 912(ab) Cohen, AM, 904(ab) 870(ab) 932(ab) Cheung, N-KY, 2020 Cohen, C, 973(ab) Coubes, P, 970(ab) Data, FL, 260, 4670e), Denis, M, 81 Cbevres, A, 2017, 835(ab), Cohen, RC, 2094, 949(ab) Coughlin, DJ, 988(ab) 833(ab), 878(ab), 892(ab), Depas, G, 976(ab), 977(ab) 1049(ab) Cohen, RM, 1383, 945(ab), Coulange, C, 990(ab) 901(ab), 1003(ab) de Paulis, T, 847(ab), Chi,SC,977(ab) 965(ab) Countryman, PH, 861(ab) Daube-Witherspoon,ME, 848(ab) Chiang, J-H, 282 Cohen,TJ, 910(ab) Countryman, Pi, 862(ab) l010(ab), 1430(le) DePuey, EG, 876(ab), Chiao, P, 933(ab) Cohen, WA, 1789 Coupal, ii, 991(ab) Dave,K, 944(ab) 928(ab),957(ab) Chiariello, M, 505 Colan, SD, 930(ab) Courtois, M, 836(ab) Davidson, J, 900(ab) Derebek,E, 1722 Chin, HW, 1047(ab) Colcher, D, 23, 1648 Cowan, Mi, 2202 Davidson, M, 856(ab) Dereme, T, 875(ab), 905(ab) Chin, J, 988(ab) Cole,WC,974(ab) Cowie, AR, 2222 Davies, H, 1935 Dereniak, EL, 1002(ab) Chin, M, 994(ab) Coleman, PS, 905(ab) Coxson, PG, 884(ab) Davis, K, 312 Derenzo, SE, 862(ab) Chinen, LK, 937(ab), Coleman, RE, 532, 575, 922, Cradduck, TD, 1005(ab), Davison, A, 558, 1357, 1949, deRidder,LW, 1167 980(ab) 825(ab),834(ab),838(ab), 1007(ab), 1043(ab) l033(ab) Derkx, FHM, 990(ab) Chinol, M, 900(ab), 942(ab), 872(ab), 879(ab), 891(ab), Crane, i, 992(ab) Dawood, FW, 978(ab) DeRogatis, Ai, 957(ab) 985(ab), l030(ab) 901(ab), 961(ab), 966(ab), Crawford,D, 858(ab) Day, DE, 1024(ab) De Roe, MJ, 551, 832(ab), Chiotelis,E, 988(ab) 1047(ab) Crawley, i, 448, 451 Dean, Ci, 2154 933(ab), 937(ab), 1032(ab) Chiron, C, 696, 976(ab), Collier,BD,2110,868(ab), Croft,BY,833(ab) Dean,GW, 1875 Dc Rosch, MA, 850(ab) 977(ab) 869(ab) Cromwell, T, 883(ab) Dean, RT, 144,845(ab) Desai, Hi, 1943 Chiu, ML, 1516,864(ab), Collier, U, 890(ab), Cronin, V, l000(ab) Deane,CP, 1468 Desai, SP, 1704 1033(ab) 1025(ab) Crouzel,C, 883(ab),896(ab) Debrand-Passard, A, 902(ab) deSilva,R,1669 Cho,DS, 1146, 1613 Coffins, REC, 313 Crouzel, M, 888(ab) Dec, GW, 477 Detry, JM, 825(ab) Cho, KS, 99l(ab) Colombo, F, 924(ab) Csernay, L, 458 De Carle, D, 2059(le) Deussen, A, 2138 Choi, BI, 2118 Colsher, iG, 1430(Ie) Cullom,Si, 161,2232, De Chiro, G, 834(ab) Deutsch, E, 981, 2190, Choi, CW, 877(ab) Comazzi,V, 850(ab), 842(ab) deCosta, BR, 981(ab) 850(ab), 899(ab), 900(ab), Choi,J, 1031(ab) 989(ab), 1034(ab) Culver, CM, 1402 Decoster, P, 905(ab) 924(ab), 937(ab), 980(ab), Choi, Y, 339, 633, 828(ab), Combs, Mi, 833(ab) Cumming, MC, 1044(ab) Decostre,P, 175 988(ab),l025(ab) 829(ab), 865(ab), 881(ab), Comerota, AJ, 952(ab) Cumming, P, 916(ab) DeDeyn, PP, 972(ab) Deutsch, EA, 993(ab) 882(ab), 944(ab), 945(ab) Comet, M, 953(ab), 1034(ab) Cummings, D, 1132, 894(ab) De Fabritiis, A, 2040 Deutsch, G, 826(ab) Chon, KS, l0l0(ab) Conlin, Ci, l042(ab) Cunningham, J, 941(ab) de Gaudlo, C, 954(ab) Deutsch, K, 2190, 900(ab), Chong, R, 900(ab), 1025(ab) Connett, iM, 1685 Cunningham, JR. 1001(ab) DeGeeter,F, 1914(le) 98l(ab), l025(ab) Choong, KKL, 2094 Conrad,G, 1046(ab) Cuocolo, A, 505, 1209, DeGrado, TR, 865(ab), Deutsch, KF, 850(ab), Chou, J-S, 10I2(ab) Conrady, A, 223 833(ab), 905(ab), 915(ab), 870(ab), 994(ab) 937(ab), 980(ab) Chou, KT, 1013(ab) Consigny, PM, 973(ab) 938(ab) De Groof, M, 825(ab), De Vernejoul, P, 409 Chow,WK,997(ab) Constantinescu, A, 974(ab), Curley,T, 859(ab) 836(ab), 1009(ab) DeVito, RP, 889(ab), Christensen, M, 975(ab) 990(ab), l003(ab), Curtet, C, 912(ab) Degrossi, OJ, 999(ab) 932(ab) Christian, BT, 850(ab), 10l0(ab) Curtis, ii, 924(ab) DeHaan, CE, 1012(ab) Devous,MD, Sr.1888, 931(ab) Conversano, A, 855(ab) Curtis,RL, 1024(ab) de iong, M, 652, 955(ab), 1919, 2030, 826(ab), Christian, PE, 467(le), Conway, JJ, 2047 Cutler, C, 899(ab) l025(ab) 827(ab), 838(ab), l018(ab) 833(ab),878(ab),892(ab), Conzo, G, 892(ab) Cutler, PD, 595, 1045(ab) de Kaski, MC, 756 deVries, DJ, 1004(ab) 901(ab), 1003(ab) Cook, SA, 1040(ab), Cyr, i, 920(ab) de Kierk, JMH, 646 Dewan, NA, 836(ab)

AuthorIndexâ€¢1992 2253 Dewanjee

Dewanjee, MK, 777, Drane,WE, 876(ab),923(ab) l026(ab) Farlow, DC, 2094 Foley,K, 859(ab) 92l(ab), 956(ab),980(ab) Driedger, AA, 1722 Elmendorf,SL, 59 Farnsworth, RH, l022(ab) Folks, R, 1620, 948(ab) Dewey,SL, 521,830(ab), Drozda, SE, 860(ab) Elmqvist, D, 868(ab) Farrell,E, 14, 959(ab), Folks, RD. 927(ab) 847(ab), 887(ab), 888(ab) Drueke,T, 913(ab) Elsinga, PH, 373, 870(ab) l000(ab) Folli, 5, 903(ab) Dewhirst, MW, 958(ab) Drum, DE, 643, 849(ab) Enirich, D, 223, 845(ab), Fass,i, l00l(ab) Fonazzari, I, 970(ab) DeWoody, K, 848(ab) Dua, G, 972(ab) 957(ab) Fawwaz,IU, 570,988(ab) Ford, K, 874(ab) Dey, HM, 1964, 878(ab), Duara, R, 1459 Emrich, JG, 942(ab), Fayad, PB, 878(ab) Ford, PY, 127 886(ab), 896(ab), 906(ab) Duatti, A, 850(ab), 989(ab) 1002(ab) Fazio, F, 834(ab), 924(ab), Forman, D, l000(ab) Dc Zwart, F, 1722 Duboc, D, 471 Enas, J, 890(ab) 925(ab), 944(ab), 959(ab), Formiconi, AR, 831(ab) Dhawan, V, 923(ab) Dubois-RandÃ©,J-L, 471, Enderle, A, 950(ab) 973(ab), l014(ab) Forrest, LI, 1542 D'Hondt, AM, 825(ab) 896(ab) Endo,K, 1181, 853(ab), Fedio, VA, N15(3), N30(9), Forster, AM, 850(ab) Dhumeaux,D, 919(ab) DUbOVSkY,EV, 1178, 905(ab), lOOl(ab) Nl4(12) Forstrom, LA, 840(ab), Diamanti, CI, 2006, 93l(ab) 924(ab) Engel,U, 251 Feine, U, 309, 956(ab) 845(ab) Diaz, C, 840(ab) duCret, RP, 873(ab) Englaro,EE,35l, 1132, Feinendegen, LE, 2138 Fossella, FV, 992(ab) Di Carli, M, 825(ab), DujiÃª,i, 1917(le), 2056(le) 894(ab) Feld,T,88 Foster, ED, 59 856(ab) Dulac, 0, 696, 977(ab) Enomoto, K, 333 Feldman, 3M, 834(ab) Foster, NL, 887(ab) DiChiro,G, 1931 Duncker, D, 840(ab), Ensing, G, 1025(ab) Feldman, M, 883(ab) Fournier, D, 973(ab) Dick, R, l020(ab) 845(ab),895(ab),994(ab) Ensminger, WD, 735 Feldstein,ML, 849(ab) FourrÃ©,C, 2162 Diego, I, 992(ab) Dunigan,KA, 975(ab) Epstein, A, 987(ab) Felix, R, 902(ab), 97l(ab), Fowler,JS,192,521,1720, Dierckx, R, 972(ab), Dunn, B, 938(ab) Erbas, B, 854(ab), 859(ab) 997(ab), 1018(ab) 830(ab), 847(ab), 853(ab), l013(ab) Dunn, EK, 117, 973(ab), Erbengi, D, 319 Feller,AM, 859(ab) 870(ab), 887(ab), 888(ab), Dieren, EV, 927(ab) l035(ab) Ercan, MT. l027(ab) Fer, MF, 1099 946(ab) Diethelm,AG, 1178,924(ab) Dunn, i, 974(ab) Erdman, WA, 992(ab) Ferguson,DM, 239 Fowler,PJ,516 Digby,WM, 595 Dunn, WL, l039(ab) Eriksson,L, 86l(ab), Fernandez,G, 854(ab) Fox,J,966(ab) Diggles, L, 835(ab), 846(ab), Dunning, Ai, 895(ab) 908(ab), 1011(ab) Fernandez-Ulloa,M, 1692, Fox,KR, 1588(le) 876(ab) du Plessis, Ai, 838(ab) Ernest, D, 1468 898(ab),978(ab),l047(ab) Fragu, P, 2162 Dilizian, V. 1209 Durack, LD, 771, 864(ab), Errico, D, 855(ab) Fernando, i, l003(ab), Fraiderik, R, l006(ab) Dilsizian, V. 815, 938(ab) 889(ab), 941(ab) Erwin, WD, 927(ab), lOlO(ab) Franceschi, G, 863(ab) Dimitrakopoulou, A, 1982, Durakc, LD, 1005(ab) 932(ab), 938(ab), 94l(ab) Ferremans, W, l427(le) Francesconi, LC, 989(ab) 1019(ab) Durski, K, 872(ab), 922(ab) Eschima, D, l029(ab) Ferrieri, RA, 847(ab) Francis,IR, 1125 Ding, XS, 10l2(ab) Duus, 5, 251 Eshbach, J, 851(ab) Fessler, JA, 831(ab), 878(ab), Francken, G, 1040(ab) Ding, Y-S, 830(ab) Duval,AM, 471 Esbima, D, 33, 1620, 882(ab) Frangin, Y, 981(ab) Di Palma, E, 999(ab) Dworkin, Hi, 1402 921(ab),990(ab),103l(ab) Fettich, JJ, 873(ab) Frank, AR, 829(ab), 836(ab), DiPaola,R, lOll(ab) Dwyer,JP,1594 Eskridge,JM, 1789 Fiasse, R, 976(ab) 975(ab) Di Rests, G, 2020 Dymond, DS, 2124 Essamii, B, 837(ab) Ficken, Vi, 927(ab), Frankar, G, 884(ab) Diril, H, 942(ab), 103l(ab) Esser,PD, 1411, 1042(ab) l034(ab) Franken, Ph, 19l4(le) Easy, iF, 748, 771, 863(ab), Essiambre,R, 1091,855(ab) DiRocco, Ri, 1152, 865(ab), 864(ab), 889(ab), 941(ab), Ficshman, AJ, 946(ab) Franklin, T, 851(ab) 993(ab) Esterbrooks, DJ, 837(ab) Fig,LM, 1608,834(ab) Franks, W, 55 960(ab), 987(ab) Esterhai, J, 902(ab) Ditlow,C, 934(ab),936(ab) EberI, 5, 90l(ab) Fink, L, 978(ab) Franzius,C, 906(ab) Divgi, C, 1002(ab) Estorch, M, 840(ab), Fink, 5, l035(ab) Freedman,N, 1209 Eberling, iL, 939(ab) 845(ab), 895(ab), 994(ab) Divgi, CR, 904(ab), 913(ab), Ebmiere, KP, 1623 Fink-Bennett, D, 1393, Freedman, NMT, 2226, 94l(ab) Estrada, WN, 898(ab) 876(ab), 898(ab), l017(ab) 88l(ab), 938(ab) Ecclcs, SA, 2154 EteroviÃª,D, l917(le), DiZio,JP, 558 Eckard, DA, 826(ab) F@in1ay,3, 867(ab) Freemer, M, 1044(ab) Dobbeleir, A, 972(ab), 2056(le) F@inn,RD, 2020, 867(ab), Frenkel, A, 49, 1774 Edelbroek, M, 1283 Evans,D, 902(ab) lOl3(ab), lO2l(ab) Edwards, B, 850(ab) 904(ab) Freudenberg, N, 1399 Dobovsky, EV, 948(ab) Evans, N, 959(ab), l000(ab) Fioravanti,C, 900(ab), Frey,D, 888(ab) Edwards, DS, 979(ab) Evans, NH, 14 Dobrinsky,C, 928(ab) Efange, SMN, 890(ab), 979(ab) Frey,EC,2238 Docter, R, 955(ab) Evans-Blumer, M, 1024(ab) Fisch, I, 1766 Frey, KA, 423, 1836, 983(ab) Even-Sapir, E, 950(ab) Dodd, T, 880(ab), 934(ab) Fischer, 5, 920(ab) 858(ab), 882(ab), 887(ab), Egbe,P, 1411, 1994 Evora, PH, 829(ab), 985(ab) Dodek, PM, 1468 Fischman, AJ, 996, 845(ab), 929(ab),1003(ab) Egeli, R, 1766 Eybalin, C, 95l(ab) Dodge, RK, 1542 867(ab), 910(ab), 915(ab), Frick, MP, 829(ab), 836(ab), Eggli,DF, 1143, 1854, Eybalin, MC, 95l(ab) Doeri, Ri, 14, 886(ab), 924(ab), 965(ab), 998(ab), 837(ab),86l(ab), 975(ab), 947(ab) Ezekowitz,MD, 777 959(ab) l024(ab), l587(le) 1026(ab) Ehrenkaufer, Ri, 829(ab), Ezuddin, 5, 839(ab), Dohi, Y, 932(ab) Fischman,S.J, 1378 Friden, A, 1304 985(ab) lOl6(ab), 1035(ab) Dohzono, H, 1033(ab) Fisher, DR, 1099, 863(ab), Fried, M, 956(ab) Ehrhardt,GJ, 558, l024(ab) Ezzeddine, B, 975(ab) Doi,T, 1637 Eichstadt, H, 902(ab), 94l(ab) FTIedIand, RP, 2184 DÃ¶kmeci,B, 866(ab) 997(ab) Faber, TL, 927(ab) Fisher, KM, 359 Friedlander-Kiar, H, 859(ab) Doll, J, l007(ab), 1045(ab) Eidelberg, D, 923(ab) Facchctti, L, 846(ab) Fisher, RS, 832(ab), 929(ab) Friedman, J, 854(ab) Donath, A, 1766 Eisenberg,B,972(ab) Fagret, D, 953(ab), 1034(ab) Fisher, Si, 869(ab), 893(ab), Friedman, JD, 1509 Dondi, M, 2040 Eisner,RL, 1571,865(ab) Fahey, FH, 537, 1859, 926(ab), 959(ab), 102l(ab) Frist, WH, 826(ab) Donna, GA, 877(ab) Elander, N, 1026(ab) 833(ab), 899(ab) Fishman, Ai, l026(ab) Fritsch, HW, 906(ab) Donohoc, IU, 947(ab), Elder,ST, 829(ab) Faivre-Chauvet, A, 943(ab) Fishman, EK, 1042(ab) Fritz,B, 1810,934(ab) 1003(ab) Elgazzar,AH, 898(ab), Falcone, 5, l016(ab) Fissekis,JD, 1373 Fritzberg, AR, 394, 1099, DOrr, U, 839(ab) 978(ab), l047(ab), Falconer,SJ, 1039(ab) Fitzpatrick, JM, 952(ab) 880(ab), 909(ab), 910(ab), Dosio, F, 924(ab) 1048(ab) Falk,P, 975(ab) Fleishman, Mi, 906(ab) 934(ab), 979(ab) Doty, R, 858(ab) EIias, AD, 1594 Fallone, PS, 904(ab) Fleming, E, 1029(ab) Fmnt, D, 1699, 1774 Doucet, 5, 875(ab) Elkowitz, 5, 914(ab) Fan, KT, 974(ab) Fleming, WK, l9l5(le) Frost, i, 883(ab) Doudet, Di, 1383, 945(ab), Ell, Pi, 1843, 903(ab), Fang, 1ST, 948(ab) Fletcher, 3W, 1046(ab) Frost, ii, 872(ab), 883(ab), 965(ab) 10l4(ab) Fang, Y-B, 982(ab) FlieMt, Evd, 859(ab) 91 l(ab), 922(ab), 929(ab) Dougall, Ni, 1623 Ellis,A, l040(ab) Fanti, 5, 2040 floyd, CE, Jr. 879(ab) Frost, MF, l042(ab) Douglas, MA, 881(ab) Ellis, WG, 939(ab) Farber, L, 913(ab) Fogarasi, M, 925(ab) Frouin,F, lOll(ab) Dove,P. 471 Ellison,D, 1121, 904(ab) Farde, L, 860(ab), 931(ab), Foged, C, 93l(ab) Frown, V, 882(ab) Dowling, D, 989(ab) Elmaleh, D, 946(ab) lOll(ab),10l6(ab) Fogelman, I, 1589 Frover-McKay, M, 1917 Downey, A, 9l2(ab) Elmaleh, DR. 946(ab), Farhangi,M, 1451 Foisie, DC, 1099 Fryer, DG, 972(ab)

2254 The Journal of Nudear Med@ne Harris

Fucdllo,AJ, 1378 Gaul, FE, 710 1040(ab), 1041(ab), Green, MV,2057(le), Haapanen, A, 1255 Fujibayashi, Y, 545, 659, Gautherot, E, 9l2(ab), l048(ab), l586(le) 852(ab) Haaparanta, M, 1255 89l(ab), l023(ab), l000(ab) Gobuty, AH, 982(ab) Green, SL, lOlO(ab) Haberkorn, U, 1981, 1026(ab) Gavin, PR, lOl2(ab) Goddard, A, 896(ab), Greenberg, ID, 2061 1019(ab) Fujii, R, 413, 466(le) Gazelle, 5, 179 91 1(ab) Greenberg, i, 985(ab), Hademenos, GJ, 605, Fujii, T, 893(ab), 933(ab), Ge, YW, 1032(ab) GOddard, AW, 1964 l012(ab) 962(ab) 969(ab), 972(ab), l004(ab) Gearhart, JP, 924(ab) Goedemans, W, 1025(ab) Greene,R, 961(ab) Hadian, D, 955(ab) Fujita, H, 135, 272, 1696, Geatti, 0, 895(ab) Goffe,DK, 943(ab) Greene, RW, 964(ab) Hagberg, C-E, 860(ab) 827(ab), 909(ab) Geckle, WJ, 968(ab) G@o@Os,T, 319 Greenough,R, 438, 828(ab), Hahn, K, 887(ab), 102l(ab) Fujita, T, 897(ab), 966(ab) Gee, A, l041(ab) Goin, J, 849(ab) 858(ab) Haire, W, 978(ab) Fukuchi, M, 834(ab) Gelfand, Mi, 351, 1048(ab) Goins, B, 984(ab), 1027(ab) Greenspan, RG, 906(ab) Haka,MS, 1125 FUkUda, H, 91 l(ab) Geltman, EM, 855(ab), Gold, RH, 1039(ab) Greer, KL, 90l(ab) Halama, JR. 1043(ab) Fukui, H, 997(ab) 1426(le) Goldberg, IE, 867(ab) Gregoir,C, 1337 Haldemann, A, 231 Fukumura, T, 877(ab), Geltof@ky,J, 1378 Goldenberg, DM, 803, 1110, GrÃ©goire,J, 875(ab) Haldin, C, lOl6(ab) 945(ab), lOlS(ab) GenÃ§,C, 866(ab) 863(ab),903(ab),904(ab), Gregory, C, 947(ab) Halkar, RK, 837(ab), Fukuyama,H, 1637,897(ab) Genna, 5, 852(ab) 910(ab), 958(ab), Grehl, 0, lOOl(ab) 991(ab) Fuiham, Mi, 1931, 834(ab) Gennaro, 0, 999(ab) 1000(ab), 1002(ab) Greitemann, B, 840(ab) Hall,H, 860(ab),93l(ab), Fulmer,H, 876(ab) Gentili, A, l044(ab) Goldenberg, JA, 516 Grenier, RP, 2124, 846(ab) 101l(ab) Fulton, RR, 90l(ab) Georgiou, M, 1035(ab) Goldhaber, SZ, 849(ab) Greve, J, 1022(ab) Hall,K, 878(ab) Funke, M, 950(ab) Gerada, B, 181, 1005(ab) Golding, R, 858(ab), 927(ab) Grierson, JR, 2202 Hall,LC, 1692 Furmanski, P, 912(ab) Germano, G, 613, 1509, Goldman, 5, 868(ab) Griffin, T, 904(ab) Haildin, C, 860(ab), 931(ab), Fusamoto, H, 997(ab) 854(ab), 91 l(ab) Goldsmith, SJ, 1175, Grifllth,J, 1183 101l(ab) Futami, 5, 97l(ab) Germine, M, 1964 949(ab), 969(ab), 995(ab), Griffith,JL, 905(ab) Hallgring, E, 1312, 887(ab) Gerrity, JI, 988(ab) 999(ab), 103l(ab) GIiffIthS,GL, 1110, 9l0(ab) Halpern, 5, 2162 Gabel, M, 993(ab) Gerson, MC, 993(ab) Goldstein,I, 46 Grill, V, 908(ab) Halpern, SE, 2148 Gabor, 1W, 1003(ab) Gestin, JF, 943(ab) Gomes, iA, 995(ab) Grinspoon,SK, 906(ab) Ham, H, 485 Gad, MA, 431, 929(ab) Geworski, L, 972(ab) Gomez-Mont, F, 287 Gritters, LS, 975(ab) Ham, HR. 174,175 Gaggi, R, 2040 Ghafouripour, AK, 92l(ab), Gona, JM, 1040(ab) Groch, MW, 927(ab), Hamacher, K, 2138 Gagne, GM, l428(le), 980(ab) Gonin, R, 1594 932(ab), 938(ab), 941(ab) Hamamoto, K, 135, 893(ab), 901(ab), 961(ab) Ghali, A, 978(ab) Goodman, MM, 885(ab), Grochowski, EW, 157 909(ab), 912(ab), 9l9(ab), Gagnon, D, 875(ab) Gianolli, L, 924(ab) 890(ab), 931(ab), 983(ab), Grond, M, 940(ab) 933(ab), 969(ab), 972(ab), Gajardo, P. 998(ab) Gianuzzi, P, 846(ab) 1025(ab) Grootoonk,5, 86l(ab) 1004(ab) Gal, RA, 2124 Gibbons, R, 927(ab) Goodrich, iK, 631Qe) Gropler, RI, 855(ab) Hamamoto, T, 976(ab) Galantowicz, P. 1040(ab) Gibbons, Ri, 176, 2080 Goodwin, DA, 1816, 2006, Groshar, D, 49,1699 Galati, MG, 892(ab) Hamblen,SM, 1047(ab) Gibson, RE, 900(ab), 880(ab), 931(ab) Grossman, A, 1121, 9l4(ab) Galen, K, 974(ab) Hamilton, SE, 908(ab) 979(ab) Gallagjier, KP, 1346 Goodwin, GM, 1623 Grossman, M, 857(ab), Hamlin, DK, 943(ab) Galle, P, 9l9(ab) Gibson,T, 1589 Goomer, NC, 990(ab), 1012(ab) Hammdll, TC, 1006(ab) Galli, M, 856(ab) Gifford, HC, 891(ab) 1010(ab) Grossman, ZD, 150 Hampel, KE, 997(ab) Gallinger, 5, 960(ab) Giganti, M, 850(ab) Gordon, E, 992(ab) Grothaus-King, A, 1789 Hamvas,A, 1661 Galloway, 5, 897(ab), Gil, M, 998(ab) Gordon, I, 1935, 2090 Grotta, J, 968(ab) Han, MC, 2118 898(ab), 954(ab) Gilardi,MC, l014(ab) Gorenberg, M, 1699, 1774 Grover-McKay, M, 19l7(le) Handa, N, 969(ab), Gait, iR, 2232, 842(ab), Gilbert, iC, 2133 Goris, ML, 1578, 933(ab) Growdon, JH, 704 1014(ab),10l5(ab) 991(ab) Gildersleeve,DL, 860(ab) Goris, RJA, 1330, 936(ab), Gruaz-Guyon,A, 9l2(ab), Hanein, LG, 972(ab) Gainbhir, SS, 613, 944(ab), Gill, HK, 850(ab) 950(ab) l000(ab) Hanna, MG, 103l(ab) l045(ab) Gilland, DR. 451, 879(ab), Gorlin, R, 995(ab) Gruber, M, 867(ab) Hanrahan, 5, 890(ab) Gan, MP, 827(ab), l043(ab) 901(ab), 961(ab) Gorrie,GH, 974(ab) Gruenewald, SM, 2094 Hanrath, P, 886(ab) Gansow, OA, 842(ab), Gilmore, MP, 846(ab), Gosfield, E III, 992(ab) Gruenwald, F, 526, 844(ab) Hansen, CL, 1574, 952(ab) 100l(ab), l031(ab) 864(ab) Gottschalk, A, 1422 Grummon, GD, 850(ab), Hansen, HI, 863(ab), Ganz, WI, 1304, 921(ab), Gilroy, J, 1017(ab) Gotzens, Y, 403, 2060(le) 1033(ab) 904(ab), 9l0(ab), 1002(ab) l016(ab), 1022(ab), Gindi, G, 963(ab) GÃ¶zÃ¼kara,I, 869(ab), Grunwald, F, 972(ab) Hansen, L, 900(ab), 921(ab) 1035(ab) Gingold EL, 1881, 90l(ab) 885(ab), 968(ab) Guerra, UP, 895(ab) Hanson, G, 1008(ab) Garada, BM, 1312, 839(ab), Giorgi, MCP, 995(ab) Grady, C, 2103 Guerrero, TM, l045(ab) Hanson, MW, 532, 838(ab), 887(ab), 970(ab), GiTC111,ME, 1478 Grady, MS. 1789 Gwbourg, HC, 999(ab) 966(ab) 1018(ab),1043(ab), Girgensohn, 5, 102l(ab) GrafstrÃ¶m,G, 953(ab) Guidry, GW, 995(ab) Hanson, 5, 968(ab) 14320e) Gitler, MS, 883(ab) Grafton, SC, 1472 Guillevin, L, 913(ab) Hantraye, P, 946(ab) Gather, CE, 876(ab), 951(ab) Giubbini, R, 846(ab) Graham, MC, 2020, 94l(ab) Guillon JM, 81 Hanyu, H, 10l9(ab) Garcia, A, 403, 2060(Ie) Gjedde, AH, 585, 847(ab), Graham, MM, 581, 2202, Guilloteau, D, 98l(ab) Hara, M, 988(ab), 1033(ab) Garcia, EV, 2232, 468(le), 848(ab),879(ab),909(ab), 944(ab), 1009(ab), Gullberg, GT, 831(ab), Harada, K, 988(ab), 842(ab), 876(ab), 927(ab), 9l6(ab) lOlO(ab), l045(ab) 878(ab), 891(ab), 892(ab), l029(ab), 1033(ab) 948(ab) Gladish, GW, l044(ab) Graham, W, 996(ab) 90l(ab), 902(ab), 96l(ab), Harapanhalli, RS, 2196 Garcia, F, 403, 2060(le) Glantz, Mi, 532 Grandin, C, 837(ab) l003(ab) Harcke, HT, 873(ab), Garcia, FA, 1949 Glaspy,JA, 828(ab) Granowska, M, 904(ab) GulyÃ£s,B, 908(ab) 874(ab) Garcia dcl Rio, H, 999(ab) Glass, i, 867(ab) Grant, A, 903(ab) Gunalp, B, 866(ab) Hardman, N, 903(ab) Gardin, D, 380 Glenn, 5, 9l2(ab), 980(ab) Grassi, F, 973(ab), 10l4(ab) Gunes, 1, 868(ab) Hardoff,R, 845(ab) Gardner, KA, 1045(ab) Glennon, P, 942(ab) Gratz, KF, 972(ab) Guo,LW, 1685 Harker, J, 827(ab) Garg, PK, 575, 934(ab) Glick, 5.1,605, 843(ab) Gray, BD,92l(ab) Guo, YZ, 870(ab), 87l(ab), Harkness,BA, 1859,833(ab) Garg, 5, 934(ab) Glickman, SL, 910(ab) Gray, BG, 55 982(ab), 989(ab) HarkoÃ±en,R, 1255 Garmestani, K, 842(ab), Glover, DK, 864(ab) Graziani, LI, 1943 Gupta, NC, 829(ab), Harp,GD, 763 100l(ab) Glowniak, JV, 431, 716, Greco, A, 1014(ab) 836(ab), 837(ab), 975(ab) Hand, CR, 963(ab), Gascon, P, 904(ab) 935(ab) Green, AJ, 1020(ab) Gupta, SM, 919(ab), l006(ab) Gaskin, G, 491 Glutowski, TD, 869(ab) Green, JF, 931(ab) l25l(le) Harris, CC, 922(ab) Gaston, RS, 924(ab) Gmeiner, B, 1028(ab) Green, JM, 989(ab) Gustavson, LM, 880(ab) Harris, GC, 867(ab) Galley, SJ, 830(ab), 853(ab), Go, A, 827(ab) Green, MA, 837(ab), Gutowski, TD, 926(ab) Harris, JM, 826(ab) 870(ab), 995(ab) Go, RT, 928(ab), 970(ab), 931(ab),l049(ab) Gyobu, T, 967(ab) Harris, RE, 1048(ab)

Author Index â€¢1992 2255 H@ris

Harris, TD, 979(ab) 10l8(ab) Hochberg,F, 867(ab) Hoshi, H, 916(ab), 97l(ab) Ikekubo, K, 659, 885(ab) Harrison,K, 978(ab) Henkin, RE, 104l(ab) Hodgson, Hi, 756 Hosono, M, 853(ab), Ikeoka,N, 744 Harrison,R, 989(ab) Henkin, RI, 996(ab) Hodson, EM, 2094 893(ab), IOOl(ab) lies, 5, 950(ab) Hartiala,i, 1255 Henneman,G, 894(ab) Hoekstra, OS, 858(ab), Hotchkiss, RS, 925(ab) Im,i-G,2l18 Hartman, JJ, 836(ab) Hennessey,iG, l042(ab) 927(ab) Hotson,G, 117 Imahori, Y, 413, 466(le) Hartman, NG, 1468 Henrich, M, 2138 Hoffer, P, 896(ab) Hotze, AL, 526, 839(ab), Imai, K, 951(ab) Hartoko, Th, lOl3(ab) Henry, TR, 929(ab) HotTer, PB, 1964, 848(ab), 844(ab), 9l4(ab) Imai, Y, 853(ab) Hartsough, NE, l002(ab) Heo, i, 186, 2086, 854(ab), 878(ab), 906(ab), 91 1(ab), HoWe,5, 960(ab) Imaizumi, M, 246 Harwood, Si, 498, 2249(le) 866(ab), 916(ab), 952(ab) 913(ab), 945(ab) Hoverath, H, 828(ab), Imaseki, K, 324 Hasan, A, 980(ab) Herbst, CP, 888(ab) HÃ¶fflcen,H, 906(ab) l007(ab), l045(ab) Imbriaco, M, 915(ab) HasÃ§elik,Z, l027(ab) Herholz,K, 940(ab) Hoffman, BJ, 935(ab) Hovsepian, D, 1042(ab) Immerzeel,DJMJ, 936(ab) Hasegawa, BH, 1881, Herman, SD, 95 l(ab) Hoffman,El, 595,613, Howell,RW, 277, 2196 Ingvar, M, 908(ab), 101l(ab) 901(ab) Herman, Z, 992(ab) I 191, 828(ab), 879(ab), Hradilek, P, 982(ab) Innis,RB, 1964,848(ab), Hasegawa, 5, 988(ab) Herrero,P. 837(ab),884(ab) lOlO(ab), 1045(ab), Hsieh,J, 852(ab) 896(ab), 91 l(ab), 945(ab), Hasegawa, Y, 208 Herrin, JT, 73 l430(le) Hsu,CY, 997(ab),l013(ab) 961(ab) Haseman, MK, 1750 Herrold,EM, 845(ab) Hoffman, JM, 532, 1472, Hsu, TH, 1034(ab) Inoue,0, 917(ab) Hasfeld,M, 9l5(ab) Herscovitch, P, 2103, 838(ab), 922(ab), 966(ab), Hua, T, 878(ab) Inoue, T, 1181, 909(ab), Hashikawa, K, 940(ab), l010(ab) 1047(ab) Huang, G, 852(ab) 912(ab), 969(ab), 972(ab), 969(ab), l014(ab), Hertel, A, 853(ab), 904(ab), Hoffman, Ti, 435, 988(ab), Huang, H, 861(ab), 974(ab), l004(ab) l015(ab) 912(ab) l032(ab), l048(ab) 1026(ab) Inoue, Y, 857(ab), 968(ab), Hashimoto,5, 934(ab) Hertzberg, VS, 1132, 894(ab) HÃ¶flich,G, 972(ab) Huang, SC, 339, 613, 633, 969(ab) Hasizume, 958(ab) Herzog,H, 2138 Hofstetter, J, 981(ab) 1235,1472,88l(ab), Inugami, A, 1696 Haspel, MV, 103l(ab) Herzog,KM, 2190 Hogberg, T, 860(ab) 882(ab), 944(ab), 945(ab) Iravani, A, 923(ab) Hasselquist, BE, 852(ab), Hess,H, 853(ab) Hoh, CK, 339, 633, 1191, Huberty, iP, 1444 Isacson,0, 946(ab) 873(ab) Hesse, B, 2106 828(ab),829(ab),867(ab), Hubner, KF, 885(ab), Isaka, Y, 246 Hatano, K, 897(ab) Heusser, CH, 903(ab) 945(ab), 1045(ab) 923(ab), 983(ab) Ishida, Y, 940(ab), 952(ab), Hatazawa,i, 1696,827(ab), Heya, T, 957(ab) Hojgaard, L, 2106 Huck, 5, 108 969(ab), l014(ab), 857(ab), 897(ab) Heyman, 5, 269, 873(ab) Holan, Y, 949(ab), 969(ab) Hudson, HM, 960(ab) 1015(ab) Hattner,RS, 115, 1444, Heyndrickx, GR, 884(ab) Holdeman,K, 978(ab) Huesman, 884(ab), RH Ishii, I, l020(ab) 918(ab) Hichwa, RD, 1008(ab), Holden,JE, 922(ab) Hughes, JA, 1048(ab) Ishii, K, l016(ab) Hauptmann, St, 100l(ab) 1027(ab),1430(le) Holman, BL, 181, 704, Hughes, JMB, 836(ab), Ish@1,5, 1016(ab) Hauser, MF, 840(ab) Hickey, J, 954(ab) 1312,1357,1516,1888, 1022(ab) Ishi@naru,T, 1023(ab) Hauser, MM, 710 Hickey, P, 838(ab) 1949, 839(ab), 852(ab), Hughey, BJ, 932(ab) Ishimura,J, 834(ab) Haustein, i, 97l(ab) Hicks, KW, 101l(ab) 887(ab), 970(ab), Huijgens, PC, 858(ab), Ishiwata,K, 1972,840(ab), Hawes, DR. 1486 Hierholzer, i, 902(ab), l005(ab), 10l8(ab), 927(ab) 841(ab),897(ab),984(ab), Hawk, TC, 1472, l047(ab) 971(ab),10l8(ab) l033(ab), 1043(ab), Hundeshagen, H, 972(ab) lOl6(ab), l025(ab) Hawkins, HH, 1044(ab) Hiesiger, E, 1720 1432(le) Hung, GL, 844(ab) Lgik,E,866(ab) Hawkins, R, 856(ab) Hiesiger, EM, 192 Holmes, DR. 845(ab) Hung, iC, 176, 306, 1613 Isitman, AT, 2110 Hawkins, RA, 339, 633, Higano, 5, 91 l(ab), 963(ab) Holmes, GL, l018(ab) Hunink, MGM, l432(le) Iskandrian, AS, 186, 2086, 1191, 828(ab), 829(ab), Higashi, K, 841(ab) Holmes, RA, 435, 1451, Hunter, DW, l039(ab) 854(ab), 866(ab), 916(ab), 867(ab), 88l(ab), 944(ab), Higashi, 5, 967(ab), 998(ab) 851(ab), 988(ab), Hupp, T, 907(ab) 952(ab) 945(ab), l039(ab), Hildebrand,i, 868(ab) 1032(ab), l048(ab) Hurwitz, RA, 9l8(ab) Iskandrian, B, 854(ab), 1045(ab) Hill, TC, 965(ab) Holoye, P, 992(ab) Hutchins, B, 934(ab) 916(ab), 952(ab) Hawkins, WG, 1007(ab) Hilleman,D, 837(ab) Holsclaw, D, 835(ab) Hutchins, G, 882(ab), Iskandrian, BB, 186 Hawman, PC, 852(ab) Hilson, AJW, 1020(ab) Holt,SA, 1417 l008(ab), l020(ab) Wan, S,435 Hayashi, H, 333, 1015(ab) Hilton, 5, l002(ab) Holthoff, VA, 10l3(ab) Hutchins, GD, 684, 1243, Isobe,M, l000(ab) Hayashida,K, 365 Hilton, TC, 847(ab), 876(ab) Holweg, R, 931(ab) 826(ab), 870(ab), 878(ab), Isono, K, 333 Haynie, TP, 828(ab), Hindmarsh, T, l016(ab) Hommeyer, SH, 748 881(ab), 933(ab), 994(ab) Israel,O, 1699, 1774 858(ab), 992(ab), lOOl(ab) Hinge, D, 875(ab) Honda, N, 969(ab) Hutchinson, Ri, 1735 Itami, J, 324 Hayostek, Ri, 1613 Hinkin, C, 967(ab) Honeyman, J, 1043(ab) Hutton, WR, 833(ab) Itami, M, 324 Haywood, L, l000(ab) Hinnefeld,JD, 1132,894(ab) Honeyman,JC, l042(ab), Hutton, BF, 901(ab), 960(ab) Itoh, H, 1696, 91 l(ab), Haze,K, 853(ab) Hirano, M, 920(ab) 1043(ab) Hvid-Jacobsen, K, 251 963(ab) Hwang, D-R, 830(ab), He, XS, 981(ab) Hirano,T, 1181 Hong, CD, 99l(ab) Itoh, M, 857(ab), 897(ab) 975(ab),983(ab) Itoh, T, 917(ab) He, Z-X, 1846 Hirata,K, 886(ab) Hong, J, 1035(ab) Hwang, YC, 830(ab) ltoi, Y, 246 Heelan, R, 345 Hirayama, K, 917(ab) Hong, MK, 892(ab) Hynes, M, 974(ab) liii, R, 874(ab),875(ab), Hefti, F, 890(ab) Hironaka, FH, 995(ab) Hong, SB, 877(ab) 101l(ab) Heidner, GL, 1542 Hirose, Y, l008(ab) Hong, WH, 962(ab) Ibis,E,2110 luliucci, JD, 978(ab) Heilckonen, ii, 913(ab) Hirth, W, 900(ab), 974(ab) Hoogeveen, EK, 990(ab) Ichihara,T, 1200,9l8(ab) Ivanovic, M, 842(ab), Heironimus,JD, 2052 Hisada, K, 179, 441, 1200, HÃ¶r,G, 853(ab), 904(ab), Ichijo,K, 1851 85l(ab), l012(ab), Heiser, RC, 468(le) 2024, 877(ab), 9l8(ab), 9l2(ab) Ichise, M, 55, 970(ab) 1015(ab) Heiss, WD, 861(ab), 940(ab), 957(ab),967(ab),1020(ab) Horai, Y, 891(ab) Ichiya, Y, 877(ab), 945(ab), Iwasaki, Y, 897(ab), 966(ab) 1013(ab) Hitchens, RE, 1430(le) Horan, PK, 899(ab), 921(ab) 10l5(ab) Iwashita,5, 996(ab) Helfaer, MA, 1004(ab) Hitzemann, 521 Hon. M, 952(ab) Ide, M, 932(ab) Iwata, R, 897(ab) Hitzemann, R, 887(ab), Horibe, K, 246 Heller,GV, 876(ab),95l(ab) Ido, T, 413, 1972, 840(ab), Izaki,M, 995(ab) Helling, D, l024(ab) 888(ab), 1046(ab) Hod, W, 859(ab) 897(ab), 984(ab) Izon, D, 904(ab) Heilman, RS, 868(ab), Hixson, DJ, 537 Horn, L, 973(ab) lervasi, G, l020(ab) 939(ab) Hnatowich, DJ, 1810, Hornu, CHG, 832(ab) Ii, M, 967(ab) Jabhour, BA, 829(ab) HellstrOm, I, 2160, 862(ab) 909(ab), 921(ab), 925(ab), Horowitz, M, 2027 lida, H, 1669, 827(ab), iabir, AM, 1044(ab), Hellstrom, KE, 2160, 934(ab), 958(ab), 1030(ab) Horowitz, M, 1283 91 l(ab), 963(ab), 994(ab), l045(ab) 862(ab) Ho, PJ, 1608, 834(ab) Horowski, R, 1018(ab) 1008(ab) iabir, R, l044(ab), 1045(ab) Helwig, A, 957(ab) Ho, YB, 1039(ab) Hortnagl, H, 108 lida, Y, 897(ab), 1024(ab) iacobs, MP, 830(ab), Hendel, RC, 1783 Hobbs, KEF, 1020(ab) Hortobagyi, G, 828(ab) lijima, N, 89l(ab) 975(ab), 983(ab) Heninger, GR, 1964 Hoberman, A, 923(ab) Hosain,F, 125l(le) ho, A, 933(ab) iacobs, W, l035(ab) Henkes, H, 97l(ab), Hoch, DB, 2211 Hoschl, R, 868(ab) Ikeda, M, 940(ab) iacobson, AF, 202, 1642,

2256 TheJournalof NuclearMedicine Krishnamurthy

849(ab), 866(ab), 1035(ab) Joshua, AV, 84l(ab) Katial,R,266 Kikuchi, H, 893(ab) Kobayashi,A, 6 Jaggi,J, l012(ab) Jouve, B, 843(ab) Kato, H, 659, 885(ab) Kikuchi, T, 333 Kobayashi,H, 853(ab), Jagust, WJ, 890(ab), 939(ab) Joyce, ME, 716 Kato,M, 1015(ab) Kilbourn, MR, 423, 861(ab), 893(ab), lOOl(ab) Jahan, 5, 978(ab) JuilliÃªre,Y, 906(ab) Kato, N, l017(ab) 870(ab), 882(ab), 982(ab), Kobayashi,K, 744 Jam, D, 874(ab),938(ab), Julian, BA, 924(ab) Katona, CE, 1014(ab) 983(ab) Koch, KT, 895(ab) 939(ab), 993(ab) Juni, JE, 239, 1206, Katsetos,CD, 2017 Kilts, CD, 922(ab) Koch, P. 959(ab) Jam, SP,981(ab) 1017(ab) Katti, KK, 9l0(ab), l032(ab) Kim, A, 836(ab) Koenders,EB, 103l(ab) Jamar, F, 73, 976(ab) Juweid, M, 873(ab), 893(ab) Katti, KY, 85l(ab), 910(ab), Kim, BT, 828(ab) Koeppe, PA, 423, 1008, Jaiig, JJ, 892(ab) Jyawook, 5, 996(ab) 979(ab), 987(ab), Kim, CK, 902(ab), 9l9(ab), 858(ab), 870(ab), 878(ab), Janicek, MJ, 1758, 970(ab) 1032(ab), 1048(ab) 999(ab) 882(ab),887(ab), Janiii, C, 1003(ab) Kabalka, GW, 890(ab), Katz, RD, l039(ab) Kim, C-W, 2118 1003(ab), 1007(ab), Jansen, J, 957(ab) 93l(ab), 983(ab), l025(ab) Katzenellenbogen,JA, 558, Kim, EE, 828(ab), 858(ab), l009(ab) Kaieda,M, 1016(ab) Jansons, D, 947(ab) 724 985(ab), 992(ab), lOOl(ab) Koga, 5, 1741, 965(ab) Janssen, AGM, 9l7(ab), Kairemo, KJA, 913(ab) Kaufman, GE, 2214 Kim, H, 974(aI@) Koh, C-S. 21 18, 877(ab), 1016(ab) Kaiser, Hi, 886(ab) Kaul, 5, 1732 Kim, H-L, 1225 892(ab),905(ab) Jarrousse, B, 9l3(ab) Kalagian,H, 867(ab) Kavanagh,P, 91l(ab) Kim, KY, 936(ab) KÃ´hler,U, 995(ab) Kaffi;v, 1346,2222 Jarry, M, 855(ab) Kawada, T, 844(ab) Kim, SB, 99l(ab) Kojima, A, 988(ab), Jaszcak, RJ, 96I(ab) Kalkowski, PJ, 881(ab) Kawai,C,659 Kim, SE, 877(ab) l029(ab), l033(ab) Kallergi, M, 889(ab) Jaszczak, RJ, 451, 879(ab), Kawai,H, 6 Kim, SM, 961(ab) Kojima, H, 998(ab) 891(ab),90l(ab),922(ab) Kalloo,AN, 1216 Kawal,K, 89l(ab) Kim, SY, 902(ab) Kolbe, H, 972(ab) Kamada, M, 998(ab) Jauch, M, 956(ab) Kawai, T, l023(ab) Kimball, AW, 869(ab) Kollman,M, 710 Kamada, T, 940(ab), Jay, M, 398, 1915(le) Kawakami,K, l004(ab) Kimball, AW Jr, 883(ab) Kollmann, M, 832(ab) 952(ab),969(ab),997(ab), Jeffery,PJ, 883(ab) Kawamoto,M, 659, 856(ab), Kimura, J, 1637 Kolodny,GM, 1699, 1774, l014(ab), l015(ab) Jehan, A, 835(ab) 885(ab),886(ab),953(ab) Kimura, Y, 893(ab), 909(ab), 947(ab), l003(ab) Kamano, T, 969(ab) Jensen, PF, 251 Kawamura,M, 1516 9l2(ab), 933(ab) Koisky, KL, 900(ab), Kamata, R, 951(ab) Jeong, JM, 889(ab), 986(ab), Kawarabayashi, C, 853(ab) Kinahan, PE, 871(ab) 980(ab), 985(ab) Kambara,H, 659,856(ab), Kawasaki, Y, 967(ab) King,HF, 963(ab) Komai, 5, 1741 1001(ab) 885(ab),886(ab),953(ab) Jerushalmi,J, 1774 Kawasuji,M, 441 King,MA, 161,605, Kondo,5,893(ab) Kaminski, MS, 893(ab) Jeusset, J, 2162 Kearfott, KY,842(ab) 842(ab), 843(ab), 962(ab) Konings, AWT, 373 KÃ£mmer,M, 1019(ab) Jewett, DM, 423, 982(ab) Keeling,CA, 1750 King, PT, 847(ab) Konishi, J, 545, 659, 897, Kammermeier, H, 102 Keenan, A, 848(ab) Kinoshita, M, 969(ab) 1263,1501,1637,853(ab), Jhingran, SG, 974(ab) Kanada,H, l00l(ab) Jia, MX, 927(ab) Kegel,J, 186 Kinoshita, R, 988(ab), 856(ab), 885(ab), 886(ab), Kanaya, K, 958(ab), Jimenez, H, 1304, 987(ab) Keiser, HR, 833(ab) 1029(ab), 1033(ab) 89l(ab), 893(ab), 953(ab), 1004(ab), 1005(ab) Keller,F, 1178 Kinoshita, 5, 932(ab) 966(ab), lOOl(ab), Jinnouchi, 5, 97l(ab) Kanaya, 5, 958(ab), Kelley,A,956(ab) Kinsey, BM, 983(ab) l023(ab), l024(ab), Jochelson, MS, 1594 1004(ab), 1005(ab) Kelley, Mi, 2222 Kinuya, K, 967(ab) l026(ab) Joensuu, H, 691 Kaneko, M, 6 Kinuya, 5, 842(ab), 889(ab), Konstam,MA,905(ab) John, @S,889(ab) Kang, SB, 905(ab) Kelly, JD, 850(ab) Kooij, PPM, 652, 894(ab), John, E, 85l(ab), 979(ab), Kanke, M, 144 Kemler, 5, 952(ab) 957(ab),986(ab),lOOl(ab) Kemp, RI,1875 Kippenhan, J5, 1459 914(ab) 987(ab) Kanmaz, B, 868(ab) Johnson, DK, 904(ab) Kanner,AM, 1014(ab) Kempf, J, 2014 Kipper, SL, 902(ab) Kooji, PPM, 990(ab) Johnson, JC, 623, 19l6(le) Kanno, I, 1696, 827(ab), Kenda, R, 873(ab) Kir, M, 464(le) KoonTe.h,S, 1312 Johnson, K, 1312 857(ab), 91 1(ab), l008(ab) Kenemans,P, 1113, 1958, Kirchner,PT, 1917(le) Koper, JW, 652 Johnson, KA, 181,704, Kanstrup,IL,251 2000 Kirsch, C-M, 832(ab), Kopicka, K, 9l0(ab), 887(ab),1005(ab), Kanvinde, MH, 981(ab) Kengen,RAM, 125l(le) 897(ab),917(ab) 979(ab),982(ab),1032(ab) Kirsh,C-M, 1291 1018(ab), l043(ab), Kao, CH, 254, 955(ab), Kennedy, DN, 867(ab) Koral, KF, 842(ab), 926(ab) l432Qe) 977(ab), 986(ab), 997(ab), Kennedy, JW, 939(ab) Kirsh, J, 960(ab) Kosslyn, SM, 908(ab) Johnson, LL, 229, 1411, 1013(ab) Kennedy, RL, 127 Kirsh, JC, 55, 970(ab) Kostakoaju,L, 345, 1396, 1994, 846(ab) Kao, PF, l022(ab) Kerr,JM, 1836 Kitamura,5,l016(ab) 843(ab), 1002(ab) Johnson, MC, 820 Kapadvanjwala, M, 956(ab), Kershaw, G, 907(ab) Kitapc;M, 319 Kaster, G, 950(ab) Johnson, SH, 575 980(ab) Kessler, J, 940(ab), 1013(ab) Kiuru, Ai, 913(ab) Kosuda,5, 844(ab),966(ab) Johnson, YE, 879(ab) Kaphan, G, 990(ab) Kessler, ML, 926(ab) Kj@ller,E, 251 Kotlyarov, EV, 966(ab), Johnston,GS, 966(ab), Kaplan,JD, 1661 Kessler, RH, 826(ab), Klauser, AG, 1291 970(ab) 970(ab) Kaplan,WD, 1594 847(ab),848(ab) Klein, BE, 1701 Kotts, C, 934(ab) Johnston, RE, 842(ab) Kappes, R, 1035(ab) Ketring, AR, 623, l916(le), Klein, HA, 996(ab) Kousaka, T, 853(ab) Jomura, I, 744 Kapucu, 0, 9l7(ab), 851(ab), 910(ab), 979(ab), Klein, HH, 223, 906(ab) Kovacs, FM, 403, 2060(le) Jones,AG,1357,1516, 1016(ab) 987(ab), 1032(ab), Klemm, E, 972(ab) Kozawa, SM, 581 1949, 937(ab), l033(ab) Karalasingam, L, l253(le) 1048(ab) Klingemmith, WC, ifi, 1417 Kozell, LB. 581 Jones, AL, 1002(ab) Karayalcin, G, 914(ab) Kettle,AG, 313 Kiinkowstein, RE, 932(ab) Kozuka,K, 952(ab), Jones, BE, 676 Karcher, G, 906(ab) Keyes,JW,Jr, 1859 Klipper, R, 984(ab), 10l5(ab) Jones, FD-L, 827(ab) Karl,B,852(ab) Khalkhali,I,835(ab) l027(ab) Kozuka,T, 365,940(ab), Jones, JJ, 10l4(ab) Karl, IE, 925(ab) Khanna, 5, 825(ab), 856(ab), Kiosa,B, 1399 969(ab), 997(ab), 10l4(ab) Jones, M, 948(ab) Karlsson, P, 860(ab) 867(ab), 944(ab), 1009(ab) Knapp, FT Jr, 910(ab), Kramer, EL, 9l2(ab), Jones, RH, 825(ab) Karp, JS, 861(ab), 862(ab), Khaw,BA, 144, 1994, 995(ab), l023(ab), 926(ab), 960(ab) Jones, RML, 1766 87l(ab), 1430(le) 895(ab), 934(ab), 936(ab), l024(ab), 1028(ab) Krasnow, AZ, 868(ab) Jones, T, 1669 Karrison,T,853(ab) 943(ab), 959(ab) Knecht, R, 9l2(ab) Krause, B, 885(ab) Jones, WT, 41 Kasahara, A, 997(ab) Khazaei, MB, 23, 1648 Kneeland, B, 992(ab) Krenning,EP, 652, 894(ab), Jonker, N, 491 Kashikura,K, 1005(ab) Khedkar,N, 258 Knight,D, 756 903(ab), 914(ab), 955(ab), Jonkhoff, AR, 927(ab) Kashiwagi, T, 997(ab) Khelifa, F, 990(ab) Knight, IC, 710, 467(le), 990(ab) JOnsson, B-A, 1654, 1825, Kasi, LP, 941(ab), 992(ab), Khonsari, A, 967(ab) 832(ab),964(ab) Kretschko, J, 859(ab) 953(ab), 954(ab) lOOl(ab) Kiat, H, 1509, 854(ab), Knobloch, E, 1035(ab) Kreuzer, H, 845(ab) JÃ¸rgensen,F, 2106 Kasper,5,972(ab) 876(ab), 91 1(ab) Knopp, MV, 828(ab), Krevsky, B, 467(le), 832(ab) Jorgenson,MA, 845(ab) Kassis,Al,384,781 Kiba,A, 1935 1007(ab), 1045(ab) Krishna, L, 2017 Joseph, JL, 968(ab) Katafuchi,T,272 Kiefer, J, 912(ab) Knusel, B, 890(ab) Krishnamurthy, GT, 431, Joseph, K, 906(ab) Katayama, 5, 968(ab) Kijewski, MF, 962(ab) Knuuti, MJ, 1255 542

Author Index â€¢1992 2257 Krishnamurthy

Krishnamurthy,S, 542 Kvols, Li, 1613 Lawson, AJ, 886(ab) Lever,SZ, 899(ab),92l(ab), Logan, KW, 1451 Krishnan, R, 910(ab), Kwan, A, 844(ab) Laxer,KD, 967(ab) 1032(ab) Logemann, TN, 884(ab) 994(ab) Kwekkeboom, Di, 652, Layer, G, 914(ab) Levina, T, 1022(ab) Loisance, D, 471, 896(ab) Krivokapich, J, 856(ab) 914(ab) Lazewatsky, J, 989(ab) Levine, MA, 869(ab) Loncaric, 5, 842(ab), 851(ab) Kroger, L, 912(ab) Le, N, 889(ab), 957(ab) Levine, R, lOl4(ab) Longford,CPD, 890(ab), Kroger, LA, 862(ab) Lear,iL, 1819, 463(le), Levivier, M, 868(ab) 931(ab), l025(ab) Krohn, KA, 581, 2202, Labresh, KA, 95l(ab) 908(ab), 947(ab) Levni, E, 932(ab) Lopez, M, 914(ab) 987(ab) Ladd, W, 1269 12 Bats, D, 953(ab), Levy, A, l046(ab) Lorenz, CH, 826(ab) Kroll,K, 2202 Laflamme, L, 696 1011(ab) Levy, AV, 287 Lorenz, Wi, 828(ab), Krom, RF, 239 LaFrance, N, 878(ab) LeBlanc, AD, 974(ab) Levy, WC, 763, 1324, 1642 1007(ab), 1045(ab) Kronauge,iF, 1357, 1516, LaFrance, ND, 968(ab) LeBouthillier, G, 1550 Lewellen, TK, 771, 2202, Losinno, F, 2040 1949,864(ab),1033(ab) Lahiri,A, 448, 874(ab), Lechevalhier, E, 990(ab) 889(ab),1430(le) LÃ´tter,MG, 777, 888(ab) Kronrad, L, 982(ab) 875(ab),938(ab) Leclerq,B, 874(ab) Lewis, DH, 1789 Lovins, K, 99l(ab), l046(ab) Kroon, D, 910(ab) Lai,i,987(ab) Leddy,C, 934(ab) Lewis, ML, 512 Low, i, 937(ab) Laks,H, 977(ab) Kroop, 5, 898(ab) Le Doussal, iM, 912(ab), Leys,D, 1431(le) Lowe, J, 860(ab) Kropp, J, 526, 844(ab), Lakshmanan, M, 1848 l000(ab) Li, i, 842(ab), 891(ab) Lowe,iL, 1919, 2030, 995(ab), 1028(ab) Lalonde, D, 866(ab) Lee, C, 964(ab) Liang, AY, 946(ab) 827(ab) Lalush, DS, 832(ab) Kruezer, H, 223 Lee, DS, 877(ab) Liang, C-H, 282 Lowenberg, B, 903(ab) Lam, C, 888(ab) Krumholtz, A, 966(ab) Lee, FA, 939(ab) Liang, Z, 872(ab) Loyalka, SK, 623, l9l6(Ie) Lam, WC, 1007(ab) Krumholz, H, l003(ab) Lee, HB, 739, 907(ab) Liao, S-C, 282 Loyd, D, 1789 Lambert, CR, 980(ab), Kuang, L-R, 985(ab) Lee, HP, 905(ab) Liao,5K, 926(ab) Lucignani, G, 944(ab), l023(ab), l028(ab), Kuba, A, 458 Lee,iD, 1183 Liao, SQ. 997(ab), 10l3(ab) 973(ab) 1029(ab) Kubo, A, 875(ab), 934(ab) Lee, K, 684 Libby, D, 880(ab), l028(ab) Ludbrook, PA, 836(ab) Lambert,R, 1091,1801, Kubodera, A, 891(ab) Lee,KS, 1579, 981(ab) Licho, R, 907(ab) Lueth, K, 853(ab) 855(ab), 866(ab), 894(ab), Kubota,K, 1972,840(ab), Lee, M, 869(ab), 963(ab) Lidgi, @,49 Luh, KE, 101l(ab),lOl8(ab) 1034(ab) 841(ab), 984(ab) Lee, MC, 877(ab), 892(ab), Lie, K!, 870(ab) Lui, D, 903(ab) Lamberts, SWi, 652, Kubota,R, 1972,840(ab), 905(ab) Liebes, L, 912(ab) Lumbroso, L, 1020(ab) 894(ab), 903(ab), 914(ab), 841(ab), 984(ab) Lee, ME, 972(ab) Liedtke, 1U, 1864 Luo, J, 926(ab) 955(ab) Kuczynski, BL, 1152, Lee, MH, 919(ab), 936(ab), Liew,SC, 1881 Lutterman, iA, 1330, Lambrecht, RM, 2020 865(ab), 993(ab) 991(ab) Lightfoote, JB, l039(ab) 950(ab) Lamki, L, 968(ab) Kuebler, WK, l007(ab) Lee, MK, 9l9(ab) Lin, H, 974(ab) Luxen, A, 1472, 868(ab) Lamki, LM, l047(ab) Lee, RF, 972(ab) Lin, KN, 10l2(ab) Lyle, LR, 2184 Kuhar, Mi, 964(ab) Lammert, G, l048(ab) Kuhl,DE,423, 1125, 1836, Lee, SF, 282 Lin, KP, 882(ab) Lyon, SG, 237 Lammertsma, AA, 1669 Lyons, EA, l044(ab) 858(ab), 882(ab), 887(ab), Landais,P, 101l(ab) Lee, SH, 936(ab) Un, MS.997(ab) Lee, TW, 986(ab) LAn,5, l033(ab) Lythgoe, MF, 1935, 2090 929(ab), 1003(ab), Landoni, C, 944(ab) Lee, YW, 463(le) Lin, W, 974(ab) 1009(ab) Lang, EV, 1797 Ma, GQ, 844(ab), 937(ab) Lee,YI, 2118 Kuhle, W, 1628 Lang,TF, 1881,90l(ab) Lin, WY,977(ab),986(ab), Maas, K, 874(ab) Lees, AM, 845(ab) 997(ab), 10l3(ab) Kuhle, WG, 1235 Lange, RC, 304 Macalintal, 5, 867(ab) Kuhlmann, L, 920(ab), Langer, R, 971(ab) Lees, RS, 845(ab) Linder, KE, 1152, 865(ab), Macapinlac, H, 867(ab) 1030(ab) Langhammer, HR. 854(ab), Lefebvre,B, 1034(ab) 920(ab) MacEwan, DW, 1044(ab) Kuijper,AFM, 1727 859(ab) Lefkowitz, D, 1047(ab) Lindsley, K, 867(ab) Macey, Di, 926(ab), 927(ab), Kuiper, MA, 917(ab), Langhorst, SM, 623, 1916(le) LÃ©ger,GC, 879(ab), 9l6(ab) Line, BR, 1939, 848(ab) 94l(ab) 1016(ab) Lanier, L, l043(ab) Lehikoinen, P, 691 Lingen, AV, 858(ab), MacFall, JR. 922(ab) Kuji, I, l020(ab) Lanigan, JP, 1024(ab) Leichner, pic l007(ab) 927(ab) MacGregor, R, 521, 887(ab), Kukis, DL, 942(ab), Lanspa, 5, 975(ab) Leighton, DM, 1022(ab) Linhart, NC, 380 888(ab) l030(ab), 1031(ab) Lantto, E, l253(le) Leisure, GP, 885(ab) Link, JM, 581 MacGregor,RR, 192, Kulkarni, PV, 974(ab), Lantto, T, 1253(le) Leitha, T, l028(ab) Links, JM, 968(ab), 847(ab), 946(ab) 990(ab), l003(ab), Larar,GN, 2209 Lemlek, i, 2086, 866(ab), 1007(ab), l430(le) Mach, JP, 1766, 903(ab) lOlO(ab) Larar, JM, 844(ab) 916(ab) Linssen, MCJG, 102 Mach,RH, 829(ab),985(ab) Kumar, A, 1548, 2103, Larar,JN, 1186 Lemmens, JAM, 1330, Liow,J-S, 87l(ab) Machac, i, 995(ab) 1013(ab) Larcos,G, l588(le) 950(ab) Lisbona, R, 1223 Machecourt, i, 953(ab) Kung, HF, 1964, 848(ab), Larkin, R, 960(ab) Leners, N, 976(ab) Lisic, E, l024(ab) Machida, K, 969(ab) 870(ab), 871(ab), 890(ab), Larock, MP, 874(ab) Lennon, SE, 1797 Lister-iames, i, 845(ab) Maclntyre, Wi, 866(ab), 896(ab), 945(ab), 954(ab), Larson, 5, 867(ab) Leon, AS, 1949 Little, JW, 1035(ab) 928(ab), 970(ab), 982(ab), 989(ab) Larson, SM, 345, 803, 1373, Leon, ET, 1949 Littlefield, JL, 1042(ab), l040(ab), l048(ab), Kung, MP, 871(ab), 890(ab), 1396, 2020, 843(ab), Leonard iC, 981(ab), l046(ab) 1586(le) 982(ab), 989(ab) 859(ab), 904(ab), 9l3(ab), l034(ab) Litton, J-E, 860(ab), Maclean, JB, 972(ab) Kuni, CC, 873(ab) 941(ab), l002(ab) Leonidas, JC, 914(ab) lOll(ab), 1016(ab) MacNabb, Ci, 870(ab) Kuniyasu, Y, 998(ab) Larsson, BS, 1825 Leppo,JA, 120, 1783, Liu, A, 724 Macy, C, 9l2(ab) Kupfer, 5, 949(ab) Laruelle, M, 848(ab), 468(le), 846(ab), 864(ab), Liu, HC, 1012(ab) Madani, 5, 458 Kurata, C, 6, 845(ab) 91 l(ab), 945(ab) 993(ab) Liu, J, 962(ab) Madar, I, 883(ab) @ Kurihara, K, 1005(ab) Lasdun, A, 98l(ab) Lerner, D, 1022(ab) Liu, RS, 997(ab), 1034(ab) Maddahi, J, 1509, 825(ab), Kurkoki, T, 744 Lasser, EC, 237 Leroy, RF, l018(ab) Liu, 5, l012(ab) 828(ab), 829(ab), 854(ab), Kursh, ED, 41 â€¢Lastoria,5, 892(ab),9l8(ab), Lescb, MD, 994(ab) Liu, T, 23, 1648 856(ab), 867(ab), 876(ab), Kurt, AM, 1766 999(ab) Leskinen-Kallio, 5, 691 Liu, Xi, 938(ab) 1009(ab), 1045(ab) Kusakabe, K, 958(ab), Latham,Th,355 Lesser, I, 838(ab) Liu, Y, 852(ab), 924(ab) MaddaX,A, 1283 l004(ab), l005(ab) LatifiÃ«-iasni@,D, 587 Lesser, RP, 929(ab) Livni, E, 924(ab) Maddock, EN, 863(ab) Kuten, A, 1774 Latino, FA, 990(ab) Lette, J, 938(ab), 951(ab) Ljungberg, M, 962(ab) Maddock, SW, 862(ab), Kutom, AH, 95 l(ab) Lattimer, iC, 1024(ab) Leuven, KU, 832(ab) Lloyd, T, 1143 863(ab) Kuwabara, H, 879(ab), Lau, A, 2059(le) Levasseur, A, 95l(ab) LoBuglio, AF, 23, 1648 Maden, HA, 464(le) 909(ab), 9l6(ab) Lauer, U, 903(ab) Levasseur, M, 1481, Loc'h, C, 1481, 883(ab), Madras, B, 946(ab) Kuwabara, Y, 877(ab), Laurent, R, 868(ab) 10l9(ab) l019(ab) Madi@s,BK@946(ab) 945(ab), 10l5(ab) Laurie, AJ, 237 LÃªveillÃ£,i, 480, 1091, Logan, i, 192, 521, 847(ab), Madsen,i, 844(ab) Kuyama, i, 324 Lavender, iP, 491, 756 1034(ab) 887(ab), 888(ab), 946(ab) Madsen,MT, 1859,1917(le)

2258 The Journal of Nuclear Medicine Moore

Maeda, H, 1741, 965(ab), Marie, PY, 906(ab) 941(ab),960(ab) MCShan, Dl, 735 1020(ab) 1023(ab) Marien, P, 1013(ab) Matthews, IU, 863(ab) McSherry, B, 1783 Mi&iski, M, 587 Maeda, Y, 967(ab) Maiienhagen, J, 903(ab) Mauls, JA, 144 McTigue, M, 2006, 880(ab), Middleton, ML, 985(ab) Maegdenberg, VVd, 832(ab) Markliam,J,1661 Matzku, S, 1366 931(ab) Mielke, R, 940(ab) Magata,Y, 856(ab),886(ab), Markham, JA, 1045(ab) Maurea, S, 833(ab), 905(ab), Meares, CE, 2006 Migneco, 0, 1846, 839(ab) 897(ab), 953(ab), 966(ab), Markowitz, A, 852(ab) 915(ab),918(ab) Meares, CF, 1685, 880(ab), Mikata, A, 324 1023(ab), l024(ab) Marks, PH, 516 Maurelli, L, 9l8(ab) 942(ab),l030(ab), Mild, H, 969(ab) Magnani, P, 834(ab), 959(ab) Marmion, ME, 850(ab), Maurer, A, 952(ab) 103I(ab) Milan, E, 846(ab) MagnÃ©,J,1846 l033(ab) Maurer, AH, 710, 467(Ie), Mease, RC, 900(ab), 942(ab), Militia, R, 945(ab) Magoun, 5, 99l(ab) Marmor, A, 938(ab) 832(ab), 964(ab) 943(ab), 985(ab), l030(ab) Milko, D, 996(ab) Maguire, GQ Jr. 960(ab) Marotta, CA, 2184 Maurer, M, 880(ab) Medina, ES, 835(ab) Millard, RW, 993(ab) Mahe, MA, 94l(ab) Marshall, RC, 938(ab) Mausner, LF, 305, 899(ab), Medrano, R, 905(ab), Miller, B, 838(ab), 839(ab) Mahler, M, 967(ab) Martin,CC, 850(ab), 900(ab), 942(ab), 980(ab), 9l6(ab) Miller, EG, 96l(ab) Mabmarian, JJ, 1600, 884(ab), 93l(ab) 985(ab),l030(ab) Meeder, JG, 870(ab) Miller, Fi, ir, 260 905(ab), 916(ab), 995(ab) Martin, GV, 2144, 2202 Maxon, HR. 1132, 894(ab), Meeuwisse,E, 955(ab) Miller,i, lOl6(ab) Mahmood, A, 937(ab) Martin, M, 912(ab), 898(ab), 937(ab), 978(ab), Megibow, A, 960(ab) Miller, JH, 930(ab) Mahoney, DK, 1472, l000(ab) 1048(ab) Mehta, BM, 1373 Miller, K, 900(ab), 1025(ab) 1045(ab) Martin, P, 863(ab), 94l(ab), Mayaud, Ch, 81 Mehta, YD, 974(ab) Miller, MI, 964(ab) Mahussain,SA,978(ab) 960(ab) Mayberg, HS, l8N(6) Meignan, M, 81, 9l9(ab) Miller, RF, 903(ab) Maier-Borst, W, 1366 Martin, SE, 865(ab) Mayeur, 5, 832(ab) Meilde, 5, 879(ab) Miller,TR,1678,1710, Mailhiard, JA, 975(ab) Martinez, C, 258 Maynard, C, 939(ab) Meikle, SR1 862(ab), 964(ab) Maincent, P, 956(ab) Maruyama, Y, 920(ab) MaZiÃ¨re,B,696, 1481, 90l(ab), l045(ab) Milet,P, lOll(ab) Maisch,B, 906(ab) Marwick, T, 825(ab), 973(ab), 977(ab), l019(ab) Meindi, J, 859(ab) Mills, BJA, 398, 1556 MaIZC1S, M, 2047 837(ab),866(ab),875(ab), MaZIÃ”IC,M, 883(ab), 973(ab) Meindok,H, 1548 Mills, SL, 981(ab), 982(ab) Majd, M, 976(ab) l04.0(ab), 1041(ab) Mazzeo,5, 954(ab) Meinken, GE, 900(ab), Miot, A, l034(ab) Majocha, RE, 2184 Marzilli, U3, 900(ab), Mazziota, JC, 867(ab) 942(ab), 985(ab), Mm, Yl, 919(ab) Makay, A, 458 92l(ab) Mazziotta,JC, 1472, l028(ab), 1030(ab) Minami, C, 835(ab) Maid, M, 958(ab) Marzullo,P, 1925 922(ab), lOlO(ab) Mekkawy, MA, 526 Minoshima, S, 1579, Makino, M, 958(ab), Masaki, K, 744 McAfee, JG, 889(ab), Melega, WP, 1472 858(ab),929(ab), 1004(ab),lOOS(ab) Mason, G, 835(ab) l428(le) Melero, M, 999(ab) l003(ab), l007(ab), Mal, H, 835(ab) Mason, GR, 836(ab), McAteer, E, 872(ab) Mein, J, 825(ab) 1008(ab), l009(ab) Malarme, M, l427(le) 1022(ab) McBride, BJ, 1836 Mein, JA, 837(ab), 875(ab), Mintun, MA, 684, 1579, Malik, AB, 1023(ab) Mason, NS, 847(ab) MCCabe, R, 103l(ab) 884(ab), 905(ab) 1007(ab), 1009(ab) Malison,RT, 848(ab), Mason, RP, 974(ab) McCall,Mi, 2006,880(ab), Melis, K, 1021(ab) Miraldi, F, 41 945(ab), 96l(ab) Mason, WH, 930(ab) 103l(ab) Melman, A, 1723 Mirelli, M, 2040 Maljkovic, V, 908(ab) Massuger, LFAG, I I 13, McCallum, RW, 833(ab) Melon, P. 826(ab) Mirick,GE, 941(ab) Malkin,RD, 876(ab) 1958 McCandless, BK, 59, 1566, Melon, P0, 865(ab), 994(ab) Miron, SD, l044(ab) Mallin, W, 993(ab) Masters, PR, 1048(ab) l023(ab) Meltzer, L, 992(ab) Mirzadeh, 5, 1024(ab) Malmud, LS, 24N(6), Mastin,ST, 923(ab) McCarthy,G, 96l(ab) Meltzer, PC, 946(ab) Mita, A, 954(ab) N3l(3) Mastrostamatis,5, 988(ab) McCartney,WH, 831(ab), Mena, I, 835(ab), 838(ab), Mitchell, DS, 973(ab) Malveaux, G, 921(ab) Masuda,K, 877(ab), 842(ab) 839(ab), 846(ab), 876(ab) Miura, 5, 827(ab), l008(ab) Mamiya, T, 969(ab) 945(ab), 998(ab), 1015(ab) McClanahan, TB, 1346 Mendelson, i, 1312, 887(ab) Miyamae, T, 932(ab) Mand, FF, 167 Masure, MC, 696 McCord,ME, 1209,2226 Meneguetti, JC, 995(ab) Miyamoto, C, l002(ab) Mandelkern,M, 967(ab), Matacchieri, R, l027(ab) McDermott, K, 904(ab) Merchant, EB, 14 Miyaoka, RS, l429(le) 10l7(ab) Matarrese,M, 924(ab), McDermott, MP, 1044(ab) Meredith, RF, 23, 1648 Miyatake,5, 893(ab) Manddll, GA, 873(ab), 944(ab), l014(ab) McDevitt, GR, Jr. 2052 Merhige, ME, l040(ab) Miyauchi, T, 967(ab) 874(ab) Mate, E, 458 McDevitt, MR. 851(ab), Merino, Mi, 1848 Miyazaki,5, 853(ab) Maneval, DC, 934(ab) Matheja, P. 9l5(ab) 986(ab) Mend, P, 471, 896(ab) MizraChi, H, 912(ab) Manglos, SH, 150, 901(ab), Mather,5,1121,9l4(ab) McDevitt, R, 898(ab), Merli, G, 999(ab) Mizukami, Y, 2024 961(ab) Mather, Si, 904(ab) 978(ab) Merola,TF, 304 M.@ller,JT,251 Mangner, T, 684 Mathews,D, 826(ab) McDonald,KL, 1040(ab) Merrick, MV, 872(ab) Mochizuki,T, 1851, Mangner, TJ, 860(ab), Mathias, Ci, 931(ab) McEntee, MC, 1542 Mertens, H, 102 9l9(ab), 976(ab), 997(ab) 86l(ab), 870(ab),882(ab), Mathieu,D, 9l9(ab) McEwan,Ai, 841(ab) Mertens, WC, 1437 Model, iG, 826(ab) 982(ab), 983(ab) Mathieu, JP, 1034(ab) McGee, S, 926(ab) Messa, C, 339, 945(ab) Modorati, G, 959(ab) Man in â€˜tVeld, AJ, 990(ab) Mathis,CA,2133,890(ab) Mcllvain, HB, 899(ab) Messian,0, 835(ab) Mody, F, 856(ab) Mankovich, NJ, 827(ab), Mathisen, G, 827(ab) Mcintyre,R, 1028(ab) Messinger, DE, 876(ab), Moerlein, SM, 848(ab), 1043(ab) Matoba, N, 966(ab) McIntyre, WJ, 104l(ab) 95l(ab) 883(ab) Manning, RG, 847(ab) Matsouka,DT, 1642 McKay, Wi, 877(ab), Mestais, C, 1003(ab) Mohamed, FB, 973(ab) Manno, M, 929(ab) Matsuda, H, 877(ab), 930(ab) Mester, i, 458 Molea, N, 845(ab), 1020(ab) Mannting,F, 928(ab) 967(ab) McKeever, PE, 735 Metherall, JA, 905(ab) Molina-Murphy, IL, 1558 Mantil, JC, 830(ab), 975(ab), Matsudaira, M, 918(ab) McKusick, KA, 9l5(ab), Metz, CE, 451 Molinoff,PB,982(ab) 983(ab) Matsumori, A, 1501 l254(le) Metz, JT, 101l(ab), MÃ¶ller,H-i, 972(ab) Maquire, GQ Jr, 926(ab) Matsumoto,K, 413, 545 McLaughlin, AF, 438 l018(ab), lOl9(ab) Molthoff,CF, 2000 Maraganore,J, 98l(ab) Matsumoto, M, 940(ab), McLean,RG, 2059(le) Meuli,R, 956(ab) Momose,T, 827(ab), Marboe,C, 1994 969(ab), lOl4(ab), McLelIan, CA, 1383, 945(ab) Meyer, E, 909(ab) 857(ab), 968(ab), 969(ab), Marciano, DM, 867(ab) l015(ab) McMahan, CA, 1496 Meyer, K, 851(ab), l032(ab) 1006(ab), l009(ab) Mardirossian, G, 909(ab), Matsunaga, T, 10l5(ab) McMahon, M, 874(ab), Meyer, MA, 887(ab), Mone, SM, 930(ab) 921(ab), 934(ab), l030(ab) Matsuoka,DT, 763 927(ab) 894(ab) Monetti, N, 2040 Mardirossian, GC, 958(ab) Matsushita, R, 998(ab) McMillin, CH, 1046(ab) Meyerrose,GE, 849(ab) Monsein, LH, 968(ab) Marengo, M, 2040 Matters, i, 855(ab), 927(ab) McMurry, TJ, 103l(ab) Meyne, NG, 895(ab) Moon, DH, 919(ab), Margouleff, D, 898(ab), Mattera, iA, 874(ab) McNamara, D, 95l(ab) Mezianne,MA, 1048(ab) 936(ab), 99l(ab) 923(ab),1027(ab) Matteucci, F, 1020(ab) McPartlin,M, 850(ab) Michel, C, 837(ab), 884(ab) Moon, 5, 869(ab), 926(ab) Mariani, G, l020(ab) Matthay,KK, 918(ab) McPherson, DW, 1023(ab), Michelson, RH, 890(ab) Moore, D, 974(ab) Mariani, M, 999(ab) Matthews, D, 863(ab), 1028(ab) Michigishi, T, 2024, Moore, JA, 467(le)

AuthorIndexâ€¢1992 2259 Moore

Moore,JO, 833(ab) 865(ab) NakatSUka, I, 848(ab) Nicol, PD, 895(ab) Odana, I, 1015(ab) Moore, M, 2059(le) MUller-GÃ£rtnerHW, Nakayama, M, 988(ab), Nicolai, E, 905(ab), 915(ab) O'Dell, M, 859(ab) Moore,RH, 948(ab), 872(ab),922(ab) 1029(ab),l033(ab) Niedzwiecki, D, 345 O'Doherty, Mi, 313 998(ab) MUller-Schauenburg, W, Naldoken, S. l027(ab) Nielsen. SL, 251 O'Donnell, SM, 934(ab), Moore, SC, 962(ab), 956(ab) Namba, Y, 893(ab) Nieman, L, 834(ab) 936(ab),959(ab) l004(ab) Mumper, RJ, 398 Nanba, R, 1023(ab) Niemeyer, MG, 1727 Odze, R, 960(ab) Moore, WH, 889(ab), Munaka,M, 91l(ab), Nappi, A, 905(ab), 9l5(ab) Niesen, A, 904(ab), 912(ab) Oei, HY, 652, 894(ab), 938(ab) 963(ab) Narabayashi, I, l023(ab) Niio, Y, 998(ab) 903(ab), 907(ab), 9l4(ab), Morabito, MD, 1002(ab) Munoz, L, 994(ab) Narahara, K, 876(ab) Nijran, KS, 676 990(ab) Morais,J, 1550 Munson,PR, 988(ab) Narahara, KA, 846(ab) Nikpoor, N, 643 Oertel, WH, 897(ab), 917(ab) Mordenti, J, 924(ab) Munz, DL, 223, 845(ab), Nariai, T, 413 Nimmon, CC, 924(ab) Offord, RE, 1766 Moresco, RH, 944(ab) 950(ab), 957(ab) Narra, RK, 88, 1152, Nishigori, H, 1025(ab) Ogata, Y, 841(ab) Morgan,HT, 892(ab), Murakami, M, 827(ab), 865(ab), 993(ab) NiSIIibaIa,M,l015(ab) Ogawa, K, 963(ab) 901(ab), 962(ab) 91l(ab), 963(ab),1008(ab) Narra, VR@277, 2196 Nishikawa, J, 857(ab), Ogawa, M, 1637 Morgan, MG, 928(ab) Muraki, A, 867(ab) Naruki, Y, 920(ab) 875(ab),968(ab), Ogawa, T, 1696 Morgenthaler, JJ, 231 Muramatsu,T, 932(ab) Narula, J, 845(ab), 9l5(ab), l006(ab), l009(ab) Ogilby, D, 866(ab), 916(ab), Morguet,Al, 223 Muramori, A, 441 934(ab), 936(ab), 943(ab), Nishimura, K, 932(ab) 952(ab) Moriarty,JM, 1758 Murase, K, 135, 909(ab), 959(ab) Nishimura, 5, 1600 Ogilby, JD, 2086 Morisco,C, 905(ab) 9l2(ab), 919(ab),969(ab), Nash, R, 924(ab) Nishimura, T, 272, 365, O'Grady, LF, 862(ab) Morishima,5, 1501 972(ab), 976(ab), 1004(ab) Natale, A, 958(ab) 1014,853(ab),875(ab), Ohashi, K, 1692 Morita, R, 998(ab) Murphey, MM, 1039(ab) Natale, D, 855(ab) 940(ab), 952(ab), 969(ab), Ohnishi, T, 971(ab) Moriwaki, H, 940(ab), Murphy,B, l040(ab) Natarajan, Tic 968(ab) 997(ab),l015(ab) Ohno,T, 9l8(ab) 969(ab), 1014(ab), Murphy, PH, 889(ab), Nathan, M, 949(ab) Nishiyama, H, 1047(ab) Ohta, 5, 969(ab) 1015(ab) 938(ab), N38(9), N32(12) Nathan,MA, lOll(ab), Nishizaki, Y, 963(ab) Ohta, Y, 958(ab) Morozumi, T, 952(ab), Murray, CL, 1623 10l2(ab), lOl8(ab) Nishizawa, 5, 966(ab) Chiake, T, 875(ab@ l006(ab), 963(ab) Murray, G, 1269 Nattel, 5, 95l(ab) Nisikawa, J, 827(ab) 1009(ab) Morrell, NW, 676 Murray, JL, 94l(ab), Navia,B, 1312,887(ab) Nitzsche, EU, 1399, 828(ab), Ohtani, H, l000(ab) Moms, G, 904(ab) lOOl(ab) Nawaz,K, 978(ab) 865(ab) Ohyama, M, 10l6(ab) Morris, HH, 928(ab) Murthy, 5, 863(ab), 904(ab) Nebandahl, K, 223 Noca, A, l003(ab) Ohyama, Y, 988(ab), Moms, JG, 438 Mut, F, 1949 Nebeling, B, 1013(ab) Nodel, D, 858(ab) 1033(ab) Morris, KDW, N30(9), Muzi, M, 944(ab) Nebendahl, K, 845(ab) NoiJ,P.485 Oja,P, 1137 N15(3),N14(l2) Muzic, RF, 885(ab) Nedelman, M, 978(ab) Noguchi,M, 2024 Okada, J, 324 Morrisey, MA, 2249(le) Muzik, 0, 684, 826(ab), Nedelman,MA, 144 Nohara, R, 659, 856(ab), Okarvi, 5, 1032(ab) Morrison, D, l012(ab) 865(ab), 882(ab) Neer, RH, 170 884(ab), 885(ab), 886(ab), Okazaki, Y, 940(ab), 969(ab), Morrison, SL, 985(ab) Muzinic, M, 969(ab) Negrin, JA, 898(ab) 953(al,) l014(ab), 1015(ab) Morrissey, MA, 498 Myers,MJ, 173 Neiman, J, 1016(ab) Northover, JMA, 904(ab) Okazurni, 5, 333 Norton, JA, 1848 Mortelmans,L, 933(ab), Na, HW, 936(ab) Nellis, SN, 1864 O'Keefe, JH, 95l(ab) 937(ab) Nelp, W, 941(ab), 960(ab) Nosco, DL, 551, 850(ab), Oku, N, 940(ab),969(ab), Naber, AHJ, 920(ab) l033(ab) Mortensen, T, 992(ab) Nadel, DM, 1013(ab) Nelp, WB, 863(ab), 864(ab), 10l4(ab), lOlS(ab) Morton, KA, 260, 833(ab), 924(ab), 987(ab), 1005(ab) NOSka,MA, 1357, 958(ab) Oku,5, l006(ab),1009(ab) Nagamachi,5, 97l(ab) Nossifi ND, 934(ab), 1003(ab) Nagashima, J, 998(ab) Nelson, AD, 41, 885(ab) Okudera, T, 1696 Moscatelli, G, 863(ab), Nemetz, ST, 468(le) 936(ab) Okumura, A, 969(ab), Nagata,K, 1696 Notghi, A, 872(ab) 9l5(ab) Nagazumi, A, 1016(ab) Netten, PM, 1330, 950(ab) 972(ab) Moser, EA, 1399 Netto, ICV, l035(ab) Noujaim, AA, 853(ab), Old, U, 913(ab) Nagel,AA,830(ab) 904(ab) Moser, L, 937(ab) Nagel, i, 1459, 998(ab) Neumann, DA, l048(ab) Oldfield,E, 834(ab) Moses, WW, 862(ab) Neumann, DR, 131, Nourigat,C, 987(ab) Olea,E, 998(ab) Nagel, iS, 704, 2209 Novak-Hofer, I, 231 Mossberg, KA, 1523 Nagle,KR, 850(ab) 952(ab), 1040(ab), Oliveira, MC, 1949 Motomura, N, 1200 lO4l(ab) Novell,JR, l020(ab) Olivier@P, 906(ab) NÃ¡gren,K, 691 Novotney, AC, 1542 Moulton, iS, 937(ab) Neumann, PH, 1566, Olsen,L, lOl6(ab) Nair, N, 914(ab) Nowak, D, 83l(ab) Mountz, JM, 826(ab) l023(ab) Ono, M, 1741 Nair, 5, 2017 Nowak, PA, 829(ab), 985(ab) Moyes,J,1121 Neumann, RD, 833(ab), Ono, 5, 856(ab), 953(ab) Nakabeppu, Y, 996(ab) Nowotnik, DP, 920(ab) Moyse, D, 471, 896(ab) 852(ab),889(ab),893(ab), Ono, Y, 994(ab) Nakagawa, I, l033(ab) Noz, ME,912(ab),926(ab), Mozley, D, 870(ab), 87l(ab), 957(ab),986(ab),lOOl(ab) Onsal, I, 1027(ab) Nakagawa, T, 1741 960(ab) 897(ab),898(ab) Neumeyer, JL, 945(ab), Oosterhuis, WP, 1727 Nakagawara,J, lOl7(ab) Nozaki, T, 1025(ab) Mozley, PD, 954(ab) 964(ab) Oosterwijk, E, 913(ab) Nakahashi, H, 413 Nunn, AD, 88, 94, 1152, Muehllehner, G, 861(ab), Newberg, A, 857(ab), Oosterwijk, J, 913(ab) Nakai, T, 853(ab), 893(ab), 850(ab), 865(ab), 920(ab), l430(le) 940(ab), 965(ab) Opie, LH, 1353 lOOl(ab) 993(ab) Mueller,51',962(ab) Newell,DW, 1789 Oratz., R, 9l2(ab) Nakajima, K, 441, 1200, Nutin, C, 977(ab) Mueller-Lissner, SA, 1291, Newman, JS, 256 Orellana, P, 998(ab) 918(ab) Nuutila, P, 1255 832(ab) Newton, MR. 930(ab) Oriuch,N, 1181 Nakajo, M, 996(ab) Nuyts, J, 933(ab), 937(ab) Mufraggi, N, 403, 2060(le) Nakaki, M, 935(ab), 936(ab) Ney, DR, l042(ab) OtT, RA, 23 Mui, F, 1949 Nakamura,J, 1017(ab) . Nguyen, BA, 263 Oates, E, 256, 905(ab), Orringer, M, 828(ab) MUirhead, KA, 899(ab), Nakamura, K, 934(ab) Nguyen,D, lOll(ab) l041(ab) Orsolon, N3, 895(ab) 92l(ab) Nakamura,M, 1851 Nguyen, N, 1346, 865(ab), Oberdorfer, F, 1982, Ortega, JC, 990(ab) Mukheijee, J, 829(ab), Nakamura, 0, 844(ab), 994(ab) 828(ab), 1019(ab) Ortiz, M, 999(ab) 982(ab) 966(ab) Ngyen, A, 865(ab) O'Brien, CP, 898(ab) Ortiz,V. 998(ab) Mulder, RU, 833(ab) Nakamura, 5, 893(ab), Nichols, DC, N30(9), O'Brien,iP, 1396 Orton, M, 2090 Muler-GÃ¤rtner,HW, 929(ab) 933(ab), 972(ab) N14(l2) O'Carroll, RE, 1623 Osaka, 6, 934(ab) Mulbolland, GK, 423, Nakane, K, 1741, 965(ab) Nichols, K, 928(ab) Ochi, H, 744 Ossenkoppele, GJ, 858(ab), 882(ab),982(ab),984(ab) Nakano, K, 958(ab) Nicholson, RL, 1875 O'Connell, JW, 1444, 927(ab) Mullan, BP, 840(ab) Nakano, 5, 208 Nickerson, JP, 975(ab) 910(ab), 935(ab) Oster, ZH, l028(ab) Muller, D, 826(ab) Nakata, 5, 972(ab) Nickerson,R, 950(ab) O'Connor, MK, 239, 1146, Ostertag, H, 828(ab) Muller,L, 93l(ab) Nakata, Y, 1023(ab) Nickles,Ri, 850(ab), 1613,l006(ab) Ostertag, Hi, l007(ab), Muller, P, 836(ab), 856(ab), NaIcatani, N, 920(ab) 884(ab), 93l(ab), 10l4(ab) Oda, K, lOl6(ab) l045(ab)

2260 The Journal of Nudear Medicine Riva

O'Sullivan, F, 944(ab), Parsons, SM, 983(ab), Phelps, M, 825(ab), 856(ab), Potvin, C, 1801, 894(ab) Rauh DA,710 l009(ab) 101l(ab) 865(ab) Poublon,RML, 894(ab) Raval,U, 875(ab) Othmer, P, 1046(ab) Pascal,S, 1459 Phelps, ME, 339, 595, 613, Powe,iE,1316,1437 Ravert, HT, 847(ab), Otsuka, M, 877(ab), 945(ab), Pasqualini, R, 850(ab), 633,945,1191,1235, Prados, MD, 2133 848(ab), 860(ab), 883(ab), l015(ab) 989(ab), l034(ab) 1472, 1628, 828(ab), Prandi, D, 403, 2060(le) 885(ab), 929(ab), 968(ab) Otsuka, S. 920(ab) Passeri, A, 831(ab) 829(ab), 836(ab), 856(ab), Prat, L, 845(ab) Ray, 5, 924(ab) Ott, Ri, 2154 Pastan, I, 842(ab) 88l(ab), 882(ab), 944(ab), Prato, FS, 355, 1875 Raylman,RR, 1243,88l(ab) Otto, CA, 423 Patch, GG, 260 l045(ab) Pi@att,JP, 947(ab) Raynaud, C, 696, 1481, O'Tuama, LA, 1758, 2098, Pate, BD,964(ab) Phillips, W, 8 19, 984(ab), Preslar,J, 1917(le) 976(ab), 977(ab), 1019(ab) 838(ab), 844(ab), 930(ab) Patel,K, 923(ab) l027(ab) Press, 0, 941(ab) Reba, RC, 1225, 883(ab), Ouchi,Y, 1637 Patel,NH, 849(ab) Phillips, WT, 1496 Press, OW, 863(ab), 960(ab) 889(ab), 996(ab) Overbeck, B, 526, 839(ab), Patel, RB, 9l4(ab) Philpou, GW, 1685 Preston, DF, 1039(ab), Reba, RS, 966(ab) 972(ab) Patterson, RE, 865(ab) Picard,D, 1550 l046(ab) Redepenning,L, 836(ab) Owens, ES, 852(ab) Pauli,S, 101l(ab) Picard,M, 1550,95l(ab) Pretorlus, PH, 888(ab) Reece,C, 161 Owunwanne, A, 978(ab) Pauwels, EKJ, 1406, 1727 Piccolo, M, 1478 Price, DC, 967(ab), 974(ab) Reed, BR, 939(ab) Oyen, WiG, 388, 1330, Pauwels, 5, 976(ab) Pich, 5, 223 Price, iC, 883(ab), 91 l(ab) Reed,i, 1366 903(ab), 920(ab), 936(ab), Pavoni, R, 959(ab) Piepenburg, R, 887(ab), Prieto, I, 866(ab) Reed,NL, 1750 950(ab), 103l(ab) Pawlik, G, 1013(ab) 102l(ab) Prigent, F, 1509 Reekers, iA, 907(ab) Ozaki, M, 333 Pawlowski, i, 852(ab) Piepsz, 175 Prince,iR, 927(ab) Reese,L,355, 1875 Ozawa,Y, 951(ab) Payne, iK, 1919, 2030, Piepsz,A, 174,485 Prior, i, l003(ab), lOlO(ab) Rege, 5, 828(ab), 829(ab) OzgUven, M, 866(ab) 827(ab) Pierfitte, M, l003(ab) Prohovnik, I, 940(ab) Rehncrona, 5, 868(ab) Ozkilic, H, 1722 Payne, SE, 990(ab) Pieri, PL, 9l5(ab) Proto, G, 895(ab) Reiche, W, 886(ab) OztÃ¼rk,E, 866(ab) Pearlson, G, 847(ab) Piers, DA, 125l(le) Provenzale,J, 248 Reid, R, 1437 Pelagi, M, 834(ab) Pierson, R, 549 Prummel,MF, 894(ab) Paans,AMJ, 373,870(ab) Reijs, AEM, 652 PÃ¨legrln,A, 1766, 903(ab) Pieterman, H, 990(ab) Przedborski, 5, 868(ab) Reilly, RM, 2248(le), 960(ab) Pabst, HW, 854(ab), 859(ab) Pelizzari, CA, 922(ab), Pietrzyk, U, 861(ab), Puma, J, 825(ab) Pace, L, 68, 505, 905(ab), Reilly,SM, 1881 l005(ab), l043(ab), 1013(ab) Purdy, PD, 826(ab) Reiman, RE, 834(ab) 9l5(ab) 1047(ab) Piffanelli, A, 850(ab) Purnell, G, 978(ab) Reinartz, R, lOOl(ab) Padhy, AK, 904(ab), 924(ab) Pellegrino-Gensey, iL, 1378 Pike, M, 910(ab) Pusey, CD, 491 Reinbold, F, 907(ab) Padilla, ML, 1175 Peller, PH, 1039(ab) Pilcher, G, 974(ab) PuskÃ¡s,C, 840(ab), 920(ab) Paganelli, G, 834(ab), Reinhardt,CP, 993(ab) Peller,Pi, 968(ab) Pileggi, F, 995(ab) Putter, D, 1030(ab) 925(ab), 959(ab) Reinhardt,M, 1981, Pellevoisin, C, 981(ab) Pinedo, HM, 2000 Pyzalski, R, 10l4(ab) Page, RL, 1542 lOl9(ab) Pellikka, PA, 2080 Pinsky, CM, 863(ab), Reiser, M, 9l4(ab) Pal, LH, 842(ab) Peltier, P, 9l2(ab) Qian, i, 932(ab), 938(ab) Reist, H, 884(ab) Paik, CH, 842(ab), 889(ab), 904(ab),l002(ab) Penney, BC, 161, 843(ab), Pipes, D, 1024(ab) Qian, W, 889(ab) Reither, H, 108 957(ab), 986(ab), lOOl(ab) Quadri, SF, 853(ab) Pak, KY, 144 l004(ab) Pippin, CG, 1031(ab) Reitz, R, l032(ab) Piret, L, 73 Quadri, SM, 987(ab) Palenker, i, 97 l(ab) Pentlow, KS, 2020 Reivich, M, 857(ab), 929(ab), Pepping, M, 972(ab) Pirro, iP, 1152, 865(ab), Quaife, RA, 927(ab) 940(ab), 965(ab), 985(ab), Palestro, Ci, 1175, 2027, Queloz, i, 956(ab) Perani, D, 973(ab), 1014(ab) 993(ab) lOl2(ab), lOl3(ab) 969(ab), 999(ab), 103l(ab), Quesenberry,i, 1024(ab) Perdikaris, N, 2059(le) Pisani,T, 870(ab) Remy, Ph., 858(ab) 1039(ab) Quick,C, 954(ab) Pereszlenyiova, E, 982(ab) Pisani,TL, 86l(ab) Renn, 0, 880(ab) Palevsky, HI, 751, 2036, Quinn, Ri, 1029(ab), Perez, iE, 855(ab), 884(ab) Piwnica-Worms, D, 1516, Reno, iM, 2184, 880(ab), 849(ab) 1252(le) Periasamy, M, 974(ab) 864(ab), 1033(ab) l028(ab) Palko, D, 1040(ab) Quinones, N, 967(ab), Penman. SB, 10l4(ab) Plaizier, MABD, l915(le) Renstrom,B, 1864 Palmer, CK, 1042(ab), lOl7(ab) Penn, M, 1766 Platt, DA, 876(ab) Reubi, JC, 652, 903(ab) l043(ab) Quint, L, 828(ab) Perlmutter, iS, 848(ab), Platts, 5, 989(ab) Reuland, P, 309 Paltiel, Hi, 35 1, l048(ab) Quintana, C, 998(ab) 883(ab) Platts, SH, 979(ab) Revkin, J, 939(ab) Pan, X, 962(ab) Quirce, iM, 955(ab) Pandian,N, 905(ab) Perrone-Filardi, P. 881(ab), Pleus, RC, 86l(ab), l026(ab) Reyes, P, 96l(ab) Pang, L, 865(ab) 938(ab) Plott,0, 1648 Rabito, CA, 948(ab) Reynolds, iC, 1848, 833(ab), Pant, KD, 1530 Perry, BD, 829(ab) Plott, WE, 23 Rabushka, IS, 1042(ab) 986(ab) Papadopoulos, SM, 1836 Perry, DL, 1002(ab) Pochon, 5, 1766 Rackover, M, l002(ab) Rhodes, BA, 1028(ab), Papapoulos,SE, 1406 Perry, iR, 451, 2238, Podoloff, D, 992(ab) Radcliffe, R, 988(ab) l029(ab), 103l(ab) Pappas, A, 978(ab) 83 l(ab), 842(ab), 96l(ab) Podoloff, DA, 828(ab), Radensky,P, 19N(l) Rhodes, CG, 1669 Parekh, iS, 97l(ab) Pestika, B, 258 858(ab), 992(ab), 100l(ab) Raisys, V, 866(ab) Riambau, V, 845(ab) Parisi, MT. 115, 9l8(ab) Peters, AM, 65, 173, 491, Poels, LG, 1958 Raja, 5, 996(ab), 997(ab) Ricard, M, l006(ab), Park,CH, 1183,1943, 756, 836(ab), l022(ab) Poewe, W, 10l8(ab) Raju, N, 920(ab) l020(ab) 961(ab) Peters, CA, 2098 Pohi,i, 98l(ab) Ram, 5, 1029(ab) Ricaurte, GA, 964(ab) Park, H, 956(ab) Peterson, CD, 830(ab), Pohost,GM, 9l5(ab) Ramalingam, K, 920(ab) Ricciardelli, B, 505 Park,iH,2118 975(ab), 983(ab) Pollard, KR, 77 1, 864(ab), Ramanathan, P, 9l4(ab) Rice, KC, 98l(ab) Park,iS, 99l(ab) Peterson, i, 9l2(ab) 889(ab), 1005(ab) Ramanna, L, 843(ab),869(ab) Richmond, JC, l027(ab) Park, 5K, 991(ab) Peterson, LM, lOlO(ab) Pomier,G, 1550 Ramos,i, 957(ab) Richmond, JCW, 1008(ab) Parker,A, 930(ab) Petiet, A, 380 Ponto, i, 1027(ab) Rampal, M, 990(ab) Richter, W, 902(ab), 997(ab) Parker,GE, ir, 1390 Petrella, G, 999(ab) Poppe, G, 937(ab) Ramsay, SC, 438 Riddell, C, 843(ab), 888(ab) Parker,iA, 849(ab),947(ab), Petrick, N, 842(ab) Porenta,G,1235,1628, Rangarajan,A, 963(ab) Rieker, 0, 839(ab),844(ab), 1003(ab) Petty, N, 684 836(ab), 856(ab), 857(ab), Rangarajan,V, 914(ab) 9l4(ab) Parkes, SL, l029(ab) Petry, NA, 423, 1836, 2067, 1009(ab) Ransone, C, 2006, 880(ab), Riesinger, U, 854(ab) Parkey, RW, 990(ab), 865(ab) Port, SC, 2124, 846(ab) 931(ab) Rifldn, CK, 896(ab) 1003(ab), lOlO(ab) Pezzullo, L, 892(ab) Portenoy, R, 859(ab) Rao, DV, 277, 2196 Rigo,P, 874(ab),875(ab) Parkinson, D, 848(ab), Pfeiffer, N, 87l(ab), 963(ab) Porter,AT, 1316, 1437 Rasey,iS, 2202, lOlO(ab) Riley,R, 964(ab) 883(ab) Phalen, ii, 975(ab) Porter, B, 863(ab) Rath, P, 859(ab) Rios, L, 998(ab) Parmentier, C. l020(ab) Pham, DH, 1548 Portlock,C, 345 Rathe, R, 1043(ab) Risler,LI, 987(ab) Parodi,O, 1925 Pham, H, 846(ab) Posniakoff, TA, 1411 Ratib, 0, 1628 Ritchie, JL, 939(ab) Parrot, A, 81 Pham, T, 965(ab) Potchen,Ei, 1807 Rathff, BA, 1099 Riva, N, 863(ab) Parsons, iA, 1039(ab) Phaneuf, DC, 1091, 855(ab) Potts, MS. 998(ab) Rattner, Z, 878(ab), 91 l(ab) Riva, P. 863(ab)

Author Index â€¢1992 2261 Rivera-Luna

Rivera-Luna, H, l004(ab) 849(ab) lOl9(ab) l047(ab) Selikson, MH, 954(ab) Rivitz, SM, 470,1905 Rozanski, A, 2074, 928(ab) Sanchez,i, 2014 Schlegel, 5, 887(ab) Selin, CE, l045(ab) Robbins,J, 1848 Rubello, D, 1478 Sanchez, iA, 1994 Schleicher, W, 950(ab) Sen, C, 969(ab) Roberson, PL, 735, 1833 Rubin, RH, 1378, 9l0(ab), Sanchez-Urdazpal, L, 239 Schlom, i, 23, 1648 Senda, M, 1016(ab), Roberts, CM, 676 924(ab) Sander, B, 971(ab) Schlumberger, M, 172 1025(ab) Roberts, R, l024(ab) Rubinstein, M, 1005(ab) Sanderson, iA, 880(ab) Schlyer, D, 995(ab) Senekowitsch, R, 859(ab) Robertson, JS, 777, 1726 Ruck,P.309 Sandler, ED, 115, 9l8(ab) Schmarkey, LS, 865(ab) Senneff, Mi, 836(ab), Robeson, W, 923(ab) Ruhrmann, 5, 972(ab) Sandler, MP, 826(ab) Schmidt, DE, 847(ab) l426(le) Robinson, RG, 1046(ab) Ruiz,M, 864(ab) Sandrock, D, 845(ab), Schmidt, DH, 2124 Senoh,M, 10l7(ab) Roca, M, 845(ab) Rumsey, WL, 94, 1152 950(ab), 957(ab) Schmidt, K, 944(ab) Seo, 5, 857(ab) Rocca, C, 953(ab) Ruotsalainen, U, 691, 1255 Sands,H, 29 Schneider, i, 956(ab) Serafini, A, l016(ab), Rockett, i, 1269 Rusckowski, 921(ab) Sanger, i, 912(ab) Schneider, RF, 1428(le) 1022(ab), l035(ab) Rocque, PA, 1685 Rusckowski, M, 1810, Sanger, JJ, 926(ab), 960(ab) Schnobrich, KE, 904(ab) Serafini, AN, 1304, 92l(ab), Rodney, RA, 1411, 846(ab) 925(ab), 934(ab) Sano, I, 968(ab) Schnur,W, 1 956(ab), 980(ab), l045(ab) Roessner, i, 841(ab) Rush, Ai, 838(ab) San Roman, F, 403 Schnyder,P, 956(ab) Serra, R, 994(ab) Rogers, GA, 1011(ab) Russell, C, 1648 Santini, L, 892(ab) Schober, 0, 840(ab), 915(ab), Serrano, J, 955(ab) Rogers, KD, 923(ab) Russell,CD, 23, 1178, Santos, 0, 1530 920(ab), 1428(le) Setaro, JF, 906(ab) Rogers, WL, 1836, 83l(ab), 924(ab), 948(ab) Santos-Ocampo, C, 95 l(ab) Schochat, D, 23 Setoain, J, 403 842(ab), 878(ab), 933(ab) Ruth, Ti, 922(ab), 964(ab) Sarangarajan,R, 2190 Schofer, 0, 1021(ab) Seymour,i, 1043(ab) Rogulski, MM, 85l(ab), Ryan, iR, 898(ab), 978(ab) Saraste,M, 1255 Schold,SC,532,966(ab) Sfakianakis, G, l022(ab) l002(ab) Ryan,Pi,1589 Sarkar, 5, l035(ab) SchÃ¶rner,W, 97l(ab) Sfakianakis, ON, 1304, Roh, iK, 877(ab) Ryo, UY, 398, l915(le) Sarkar,SD,1551 Schrader,J, 2138 921(ab), 956(ab), 980(ab), Rojas-Burke, i, 13N(6), Rysavy,i, 829(ab),975(ab) Sarkar,SS, 117 Schroder, LE, 937(ab) l016(ab), l035(ab), l045(ab) 17N(6), 24N(5), N 19(9), Rysavy, iA, 861(ab), Sasaki, H, 857(ab) Schroettle W, 1291 Sgouros, 0, 2167, 941(ab) N22(9), N24(9), N34(9), 1026(ab) Sasaki, M, 877(ab), 1015(ab) Schroff, RW, 1099 Shah,A, 977(ab) N9(2), N13(4), N 13(7), Ryser,iE, 1766 Sasald, T, 1016(ab), 10l7(ab), Schubiger, PA, 231 Shalaby, K, 934(ab) N15(1), N15(7), N16(lO), Ryu, M, 333 l025(ab) Schuhmacher, i, 1366 Shani,i, lO3l(ab) Nl8(l), N23(l 1), N25(l), Sasaki, W, 945(ab) Schulmberger, M, l020(ab) Shanker,R, 977(ab) Sabbe, i, 827(ab) N27(3), N28(8), N35(l 1), Sasaki, Y, 827(ab), 857(ab), Schultz,B, 2027 Sacker, D, 85 l(ab) Shao, L, 870(ab), 963(ab), N25(12), N30(l2), 875(ab), 968(ab), l006(ab) Schulzer, M, 964(ab) 985(ab) Sacker, DF, l028(ab) N31(12) Sasner, JJ, 998(ab) Schumpelick, V, 1001(ab) Sadato, N, 886(ab), 897(ab), Shapiro, B, I 125, 1608, 1735, Rokhsar, 5, 856(ab) Sassaman, MB, 98l(ab) Schuster, DP, 1661 966(ab) 834(ab), 895(ab) Sastry, KSR, 2196 Roman, R, 2017, l049(ab) Sadatoh, N, 1637 Schuster, JM, 958(ab) Sharkey, RM, 863(ab), Satake, R, 2024 Romano, i, 832(ab) Saerens, i, lOl3(ab) Schwaiger, M, 684, 1125, 904(ab), 958(ab), l000(ab), Romoio,G, 846(ab) Saffer, iR, 879(ab) Satin,A, 181 1346, 2067, 826(ab), 1002(ab) Roodt, A, 899(ab) Saga, T, 853(ab), 889(ab), Satlin,A, 1432(le) 834(ab), 865(ab), 870(ab), Shattuc, 5, 866(ab) Rooholamini, SA, 1486 957(ab), 986(ab), lOOl(ab) Sato, i, 893(ab), 957(ab) 882(ab), 933(ab), 994(ab), Shaw,R, 161 Roos, iC, l915(le) Sager, LH, lOOl(ab) Sato,K, 10l7(ab) l008(ab) Shaw,SM, l049(ab) Ropchan, JR, 10l7(ab) Saha, GB, 928(ab), 1040(ab), Sato,S, 958(ab) Schwartz, D, 910(ab) Shaya, E, 847(ab), 848(ab) Roque, C, l046(ab) 104l(ab) Sato, T, 84l(ab) Schwartz,DA, 710 Shaya, EK, 964(ab) Ros,P, l043(ab) Sahajwalla, M, 996(ab) Satyamurthy, N, 633 Schwartz, iG, 1496 Shea,C, 830(ab),853(ab) Rosa, E, 1373 Saika, Y, l023(ab) Sauter, MK, 970(ab) Schwartz, RB, 839(ab), Shea,NL, 905(ab) Rose,A, l021(ab) Sai-Maurel, C, 943(ab) Saw, A, 924(ab) 970(ab) Sheehan, FH, 763, 1642 Rose, EA, 1994 Saing, H, 899(ab) Sawamura, H, 988(ab) Schwartz, RS, 845(ab) Shefer, RE, 932(ab) Rose, K, 1766 Saini, 5, 1344 Sayman, HB, 629(le) Schwarz, i, 897(ab), 9l7(ab) Shelton,ME, 836(ab) Rosebrough, SF, 880(ab) Saito,iM, 1042(ab) Schaab, K, 899(ab) Schwarz, SW, 1685 Shen,LH, 986(ab) Rosen,BR, 867(ab) Saito, N, 967(ab) Schad, N, 1269 Schwarzer, A, 868(ab) Shen, 5, 926(ab) Rosen, G, 843(ab), 869(ab) Saito, 5, 95 l(ab) Schafers, M, 9l5(ab) Schweighardt, 5, 14, 959(ab) Shepard, HM, 934(ab) Rosen, I, 868(ab) Sail, H, 848(ab), 891(ab), Schaible, T, 848(ab) Schwimmer,JJ, 926(ab) Sheperd,JH, 904(ab) Rosen, T, 830(ab) 897(ab), 1023(ab), 1024(ab) Schaible, TF, 978(ab) Schwizer,W, 956(ab) Sherman,P, 870(ab) Rosenblate, H, 258 Sakahara, H, 853(ab), Schalekamp, MADH, 99@ab) Schyler, D, 521 Sherman,PS,423, 86l(ab) Rosenfeld, SS, 532 893(ab), 905(ab), lOOl(ab) Schapiro, M, 2103 Sciuk, J, 840(ab), 920(ab), Sherman, T, 856(ab) Rosenkranz, K, 97l(ab) Sakal, 5, 1015(ab) Scharf, 5, 992(ab) 1428(le) Sherwood,DF, 359 Rosenpire, KC, 1125 Sakaki, 5, 135, 909(ab), Scharff, MD, 985(ab) Sclafani, 5, 117 Shi, QX, 993(ab) Rosenquist, G, 836(ab), 9 12(ab), 969(ab) Scheffel, U, 860(ab), 883(ab), Scott, A, 867(ab) Shibasaki, H, 897(ab) 1009(ab), l045(ab) Sakakibara, E, 1741, 965(ab) 885(ab), 964(ab) Scott, AM, 1396, 868(ab), Shibata, N, 208 Rosenqvist, G, 1191, 856(ab) Sakowski, R, 878(ab) Scheinberg, DA, 94l(ab) 904(ab) Shidara, N, 844(ab), 966(ab) Rosenson, AS, 1022(ab) Sakurai,Y, 827(ab) Scheipers,C, 1191 Scott, JA, 407, 470, 820, 1918, Shieh, CB, l022(ab) Rosenspire, KC, 94 Salako, QA, 982(ab), Schelbert, H, 825(ab), 2061, 2249, 2250, l254(le) Shields, AF, 58 1, 1009(ab) Rosenthall,L, 950(ab) 1030(ab) 856(ab), 865(ab), 882(ab), Scott,iR, 841(ab) Shields, AT, 115, 967(ab) Rossi,MA, 952(ab) Saleh, MN, 23 l009(ab) Scott, RM, 844(ab) Shields, 5, 847(ab), 876(ab) Rossini, P, 846(ab) Salford, L, 868(ab) Schelbert, HR. 1235, 1263, Seabold,JE, 1486 Shigesawa, T, 919(ab), Rossleigh, MA, l022(ab) Sallan, SE, 844(ab) 1628, 836(ab), 856(ab), Sedvall,G, 860(ab),1016(ab) 976(ab) RÃ£ssler,B, 839(ab) Salmon,Y, 175 857(ab), 88 1(ab), 945(ab), Seed, WA, 676 Shigeta, A, 958(ab) Rosso, i, 81 Saltzberg, MT. 993(ab) 977(ab) Seeger,LL, 1399,1039(ab) Shih, W-i, 1556, 99l(ab), Roszell, N, 993(ab) Salvatore, M, 68, 505, Schelosky, L, lOl8(ab) Seftel, AD, 46 l046(ab) Roth, CA, 988(ab) 892(ab), 905(ab), 9l5(ab), Schelstaete, KHG, 1167 Segall, GM, 1797, 629(le) Shimizu, M, l023(ab) Rothberg, ML, 836(ab) 9l8(ab), 999(ab) Schembri, GP, 840(ab) Segers, MFG, 1958 5k@mcse@wa,E, 16%, 827(ab) Rothpearl, A, l042(ab) Samaratunga, R, 937(ab) Scher, H, 859(ab) Sehgal, VJ, 895(ab) Shinotoh, H, 9l7(ab) Rothstein, RD, 1707 Samaratunga, RC, 783 Scherrer, M, 81 Seibyl, JP, 1964, 896(ab), Shiomi, 5, 744 Rottenberg, DA, 200 Sambuceti, G, 1925 Schiepers,C, 633, 827(ab), 91 l(ab) Shirato,M, 853(ab),893(ab) Roussel, P, 947(ab) Samiuthkumamn, KS, 855(ab) 933(ab),937(ab) Seller,CA, 1099 Shiue, CY, 86l(ab), 975(ab), Rowe,CC,930(ab) Sampathkumamn, R, 9l2(ab) Schiff, RG, 9l4(ab), 1042(ab) Seki, C, 885(ab), 968(ab) l026(ab) Royal, HD, 330, 835(ab), Samson, Y, 1481, 858(ab), Schifter, T, 838(ab), 966(ab), Seldin,DW, 1411, 1994 Shiue, OG, 86l(ab), l026(ab)

2262 The Journal of NuclearMedicine Tilbury

Shochat, D, 1648 10l3(ab) 1030(ab) Summers, B, l035(ab) Tanada, 5, 135, 893(ab), Shoemaker,RL, 851(ab) Smith, RL, 512 Stepniak-Biniakiewicz, D, Sumrani,N, l035(ab) 909(ab), 912(ab), 969(ab), Shortkroff, 5, 937(ab) Smith, WH, 668, 864(ab) 924(ab),988(ab) Sun, B,957(ab) 972(ab), 1004(ab) Shoup, TM, 946(ab), Snelling, LK. l004(ab) Stem, H, 960(ab) Sun, K, 865(ab) Tanaka, K, l008(ab) 1026(ab) Snider,RM, 860(ab) Stem, R, 898(ab) Sunderland, I, 829(ab), Tange, 5, l004(ab), 1005(ab) Shreve, PD, 860(ab) Snitcowski, R, 995(ab) Stern, @,2061 975(ab) Taniuchi,H, 1026(ab) 5huke, N, 1200,2024, 877(ab), Snook, D, l022(ab) Stem, Y, 940(ab) Sung, KB, 9l9(ab) Tansey, W, 985(ab) 957(ab), l020(ab) Snow,BJ,922(ab),964(ab) Stevick,CD, 1797 Susaki, Y, l009(ab) Tararine,M, 1003(ab) Shulkin,BL, 1125,1735 Snyder, DL, 964(ab) Stewart,CA,844(ab) Susskind,H, 1717,1012(ab) Tarbell, NJ, 844(ab) Siccardi, AG, 834(ab) Soares, i ir, 995(ab) St. Gibson,W, 2080 Sutor, R, 826(ab) Tarburton, iP, 2148 Siegel, A, 269 Sobel, BE, 836(ab), 855(ab) Stocklin, G, 2138, 1013(ab) Suzuki, K, 844(ab), 9l7(ab), Tardieu, M, 976(ab) Siegel, BA, 855(ab) Sobus,KS,873(ab) Stocks, 0, 865(ab) 966(ab) Tarry, CT, 2059(le) Siegel, i, 904(ab) Sokoloff,L, 944(ab) Stoffer, 55, 1393 Suzuki, 5, 932(ab), 998(ab) Tateno,M, 1181 Siegel,iA, 1574 Solanki, K, 924(ab) Stone, CK, 850(ab), 884(ab), Suzuki, T, 932(ab),998(ab), Tateno, Y, 9l7(ab) Siegel, ME, 844(ab), 937(ab) Som, P, l028(ab) 931(ab) l019(ab) Tatsch, K, 1291, 832(ab), Sievanen, H, 1137 Song, iH, 991(ab) Stone-Elander, S, 908(ab), Swartz, BE, 1017(ab) 897(ab), 917(ab) Silagan,GT, 1509, 854(ab), Song, S-K, 925(ab) 101l(ab) Sweeney,DC,996(ab) Tatum, WO,929(ab) 876(ab) Songini, C, 834(ab), 959(ab) Stone-Elander, SA, 1026(ab) Swenson, ER, 581 Tauxe,N, 997(ab) Silberstein, EB, I, 2190, Soobramoney,5, 904(ab) Storb, R, 924(ab) Swyer,AF, 1175 Tawarahara, K, 6 1025(ab) Sood, VK, 986(ab) Storey, AE, 850(ab) Swyer, AJ, 2027, 999(ab) Taylor, A, Jr. 33, 296, 1620, Silberzweig,i, 973(ab) Sorandes, T, 966(ab), 970(ab) Stoub,EW, 1430(le) Sybirska, EH, 848(ab), 2055(le), 900(ab), 921(ab), Silbiger, M, 161 Soroa, YE, 999(ab) Stowers,SA,847(ab),876(ab) 945(ab) 948(ab), 99l(ab) Siles,5,990(ab) Sorrentino, @,68 Strand,S-E, 1654, 1825, Syrota, A, 471, 696, 976, Taylor, LP, 972(ab) Silveira, ST, 826(ab) Sossi, V, 922(ab) 953(ab), 954(ab), 962(ab) 1481, 843(ab), 858(ab), Taylor, 5, 890(ab) Silverman,C, 1780 Sostre, 5, 1216, 869(ab), Strashun,A, 117,215,973(ab), 882(ab), 883(ab), 888(ab), Taylor, SF, 1836, 1007(ab), Silverman, CL, 964(ab) 924(ab), 968(ab), 1004(ab) 102l(ab), 1035(ab) 896(ab), 943(ab), 977(ab), l008(ab) Silverstein, EA, 946(ab) Soto, R, 1035(ab) Stratton,JR, 763, 1324, 1642 l019(ab) Testes,CD, 833(ab),97l(ab) Silzofski,WJ, 2017 Souder, E, 857(ab), 858(ab), Straub,R, 900(ab) Szabo, Z, 869(ab), 885(ab), Tedder,TE, 852(ab) Simanis, iP, 864(ab) 940(ab), 965(ab) Straub, RF, 307, 900(ab), 968(ab),1004(ab) Teixeira, JP, III, 59 Simmons, G, 1046(ab) Soufer, R, 886(ab) 989(ab) Szlaczky, LA, 990(ab) Tenenbaum, F, 1020(ab) Simons,ME, 1548 Southee, AE, 1594 Strauss,Di, 1396 Tabuchi,K, l023(ab) ten Haken, RK, 735 Simpson, N, 938(ab) Southern,iF, 1558 Teoh, 5K, 887(ab) Strauss, HE, 3A(7) Taegtmeyer, H, 1523 Sinclair, I, 924(ab) Spaulding, MB, 14 Ter, S-E, 999(ab) Strauss, HW, 3A, 144, 935, Taguchi, T, 6 Singer, H, 848(ab) Specker, B, 898(ab), 978(ab) 1378, 2246, 3A(5), 3A(6), Taillefer,R,668, 1091, 1801, Terada, K, 966(ab) Singh, A, 435, 1451 Speelman, iD, 9 17(ab), TerÃ¤s,M, 691, 1255 3A(1),3A(2),845(ab), 855(ab), 866(ab), 894(ab), Singh, i, 469(Ie) l016(ab) 910(ab), 915(ab), 924(ab), 1034(ab) Terashi,A, 10l6(ab) Singh, M, 974(ab) Spence, A, 944(ab) 934(ab), 936(ab), 946(ab), Tainturier, C, 991(ab) Tercilla, OF, 2059(le) Singh, PR, 85l(ab), 9l0(ab), 959(ab), 996(ab), 998(ab), Spence,AM, 581 Takahashi, 885(ab) Ter-Pogossian, MM, 1214 9387(ab), 1032(ab), l000(ab), l026(ab), Spencer,RP, 1701,999(ab), Takahashi, A, 994(ab) Terry, iA, 96l(ab) l048(ab) l028(ab), l587(le) 1251(le) Takahashi, M, 930(ab), Terry, iD, 829(ab) Singletary, 5, 828(ab) Sperling, M, 930(ab) Strauss, LG, 1981, lOl9(ab) l029(ab), l033(ab), 988(ab), Testa,D, 1014(ab) Sinusas, A, 874(ab), 927(ab) Sperling, RA, 704 Stray, iE, 943(ab) 017(ab) Teule,Gii, 1915(le), Sinusas, Ai, 855(ab), 993(ab) Spetsieris, P, 923(ab) Strelkov,AB,84l(ab) Takahashi, N, 659, 856(ab), 858(ab), 927(ab) Sisson, iC, 1125, 894(ab), Speyer, J, 9l2(ab) Striano, 0, 973(ab), 10l4{ab) 886(ab), 953(ab), 1015(ab) Tewson,Ti, 983(ab) 102l(ab) Spicer, K, 888(ab) Stritzke, P, 969(ab) Takahashi, T, 897(ab),969(ab) Thakur, ML, 851(ab), 973(ab), Sitbon,R, 973(ab) Spiegelhoff, D, 839(ab) Stritzke,PH, 949(ab) Takamori,M, l020(ab) 979(ab), 986(ab), 987(ab) Sitomer,i, 1008(ab) Spiegler, EJ, 1216 Strom,P, 860(ab) Takano, M, 920(ab) Thaler,H, 859(ab) SjÃ´holm,H, 868(ab) Spies, SM, 946(ab) Strother,SC,871(ab) Takasaki, M, 10l9(ab) Thedrez, Ph, 943(ab) Skagen, K, 251 Spies, WG, 946(ab) Stubgaard,M, 2106 Takashima, Y, 744 ThÃ©roux,P, 875(ab) Skamel, Hi, 906(ab) Spinelli, A, 9l5(ab) Studer,M, 880(ab),942(ab) Takasiro, K, 857(ab) Thie, iA, 923(ab) Skaug, I, 9l2(ab) Spitzer, AR, 1943 Stuttle, AWJ, 756 Takechi, T, 9l9(ab), 976(ab) Thierens, HMA, 1167 Sketch,M, 825(ab) Sridhant, BS@875(ab),938(ab) Styles, iM, 2154 Takeda,R, lOl7(ab) Thies, P. 997(ab) Sledge,CB,937(ab) Srinivasan, A, 880(ab) Su, F-M, 880(ab), 909(ab), Takeda, T, 1023(ab) Thiessen, ii, 2248(le) Sleiman, C, 835(ab) Srivastava, PC, 980(ab) 910(ab), 934(ab), 979(ab) Takehara,Y, 1851 Thoams, SR. 937(ab) Slichter, Si, 924(ab) Srivastava,SC, 305, 307, 989, Subramanian, G, l428(le) Takemoto, K, 854(ab) Thomas,CMG, 1958 Slinkin, MA, 943(ab) 899(ab),900(ab), 942(ab), Subramanian,R, 103l(ab) Takemura, Y, 545 Thomas,FD, 150,961(ab) Slizofski, Wi, 2017, 835(ab), 943(ab), 980(ab), 985(ab), Sucharski, LA, 2067 Takeshita, 0, 1741, 965(ab) Thomas,JR. 890(ab) 1049(ab) l030(ab) Sudati,F, 959(ab) Takeuchi, A, 1741, 965(ab) Thomas, SR, 783, 1132, Slowikowski, i, 928(ab) Sisal,,EY,1042(ab),1043(ab) Suehiro,M, 860(ab) Taki, i, 441, 1200, 918(ab), 1717, 894(ab) Smart, RC, 2059(le) Stabin,M, 33 Suematsu, K, 1017(ab) 1020(ab) Thompson,NW, 1125 Smekal, AV, 9l4(ab) Stabin, MG, 783 Suess,E, 108 Taki, 5, l020(ab) Thompson, RB, 2059(1e) Smekal, Av, 995(ab) Stack,R,825(ab) Suey,C, 9l2(ab) Takikawa, H, 998(ab) Thompson, RC, 847(ab), Smith,AM, 878(ab) Stafford,KA, 2067 Sueyoshi, K, l023(ab) Takikawa, S, 923(ab) 876(ab) Smith, AP, 852(ab) Stanus, E, 868(ab) Sufka, B, 970(ab) Takizawa, K, 998(ab) Thompson,5, 41 Smith,CA, l049(ab) Starren, iB, 1042(ab) Sugawara, T, 972(ab) Tamahashi, N, 1972 Thompson,W, 908(ab) Smith, E, 896(ab) Staudenherz, A, 1028(ab) Sugawara, Y, 909(ab), Tamaki, N, 659, 1263, 1501, Thoolen,Mi, 989(ab) Smith, EO, 1964, 848(ab), Stecker, MM, 929(ab) 912(ab), 969(ab), 1004(ab) 1637, 856(ab), 875(ab), Thorson,A, 975(ab) 91l(ab), 945(ab) Steelhammer, LC, lOOl(ab) Sugli, A, 988(ab), l029(ab), 885(ab), 886(ab), 897(ab), Thorson, LL, l006(ab) Smith, 0, 847(ab) Steinert, H, 887(ab) 1033(ab) 953(ab), 966(ab), 1026(ab) Thouvenot,P, 956(ab) Smith, GT, 172, 885(ab), Steinling, M, 143l(le) Suhara,T, 9l7(ab) Tamburro, F, 992(ab) Thrall, DE, 1542 923(ab), 983(ab) Stella, A, 2040 Sulavic, SB, 999(ab) Tamura, Y, 994{ab) liel-van Buul, MMC, 907(ab) Smith, H, 1132, 894(ab) Stephens, TS, 923(ab) Sultzer, D, 967(ab) Tan, J, 935(ab) Tien, R, 1047(ab) Smith, RH, 1042(ab) Steplewski, Z, 900(ab), Sumida, R, 865(ab) Tan, P, 901(ab) Tikofsky, RS, 939(ab) Smith, Ri, 86l(ab), 862(ab), 942(ab), 985(ab), l002(ab), Sumiya, H, 877(ab), 967(ab) Tanabe, H, 940(ab) Tilbury,R, 985(ab),992(ab)

Author Index â€¢1992 2263 Tilbury

Tilbury,RS, 828(ab) Turpin, 5, 1034(ab) van Heerden, BB, 883(ab) Virzi, F, 921(ab), 925(ab), Wang, MF, 1044(ab) Ting,G, 986(ab) Twiford, TW, l047(ab) Van Heertum, R, 939(ab) 934(ab) Wang, PY, lOl3(ab) Tison,V, 863(ab) Tzen, KY, l022(ab) Van Heertum, RL, 906(ab), Visser, 0, 858(ab) Wang, R, 99l(ab) TISSe1Ii,A, 915(ab) 988(ab) Visser, GM, 870(ab) Wang, 5, 868(ab) Tobin, M, l073(ab) Ucar,N, 859(ab) van het Schip, AD, 646 Visser, Ti, 652, 955(ab) Wang, S-i, 254, 955(ab), Todde,5, 973(ab) Uccelli, L, 850(ab) van Kaick, 0, 1982, 828(ab), Vitols,Pi, 993(ab) 977(ab), 986(ab), 997(ab), Todd-Pokropek, A, 1007(ab) Udelson, iE, 905(ab) 907(ab), 10l9(ab), l045(ab) Vleugels, S, 937(ab) 10l2(ab), 1013(ab) Tomiguchi, S, 988(ab), Uebis, R, 886(ab) van Lingen, A, l915(le) Voderholzer,A, 1291 Wang, TST, 570, 1994, l029(ab), l033(ab) Ueda, 5, 413, 466(le) van Montfrans, GA, 907(ab) Voderholzer, W, 832(ab) 988(ab) Tomita, i, 998(ab) Ueda, T, 744, 97 l(ab) Van Nerom,C, 1032(ab) Vogel,iM, 127 Wang, X, 842(ab) Tomiyoshi,K, 1181 Uehara, T, 272, 365 Van Nerom, CO. 551 Voipio-Pulki, L-M, 1255 Ward, R, 898(ab) Tonami, N, 441, 2024, Uemura, K, 1696, 827(ab), Vanoverschelde, iL, 837(ab), Volkert,EW, l024(ab) Ware, RW, 1857 877(ab), 957(ab), 967(ab), 857(ab), 91 l(ab), 963(ab), 884(ab) Volkert, WA, 623, 1451, Warhoe, KA, 862(ab) l020(ab) 1008(ab) van Rensburg, AA, 888(ab) l916(le), 85l(ab), Waiiski, M, 843(ab), 888(a),), Tondeur,M, 485 Ueno,A, l023(ab) van Rijk, PP, 646 9l0(ab), 979(ab), 947(ab) Toney, MO, 2052 Underwood, D, 866(ab) van Royen, EA, 894(ab), 987(ab), 988(ab), Washburn, LC, 937(ab), Toni, MG, 954(ab) UnlU,M, 319 895(ab), 907(ab), 9l7(ab), l032(ab), l048(ab) 993(ab), 1048(ab) Toorongian, SA, 870(ab), Uno, K, 324 lOl6(ab) Volkow,N, 995(ab) Waskin, HA, 838(ab) 982(ab), 983(ab), 994(ab) Unsworth, C, 982(ab) Van Train, K, 854(ab), Volkow, ND, 521, 1720, Wasserman, L, 1411 Topchik, 5, 1304 Untereker,Wi, 2086, 876(ab) 2020, 830(ab), 847(ab), Watabe, K, 897(ab) Torchilin, VP, 943(ab), 866(ab) Van Train, KF, 1509 887(ab), 888(ab), Watanabe, E, 857(ab) 959(ab) Ur, E, 1121, 9l4(ab) van Ylies,B, 895(ab) 946(ab), l046(ab) Watanabe, K, 971(ab) Torelli, i, 866(ab) Urbain, iL, 832(ab) van Waarde, A, 870(ab) vom Dahl, i, 886(ab) Watanabe, N, I 181 Torizuka, T, 886(ab) Urion, DK, 1758 Yarastet, M, 883(ab), 973(ab) von Smekal, A, 536 Watanabe, R, 1033(ab) Torres, 0, 840(ab), 845(ab), Urita, Y, 920(ab) Vardi, Y, 49 Vorne, M, l253(le) Watanabe, T, 100 l(ab), 895(ab), 994(ab) Utsunomiya, H, 575 Yargas, K, 985(ab) Votaw, iR, 826(ab), 847(ab) 1006(a),), l009(a.b), 827(ab), Toth-Abonyi,M, 1935 Uyan, C, 866(ab) Varma, YM, 996(ab) VraI,AM, 1167 68(ab) Tournier, E, 1003(ab) Uygur, 0, 868(ab), 869(ab) Varney,DM, 748 Vuori,I, 1137 Watanabe, Y, 9l9(ab), Tow,DE,964(ab) Uzum, F, 868(ab) Yavouraki, H, 988(ab) 976(ab), 1020(ab) Wackers, FJTh, 855(ab), Toyama, H, 1741, 965(ab), Veilleux,M, 951(ab) Watanuki, 5, 857(ab) Vaalburg, W, 373, 870(ab) 874(ab), 886(ab), 927(ab), 970(ab), 1016(ab) Veith R, 1324 Waters, D, 951(ab) Vaccarino, RA, 1411, 1994, 938(ab), 939(ab), 993(ab) Tran, H, 968(ab) Vekemans, MC, 832(ab) Watkins, GL, 1008(ab), 846(ab) Wada,A, 208 Tran, HD, 1047(ab) Velasquez-Rocha, 5, 935(ab) l027(ab) Vaajaiwalla-Mody,F, 856(ab), Wada,K, 545, 1026(ab) Tranel,D, 1008(ab) Yellet,AD, 516 857(ab) Wada, M, l029(ab) Watson, DD, 668, 864(ab) Travagli, JP, l020(ab) Yemon, P, 831(ab) Vaghi, M, 924(ab) Wadas, MA, 2214 Watson, E, 777 Yemuru, RP, 919(ab) Travin,MI, 876(ab) Vahjen, GA, 304 Wagner, HN, ir, 1216, Watson, EE, 819 Treffeii@JD, 932(ab),947(ab), Vaidyanathan, 0, 1535, Venkatesan,P, 979(ab) 847(ab), 848(ab), 860(ab), Wauters, E, 1427(le) Yenkatesan, PP, 987(ab) 949(ab) 88l(ab) 869(ab), 885(ab), 929(ab), Waxman, AD, 843(ab), Yera,DR, 1160 Trehan,i, 825(ab) Valette, H, 47 1, 843(ab), 964(ab), 968(ab), l004(ab), 869(ab) Treves, ST, 1758, 2098, 888(ab), 896(ab) Yerani,M, 927(ab) Nl0(8) Webb,D, 925(ab) 838(ab), 844(ab), 930(ab), Valk,PE, 2133 Verani, MS. 1600, 905(ab), Wagner, R, lOl3(ab) Webber, D, l041(ab) 1018(ab) Valkow, ND, 287 9l6(ab), 995(ab) Wagner, RH, lO4l(ab) Weber, DA, 1717, 842(ab), Trimarco, B, 505, 905(ab), Vallabhajosula, S. 969(ab), Verbruggen, A, l032(ab) WahI, RL, 975, 828(ab), 851(ab),1012(a),),l015(ab) 9l5(ab) 995(ab), 103l(ab) Yerbruggen, AM, 551 84l(ab), 869(ab), 893(ab), Weber, W, 859(a),) Trivedi, MH, 838(ab) van Aswegen, A, 888(ab) Yerdera, ES, 1949 894(ab), 926(ab), 959(ab), Webster, WB, 498, 2249(le) Tromholt, N, 2106 Van Cauteren, i, 832(ab) Verdy,M, 894(ab) l020(ab), 102l(ab) Wegelius,U, 1255 Troutner,DE,899(ab),921(ab) van den Mieracker, AH, Yergara,E, 892(ab),9l8(ab), Wahner, HW, l039(ab) Weiden,PL, 1099 Trubetskoy, V, 959(ab) 990(ab) 999(ab) Waite, SD, 1006(ab) Weiland, DM, 1125 Trubetskoy, YS, 943(ab) Vanderheyden, i-L, 1099, Vergnes, R, 947(ab) Wakasugi, 5, 208, 935(ab), Weinberger, DR. 98l(ab) Trulock, EP, 835(ab) 900(ab), 934(ab), 979(ab), Yerheggen, R, 957(ab) 936(ab) Weindling, SN, 930(ab) Tsang, BW, 931(ab) 98l(ab), l025(ab) Yerheij, LF, 1406 Wakisaka, 5, 971(ab) Weiner,RE, 1701 Tse, N, 828(ab) van der Meer, JWM, 388, Verheijin,RHM, 1958 Wakita, K, 413 Weinheimer, Ci, 884(ab) Tselentakis,M, 886(ab) 1330, 903(ab), 920(ab), Verhoeff, NPLG, 9l6(ab), Walker, B, 992(ab) Weinreich, R, 884(ab) Tselfes,i, l003(ab) 936(ab), 950(ab), 103l(ab) 917(ab), l016(ab) Walker,BS,826(ab) Weinstein, H, 1783, 993(ab) Tsuchida, T, 897(ab), 966(ab) van der Pluijm, M, 955(ab) Verma, R@ 827(ab), 1043(ab) Walker, Wi, Jr. 20N(6) Weinstein, i, 957(ab), Tsuda,T, 9l2(ab), l004(ab) van der Yliet, iA, 1330, Vernick,i, 1183 Wallace, R, 974(ab) l022(ab) Tsui, BMW,451, 2238, 950(ab) Vervaet,A, 10l3(ab) Wallace, 5, 985(ab) Weinstein,iN, 893(ab) 83 l(ab), 832(ab), 842(ab), Vandervoot, PM, 1558 Yerzijlbergen, Fi, 1727 Wallich, R, 1982, lOl9(ab) Weise, SB, 908(ab) 892(ab), 96l(ab) van der Vusse, Gi, 102 Vespie, A, 937(ab) Wallis,JW, 1678, 1710,964(ab) Weisman, H, 848(ab) Tsuji, 5, 877(ab), 967(ab) van der Wall, EE, 1727 Yessella,RL, 943(ab) Walovitch, RC, 480, 878(ab), Weisman, HF, 978(ab) Tsutsumi, K, 969(ab) Vander Zwagg, R, 1269 Yetter,RJ, 1613 968(ab) Weiss, A, 843(ab) Tuama, LAO, l018(ab) Vandevivere, i, 972(ab), Yetterlein,D, 934(ab) Walsh, C, 912(ab) Weiss, Mi, 1291 Tukhinsky, M, 1854,947(ab) lOl3(ab), lO2l(ab) Yezina, WC, 516 Walsh, J, 438 Welch, Mi, 558, 724, 1685, Tuli, M, 978(ab) Van de Wide, C, 1167 Yidaihet, M, 1019(ab) Walsh, RA, 993(ab) 837(ab), 925(ab), 932(ab) Tumeh, 55, 1186 Yandewoude, M, l013(ab) Vidailhet, M, 1481 Waltman,AC,948(ab) Welcke, U, 906(ab) Tune, L, 847(ab) van Dieren,EB, l915(le) Yieregge, P, 1013(ab) Wanet, P, 1005(ab) Weilman,H, 9l8(ab) Tung, C-H, 90l(ab), 902(ab) van Dijk, A, 646 Yijayakumar, 5, 853(ab) Wang, AK, l039(ab) Wells, P. 313 Tupler, RH, 1553 van Dongen,A, 907(ab) Yijayakumar, Y, 853(ab) Wang, F, 854(ab) Welt, 5, 9l3(ab) Turbiner,EH, 1553 Van Frank, R, l427(le) Ylllanueva-Meyer, i, 838(ab), Wang,FP, 1509 Wernovsky, 0, 930(ab) Turkheimer, F, 944(ab) VanHaelst,JP, 1167 839(ab), 846(ab), 876(ab) Wang,GJ, 521,2020,887(ab), Wernz, J, 912(ab) Turkington, TO, 901(ab), van Hagen, PM, 652 \rilleb, MA, 942(ab), l03@ab) 888(ab), 946(ab), l028(ab), Wese, F-X, 73 922(ab), l047(ab) Yanhagen, PM, 903(ab) Vining, Di, l044(ab) 1046(ab) Wessel, D, 838(ab) Turner, FE, 716,935(ab) Van Haight,C, 2184 Yinitski, S, 973(ab) Wang, H, 891(ab) Wetzel, H, 887(ab) Turner, M, 1045(ab) Vanhaverbeek, M, 1337 Vinson, EL, 668 Wang, KY, 955(ab) Wetzel, LH, l039(ab)

2264 The Journal of NuclearMedicine Zwinderman

Wheeler, RH, 23, 1648 Winn, HR. 1789 Worthy, M, 865(ab) Yeo, E, 937(ab) 993(ab) White, D, 974(ab) Winnard,P, 909(ab) Wszolek, Z, 964(ab) Yeung, DW, 899(ab), Zasadny, K, l020(ab) White, DL, 974(ab) Wironen, J, 993(ab) Wu, AM, 953(ab) 954(ab) Zasadny, KR, 926(ab) Whiting, JH, ir, 260 Wiseman, iC, 868(ab) Wu, C, l030(ab), 1031(ab) Yokoi, T, 91 I(ab) Zea-Ponce, Y, 1964, 848(ab), Widen, L, 908(ab), 101l(ab) Wisenberg, 5, 355 Wu, KH, 977(ab) Yokota, A, 1025(ab) 896(ab), 91 l(ab), 945(ab) Widman, J, 21 16 Wisniewski, 0, 848(ab), Wyatt, Ri, 1383, 965(ab) Yokoyama, A, 545, 89l(ab), Zeeberg, BR, 883(ab) Wiebe, LI, 841(ab) 945(ab) Wysor, W, 2067 897(ab), l023(ab), l024(ab), Zeeburg, BR, 1225 Wiegand, V, 845(ab) Wittry,MD, 1046(ab) l026(ab) Zeiter, PC, 863(ab) Wieland, DM, 860(ab), Woda, A, 897(ab) Xu, X-L, 871(ab) Yokoyama, K, 957(ab), Zeng, GL, 831(ab), 89l(ab), 870(ab) Wolber, 0, 828(ab) 1020(ab) 892(ab), 90l(ab) Wielopolski, L, 1278 Wolf, A, 995(ab) Y@hmai, I, 827(ab), 1043(ab) Yonekura, R, 996(ab) Zhang,JJ, 1943, 961(ab) Wienhard, K, 861(ab), Wolf,AP, 192,521, 1720, Yamada, i, l024(ab) Yonekura, Y, 545, 659, 1023, Zhang, XX, 989(ab) 1013(ab) 830(ab), 847(ab), 853(ab), Yamada, 5, 1972, 840(ab), 1263, 1637, 856(ab), Zhang, Y, 83l(ab) Wieringa, AR, 373 870(ab), 887(ab), 888(ab), 841(ab), 984(ab) 885(ab), 886(ab), 891(ab), Zhao, XD, 83l(ab) Wiersinga, WM, 894(ab) 946(ab) Yamada,T, 1501 897(ab), 953(ab), 966(ab), Zheng,J, 984(ab) Wiesner, RF, 239 Wolf, F, 903(ab) Yamagami, H, 952(ab) 1024(ab), 1026(ab) Thu, X, 954(ab) Wiesnewski, 0, 9ll(ab) Wolf, JE, 953(ab) Yamaguchi, N, 967(ab) Yoon, B-W,877(ab) Ziegler, SI, 1007(ab) Wijngaarde, R, 894(ab) Wolf, SB, 1099 Yamaguchi, 5, 1637 Yoshida, A, 1501 Zierz, St, 995(ab) Wijns, W, 825(ab), 837(ab), Wolf, W, 830(ab) Yamamoto, H, 333 Yoshikawa, K, 324 Ziessman, HA, 266, 537, 875(ab), 884(ab), 905(ab) Wolfangel, R, 1024(ab) Yamamoto, I, 998(ab) Yoss,RG,2llO 833(ab), 899(ab) Wikander, R, 832(ab) Wolfangel, RG, 308, 989(ab), Yamamoto, Y, l008(ab) Yost, RW, l046(ab) Ziffer, i, 876(ab) Wilbur, DS, 465(le), 943(ab) 1033(ab) Yamanaka, M, 998(ab) You, DL, l022(ab) Ziffer, iA, 927(ab) Wilder, 5, 85 l(ab), 979(ab), Wolfe, E, 882(ab) Yamasaki, T, 917(ab) Young, ET, 1002(ab) Zilbovicius,M, 696, 1481, 987(ab) Wolfe, ER, l008(ab) Yamashita, i, 967(ab) Young, P, 1789 858(ab), l019(ab) Zilleruelo, GE, 956(ab) Wilkinson, 0, 872(ab) Wolk, AP, 2020 Yamashita, 5, 932(ab) Yu, CC, 964(ab) Zimmer, AM, 946(ab) Wilkinson, R, 936(ab), Wolters, EC, 9l7(ab) Yamauchi, H, 1637 Yu, DC, l045(ab) Zimmerman, RE, 839(ab), 996(ab) Wolters, ECMJ, 10l6(ab) Yamazaki, N, 6 Yu, L, 868(ab) 852(a),), 1005(a),), l018(ab), Wilkinson, RA, 845(ab), Wong, A, l045(ab) Yang, D, 985(ab) Yu, 5, 926(ab) l043(ab) I024(ab) Wong, C, 85l(ab) Yang, DJ, 828(ab), 992(ab) Yu, SL, 997(ab) Zingraff, J, 913(ab) Wilkinson, RW, 1028(ab) Wong, CTC, 10l2(ab), Yang, KTA, 282 Yuen-Green, MS. 1444 Zinn, KR, 1685 Willemart, B, 825(ab), l015(ab), 1028(ab) Yang, SH, 1008(ab) Yuille, D, 839(ab) Zito, F, 959(ab) 875(ab), 905(ab) Wong, DF, 847(ab), 848(ab), Yang, 5K, 919(ab) Yuille,DL, 1704 Zito, V. 1859 Williams, CC, 1048(ab) 964(ab), 968(ab) Yang, 5-0, 2118 Yung, B, 847(ab), 964(ab) Zloty, M, 886(ab), 913(ab) Williams, Hi, 847(ab), Wong, GY, 904(ab) Yang, Wi, 924(ab) Yung, BCK, 924(ab) Zoccarato, 0, 846(ab) 876(ab) Wong, 5, 945(ab) Yang, Y, 989(ab) Zoghbi, 55, 1964, 848(ab), Williams, iR, 987(ab) Wong, WH, 828(ab), Yang, Z-Y, 829(ab), 982(ab) Zaidel, M, 947(ab) 896(ab), 91 l(ab), 945(ab) Williams, KA, 359 985(ab), 992(ab), 101l(ab), Yao, T-i, 345 Zaino, EC, 1278 ZÃ´ller,M, 1366 Williams, LE, 953(ab) 1430(le) Yap, iT, 947(ab), 949(ab) Zalutsky, MR. 575, 1535, Zonnenberg, BA, 646 Williams, RG, 977(ab) Woodin, M, 878(ab) Yarmush,ML, 1378 88l(ab), 934(ab), 958(ab) Zubal,G, 1964,906(ab) Wilson, A, 834(ab) Woodle, DR. 880(ab) Yasuda,T, 1558, 1905 Zambuto, 0, 989(ab) Zubal, IG, 1712, 963(ab), Wilson, AA, 847(ab), Woods, RP, 922(ab), Yasugi, T, 95 l(ab) Zamora, P0, l029(ab), l006(ab) 848(ab), 883(ab), 929(ab) lOlO(ab) Ye, i, 842(ab) 103l(ab) Zubieta, JA, 882(ab) Wilson, CR, 21 10, 869(ab) Woods, 5, 896(ab) Yeh, 5, 867(ab) Zang, Y, lOlO(ab) Zuccala, A, 2040 Wilson, 1K, 830(ab) Woods, SW, 1964 Yeh, SDi, 345, 2020, Zanzi, I, 898(ab), 923(ab) Zuckier, IS, 1723, 985(ab) Wilson, LA, 953(ab) Woolfenden, iM, 85 l(ab), 843(ab), 859(ab) Zanzonico, P, 2180, 845(ab) ZuÃ±iga,EH, l047(ab) Wilson, ME, 306 879(ab), 1002(ab) Yeh, SH, 955(ab), 977(ab), Zaret, B, 927(ab) Zwas, ST. 859(ab) Wilson, RA, 716 Wooter, W, 33 997(a),), 1012(a),), lOl3(ab), Zaret, BL, 855(ab), 874(ab), Zwinderman,AH, 1406, Wilson, SD, 869(ab) Worth,i, 1312,887(ab) 1034(ab) 886(ab), 938(ab), 939(ab), 1727

Author Index â€¢1992 2265 A jeopardy, combination of flow reserve with -dependent men, C-ll flumazenil binding, Abdomen metabolic assessment, 837(ab) benzodiazepine receptors, 1016(ab) diffuse uptake ofTc-99m MDP, continuous extent and location of CAD, patients without diffuse liver disease, emission tomography, 1337 ambulatory dialysis, bone scintigraphy, prior myocardial infarction, 2067 intoxication, cocaine distribution and kinetics, 2052 -induced coronary hyperemia, early thallium human brain and heart, 946(ab) fast diagnosis ofinfections, Tc-99m HMPAO imaging after PTCA, 2086 young alcoholics, brain deficits, PET and MRI, lymphocytes, l253(le) infusion, myocardial ischemia, hemodynamic 1070(ab) Abscess scintigraphic study, 952(ab) Aldosteromsm, primary, adrenal SPECT, without focal infection, radiolabeled proteins, myocardial perfusion imaging, serum caffeine dexamethasone suppression, 834(ab) biodistribution and kinetics, 388 levels, 24-hour abstention, 866(ab) Algorithms intracranial, differential diagnosis, Tc-99m regional cardiac, noninvasive assessment, PET, accelerated reconstruction, ordered subsets, antigranulocyte antibody, 957(ab) 2138 960(ab) odontogenic, spread of infectious complications, stress N-l3 ammonia myocardial perfusion cone beam reconstruction, displaced center-of Tc-99m HMPAO white blood cells, 254 PET, coronary arterydisease, 825(ab) rotation, 891(ab) Absorptiometry teboroxime myocardial perfusion imaging, estimation ofslope in PATLAK analysis, dual energy X-ray accuracy, optimal imaging time, 854(ab) dynamic PET data, 944(ab) bone mineral and body composition, fan thallium scintigraphy, high cardiac risk, patients fan beam convolution reconstruction, variable beam design, l063(ab) referred for vascular surgery, 952(ab) focal length collimators, 89l(ab) bone mineral density, skeletal sites, 1137 11-201 compared to Tc-99m teboroxime, F@FTinterpolation, 1007(ab) dual photon absorptiometry coronary stenosis, 864{ab) generalized Gibbs prior, maximum a posteriori single-photon, utility of, 170 11-201 scintigraphy, lung thallium uptake, 1600 EMSPECTreconstruction,832(ab) Acetate, cellulose-, hemodialyzer, comparative S-Adenosyl-L-homocysteine hydrolase, potential image reconstruction, brain phantom design, thrombogenicity, 956(ab) inhibitor, synthesis and metabolism, 1-125 computer simulation studies, 10l2(ab) Acetazolamide iodocycloadenosin-4'-ene, 980(ab) improved signal-to-noise, 3D ML-EM cerebrovascular response, Tc-99m DTPA-HSA, Adhesion molecules, intercellular, lung neutrophil reconstruction, 961(ab) new method for monitoring, 969(ab) sequestration, endotoxemia, l023(ab) issues in quantitation, reoriented cardiac PET effect on vascular response, diaschisis, Tc-99m Adrenalgland images,1235 HMPAO SPECT, 967(ab) adrenocorticalscintigraphy,unilateral iterative linear, filtered back-projection, image Tc-99m HMPAO SPECT, PET and, incidentally discovered adrenal or reconstruction, 871(ab) cerebrovascular disease, 877(ab) juxtaadrenal masses, 996(ab) iterativereconstruction,5PECTgreymatter Acetylcholine, release and endogenous dopamine, C-il cocaine, distribution and kinetics, 521 imaging, 1225 GABAergic modulation, PET, 847(ab) C-l 1 HED PET, localization, knowledge-basedboundarydetector,clinical Achalasis, esophageal scintigraphy, 590 pheochromocytoma, 1125 verification, 938(ab) Acquired immunodeficlancy syndrome (AIDS) SPECT, without dexamethasone suppression, least squares, region-of-interest evaluation, cerebral perfusion imaging, 827(ab) primaryaldosteronism,834(ab) emission tomography, 831(ab) dementia complex, cocaine abuse, brain Adrenoceptors linearization, cerebral blood flow, Tc-99m perfusion SPECT, 887(ab), 1312 a!pha-2,ligands,C-l 1MK-912and C-i 1WY HMPAO SPEd, 912(ab) differentiation of infectious from malignant 26703, 86l(ab) lung scan interpretation, 1417, 1422 CNS lesions, FDG-PET, 838(ab) beta, use ofCGP-12177 and CGP-26505, mathematical modeling and dosimetry, gastric uptake ofGa-67, 643 870(ab) plasmapheresis, radioimmunotherapy of infectious diseases and, Annual Meeting Adriamycin micrometastases, 941(ab) highlights,24N(8) acute cardiotoxicity, Tc-99m sestamibi, chick multi-energy maximum-likelihood noninvasive monitoring ofdrug targeting, 3'- heart cells, 864(ab) reconstruction, SPECF and PET, 831(ab) fluoro-3'-deoxythymidine, 830(ab) cardiomyopathy reconstruction Pnewnocystispneumonia,pulmonary abnormal cardiac adrenergic neuron activity, fast interactive method, functional regions, disposition, Ga-67, 512 1-125 MIBG, 208 83l(ab) Acromegaly disturbed neuronal energy metabolism, singular value decomposition, attenuation in active, rest and exercise radionuclide 935(ab) SPECT, 83l(ab) ventriculography, 834(ab) myocardial damage, In-lll antimyosin restoration and correction, improved bone mineral density, axial skeleton, 1608 antibody, 936(ab) quantitation ofsmall objects, PET, 872(ab) Actomyosin, contraction/relaxation, T2 relaxation prediction ofcongestive heart failure, 1-125 subtraction, parathyroid scintigraphy, 996(ab) behavior, 974(ab) MIBG,935(ab) three-dimensional functional brain images, Acupuncture congestive cardiomyopathy, 1-125 MIBG, 215 automated method, rotational correction, anatomic divisions, 407 risk ofcongestive heart failure, In-ill 1579 message transmission, nuclear medicine, 409 antimyosin studies, 895(ab) Alkylamine, conjugation chemistry for labeling ADAC Laboratories, lawsuit filed by Trionix, Aging antibodies, 986(ab) gammacameratechnology,l8N(2) central dopamine D2 receptors, specific and Alliedhealth, Title VIIappropriations,26N(3) Adenocarcinoma, CEA concentration non-specific binding, C-l 1 YM-09151-2, Allograft, cardiac, rejection detection, 1-123 anti measurement, quantitative 897(ab) ICAM-l imaging, l000(ab) autoradiography, 892(ab) decline ofL-6-[F-l8jfluorodopa rate constant Alzheimer's disease Adenoma K,, 964(ab) absolute whole brain glucose metabolism, parathyroid declining myocardial flow reserve, higher sensitive marker, 940(ab) hyperparathyroidism, Tc-99m sestamibi, 1801 cardiac work at rest, 836(ab) atypical dementia and comparison, FDG PET Tc-99m sestamibi double-phase study, dopamine receptors, SPECT and IBZM, 897(ab) and MRI data, 965(ab) primaryhyperparathyroidism,894(ab) older adults, blunted response of myocardial cerebral perfusion abnormalities, SPECT, parathyroid imaging, 1807 perfusion, dipyridamole, 1425(le) 973(ab) Adenosine Air pollution, exposed persons, burning oil wells in cognitive and pharmacological challenges, brain choice ofstress for diagnostic perfusion, wall Kuwait, lung imaging studies, 978(ab) disease detection, 1019(ab) motion imaging,MIBI-SPECTand stress Alcohol cortical perfusion deficit, demographic and echocardiography, 825(ab) acute and chronic, antral processing, solid meal, cognitive variables, 940(ab) detection oftotal ischemic myocardium at 832(ab) delayed SPECT and regional cerebralblood

2266 The Journal of Nuclear Medicine Atomic Energy of Canada, Ltd.

flow, 1-123 IMP, 10l5(ab) indeterminate lung scans, 849(ab) 97l(ab) diagnostic accuracy ofSPECT, 10l9(ab) Tc-99m HMPAO, quantitative approach, brain, Tc-99m HMPAO injection, recurrentglioma, differential diagnosis ofdementia, cerebral 877(ab) 966(ab) blood flow, 5PECT and MRI, l014(ab) Angiography, radionuclide carotid, external-to-internal, SPECF/MRI/ evaluation of neural-network classifier, PET first-pass, count-based ratio method, left angiography, moyamoya disease, 1692 scans, 1459 ventricular volume, 2124 carotid, internal, occlusion, Tc-99m HMPAO functional brain SPECT, powerful clinical left ventricular diastolic function, systemic evaluation ofcerebral perfusion, 969(ab) method,1888 sclerosis, 68 cerebral, unilateral occlusive disorders, crossed hippocampal blood flow, SPECT, 940(ab) SPECT myocardial perfusion and, Tc-99m cerebellar hypoperfusion, 1637 hypometabolic parietal cortex, unaltered MIBI, dipyridamole, 846(ab) changing the level ofpartial pressure, photic benzodiazepine receptors, 887(ab) Tc-99m in thrombosis detection, left atrial stimulation, carbon dioxide, 827(ab) monoclonal antibody specific for @/A4amyloid, appendage, 365 coronary angiopathy, brain, 2184 Angioplasty, cerebral, delayed ischemia due to acute onset, cardiogenic shock, 1558 patterns ofdementia, 143l(le) vasospasm, brain SPECT, 1789 bypass graft, C-VEST, 1914(le) scintigraphic appearance, Tc-99m HMPAO Angioplasty, percutaneous transluminal coronary bypass grafting, continuous ventricular SPECT, 181, 312 early thallium imaging, 866(ab) function monitor with miniature cadmium American College of Cardiology (ACC), utility ofTc-99m SPECT, spontaneous chest telluride detector, 441 standardization, cardiac tomographic pain, prediction ofclinical improvement, cardiacperfusionabnormalities,Kawasaki imaging, 1434 875(ab) syndrome, 929(ab) American College of Nuclear Medicine (ACNM), Angiotensin converting enzyme, renal functional fibrin deposition following injury, 1-125 petition would ease strictures, outpatient response, captopril, diuretic therapy, 739 fibrinogen,845(ab) nuclear medicine therapy, 13N(7) Angiotensin II, receptor ligand, distribution, myocardial viability, status ofcollateral flow, American College of Nuclear Physicians (ACNP) imaging potential, 900(ab) 856(ab) budget testimony, 13N(6) Animal research occlusion, myocardial perfusion and government relations update, 30N(9) campaign against animal activists, engaging ventricular function, 825(ab) licensing decision, California radioactive waste physicians, 24N(5) coronary LAD site, 40N(9) design feature and performance, PET system, imaging regional hypoxia, Tc-99m 2- SNM and, Medicare fee schedule, 18N(l) 595 nitroimidazole, 865(ab) American Heart Association (AHA), thwarting attacks, 19N(2) misonidazole retention after occlusion, standardization, cardiac tomographic Animals, small myocardial metabolism and blood flow, imaging, 1434 scintillating fiber detector module, Cu-64 993(ab) American Medical Association (AMA), revisions radiopharmaceuticals, PET, lOlO(ab) experimental wall injury, uptake, In-ill to RYU update, 36N(9) SPECT imaging, 852(ab) polyclonal IgG and 1-125 LDL, 845(ab) â€˜y-Amlnobutyricacid, modulation of endogenous Anti-antibody, prospects and problems, iliac, stenosis, renal transplant hypertension, dopamine, acetylcholine release, PET, radioimmunotherapy, 958(ab) 1178 847(ab) Antibodies, radioimmunodetection and cancer patency, serial tomographic imaging, Tc-99m l-Aminocyclobutane(C-lljcarboxylic acid, identification, 803 sestamibi, 2080 dynamic PET, 2-compartment model, Anticoagulants renal brain tumors, 922(ab) platelet/fibrin deposition, coronary stents, segmental branch stenosis, captopril Amino-dextran, poly-lysine and, In-l 11 labeled minipig model, 845(ab) renography, 266 MAB, 988(ab) UltraTag RBC kit, 989(ab) stenosis, captopril renal scintigraphy, 2045 Amygdala, quantitation in PET, two-dimensional Antimyosin stenosis, captopril-stimalated PRA, 907(ab) restoration filter, 921(ab) cardiac transplantation rejection, primates, 1994 stenosis, cortical residual activity on captopril Amyloid imaging to detect tumor invasion, muscle layer, renography,906(ab) angiopathy, monoclonal antibody specific for @/ 841(ab) stenosis, en-bloc pediatric renal transplant, A4 amyioid, Alzheimer's disease, 2184 negatively charged-polymer-modified, infarct 263 P-component, radiolabeiing, kinetic and imaging, different cross-linkers, 959(ab) stenosis, renal kinetics in transplants, 923(ab) scintigraphic studies, 9l3(ab) Antisense oligonucleotide, In-I 11, direct method stenosis, Tc-99m MAG, scintigraphy with Anatomy ofcell-labeling, whole blood, 980(ab) captopril, 990(ab) cross-sectional, Macintosh tutorial, 1063(ab) Anti-thyroglobulin antibodies, circulating, clinical Artifacts radiologic, 1067(ab) meaning, differentiated thyroid neoplasms, nuclear medicine, 1068(ab) Aneurysm 1478 PET image reconstruction, 1069(ab) bleeding mycotic iliac, Tc-99m renal scan, 1548 Aorta Ascites, bile extravasation, hepatic inflammatory abdominal aortic, In-l 11 abdominal, arterial input function transplantation, scintigraphy, I 15 imaging, 1553 determination, hepatic and renal PET Asphyxia, perinatal, cerebral palsy, Tc-99m mycotic, diagnosis, leukocyte scintigraphy, 1486 studies, 613 HMPAO SPECT, 977(ab) Anglna injured tissue, radioiodinated endothein-1, Assays, robotic solid phase extraction, C-Il -likechestpain,abnormalesophagealmotility, cholesterol-fed rabbits, 845(ab) raclopride, plasma, 853(ab) gastroesophageal reflux, 955(ab) Aphasia Astrocytoma, low grade and anaplastic, FDG PET unstable, In-l I 1 antimyosin uptake, acute and acute, Tc-99m HMPAO brain perfusion brain imaging, 966(ab) remote myocardial infarction, 587 SPECT, 970(ab) Atelectasis, infrequent chest X-ray finding, Anglography childhood, regional cerebral perfusion, Landau pulmonary embolism, 849(ab) comparativestudyofTl-20l, CTIMRI, bone Kleffner syndrome, 1758 Atherosclerosis and soft tissue sarcoma, 843(ab) progressive imaging lesions with monoclonal antibody first-pass radionuclide pathophysiological evaluation, PET, 1016(ab) Z2D3, antibody-avidin-biotin interactions, exercise-induced myocardial ischemia, upright PET and MRI, 857(ab) 934(ab) bicycle ergometry, 359 Arteriography, contrast, peripheral vascular imaging with 1-123 SP4, 845(ab) ordinary gamma camera, computer program, disease, 1797 localization oflesions, class-switched 1064(ab) Arteriovenous malformations, hepatic, monoclonal antibody Z2D3, 936(ab) moyamoya disease, before and after external-to embolization, hereditary hemorrhagic Athletes, myocyte damage, pathologic cardiac internal carotid artery bypass, 1692 telangiectasia, 260 hypertrophy, In-lu antimyosin antibody, planar myocardial perfusion imaging, Tc-99m Artery 994(ab) tebo, 1783 carotid Atomic Energy ofCanada, Ltd. (AECL), pulmonary, intermediate probability/ stenosis, cerebrovascular reserve capacity, threatened reactor worker strike, 19N(9)

Subject Index â€¢1992 2267 Atrophy

Atrophy, multi-system, 1-123 IBZM SPECT, 878(ab) fluorodeoxyglucose, 1819 lOl8(ab) uptake,quantitationwith SPECT,monkey transport ofglucose and fluorodeoxyglucose, Attenuation correction brain phantom, 963(ab) regional variations, 908(ab) accuracy of, PET, transmission processing, B-cells, anti-pan B-cell antibodies, 1-131 Blood flow 862(ab) radioimmunotherapy, B-cell lymphoma, bone, influx rate, F-l8 PET, 937(ab) breast tissue, myocardial imaging, 96l(ab) 863(ab) brain cardiac PET, three-dimensional registration, Behavior, obsessive-compulsive disorder, cerebral high-resolution 1-125 imaging, plastic 881(ab) blood flow, defects demonstrated by three scintillation detectors, l003(ab) comparison ofieft anterior oblique, geometric dimensional SPECT, 838(ab) interventional neuroradiology, SPECT, mean method, gastric emptying, 833(ab) Benperidol analogs, D-2 receptor-specific PET 826(ab) Cramer-Rao bound analysis of effects, feature tracers, 848(ab) cerebral size and activity estimation, SPECT, Benzamides, substituted, superior PET ligand, brain maturation, children and adolescents, 962(ab) cerebral dopamine D2 receptors, 847(ab) 696 effect on brain SPECT, 961(ab) Benzodiazepine brain perfusion Tc-99m ECD SPECT, PET factors, Bremsstrahlung imaging, gamma central type receptors in baboons, triazolam, comparison, 966(ab) camera, 161 PET, 973(ab) brain tumors and strokes, HMPAO-5PECF non-uniform, emission and transmission noise medication, benzodiazepine receptor and MRI technique, 97l(ab) propagation, cardiac SPECT, 902(ab) occupancy, SPECF, 887(ab) brain tumors and strokes, Tc-99m HMPAO oftheoretical derivations, empirical evidence, Berson-Yalow Award, FDG uptake in tumors, SPECT, 97l(ab) 1578 l5N(7) dementia, differential diagosis, l014(ab) scanning line source, simultaneous emission! Bicycle ergometry, first-pass radionucide dementia, Parkinson's disease, 1012(ab) transmission SPECT, 901(ab) angiography, exercise-induced myocardial Down's syndrome, Tc-99m HMPAO brain scatter and depth-dependent resolution, 180' ischemia, 359 SPECT, 1013(ab) myocardial SPECT, 842(ab) Bile glucose metabolism, patient surviving after scatter correction and, SPECT quantification, extravasation in presence ofascites, hepatic CO intoxication, 1696 cardiac imaging, 2232 transplantation, scintigraphy, 115 hyperventilation, temporal lobe epilepsy, simultaneous transmission and emission, three lakes in liver transplant infarcts, hepatobiliary 968(ab) detector SPECT, 90l(ab) scintigraphy, 997(ab) 1-123 IMP SPECr, no arterial sampling, SPECT Bile duct, clearance measured by radionudide 969(ab) dual-energy X-ray CT, 901(ab) injection, endoscopic nasobiliary drainage impairment in myotonic dystrophy, 839(ab) iterative methods, 962(ab) tube, gallbladder stone, 997(ab) improvement with treatment, chronic cocaine use ofmap, simple method, 843(ab) Biliary atresia, diagnostic Criteria, neonatal polydrug users, 887(ab) Tc-99m HMPAO SPECT brain imaging, 1875 jaundice, Tc-99m EHIDA hepatobiliary infantile spasms, l018(ab) 11-201 SPECT, differential attenuation, scintigraphy, 899(ab) linearization algorithm, Tc-99m HMPAO thallium photons, 1574 Biopsy, -confirmed residual Hodgkin's disease, SPED', 912(ab) volume imaging PET scanner, 862(ab) mediastinum, Oa-67 SPECT, 345 mapping of, 1843 whole body PET, 862(ab) Biotin mean transit time, index oforgan perfusion, Autopsy,-diagnoseddementia,SPECTperfusion -avidin, localization ofinfection, 1816 l004(ab) imaging, 939(ab) -chelate conjugates, pharmacokinetics, N-isopropyi[I-123J1MPSPECT, 1741 Autoradlography pretargetedavidin-biotin N-isopropyl-(I-123) p-iodoamphetamine, dual-isotope immunoscintigraphy, 880(ab) SPEC!',965(ab) computed radiography, 1005(ab) conjugates, anti-pan-carcinoma NR-LU-lO obsessive-compulsive disorder, defects Tc-99m sestamibi and 11-201, uptake in monoclonal antibody, demonstrated by three-dimensional rabbits, 993(ab) radioimmunotherapy, 880(ab) SPED.',838(ab) electron microscopic, intracellular distribution conjugation of human immunoglobulin, partition coefficient, 1-123 IMP SPECT and ofl-125 MIBG, neuroblastoma xenografts, dendrimers as linker molecules, 0-15 water PET, 91 l(ab) 102l(ab) inflammation detection, 986(ab) partition coefficient, 1-123 IMP SPECT, heterogeneous activity distribution, In-lll -deferoxamine derivatives, plasma stability, 91 l(ab) radiopharmaceuticals, rat tissues, 1825 pharmacokinetics, 880(ab) photic stimulation study, arterial partial quantitative derivatives, evaluation, Tc-99m, 920(ab) pressure ofcarbon dioxide, 827(ab) CEA concentration measurement, imaging atherosclerotic lesions, monoclonal predetermined ROIS,Xe-l33 SPECF in adenocarcinoma, 892(ab) antibodyZ2D3,934(ab) children, 977(ab) radiopharmaceutical uptake, dose radiolabeled, imaging infection/inflammation, regional variation in Statisticalmaps, 1008(ab) heterogeneity, 1833 streptavidin, 924(ab) rotating gamma camera, 1-123 IMP, 963(ab) Avidin streptavidin simultaneous SPECT acquisitions, glucose -biotin, localization ofinfection, 1816 localization ofinfection, 1810 metabolism, 965(ab) -biotin immunoscintigraphy, pharmacokinetics, and tumor localization, substitute for Tc-99m HMPAO and 1-123 IMP, SPECT and biotin-chelate conjugates, 880(ab) antibody, 934(ab) MRI, lOl2(ab) imaging atherosclerotic lesions, monoclonal Bis(dlthlocarbsmato)nltrido Tc(V), subcellular Tc-99m HMPAO brain SPECT, choreo antibody Z2D3, 934(ab) distribution, myocardium cells, male rats, athetoid syndrome, 838(ab) kidney uptake, isoelectric point, 986(ab) 850(ab) Tc-99m HMPAO brain SPECT, variability, Blood 826(ab) B clot imaging, preparation and evaluation, 1-123 Tc-99m HMPAO SPECT, chronic subdural 4-BACE, 4-ICE and, chelating agents, 985(ab) hirulog, 98l(ab) hematoma, 246 Back continuous withdrawal and counting systems, Tc-99m HMPAO SPECF, Wisconsin card low pain factors affecting dispersion correction, sorting test, 967(ab) 180 SPECT ofthe spine, 950(ab) l010(ab) coronary, uptake oftetrofosmin, rabbit heart, SPECF vs. planar bone scintigraphy, 868(ab) myocardial extraction ofteboroxime, 94 846(a),) zygopophysealjoint injection, SPECT and reinfusion,infection-controlproblems,nuclear flow reserve measurements and, viable and non planar bone scintigraphy, 868(ab) medicine departments, 13N(4) viable myocardium, 856(ab) Barre-Llou syndrome, Tc-99m HMPAO SPECT, whole, direct method ofcell-labeling, In-l 11 global cerebral, Tc-99m ECD and planar cervical manipulation, 972(ab) antisense oligonucleotide, 980(ab) imaging, Rhesus monkeys, 979(ab) Ba@ gangila Blood-brain harrier hepatic arterial-to-portal venous, ratio, quantification, reiterative reconstruction, regional transport, glucose and radionucide techniques in an animal

2268 The Journal of NuclearMedicine Brain

model, 239 1063(ab) infections, 840(ab) hippocampal, diagnosis ofAlzheimer's disease, mineral assessment, forearm, 125i(le) Book reviews SPECT, 940(ab) mineral content and density, healthy twelve Biochemistry oflonizing Radiation, 1725 MIBG heart and lung extraction fraction, first year-old white females, 1143 Computed Tomography and Magnetic passanalysis, 716 mineral density Resonance ofthe Thorax, 470 myocardial axial skeleton, acromegaly, 1608 FutureofHu,nan RadiationResearch,The, 821 co-injection technique, 1152 dual-energy X-ray absorptiometry, skeletal Guidelinesforthe Evaluationof Radiologic deoxygiucose uptake, myocyte viability in sites,1137 Technologies. BIR Working Party Report, ischemia, 1353 influence ofparathyroidectomy, 869(ab) 819 expected variability, anesthetized canine, predictor for osteoporosis, risk factor Handbook ofNuclear Medicine: Volume 2: 884(ab) assessment, 869(ab) Heart, 1918 glucose uptake in ischemic myocardium, F-18 mineraldensityand spine fracture,cyclicoral JCRP Publication 60, 1990 Recommendations deoxyglucose, 1346 phosphate, etidronate, 1 ofthe InternationalCommissionon methods for quantification, N-l3 ammonia pain, prostate carcinoma, Re-186 HEDP, RadiologicaiProtection, 821 PET, 881(ab) 859(ab) Imaging ofthe Thyroid andParathyroid Glands, misonidazole retention, occlusion of LAD pain from metastases, different therapeutic 820 coronaryartery,993(ab) doses, Sr-89, 937(ab) InterventionalComputed Tomography, 179 perfusion, Tc-99m tetrofosmin, 993(ab) planar scintigraphy and SPECT, zygapophyseal MedicaiRadiasion Protection Practice Within polar map displays, cardiac PET, 1628 joint injection, chronic low back pain, the EEC, 820 quantification, l72(le) 868(ab) Muscu/oskeletalimaging:MRJ. CT, Nuclear Tc-99m Q12 activity, canine heart, 993(ab) radionuclide scan Medicine and Ultrasound in Clinical penile, tumescence, dual-radioisotopic MRI imaging, detection ofspinal metastases, Practice, 1254 technique, 41 992(ab) NCRPREPORTNo. 110, SomeAspects of portal venous, pulsed Doppler and per-jejunum osteoid osteoma, 269 Strontium Radiobiology, 819 scintigraphy, liver cirrhosis, 997(ab) scan Nuclear Hepazology, 1254 pulmonary, protein flux measurements, PET, chest X-rays and 1-131 scans, well NuclearMedicine: A Teaching File, 1918 1661 differentiated thyroid cancer, 894(ab) Nuclear Medicine in Gastroenterology, 470 regional cerebral, 14N(8) skeletal nonvisualization, intravenous Radiation and Thyroid, 179 renal, convection-diffusion model, 949(ab) etidronate therapy, 748 Safe Use ofDiagnostic Ultrasound, The, 820 stroke, clinical prognosis, SPECT, 878(ab) scintigraphy SelectedAtlasesof GastrointestinalScintigraphy, tumor, breast cancer, before and after intravenous pamidronate, Paget's disease, 1254 treatment, i020(ab) 1589 Texthook ofRadiopharmacy: Theory and unilateral major cerebral artery occlusive SPECT, low back pain, 868(ab) Practice, 819 disorders, crossed cerebellar hypoperfusion, Tc-99m MDP abdominal uptake, continuous Brain 1637 ambulatory dialysis, 2052 accuracy ofperfusion SPECT, differential variations, N-l3 ammonia, lack of correlation scintigraphy and 1-131 MIBG, detection of diagnosis, dementia, l017(ab) with other methods, 837(ab) neuroblastoma, 1735 adult mouse, activity-related plasticity, Blood pool imaging, spiliover, method for scintigraphy in preschool children, lower benzodiazepine receptors, 883(ab) correction, dynamic cardiac FDG PET, extremity pain of unknown origin, 351 alcohol intoxication, cocaine distribution and 882(ab) -seekingagents,comparision,mechanistic kinetics, 946(ab) Blue Cross/Blue Shield, approval of neurological implications, 899(ab) altered tritiated nicotine accumulation, indications for PET, 40N(1l) skeletal kinetics, F-18 fluoride ion PET, 633 senescence accelerated mouse, 1023(ab) Bone soft tissue sarcoma and, 11-201 scan patterns, arrival delay ofO-l5 tracers, intravascular benign and malignant lesions, Tc-99m MIBI 843(ab) radioactivity, 909(ab) uptake, Tc-99m MDP, 319 l80 SPECT ofthe spine, patients with LBP, auditory cognitive task, event-related potentials, blood flow and influx rate, F-18 PET, 937(ab) 950(ab) 0-15 water PET, lOl6(ab) diagnosisof femoralhead avascularnecrosis, stress fractures, osteosarcoma, lower limb, 1699 benzodiazepine receptors, C-ll flumazenil PET, triple-head high-resolution SPECT, 936(ab) subchrondral infractions, acute ligamentous 101l(ab) dual bone and WBC scan imaging, osteomyeitis knee injuries, scintigraphy and MRI, 516 biodistribution and monkey PET imaging, C-li and cellulitis, planar and SPECT imaging, suspected infections, Tc-99m anti-granulocyte tetrabenazine, monoaminergic neurons, 839(ab) antibodies, 526 870(ab) extraosseous Tc-MDP uptake, pathophysiologic -to-marrow interface blood flow, interventional neuroradiology, approach, 1063(ab) calulation ofradiation dose, 1915(le) SPECr, 826(ab) formation, radiotherapy and, 1780 radiation dose calculation, Monte Carlo blood flow and high-resolution 1-125 imaging, fracture,accumulation ofF-18 FDG, Tc-99m modeling, 623 plasticscintillationdetectors,position MDP, 869(ab) Bone marrow sensitive photomultipliers, 1003(ab) joint inflammation body and blood clearance, 1-131 Lym-l, B-cell C-il cocaine, distribution and kinetics, 521 Tc-99m HIG, 839(ab) malignancies,941(ab) cerebral blood flow, glucose metabolism, patient Tc-99mHIG, rheumatoidarthritis,840(ab) hypermetabolic, 11-201-chloride uptake, surviving after CO intoxication, 1696 lesions, 11-201 uptake pattern, 869(ab) granulocyte stimulating factor, 2014 cerebral cortical activity, Tc-99m HMPAO, mass, optimization, follow-up measurements, macro- and microscopic biodistribution, In-I 11, scintigraphy,I17 1406 rats, 954(ab) cerebral dopamine D2 receptors, superior PET metabolism, local and systemic effects of MRI and scintigraphy, staging, breast cancer, ligand, 847(ab) radiation, quantitative SPECT, 1774 9l4(ab) cerebral glucose uptake, hyperglycemia, l-(C-l 1) metastases, pharmacokinetics, Re-i86 after Re radiationabsorbeddoseestimation,1-131 D-glucose, 908(ab) 186-HEDP, 646 radioimmunotherapy,leukemia,94l(ab) cerebral language area, 0-15 water PET, 2D metastases ofprostate carcinoma, strontium-89, scintigraphicchanges,hormonal changes, brain surface map, 857(ab) low-dose infusion cisplatin, 1437 1427(ie) cerebral metabolism metastatic cancer, escalating dose schedule, Sm suppressioninducedby 1-131monoclonal epilepsyand diseaseduration, PET, 10l8(ab) 153EDTMP, 1451 antibody therapy, recombinant G-CSF, standardized approach, controlled behavioral metastatic disease, muitidose Sm-153 EDTMP, 933(ab) conditions, 101l(ab) pain palliation, 992(ab) toxicity ofl-131 monocional antibody cerebral perfusion mineral and body composition, dual energy X fragments, 941(ab) abnormalities, SPECT and Alzheimer's ray absorptiometry, fan-beam design, value ofscanning, possible orthopedic disease, 973(ab)

Subject Index â€¢1992 2269 Brain neoplasms

imaging in AIDS, 827(ab) hypometabolic parietal cortex, unaltered vasospasm, 1789 progressive supranuclear palsy, 704 benzodiazepine receptors, Alzheimer's D-2 dopamine receptors, 2'-iodospiperone, Tc-99m HMPAO, internal carotid artery disease, 887(ab) 897(ab) occlusion, 969(ab) imaging of subdural hematoma, current role of dual radionucide data acquisition, Tc-99m cerebrovascularreservecapacity,stenosisof SPECT, 248 and1-123,972(ab) carotid artery, thrombendarteriectomy, 1-131 MIBG approval, 33N(9) extracorporeai membrane oxygenation, 97l(ab) immature third ventricle teratoma, radiographic neonates, 1943 cerebrovascularresponse to acetazolamide, and neuro-SPECT imaging, 435 multimedia multimodality interactive Tc-99m DTPA-HSA, new method for improved SPECF, maximum-likelihood computer tutorial, 107l(ab) monitoring,969(ab) reconstruction, 964(ab) relative error-estimation, regional analysis, cerebrum and cerebellum, carbon dioxide independent aura/ictal/interictal cerebral 969(ab) reactivity, Tc-99m HMPAO SPECT, perfusion, 438 transcranial Doppler, acute ischemic stroke 1014(ab) interictal cerebral glucose metabolism, therapy, 968(ab) chronic subdural hematoma, cerebral blood spontaneously epileptic rat, l024(ab) SPECT grey matter imaging, iterative flow, Tc-99m HMPAO SPECT, 246 intracranial abscess, differential diagnosis, Tc reconstruction algorithm, 1225 clinical neurological PET, interactive computer 99m antigranulocyte antibody, 957(ab) stereotactic biopsy, PET-defined targets, 868(ab) based atlas, 1071(ab) kinetic behavior, Tc-99m HMPAO SPECT, 135 stereotactic metabolic atlas, functional brain cortical areas, visual imagery ofreading, PET left premotor cortex specialization, finger imaging, 858(ab) studywith0-15 butanol, 908(ab) movements, FDG PET, 857(ab) stimulated auditory cortex, proton NMR crossed cerebellar diaschisis, cerebral infarction, living human; C-ll WIN 35,428; dopamine spectroscopy, 974(ab) 877(ab) transporter site, 964(ab) striatal FDOPA uptake, cerebral glucose crossed cerebellar hypoperfusion, unilateral low grade and anaplastic astrocytomas, FDG metabolism, patients with chorea, 1015(ab) major cerebral artery occlusive disorders, PET, 966(ab) surgery and irradiation, Tl-20l imaging, 1637 maturation in children and adolescents, quantification using an animal model, cylindrical SPECT system, MCSPECT changes, regional cerebral blood flow, 696 964(ab) prototype, 852(ab) model-based quantitation, knowledge-based synthesis, isomers ofTc-99m ECD, monkeys, death factor analysis, 947(ab) 979(ab) assessment, Tc-99m CEROTEC scan, 970(ab) monoclonal antibody specific for @9/A4amyloid, Tc-99m, elimination ofchiral centers, comparative study, TCGH and TcHMPAO, Alzheimer's disease, angiopathy, 2184 coordination sphere, 920(ab) l016(ab) neopiasms, see Brain neoplasms Tc-99m HMPAO diagnostic dilemma, 2211 neural crest tumors, 1-123 MIBG, l072(ab) angiography, quantitative approach, 877(ab) timelydeclaration,Tc-99mHMPAOcerebral neuroma,PET-fluorodeoxyglucose,1931 high-resolution SPECF, neurofocal imaging, perfusion scintigraphy, 2209 aigrostriatal function in FDOPA PET studies, l070(ab) decreased binding ofC-ll cocaine, cocaine ratio method and graphical analyses, Tc-99m HMPAO SPECF addicts,888(ab) 945(ab) bilateral and symmetrical anomalies, 485 decreased glucose metabolism, Cushing disease, non-human primate, monoamine transporter cerebral blood flow, choreo-athetoid FOG PET, 834(ab) sites, 1-123 CIT SPECT, 945(ab) syndrome, 838(ab) developmental cognitive disorders, F-l8 FDG perfusion pattern in late life depression, 838(ab) rCBF variability, 826(ab) PET,973(ab) perfusion SPECT, cocaine abuse, AIDS regional cerebralblood flow, Down's disease detection, cognitive and pharmacological dementia complex, 887(ab), 1312 syndrome, lOl3(ab) challenges, l019(ab) perfusion SPECF with Tc-99m ECD, regional temporal lobe metabolism, refractory epilepsy, dopamine changes in cocaine abusers, 887(ab) cerebral blood flow, PET comparison, asymmetry in FDG PET scans, 928(ab) dual-isotope brain SPECT, Tc-99m and 1-123, 966(ab) three-dimensional functional images, automated 2030 PET method, rotational correction, 1579 dual-isotope imaging in normal volunteers, automated stereotactic transformation, three-dimensional images, automated method, Tc-99m HMPAO, 1-123 IMP, 827(ab) 1007(ab) anatomical standardization, 1003(ab) dual-isotope 5PECF, headtome set 031, MR images and, accuracy ofsurface fit 11-201SPECT,re-evaluationfor brain tumor, phantom study, l017(ab) registration, 921(ab) 844(ab) examination ofvisual mental imagery with use oflinear programming, glucose traumatic injury PET, 908(ab) utilization, 944(ab) remote history of, Tc-99m HMPAO SPECT, F-18DOPAuptake,delayedL-phenylaiarnne phantom design for computer simulation, image 52 infusion, 1383 reconstruction algorithms, physiologic skeletal screening, children, 873(ab) F-i8 FDGPETandMRIanatomy,registered models, 1012(a),) tumor marker, [l-â€•Cjputrescine,192, 200 atlas, 107l(ab) quantification of human basal ganglia, iterative uptake of6-[F-18J FDOPA, 916(ab) F-l8 4-fluoro-4-deoxy-D-glucose imaging agent, reconstruction, 878(ab) Brain neoplasms 983(ab) quantitation ofbasal ganglia uptake, SPECF, childhood, Tc-99m MIBI/TI-201 SPECT, feasibility ofcorticai activation study, sequential monkey brain phantom, 963(ab) 844(ab) Tc-99m HMPAO SPECT, subtraction rapid registrationand review, MR. CT and comparison ofkinetics, Tc-99m ECD and Tc method, 1015(ab) SPECT, l067(ab) 99m HMPAO, SPECF and compartment functional, SPECT, powerful clinical method, regional cerebral perfusion model, 969(ab) 1888 Landau-Kleffner syndrome, related childhood dynamic PET, l-aminocyclobutane[C-l 1] functional and structural deficits, young aphasias,1758 carboxylic acid, 2-compartment model, alcoholics, PET and MR.!, l070(ab) precinicai studies, Tc-99m T69l, 1836 922(ab) functional scans, evidence in criminal court, regional cerebral uptake, Tc-99m exametazine, FDG studies, PET resolution, visual 18N(6) unilateral voluntary hand movement, 1623 interpretation, 872(ab) glucose metabolic rates, 30- and 45-minute retention of Tc-99m bicisate, effect of primary, MRI and PET studies, 867(ab) acquisitions, 2103 radiolabeled impurities, dosimetry, 989(ab) recurrence glucose metabolism, sensitive marker, same living human, dopamine receptor density, 11-201and Tc-99mMIBIMRI, 867(ab) Alzheimer'sdisease,940(ab) C-l1racloprideandNMSP,847(ab) 11-201SPECTstudies,867(ab) grammatical and semantic components, somatosensory stimulation in thalamic lesions, recurrent primary, 11-201 SPECT, 107l(ab) sentence comprehension, PET activation 0-15 water PET, 858(ab) recurrent supratentorial and infratentorial, 11- study, 10l2(ab) SPECT 201 SPECT and F-18 FDG PET, MRI, hippocampal blood flow, diagnosis of attenuation effect, 961(ab) 867(ab) Aizheimer's disease, 5PECT, 940(ab) cerebral angioplasty, delayed ischemia due to strokes and, cerebral blood flow, HMPAO

2270 The Journal of NuclearMedicine Carbon dioxide

SPECTandMRItechnique,971(ab) diuretic therapy, renal functional response, 739 Carbon-liHED therapy, F-l8 FDG PET, 107l(ab) -enhanced scintigraphy, renal artery stenosis, en kinetics in rat heart, 870(ab) Breast, tissue attenuation, myocardial imaging, blocpediatricrenaltransplant,263 PET, localization ofpheochromocytoma, 1125 96l(ab) -mediated hemodynamic changes, renal trans-Carbon-li McN-5652, PET, serotonin Breast neoplasms ischemia, 907(ab) uptake sites, 860(ab) autogenous reconstruction, transverse rectus renal scintigraphy Carbon-il methionine, PET, effective method, abdominus myocutaneous flap, Tc-99m distinguishing functional from anatomic renal imaging of head and neck cancer, 691 dextran lymphoscintigraphy, 859(ab) artery stenosis, 2045 Carbon-li methylaitanserin, C-l I before and after treatment, tumor blood flow, prognostic value, renovascular hypertension, methylketansermn and, mapping serotonin 1020(ab) 2040 receptors, l026(ab) c-erbB2proteinoverexpression,1-124 unexpected pressor responses, 906(ab) 2-Carbon-il methyl-amlno-2-methyi-3-phenyl-l- monoclonal antibodies, PET, 2154 vs. captopril test, renovascular hypertension, propanol, PET, serotonin uptake sites, labeledBC-2monocionalantibody,999(ab) 907(ab) 861(ab) locoregionaliy advanced, preoperative renography Carbon-il MK-912, compared to C-i 1 WY chemotherapy, F-i8 FDG-PET, 828(ab) cortical residual activity, renal artery stenosis, 26703, alpha-2 adrenoceptor ligands, metastatic 906(ab) 86l(ab) clinical value, CA 15-3 plasma levels, 854(ab) segmental branch renal artery stenosis, 266 Carbon-li monoxide, ECG gated PET, radioimmunotherapy, 862(ab) -stimulated PRA, bilateral renal artery stenosis, â€œbackgroundâ€•question, planar Tc-99m prognosis, internal mammary 907(ab) gated blood-pool imaging, 938(ab) lymphoscintigraphy, 859(ab) Tc-99m MAO3 scintigraphy, renal artery Carbon-li NMPB, tracer kinetic analysis, quantitative dynamic and whole body FDG stenosis, 990(ab) binding, muscarinic cholinergic receptors, PET, 828(ab) CARBIDOPA 882(ab) radioimmunoiocalization, In-ll 1 BrE-3 FDOPA PET studies, nigrostriatal function, Carbon-il NMSP, PET, D-2 dopamine receptor antibody, Phase I study, 912(ab) ratio method and graphical analyses, densities, 848(ab) radiolabeled antibodies, oncogene-encoded 945(ab) Carbon-li NNC 722, potential radioligand, molecules, tumor imaging and therapy, 6-[â€•F]fluoro-L-dopakinetics, PET, 1472 dopamine uptake system, 931(ab) 2160 Carbohydrate, modification, localization of Carbon-li putrescine staging, MRI and scintigraphy, bone marrow, human polyclonal IgG, sites of bacterial brain tumor, 200 914(ab) infection, 1378 usefulness as brain tumor marker, 192 Bremsstrahiung, imaging using gamma camera, Carbon-li Carbon-li pyrilamine factors affecting attenuation, 161 alkylations, radiochemistry, microwave fields, C-il doxepin and, imaging ofHl histamine Bronchoalveolar lavage, pulmonary disposition of 1026(ab) receptors, heart, 885(ab) Ga-67, Pneumocystis pneumonia, 512 contribution to PET imaging, labeled carbon distribution, Hi receptor blocking drugs, Budd-Chiarl syndrome dioxide,581 968(ab) hepatic necrosis, Tc-99m medronate, 1390 incorrectly labeled reagent, 465(ie) Carbon-il raciopride monitoring by 1-123 iodoamphetamine Carbon-li l,2-diacylglycerols, membrane NMSP and, dopamine receptor density, same scintigraphy, per os and per rectum, 744 trapping, phosphatidylinositol turnover, living human brain, 847(ab) neurotransmission process, 413 plasma, robotic solid phase extraction assay, C Carbon-i I acetate 853(ab) CA 15-3, clinical value ofpiasma levels, follow-up, accelerated clearance, PET ischemic segments, Carbon-il RO 15-4513, visualization of metastatic breast cancer, 854(ab) 856(ab) benzodiazepine receptor binding, 860(ab) PET CA 125 Carbon-li SAH human/mouse chimeric monocional antibody, compared with F-l8 FDG, recovery after PET ovarian cancer radioimmunoimaging, revascularization, 855(ab) myocardial energy balance, 2144 i00l(ab) oxidative metabolism, infarcted and regional cardiac adenosine, 2138 Tc-99m monoclonal antibody, early detection, periinfarcted myocardium, 953(ab) Carbon-il tetrabenazine ovarian cancer recurrences, 904(ab) Carbon-li carazolol, PET, evaluation in pigs, PET Caffeine, serum levels following 24-hr abstention, 885(ab) brain biodistribution, monoaminergic myocardial perfusion, dipyridamole or Carbon-li carfentanil, PET, effect of nitrous neurons, 870(ab) adenosine, 866(ab) oxide, endogenous opiate system, 883(ab) monoamine terminals, 983(ab) Calcium carbonate, cyclic oral phosphate and Carbon-li CFF, dopamine fiber loss in synthesis, PET imaging, monoamine terminals, etidronate, bone mineral density, spine Parkinsonism, 946(ab) 983(ab) fracture, 1 Carbon-li COP 12177, PET, mechanisms of Carbon-li thymidine, PET, kinetic modeling, California, radioactive waste site, licensing down-regulation, idiopathic DNA synthesis, i009(ab) decision, 40N(9) cardiomyopathy, 896(ab) Carbon-li 2a-tropanyl benzllate, synthesis and Camera: see also Gamma camera Carbon-li cocaine biodistribution, muscarmnicreceptor -based method, calculation, Tc-99m MAO3 decreased binding in brain, cocaine addicts, imaging agent, 423 clearance, 948(ab) 888(ab) Carbon-li tyrosine, PET, radiation-induced major changes in nuclear cardiovascular codes, distribution and kinetics, PET, human body, inhibition, tumor growth, 373 19N(l) 521 Carbon-li WIN 35,428, imaging of dopamine multicrystal scintillation, single Carbon-il doxepin, C-il pyrilamine and, imaging transporter site, living human brain, radiopharmaceutical, left ventricular ofHl histamine receptors, heart, 885(ab) 964(ab) perfusion and performance, 1411 Carbon-li FLB 457, preparation of, 860(ab) Carbon-il YM-0915i-2, specific and non-specific Carbon-il flumazenil binding, age dependency, dopamine D-2 CEA-producing, radioimmunodetection, 1750 binding to benzodiazepine receptors, chronic receptors, 897(ab) clinical applications of PET, 330 alcohol-dependent men, PET and MRI, Carbon dioxide imaging with two diasteromers, octreoscan-li 1, l016(ab) arterial partial pressure, photic stimulation 900(ab) PET, benzodiazepine receptors, human brain study, 827(ab) methods and performance characteristics, homogenates, 101l(ab) labeled whole-body PET, 1191 Carbon-li forskolin, potentiality for imaging, contribution to PET imaging, C-i 1 labeled radioimmunotherapy, 1110 cAMP-related second messenger system, compounds, 581 therapy, absorbed dose calculations, rapidly i025(ab) transient metabolite, 585 growing tumors, 277 Carbon-li n-glucose, cerebral glucose uptake, reactivity in cerebrum and cerebellum, Tc-99m Captopril hyperglycemia, 908(ab) HMPAO SPECT, 10i4(ab)

Subject Index â€¢1992 2271 Carbon monoxide

Carbon monoxide, intoxication, cerebral blood Carcinoma, thyroid 977(ab) flow and glucose metabolism, 1696 autonomously functioning, euthyroid Graves' Cerebrovascular disease, acetazolamide Tc-99m 2fl-Carboxymethoxy-3fl-(4-chlorophenyl)-8-(3E- disease, 2024 HMPAO SPECT study with PET, 877(ab) and 3Z-lodopropen-2-yl)nortropanes, detection ofmetastases, Tc-99m TB! Cesium-137, myth-making at Hanford, l9N(7) radioiodinated, cocaine receptor site scintigraphy, 914(ab) CGP-12i77, CGP-26505 and, characterization, @- mapping, SPECT, 890(ab) differentiated adrenergic receptors, 870(ab) Carcinoembryonic antigen contribution ofTi-201 scan, 955(ab) Chelating agents clinical value ofCA 15-3 plasma levels, follow-up, Tc-99m MIBI and 11-201 chloride, alkylamine conjugation chemistry, labeling of metastatic breast cancer, 854(ab) 844(ab) antibodies, 986(ab) concentration measurement, adenocarcinoma, 1-123, scintigraphic follow-up, l020(ab) bifunctional, copper-67, 942(ab) quantitative autoradiography, 892(ab) Hurthle cell, Tc-99m sestamibi uptake, 1393 -biotin conjugates, pharmacokinetics, content, role in gastrointestinal tumor targeting, 1-131 therapy, complications, sequela and pretargeted avidin-biotin Tc-99m F023C5 anti-CEA IgGi, 892(ab) dosimetry, 2214 immunoscintigraphy, 880(ab) In-ill anti-CEA-F(ab'), fragments, radiation 1-131 whole-body scan, replacement with comparison ofTc-99m direct vs. N2S2 chelate, dosimetry, tissue distribution in rats, 1654 thyroglobulin measurement, 172(le) labeled NR-LU-lO Fab', tumored nude monoclonal anti-CEA antibody, Ga-67 anti two-step immunoscintigraphy, anti-CEA/anti mice, 909(ab) CEA 35, colon carcinoma DTPA bispecific monoclonal antibody, In 4-ICE and 4-BACE, 985(ab) immunoscintigraphy, 1766 111 DTPA dimers, 912(ab) In-l 11 BAD-Lym-l, radiochemistry and -producing cancer, radioimmunodetection, 1750 Carcinoma, thyroid meduilary, facile synthesis of pharmacokinetics, l030(ab) second generation high-affinity anti-CEA Re-l88-labeled Rc(V)-DMSA, In-l 11 cyclohexl EDTA, anti-CEA F(ab'), monoclonal antibody, 904(ab) triphenylphosphine reduction, perrhenate monoclonal antibody, human tumor Carcinoid neoplasms at room temperature, l024(ab) xenografted nude mice, 943(ab) metastatic, scintigraphic comparison, 1-123 Cardiolite, vials and microwave boiling procedure, methylene bridged phosphineoxide-phosphine, MIBGandI-123TOCT, 1121 468(le) Re-l88, 979(ab) somatostatin analog, 914(ab) Cardiology Pd-109, bioconjugates and, 987(ab) Carcinoid syndrome, 1-131 MIBG therapy, 834(ab) nuclear probes, 448 phosphorus hydrazide, bifunctional frameworks, Carcinoma, breast, radioimmunodetection, 803 second Sino-American nuclear medicine Tc-99m and Re-l88, 9i0(ab) Carcinoma, colonic, immunoscintigraphy, conference, 16N(4) radiolabeling, antibody-macrocycic chelate monocional anti-CEA antibody, Ga-67 Cardiomyopathy conjugates, 103l(ab) anti-CEA 35, 1766 Adriamycin Re-l86 direct vs. chelate labeled NR-LU-l0 Carcinoma, colorectal disturbed neuronal energy metabolism, MAb,tumored nude mice, 9l0(ab) efficacy and safety, In-i 11 IYP ZCE 025 935(ab) rigidity and denticity, biodistribution, Y-88 and monocional antibody, 959(ab) myocardial damage, In-i 11 antimyosin Pb-203 labeled immunoconjugates, immunoscintigraphy, Loch Ness monster and, antibody, 936(ab) l030(ab) 1756 prediction ofcongestive heart failure, 1-125 structure, In-lli labeled Ab-chelator, liver, improved demarcation of tumors, dual isotope MIBG, 935(ab) lOOi(ab) SPECT immunoscintigraphy, l000(ab) Adriamycin-induced, abnormal cardiac Chemistry, targeted proteins for diagnostic metastases detection, In-lll CllO anti-CEA adrenergic neuron activity, 1-125 MIBG, imaging, 394 monoclonal antibody, CT, 904(ab) 208 Chemotactic peptides, Tc-99m hydrazino metastatic, Phase I trial, 1-131 chimeric B72.3, congestive, Adriamycin, 1-125 MIBG, 215 mcotinamide, imaging focal sites of 23 hypertrophic infection, 9l0(ab) pharmacokinetics ofln-Ill B72.3 monoclonal BMIPP, l9l4(ie) Chemotherapy antibody, 498 myocardiai emission computed tomography, early detection ofimpact, F-18 FDG pre-operative staging, F-l8 FDG PET, 975(ab) 6 scintigraphy, malignant lymphoma, 858(ab) radioimmunodetection, 803 idiopathic, mechanisms of down-regulation, C- enhanced fluorodeoxyglucose uptake, metabolic safety and role, In-li 1 anti-CEA monoclonal 11 COP 12177 PET and MIBG imaging, design, combination therapy, 1981 antibody ZCE 025, 14 896(ab) -induced kidney disorder, antimyosin antibody Carcinoma, epidermoid, xenografts, Cardiotoxicity, Adriamycin, Tc-99m sestamibi, uptake, 309(le) biodistribution, In-lll B3 monoclonal chick heart cells, 864(ab) intrarterial carotid artery injection, Tc-99m antibody, 842(ab) Cardiovascular system, major changes in CPT HMPAO, recurrent glioma, 966(ab) Carcinoma, hepatoceilular, high-dose targeted code, 19N(l) preoperative, F-18 FDG PET evaluation, irradiation, 1-131 lipiodol, 1020(ab) Carditis, rheumatic fever, importance, locoregionally advanced breast cancer, Carcinoma, ovarian scintigraphic diagnosis, 995(ab) 828(ab) immunoscintigraphy, 1-131 labeled 145-9 Catecholamines Chernobyl, surprise findings ofthyroid cancer, monoclonal antibody, 905(ab) C-il cocaine,distributionandkinetics,human 23N(l 1) radioimmunodetection, 803 body, 521 Chest, FDG PET imaging, 975(ab) Carcinoma, papillary, thyroidectomy, pelvic serial measurements ofcardiac volumes, count Chest pain radioiodine uptake, rectal wall teratoma, based methods, 1324 acute, myocardial reperfusion imaging, Tc-99m 1848 Cations, organic, labeling with Tc-99m, synthesis sestamibi, 876(ab) Carcinoma, prostatic and renal excretion, 2190 angina-like, abnormal esophageal motility, marrow scintigraphic changes, hormonal Cellulitis, osteomyeitis and, dual bone and WBC gastroesophageal reflux, 955(ab) therapy, 1427(le) scan imaging, planar and SPECT imaging, spontaneous, coronary intervention, Tc-99m metastatic 839(ab) sestamibi SPECT, 875(ab) preoperative identification, In-lu CYT-356, Cellulose, -acetate hemodialyzer, comparative Chhnera, radiolabeled monoclonal antibodies, 29 l00l(ab) thrombogenicity, 956(ab) Chloramine-T, TCB radioiodinated monomeric Sr-89 radiotherapy, 1316 Central nervous system antibody P-67, improved tumor retention, metastatic to bone, strontium-89, low-dose infectious or malignant lesions, differentiation 987(ab) infusion cisplatin, 1437 with FDG PET, AIDS, 838(ab) Cholecystectomy, laparoscopic, utility of Re-186 HEDP, bone pain treatment, 859(ab) primary, lymphoma, F-18 fluorodeoxyglucose cholescintigraphy, 898(ab) Carcinoma, renal cell, radioimmunoscintigraphy, PET, 532 Cholecystitis 1-131 monocional antibody, 913(ab) Cerebellum, dissociated postnatal rat, uptake acute, significance, duodenogastric reflux, Carcinoma, squamous cell, head and neck, mechanisms, Tc-99m D.L-HMPAO, 108 898(ab) radiation-induced response, FDG PET, Cerebral palsy, children, quantitative perfusion chronic acalcuious, specificity, gallbladder 829(ab) defect indexes, Tc-99m HMPAO SPECT, ejection fraction, 899(ab)

2272 The Journal of Nudear Medicine Contrast material

grading ofhyperperfusion and rim sign, biliary imaging, 889(ab) -aidedinstruction scintigraphy, 898(ab) rotating slit, planar scintigraphy, SPECT, nuclear medicine, l073(ab) Cholecystokinin, calculation of gallbladder 1005(ab) slide presentations, image acquisition, ejection fraction, continuous sincalide SPECT collimation, spatially variant focusing, l066(ab) infusion, 3-mm infusion method, 537 89l(ab) system for radiology, 1066(ab) Cholescintigraphy structure, i006(ab) -assisted diagnosis morphine-augmented ultra high resolution, unitary construction, artificialneuralnetwork,coronaryartery false-negative, subacute gallbladder cylindrical gamma camera, 852(ab) disease, 272 perforation, 256 variable focal length, fan beam reconstruction pulmonary embolism, ventilation-perfusion potential pitfalls, 898(ab) algorithms, 891(ab) lung scanning, l003(ab) Tc-99m IDA, differentiation, congenital Colon, improved transit procedure, easily prepared -based atlas, clinical neurologic PET, 107l(ab) gallbladder abnormality, 431 marker, SPECT, 833(ab) -based radiology teaching files, 1066(ab) Cholestasis, intrahepatic vs. extrahepatic, Colonic neoplasms, metastatic, dose fractionation, -based renal nuclear medicine teaching file, hepatobiliary scintigraphy, I 186 radioiabeied antibodies, 1648 i073(ab) Cholesterol, -fed rabbits, radioiodinated Colony-stimulating factor clinical validation ofprogram, ordinary gamma endothelin-l, injured aortic tissue, 845(ab) granulocyte, bone marrow suppression, 1-131 camera first pass radionuciide angiography, Chores, cerebral glucose metabolism, striatai F- monoclonal antibody therapy, 933(ab) i064(ab) DOPA uptake, PET, iOlS(ab) granulocyte-macrophage, thrombocytopenia, -directed coregistration, multislice functional Choreo-athetoid syndrome, cerebral blood flow, hepatic sequestration of In-I 11 platelets, and anatomic images, external fiducials, brain Tc-99m HMPAO SPECT, 838(ab) 923(ab) 96i(ab) Chromaffin cells Colorectal neoplasms graphics for radiologic images, l068(ab) C-i1cocaine,distributionandkinetics,human advanced, radioimmunotherapy 1-131 CC49 high-resolution plain-paper laser printers, body, 521 SPECT, CT, i002(ab) hardcopy, nuclear medicine images, MIBG heart and lung extraction fraction, first Cu-64 antibodies for PET imaging, 1685 947(ab) pass analysis, 716 imaging considerations, 1-131 labeled CC49 instrumentation and, SNM Mid-Winter Chromatofocusing, monoclonal Fab', 2148 monoclonal antibody, lOOi(ab) Meeting, 23N(l) Clntichem Corporation, government molybdenum management with Tc-99m monoclonal interfile file format, transfer of nuclear medicine 99 plan, 1lN(2) antibodies, 904(ab) images, 1007(ab) Cirrhosis, liver, portal venous blood flow, pulsed two-step targeting ofiodinated bivalent haptens, Macintosh programs for PET, 1069(ab) Doppler and per-jejunum scintigraphy, dosimetry, nude mice hosts, l000(ab) Macintosh tutorial, cross-sectional anatomy, 997(ab) Commentary i063(ab) Qsplatin, low-dose infusion and strontium-89, Lines from the President, 31N(3) major changes in nuclear cardiovascular codes, hormone refractoryprostate carcinoma radiation safety for beginners, 167 l9N(l) metastatic to bone, 1437 utility ofsingle-photon absorptiometry, dual model-based quantitation, knowledge-based atrate dextrose, heparmnand, preparation, Tc energy X-ray absorptiometry, 170 factor analysis, 947(ab) 99m red blood cells with UltraTag RBC kit, value of â€œtheputrescine experienceâ€•,1720 multifunctional image-containing database, 306(le) Computed tomography (CT) 947(ab) Clean Air Act, amendments, 29N(iO) brain images, rapid registration, l005(ab) multimedia multimodality interactive tutorial, Cocaine comparative study ofTi-20i, MRI/angiography, brain SPECT, 107I(ab) abuse and AIDS dementia complex, brain bone and soft tissue sarcoma, 843(ab) nuclear medicine perfusion SPECT, 1312, 887(ab) cone beam, image truncation, SPECT gamma efficient management, imaging and non abusers camera, 901(ab) imaging information, i006(ab) brain dopamine changes, 887(ab) cone beam transmission, imaging of human multi-media workstation, 947(ab) decreased binding, C-I 1 cocaine, 888(ab) torso, gamma camera, 150 workstation, all digital department, 947(ab) distribution and kinetics, alcohol intoxication, dual-energy X-ray, attenuation correction, radiologic anatomy, 1067(ab) human brain and heart, 946(ab) SPECTimages,90i(ab) simulations intravenous injection, myocardial sympathetic emission-transmission, prototype imaging brain phantom design, image reconstruction neuronal function, dogs, 994(ab) system, 1881 algorithms, lOi2(ab) no-carder added radioiodinated analogs, ligand fusion with SPECT images, radiolabeled coilimatorless coincidence imaging, 879(ab) binding, animal biodistribution, 98l(ab) monocional antibodies, 960(ab) teaching file for nuclear medicine, 1066(ab) polydrug users, regional cerebral blood flow, Ga-67 scan and, extrapulmonary tuberculosis, use oflnternet, communications to world improvement with treatment, 887(ab) 2118 community, nuclear medicine, i067(ab) radioiabeied analogs, receptor imaging agent, In-I 11 Ci 10 anti-CEA monoclonal antibody, use oflinear programming, glucose utilization PET, l025(ab) metastases detection, colorectal carcinoma, and receptor binding, PET studies of heart receptors, PET imaging probes, non-human 904(ab) and brain, 944(ab) primate model, 946(ab) 1-131 QSPECT, manual alignment-error use oflocal area networks, intradepartmental receptor site mapping, radioligands, SPECT, compensation, 925(ab) distribution, nuclear medicine imaging 890(ab) osteoid osteoma, 269 data, 946(ab) Tc-99m D,L-HMPAO, uptake and respiration, radioimmunotherapy 1-131 CC49 SPECT and, Congress rat brain slices, 964(ab) advanced colorectai cancer, 1002(ab) government will respond to those who seek Cole, Donald W., Jr., In memoriam, 1726 rapid registrationand review, brain, 1073(ab) influence, 25N(iO) Collimator standardization, cardiac tomographic imaging, report ofdisturbing findings, Secretaryof cardiofocal, cardiac SPECT, 852(ab) 1434 Energy, 22N(lO) collimatoriess coincidence imaging, computer Tc-99m HMPAO SPECT, remote history, subcommittee, U.S. radioisotope supply crisis, simulations, 879(ab) traumatic brain injury, 52 i6N(l0) detector interactions and, In-i 11 imaging, Tc-99m HMPAO SPECT and MR. diagnosis of support ofNational Biomedical Tracer Facility, l004(ab) dementia, 972(ab) 35N(l 1) distance-dependent blur in SPECT, restoration Tc-99m MIBI and 11-201 scintigraphy, Contamination filter approach, 843(ab) localization, parathyroid enlargement, management of exposed or contaminated fan-beam, myocardial SPECT, newborn period 895(ab) patient, 1065(ab) and early infancy, 930(ab) Computer and Instrumentation Council, sponsor of prevention of, IV. administration, multi-head SPECT camera, sensitivity, first Young Investigators Symposium, radiopharmaceuticals, 1027(ab) resolution and image quality, 1859 32N(lO) Contrast material, iodidcs, potential effects, penetration, camera-induced scatter, 1-131 Computers radioactive thyroid uptake, 237

Subject Index â€¢1992 2273 Copper-61 pyruvaldehyde

Copper-6i pyruvaldehyde thiosemicarbazone, Tc-99m sestamibi and Tc-99m teboroxime, sensitivity and specificity, Tc-99m HMPAO quantification of regional canine 1091 SPECT, 1013(ab) myocardial perfusion, 884(ab) predictive value ofdipyridamole thallium Deoxyglucose, hexadecylphosphochoiine and, Copper-62 FrSM imaging, myocardial bridging, 1905 design ofcombination therapy, FDG kinetics in the non-human heart, 684 regional glucose metabolism, relation to uptake measurements, 10i9(ab) regional myocardial perfusion, 837(ab) perfusion, 856(ab) Department of Energy (DOE) Copper-64, PET, scintillating fiber detector regional perfusion reserve, noninvasive competitionfor researchdollars, 15N(2) module, small animals, iOlO(ab) determination, N-i3 ammonia PET, GAO probe of U.S. isotope troubles, 22N(9) Copper-64 antibodies, PET imaging, 1685 826(ab) government molybdenum-99 plan, slow Copper-67 retrospective post therapy evaluation, cardiac advancement, 11N(2) bifunctional chelating agents, 942(ab) function, PET, 885(ab) government relations update, 16N(3) Sm-153 immunoconjugates, tumor therapy, Tc-99m sestamibi myocardial SPECT imaging, isotope problems, 34N(l0) 942(ab) comparison, short and standard data myth-making at Hanford, i9N(7) Copper-PTSM, retention of, complete ischemia acquisition, 855(ab) National Biomedical Tracer Facility, 33N(9) reperfusion, 1026(ab) Tc-99m sestamibi perfusion, left ventricular panel to reconsider advanced neutron source, Coronary artery disease (CAD) ejection fraction, 847(ab) 32N( 10) adenosine stress, N-13 ammonia myocardial teboroxime resting washout, stress thallium questions about future, isotope production and perfusion PET, 825(ab) SPECT, 876(ab) research, 13N(6) adenosine thallium scintigraphy, high cardiac Coronary stents, platelet/fibrin deposition, research appropriations, 30N(12) risk, patients referredfor vascular surgery, anticoagulation, minipig model, 845(ab) Depression 952(ab) Corticotropin-releasing factor, radioiodinated, late life areas of reverse redistribution, planar thallium potential tracer, CRF-receptor imaging, brain perfusion pattern, 838(ab) imaging, viability with PET, 886(ab) 996(ab) F-l8 FDG PET, 1013(ab) chronic Cortisol, adrenocortical scintigraphy, unilateral schizophrenia and, Tc-99m HMPAO SPECT, identification ofviable myocardium, 505 incidentally discovered adrenal or 972(ab) rest-redistribution 11-201, relation to Tc-99m juxtaadrenal masses, 996(ab) Dexamethasone, lack of suppression, adrenal MIBI, 905(ab) Court system, criminal, functional brain scans, SPECT, primary aldosteronism, 834(ab) clinical validation ofcomputer program, i8N(6) Diabetes ordinary gamma camera, first pass Crossed cerebellar diaschisis, hypoperfusion, gastric motility disturbances, scintigraphy, radionuciide angiography, 1064(ab) unilateral major cerebral artery occlusive 832(ab) comparison of rest-redistribution Tl-20i uptake, disorders, 1637 gastroparesis, gastric emptying rate, variable oral resting sestamibi uptake, 905(ab) Curshmann-Steinert, myocardial involvement, I- erythromycin, 833(ab) computer-aided diagnosis, artificial neural 123 IPPA SPECT, 995(ab) infectious foot complications, In-l 11 human network, 272 Cushing's disease, decreased cerebralglucose nonspecific IgG, 950(ab), 1330 continuous SPECT imaging protocol, Tc-99m metabolism, FDG-PET, 834(ab) insulin-dependent, secondary gastroparesis, teboandTl-20i, 1304 Cyclic AMP, -related second messenger system, 1707 detection oftotal ischemic myocardium at potentiality, C-ll forskolin, 1025(ab) type 2 patients, oral glucose solution, rapid jeopardy, combination of flow reserve with Cyclotron, industry split over approval, PET gastric emptying, 1496 metabolic assessment, 837(ab) tracers, 24N(9) Dialysis, continuous ambulatory, diffuse dobutamine and exercise, Tc-99m sestamibi, Cyst, epidermoid inclusion, 11-201 accumulation, abdominal uptake ofTc-99m MDP, bone 95 l(ab) 1857 scintigraphy, 2052 dobutamine Tc-99m sestamibi SPECT, 866(ab) Cystic fibrosis, effectiveness of PEP mask, Tc-99m Diaminedithiol, ligand system, labeling with early and delayed myocardial Tc-99m sestamibi DTPA aerosol ventilation, 835(ab) Re-l86, i032(ab) SPECT, 855(ab) Cystography Diaschisis echocardiography, 866(ab) cyclic voiding, vesicoureteral, asymptomatic cross cerebellar, neurolite imaging, stroke, effect of patient motion, tomographic perfusion siblings, 873(ab) 968(ab) imaging, 1566 radionuclide, vesicoureterai reflux, children and vascular response to acetazolamide, Tc-99m exercise-induced myocardial ischemia, first-pass adolescents, l022(ab) HMPAO SPECT, 967(ab) radionuclide angiography, bicycle Cytomegalovirus, accuracy ofearly gallium Digoxin ergometry, 359 imaging, pulmonary infection, possible imaging agent, 549 immunocompromised patients, 957(ab) extent and location, Tl-201 tomography with radioiodinated derivative, myocardial pharmacologic stress, 2067 accumulation, possible Na,K-ATPase D incremental diagnostic value and impact, imaging agent, 545 patient treatment, thallium scintigraphy, Deferoxamine, -biotin derivatives, plasma stability, a-Dihydrotetrabenazine, C-i 1 tetrabenazine and 1727 pharmacokinetics, 880(ab) C-i 1 methoxy derivative, PET, monoamine incremental value of diagnostic test, cost Dementia terminals, 983(ab) consciousness, 1732 accuracy in diagnosis, PET imaging, 967(ab) Dipyridamole integration ofwali kinetic and perfusion data, atypical, comparison, FDG PET and MRI data, blunted response ofmyocardial perfusion, older tomographic myocardial perfusion 965(ab) adults, 1425(ie) scintigraphy, 933(ab) autopsy-diagnosed, SPECT perfusion imaging, effects on renal function, Tc-99m DTPA, 355 lung thallium uptake, adenosine 11-201 939(ab) -induced left ventricular cavitary dilatation, scintigraphy, 1600 delayed SPECT and regional cerebral blood exercise, thallium imaging, 951(ab) metaboliccardiacimaging,1-123IPPA, flow, 1-123 IMP, 1015(ab) lack of thallium redistribution, postoperative multicrystal gamma camera, 1269 differential diagnosis and long-term outcome, 95 l(ab) myocardial imaging, Tc-99m tetrofosmin, brain perfusion SPECT accuracy, 10i7(ab) myocardial perfusion imaging, serum caffeine 875(ab) rCBF/SPECT and MRI, 1014(ab) levels, 24-hour abstention, 866(ab) myocardial ischemia, hemodynamic Tc-99m HMPAO, 939(ab) stress, metabolic evidence of ischemia, 866(ab) scintigraphic study, adenosine infusion, functional brain SPECT, powerful clinical Tc-99m MIBI radionucide angiography, 952(ab) method, 1888 SPEC!' myocardial perfusion, 846(ab) myocardial viability, 11-201 SPECT vs. F-18 HIV, qualitative approach, SPECT, lOl8(ab) 11-201 imaging FDO PET, 886(ab) multiinfarct and degenerative, impairment of dose comparisons, coronary arterydisease, nuclear probes in cardiology, 448 cognitive functions, extent of disturbance, 866(ab) planar gated imaging, 866(ab) 940(ab) improvement of image quality, walking planar myocardial perfusion imaging, 11-201, patterns of, Alzheimer's disease, 143l(le) exercise, 2061

2274 TheJournalof NuclearMedicine Electronmicroscopy

predictive value, myocardial bridging, 1905 cancer, 894(ab) mapping cerebral blood flow, 1843 Diuresis radioimmunotherapy in a child with MIRD approach and limitations, 781 captopril, renal functional response, 739 neuroblastoma, 1-124 3F9 PET, 2020 misalignment between PET transmission and renogram, functional assessment, pro- and post regional dose distribution to hands, staff emission scans, myocnrdiai imaging, 1214 pyeloplasty, 977(ab) formulating/dispensing/administering myocardiai blood flow, deoxyglucose uptake, renography, gravity-assisted drainage view, radiopharmaceuticais, 1065(ab) myocyte viability in ischemia, 1353 1022(ab) Sr-89radiotherapy,metastaticprostatic myocardial FDG PET studies, oral glucose Tc-99m DTPA renography, ureteral status in carcinoma, 1316 loading or insulin clamp methods, 1263 children, kidney washout, 73 Tc-99m MAG3, Tc-99m DTPA and 1-131 OIH, natural history ofinfantile hydronephmsis, DNA, synthesis, kinetic modeling, C-l 1 thymidine human biodistribution studies, 33 diuretic renography, 2098 PET, 1009(ab) Tc-99m mapping ofleukocytes, secondary ion new methods for localizing infection, avidin DObutamIne mass spectrometry microscopy, 2162 biotin, 1816 choice ofstress for diagnostic perfusion, wall three-dimensional tumor, hepatic Y-90 nonuniformity ofdose, implications, radiation motion imaging, MIBI-SPECT and stress microsphere therapy, 735 protection, 384 echocardiography, 825(ab) two-step targeting ofiodinated bivalent haptens, nuclear medicine, acupuncture message exercise and, Tc-99m sestamibi, coronary artery colorectal tumors hosted in nude mice, transmission, 409 disease, 951(ab) l000(ab) nuclear probes in cardiology, 448 stress thallium scintigraphy, usefulness and Down's syndrome oftheoretical derivations, empirical evidence, safety, 95l(ab) nondemented old patients, 1-123 IMP SPECT, 1578 Tc-99m sestamibi SPECT, detection, coronary 967(ab) parathyroid imaging, 1807 artery disease, 866(ab) regional cerebral blood flow, Tc-99m HMPAO prognosis in congestive heart failure, 477 Depamine brain SPECT, 10i3(ab) quantitating tumor glucose metabolism, FDG acetylcholine release and, GABAergic Drug abuse, comparative uptake, Tc-99m and PET, 339 modulation, PET, 847(ab) HMPAO, 1-123 IMP TCBF,iOlS(ab) quantitative autoradiography, changes in brain, cocaine abusers, 887(ab) Dual-photopeak window, method for scatter radiopharmaceutical uptake, dose Dl ligand, synthesis and in vivo evaluation, F- correction, 605 heterogeneity, 1833 18 BT-SCH PET, 829(ab) Dysphagla, esophageal disorders and scintigraphy, radioimmunotherapy ofcancer, 1110 D2receptors,chemicalfamilyofligands, 1301 continuing evolution, 2180 98l(ab) Dystonia, 1-123 IBZM SPECT, iOl8(ab) radiolabeled antibodies, oncogene-encoded fiber loss in Parkinsonism, C-i 1 CFT, 946(ab) molecules, tumor imaging and therapy, â€œinternalizationâ€•ofF-i8 N-methyl-spiroperidol, E 2160 870(ab) radiolabeled monoclonal antibodies, cancer Ebstein's deformity, radionucide evaluation, striatal F-DOPA uptake, cerebral glucose therapy and diagnosis, chimera, 29 symptomatic infants and children, 930(ab) metabolism, patients with chorea, 1015(ab) radiotherapy and regional bone formation, 1780 Echocardlography transporter site; C-l I WIN 35,428; living detection ofcoronary artery disease, 866(ab) referral bias, efficacy, radionucide stress tests, 2074 human brain, 964(ab) stress and MIBI SPECT, choice ofstress for uptake system, C-l 1 NNC 722, 931(ab) diagnostic perfusion, wall motion imaging, risk to others, 1-131-treated patients, 2116 DOppler@see Uitrasonography 825(ab) scintigraphic appearance, Alzheimer's disease, Dosimetry Editorials Tc-99m HMPAO SPECT, 312 absorbed dose and contamination risk, In-lll Adriamycin and congestive cardiomyopathy, I- scintigraphic evaluation, Sphincter of Oddi oxine, 953(ab) 125 MIBG, 215 dysfunction, 1223 absorbed dose calculations, rapidly growing anatomic divisions, 407 sensitivity ofSPECT 11-201 myocardial tumors, 277 bloody future for clinical PET, 620 perfusion, patient motion, 1571 cellularlevel ofKupffer cells, Tc-99m sulphur brain death, diagnostic dilemma, 2211 SPECT,rapidlyclearedtracers,1206 colloid injection, 380 captopril renal scintigraphy, distinguishing targeted proteins for diagnostic imaging, does C-i12a-tropanylbenzilate,synthesis, functional from anatomic renal artery chemistry make a difference, 394 biodistribution, 423 stenosis, 2045 11-201andTc-99msestamibi,viable effect ofradiolabeled impurities, brain retention, carbon-Il putrescine, 200 myocardium, 815 Tc-99m bicisate in monkeys, 989(ab) clinical applications of PET in cancer, 330 transmural uptake ofperflision tracers, infarct immunoscintigraphy, In-ill monocional C-l 1 SAH PET, myocardial energy balance, specific tracers, 229 antibody fragments, ovarian cancer, 1113 2144 ureteral function, assessment of hydronephrosis, 1-131 QSPECT ofphantom, transferofCT vols, current role ofSPECT, imaging of subdural 78 manual alignment, 925(ab) hematoma, 248 vascular testing for impotence, 46 1-123 somatostatin analog, neuroendocrine detection ofcardiovascular infections, Ejection fraction tumors, 1613 radiolabeled leukocytes, 1493 gallbladder, specificity, chronic acalculous 1-131 therapy for thyroid carcinoma, diagnostic imaging ofliver, 1344 cholecystitis, 899(ab) complications, sequela, 2214 esophageal disorders and scintigraphy, 1301 leftventricular 1-123TISCH,954(ab) euglycemic hyperinsulinemic clamp, myocardial correlation with lung uptake, Tc-99m management of exposed or contaminated glucose utilization, PET, 1263 sestamibi, 846(ab) patient, l065(ab) gallbladder ejection fraction, decade of progress, gatedblood-poolstudies,932(ab) mathematical modeling, plasmapheresis, future promise, 542 gated Tc-99m sestamibi SPECT, 927(ab) radioimmunotherapy of micrometastases, go with the flowâ€”buthow far?, 1939 Tc-99m sestamibi perfusion, coronary artery 941(ab) hepatic clearance ofTc-99m HIDA derivatives, disease, 847(ab) MlRDdoseestimateReportNo. 16, 1717 hyperbilirubinemic states, 1551 radionucide evaluation of Ebstein's deformity, MIRDOSE software protocol, monocional how magic is the bullet, what will it do?, 549 symptomatic infants and children, 930(ab) antibody radloimmunotherapy, 926(ab) imaging inflammation, current role, labeled reduced exercise capacity, Starling effect, cardiac modeling, anti-CD33 monoclonal antibody autologousleukocytes, 65 transplantation, 939(ab) M195, acute myelogenous leukemia, immunoscintigraphy ofcolorectai carcinoma, Electric Power Research Institute (EPRI), vote on 941(ab) Loch Ness monster and, 1756 epidemiology study, 26N(l) nuclear quantitation oftumor size and 1-131 incremental value ofdiagnostic test, cost Electrocardiography amount, planar imaging, 925(ab) consciousness, 1732 response and perfusion images, thallium stress plasmapheresis in radioimmunotherapy, labeled carbon dioxide, transient metabolite, test, 1723(Ie) micrometastases, 2167 585 thallium scan, court litigation, 120 quantitative approach, 1-131 therapy, thyroid lung scan interpretation, 1422 Electron microscopy, autoradiography,

SubjectIndexâ€¢1992 2275

6-fluorine-IS fluoro-L-dona kinetics@carbidona malignancies, 829(ab) G*lllum-67 Emission tomography

intracellular distribution ofl-125 MIBG, angina-like chest pain, 955(ab) OMFD and, combined modeling analysis, non neuroblastoma xenografts, 102l(ab) bolus transport and contraction parameters, human primates, 945(ab) Emission tomography multiple-swallow investigations, 1291 PET, nigrostriatalfunction, ratio method and diffuse alcoholic liver disease, 1337 disorders and scintigraphy, 1301 graphical analyses, 945(ab) 1-123 beta-methyl-branched fatty acid, motility after reconstructive operation, 955(ab) Fe-PDGF, potential new hepatobiliary MR hypertrophic cardiomyopathy, 6 scintigraphy contrast agent, 974(ab) iodinated branched fatty acid analog, regional achalasia and achalasia-like disorders, 590 Ferrum, evaluation as MR contrast agent, 973(ab) metabolic abnormality, relation to reproducibility, normal ranges, 2106 Fever, unknown origin, Tc-99m antigranulocyte perfusion and wall motion, 659 ROC-analysis, 832(ttb) monoclonal antibody, 902(ab) region-of-interest evaluation, least squares Estradiol, -stimulated rat liver, binding of Tc-99m Fibrin algorithm, 831(ab) LDL and 1-125 LDL, 1028(ab) deposition following coronary artery injury, Encephalopathy, opsoclonus-myoclonus, location Estrogen, receptor imaging and PET, F-18 fluoro 1-125 fibrinogen, porcine restenosis model, ofneuroblastoma, MIBO usage, 930(ab) analog, tamoxifen, 985(ab) 845(ab) Endocrine neoplasms, gastro-entero-pancreatic, In Ethanol, percutaneous injection, autonomous deposition on coronary stents, anticoaguiation, 1 1 1 pentatreotide scintigraphy, 976(ab) thyroid nodule, 954(ab) minipig model, 845(ab) Endocrinology, second Sino-American nuclear Ethics, knowing what is right, 296 D-dimer plasma concentration, suspected medicine conference, l6N(4) (@N4(1-Ethyl-2-p@olidinyl)methyl@5-(3-I18F@ pulmonary emboius, 978(ab) Endoprostheses, septic loosening, WBC fluoropropy l)2,3-dimethoxy-6-hydroxy Fibroblast, -like cells and uptake kinetics, Tc-99m scintigraphy with monoclonal antibodies, benzamide, superior PET ligand, cerebral sestamibi, 11-201, 102 840(ab) dopamine D2 receptors, 847(ab) Filters Endothellalcells,uptake kinetics,Tc-99m Etidronate gamma camera images, beta-emitters, neural sestamibi, 11-201, 102 cyclic oral phosphate and, bone mineral density, network restoration, 889(ab) Endothelin-l, radioiodinated, injured aortic tissue, spine fracture, 1 restoration cholesterol-fed rabbits, 845(ab) intravenous, skeletal nonvisualization, bone defect detection, cardiac SPECT, 842(ab) Endotoxemia, lung neutrophil sequestration, scan, 748 distance-dependent collimator blur, SPECT, intercellular adhesion molecules, 1023(ab) Exercise 843(ab) Environmental Protection Agency (EPA) dipyridamole-induced left ventricular cavitary two-dimensional restoration, quantitation of costs ofdual regulation, 29N(l0) dilatation, thallium imaging, 951(ab) amygdala, PET, 921(ab) mixed waste petition, 33N(9) dobutamine and, Tc-99m sestamibi, coronary Flumazenil, ligand, quantification of national emission standards, 33N(9) artery disease, 95 l(ab) benzodiazepine receptors, PET, 883(ab) National Emission Standards for Hazardous Air -induced perfusion defects, delay of image Fluorine-iS Pollutants, 24N(3) acquisition, Tc-99m TEBO SPECT, acyclic analogues of vesamicol, potential Epigastric impedancemetry, gastric emptying of 952(ab) cholinergic neuron markers, 983(ab) liquids, 956(ab) left ventricular function, coronary jeopardy labeling ofmonocional antibodies, N- Epilepsy score, 938(ab) succinimidyl 4-[F-18]fluorobenzoate, Annual Meeting highlights, 22N(8) reduced capacity, cardiac transplantation, 881(ab) cerebral metabolism, effect of disease duration, Starling effect, 939(ab) PET PET, l018(ab) serial measurements of cardiac volumes, count bone blood flow and influx rate, 937(ab) functional brain SPECT, powerful clinical based methods, 1324 derivatives ofSCH 38548, dopamine Dl method, 1888 walking, improvement, dipyridamole 11-201 receptors, 829(ab) interictal localization offoci, Tc-99m image quality, 2061 ligands, benzodiazepine receptor studies, CEROTEC SPECT, 966(ab) Extraceilular fluid, volume measurements, 883(ab) intractable temporal lobe, 3-D semiquantitative reproducibility, critically ill patients, 1468 production of, cryogenic 0-18 water target, method, F-18 FDG PET and Tc-99m Extracorporeal membrane oxygenation, brain 932(ab) HMPAO SPECT, 970(ab) SPECT, neonates, 1943 Fluorine-iS androgens, potential imaging agents, parietal lobe, F-18 FDG PET, 10l7(ab) Extremity prostatic cancer, 724 presurgical localization ofzones, F-18 FDG lower Fluorine-iS antimyosin monoclonal antibody PET, 928(ab) bone scintigraphy, preschool children, 351 fragments, preliminary investigations, refractory, temporal lobe metabolism, site of fracture or surgery, chronic canine myocardial infarct model, 575 osteomyelitis, 902(ab) asymmetry in FDG PET scans, 928(ab) fluorine-iS biotin, tumor localization with PET, simple and partial complex seizures, foci i026(ab) localization, Tc-99m HMPAO SPECT, F fluorine-iS BMY 14802, synthesis and resolution, 971(ab) Fab fragments PET studies, baboons, 830(ab) spontaneously epileptic rat, interictal cerebral cross-linking, synthesis and radioiodination, Fluorine-iS BT-SCH, synthesis and in vivo glucose metabolism, l024(ab) ETAC reagent, 943(ab) evaluation,dopamineDl ligand,PET, status epilepticus, Tc-99m HMPAO SPECT, linker-conjugated, monoclonal antiferritin 829(ab) 928(ab) antibody, nude mouse model, 987(ab) fluorine-iS 2-deoxy-2-fluoro-D-glucose, time temporal lobe monocionalantibodyF(ab')@uptakein tumor, course of skeletal muscle glucose uptake, decreased binding ofl-l23 IDEX, muscarmnic hyperthermia, 958(ab) euglycemic hyperinsulinemia, 1523 cholinergic receptors, 928(ab) negatively charged-polymer-modified Fluorine-iS deoxyglucose hyperventilation, cerebral blood flow, 968(ab) antimyosin, infarct imaging, 959(ab) myocardial blood flow, glucose uptake, ischemic mesial temporal origin, PET scan findings, NR-LU-lO, CH2 domain deletion mutant, canine myocardium, 1346 lOi4(ab) radioimmunotherapy potential, 1028(ab) PET, mediastinal lymph node mapping, 828(ab) presurgical evaluation, ictal Tc-99m HMPAO transferrin and IgO, preparation, Fluorine-iS DOPA, uptake in brain, delayed L SPECT, 929(ab) characterization, 986(ab) phenylalanine infusion, 1383 surgical outcome, Xe-133 SPECT, l018(ab) Fast Flux Test Facility, halt ofactivities, 16N(6) 6-Fluorine-IS DOPA, parametric Dopa temporal lobe surgery, prognostic implications, Fatty acid analog, iodinated branched, regional decarboxylase imaging, 879(ab) FDG PET, 929(ab) metabolic abnormality, relation to Fluorine-iS FDG Erythrocytes, modification ofTc-99m labeling perfusion and wall motion, 659 accumulation in bone fracture, correlation, method, effectiveness, 2222 Fatty acids Tc-99m MDP, 869(ab) Erythromycin, oral, gastric emptying rate, diabetic iodo-labeled methyl fatty acid, myocardial infection and reactive lymph nodes, 925(ab) gastroparesis, 833(ab) viability, FDG PET, 953(ab) method for comparing different procedures, Esophagus kinetics in aerobic myocardium, 1864 regional glucose metabolism, 157 abnormal motility, gastroesophageal reflux, FDOPA microautoradiography, granulation tissues and

2276 The Journal of Nuclear Medicine Gallium-67

phagocytes, mouse tumor tissue, 840(ab) administration, PET, 1472 prognostic implications, temporal lobe PET 3-O-methyl-6-fluorine-1S fluoro-@-dopa, FDOPA surgery, 929(ab) accuracy, dementia diagnosis, 967(ab) and, combined modeling analysis, non quantitative dynamic and whole body, breast brain, registered atlas, 107l(ab) human primates, 945(ab) cancer, 828(ab) brain tumor therapy, 107l(ab) fluorine-iS fluoromisonidazole radiation-induced response, head and neck compared with C-l 1 acetate, recovery after cellular hypoxia in sepsis, 924(ab) carcinoma, 829(ab) revascularization, 855(ab) PET,hypoxiain humangliomas,2133 temporal lobe metabolism, refractory developmental cognitive disorders, 973(ab) 4-(4-IFluorine-lSjfluorophenyl)-244(5)-methyl epilepsy, 928(ab) 3-D semiquantitative method, intractable 5(4)-imidazolylmet hyijthiazole, synthesis TSH stimulation ofthyroid cancer, T4 temporal lobe epilepsy, 970(ab) and biodistribution, imaging 5-HT3 replacement therapy, 894(ab) evaluation ofliver tumors, 333 receptors, 830(ab) PETimagingofthe chest,975(ab) glucose loading or insulin clamp methods, Fluorine-iS FMISO purification ofused 0-18 target water, myocardium, 1263 PET photochemical combustion, 982(ab) hibernating myocardium, irreversible noninvasive detection, hypoxic myocardium, uptake in tumors, Berson-Yalow Award perfusion defects, 105(ab) 2202 winners, 15N(7) insulin clamp, myocardial glucose utilization, quantification, tumor oxygenation status, uptake into human cancer cells, hypoxia, 1255,1263 lOlO(ab) 841(ab) late-life depression, I013(ab) Fluorine-iS MABN, F-l8 MBP and F-l8 NMSP uptake kinetics in liver, impact of glucose lymphoma, 532 PET, comparative imaging studies, 985(ab) ingestion, dynamic PET, 945(ab) malignant lymphoma, proliferative activity, Fluorine-iS monoclonal antibody fragments uptake measurements, design of combination 325 combination of radioimmunoscintigraphy and therapy, hexadecylphosphocholine and malignant melanoma, 975(ab) PET, 1535 deoxyglucose, 10l9(ab) multiple systemic atrophy, selective metabolic PET, 934(ab) 3'-Huorn-3'-deoxythymidine, noninvasive involvement, l014(ab) Fluorine-iS NCQ 616, preparation of, 860(ab) monitoring oftargeting ofdrugs, AIDS, myocardial viability, coronary artery disease, fluorine-iS N-methyl-spiroperidol, 830(ab) 886(ab) â€œinternalizationâ€•,870(ab) Food and Drug Administration (FDA) parietal lobe epilepsy, 1017(ab) Fluorine-lS NMSP approval ofdrug master file, PET, 33N(9) preoperative chemotherapy, locoregionally PET government relations update, 15N(3) advanced breast cancer, 828(ab) benzamide analogs and, 985(ab) PETtracers,industrysplitoverapproval, pre-operative staging, colorectal carcinoma, F-l8 MABN and F-18 MBP, comparative 24N(9) 975(ab) imaging studies, 985(ab) Foot presurgical localization, epileptogenic zones, Fluorine-iS N-(2-(pyrrolidinyl)-1- diabetic complications, In-l 11 human 928(ab) phenylethyl)acetamide analog, synthesis, nonspecific IgG, 950(ab) quantitation, tumor glucose metabolism, 339 kappa opiate receptor, 830(ab) infectious diabetic complications, In-li 1 human radiation-induced inhibition, tumor growth, Fluorodeoxyglucose nonspecific immunoglobulin 0, 1330 373 areas of reverse redistribution, planar thallium Forearm, bone mineral assessment, 125l(le) recurrent brain tumors, 867(ab) imaging, viability with PET, 886(ab) Fourier residual or recurrent musculoskeletal blood-brain transport, regional variations, amplitude and phase, three-dimensional sarcoma, 992(ab) 908(ab) presentation, gated cardiac blood-pool SPECT and, myocardial viability, 1064(ab) brain tumor studies, PET resolution, visual SPECT,458 treatment planning and monitoring, lung interpretation, 872(ab) approach to gastric motility, 956(ab) tumors, 975(ab) enhanced uptake caused by chemotherapy, Fracture scintigraphy, chemotherapeutic impact, metabolic design, combination therapy, bone, accumulation ofF-l8 FDG, Tc-99m malignant lymphoma, 858(ab) 1981 MDP,869(ab) synthesis, simple procedural change, recovery of glucose and, regional blood-brain transport, stress, osteosarcoma, lower limb, 1699 0-18 enriched water, l027(ab) 1819 Tc-99m sestamibi SPECT and, malignancy, increased uptake as prognostic indicator, G 858(ab) myocardial infarction, 886(ab) Gadolinium-DTPA, MRI, recurrent brain tumors, thermally stable ion exchange, heterogeneous PET 867(ab) nucleophilic radiofluorination, 984(ab) Bayesian regression, metabolic rate of glucose Gadolinium (III) D'l'PA-bisamide complexes, 2-Fluorine-iS FDOPA, high accumulation in non utilization, 944(ab) nonionic, MRI contrast agents, 974(ab) S phase melanocytes, Bl6 melanoma, decreased cerebral glucose metabolism, Gallbladder microautoradiography, 984(ab) Cushing's disease, 834(ab) biliary scintigraphy, grading of hyperperfusion, 6-fluorine-iS FDOPA differential diagnosis, solitary pulmonary rim sign, 898(ab) decline of rate constant K1 vs. age, 964(ab) nodule, 836(ab) calculation ofejection fraction, continuous loss ofmetabolites in striatum, 916(ab) differentiaton of infectious from malignant sincalide infusion, 3-minute infusion OMFD and, combined modeling analysis, non CNS lesions, AIDS, 838(ab) method, 537 human primates, 945(ab) fully quantitative neurological studies, differentiation ofcongenital abnormality, uptake in human brain, 916(ab) without arterialblood sampling, 922(ab) quantitative Tc-99m IDA fluorine-IS fleroxacin, PET, pharmacokinetics, HIV-l-infected children, seropositive cholescintigraphy, 431 rabbits, 924(ab) mothers, 976(ab) ejection fraction fluorine-IS fluconazole, PET, pharmacokinetics, investigation ofolfactory system, 858(ab) decade ofprogress, future promise, 542 humans, 924(ab) left premotor cortex specialization, finger specificity, chronic acalculous cholecystitis, Fluorine-IS fluoride ion, PET, evaluation, skeletal movements, 857(ab) 899(ab) kinetics, 633 low grade and anaplastic astrocytomas, brain hepatobiliary scintigraphy, intrahepatic vs. fluorine-iS fluorocarazolol imaging, 966(ab) extrahepatic cholestasis, 1186 fl-adrenergic radiotracer for PET, 984(ab) mediastinum, lung cancer, 828(ab) perforation, false-negative, morphine synthesis, ligand for @-adrenergicreceptors, method for correcting myocardium to blood augmented cholescintigraphy, 256 983(ab) pool spillover, 882(ab) stone, common bile duct clearance, Fluorine-iS fluorodeoxyglucose, PET, cranial and MIHA, myocardial viability, 953(ab) radionuclide injection, 997(ab) spinal neuromas, 1931 MRI data and, atypical dementia and Gallium, octahedral gallium chelate, monoclonal fluorine-iS 4-fluoro-4-deoxy-n-giucose, potential Alzheimer's disease, 965(ab) antibodies, immunoscintigraphy with PET, brain/heart/tumor imaging agent, 983(ab) post-treatment evaluation, genitourinary 1366 6-Fluorine-iS fluoro-L-dopa, kinetics, carbidopa malignancies, 829(ab) Gallium-67

Subject Index â€¢1992 2277 Gallium-67citrate

accuracy of early imaging, pulmonary infection, penetration, 1-131 imaging, 889(ab) scrutiny offederal isotope supply effort, l6N(2) immunocompromised patients, 957(ab) multicrystal, metabolic cardiac imaging, severe Genitourinary system, malignancy, post-treatment aminooxyacetyldeferroxamine, monoclonal coronary disease, 1269 evaluation, FDG PET, 829(ab) anti-CEA antibody, colon carcinoma piled-up events, digital processing, signal Glioma immunoscintigraphy, 1766 deconvolution, 1003(ab) biodistribution ofl-l25 monocional antibody, chest X-ray patterns in HIV-positive patients, rotating, cerebral blood flow, 1-123 IMP, hand-held Nal-crystal detector, l002(ab) 999(ab) 963(ab) distinction ofhigh-grade from low-grade, 11-201 clinical experience with Tc-99m nanocolloid, sensitivity per unit area, true characteristic, SPECT,868(ab) 999(ab) i068(ab) human, hypoxia, F-l8 fluoromisonidazole PET, computed tomography and, extrapulmonary single-headed, rapid radiotracer washout from 2133 tuberculosis, 21 18 the heart, SPECT, 1146 microdosimetry estimations, 1-125 labeled distribution in man, decrease in both transferrin SPECT,imagetruncation,conebeamCT, monoclonal antibody 425, 942(ab) and hepatic Ga-67 concentration, 1701 90l(ab) recurrent, intraarterial carotid artery injection, gastric uptake, AIDS, 643 technology, lawsuit filed by Trionix against Tc-99m HMPAO, 966(ab) In-i 11 leukocyte and, acute sarcoidosis, 2027 ADAC Laboratories, 18N(2) Glomerular filtration rate (GFR) kinetics and therapeutic potential, malignant three-head rotating, Tc-99m DMSA SPECT, measurement in children, adequacy of one lymphoma, 926(ab) renalscan, 102i(ab) blood sample, 873(ab) limitations in usefulness, prediction of Gastric emptying quantitative analysis, dynamic renal studies, recurrences, Hodgkin's disease, 913(ab) attenuation correction, left anterior oblique, factor analysis, 949(ab) metastatic and recurrent soft-tissue sarcoma, geometric mean method, 833(ab) renal plasma flow and, spinal cord injury, 1594 determination oftime, different views, 127 1035(ab) pulmonary disposition, Pneumocyslis gastric motility disturbances, diabetes, single plasma, children, 173(le) pneumonia, 512 scintigraphy, 832(ab) Tc-99m DTPA renal uptake, plasma volume role in staging lymphoma, 1588(le) intragastric distribution and, oil, presence of product, 1712 scanning and MRI, effect oftherapy, Hodgkin's liquid or solid meal, 1283 Glucose lymphoma, 914(ab) measurement ofliquids, 956(ab) absolute whole brain, sensitive marker, scintiscan, primary picnic non-Hodgkin's normal and pathological, magnetic resonance Alzheimer's disease, 940(ab) lymphoma, treatment of Hodgkin's disease, imaging, nuclear medicine techniques, blood-brain transport, regional variations, 1183 956(ab) 908(ab) Tc-99m DTPA aserosol, pulmonary oral glucose solution, type 2 diabetic patients, cerebral metabolism in patients with chorea, complications, HIV infection, 81 1496 striatal F-DOPA uptake, PET, l015(ab) Tc-99m MDP and, scintigraphic differentiation, radionuclide, correlation, anterior-only and deoxyglucose uptake and myocardial blood osteogenic and Ewing's sarcoma, 1063(ab) geometric mean method, 956(ab) flow, ischemia, myocyte viability, 1353 Gallium-67 citrate rate, variable oral erythromycin, diabetic fluorodeoxyglucose and, regional blood-brain disease activity in sarcoidosis, 751 gastroparesis, 833(ab) transport, 1819 scanning in patients with sarcoid uveitis, 1851 secondary gastroparesis, insulin-dependent ingestion, hepatic FDG uptake kinetics, SPECT, biopsy-confirmed residual Hodgkin's diabetes mellitus, 1707 dynamic PET, 945(ab) disease, mediastinum, 345 solid foods, proper definitions, lag phase, 466(le) interictal cerebral metabolism, spontaneously Gallium-68, radiopharmaceuticals that are Gastroenterology, nuclear, Annual Meeting epileptic rat, 1024(ab) retained in myocardium, 931(ab) highlights, 26N(8) metabolic rates, 30- and 45-minute acquisitions, Gallium-68 DF-NGA, regional measurement, Gastro-entero-pancreatic neoplasms, In-i 11 cerebrum, 2103 hepatic receptor biochemistry, 1160 pentatreotidescintigraphy,976(ab) metabolism Gallium-68 platelets, PET imaging, 931(ab) Gastrointestinal neoplasms, metastatic, method for comparing different procedures, Gallium-67 polyclonal IgG, In-i I 1 leukocytes and, radioimmunotherapy, 863(ab) F-18FDO, 157 acute focal inflammatory lesions, l428(ie) Gastrointestinal tract MPTP-primate model, Parkinson's disease, Gamma camera advanced ulcer avid agent, new procedure, 965(ab) Bremsstrahlung imaging, factors affecting Tc-99 phytate sucralfate, l033(ab) metabolism and cerebral blood flow, patient attenuation, 161 bleeding studies, Tc-99m red blood cells, early surviving after CO intoxication, 1696 clinical, imaging therapeutic doses, 1-131, 771 negative images, 202 metabolism and rCBF, simultaneous SPECT collimator structure, l006(ab) gastric bleed studies, applications of amplitude acquisitions, 965(ab) cone-beam transmission CT, imaging, human images, l006(ab) metabolism in tumor, quantitation, FDG and torso, 150 tumor targeting with Tc-99m F023C5 anti-CEA PET,339 cylindrical, unitary construction, ultra high IgG1, role ofCEA content, 892(ab) myocardial utilization, insulin clamp, F-18 resolution collimator, 852(ab) Gastroparesis, secondary to insulin-dependent FDO PET, 1255,1263 event loss estimation, radioimmunotherapy, diabetes mellitus, 1707 oral solution, rapid gastric emptying, type 2 1005(ab) Gated blood-pool imaging diabetic patients, 1496 experimental myocardial infarction in rabbits, cardiac scintigraphy, Tc-99m liposomes, 984(ab) regional metabolism in relation to perfusion, antimyosin Fab conjugation, N-terminal clinical verification, knowledge-based boundary coronary arterydisease, fasting and loading modified DTPA-succinylated polylysine, detector, 938(ab) states, 856(ab) 943(ab) heart, three-dimensional presentation, Fourier time course of uptake in skeletal muscle, first pass radionuclide angiography, clinical amplitude and phase, 458 euglycemic hyperinsulinemia, F-18 2- validation, computer program, l064(ab) knowledge-based LV detection, automatic EF deoxy-2-fluoro-D-glucose study, 1523 gamma-ray calculation, 932(ab) uptake and myocardial blood flow, ischemic miniature CsI photodiode detectors, 1004(ab) left ventricular regions of interest, simulated myocardium, F-18 deoxyglucose, 1346 multiplexer and semiconductor detectors, annealing, 932(ab) utilization, Bayesian regression, estimation of i002(ab) SPECT metabolic rate, 944(ab) gamma variate fit, camera-based method, parametric display, 3-D biventricular utilization and receptor binding, use of linear Tc-99m MAO3 clearance, 991(ab) function, 952(ab) programming, PET studies ofheart and high-resolution plain-paper laser printers, potential added clinical value, 910(ab) brain, 944(ab) hardcopy, nuclear medicine images, Tc-99m, ECG gated PET C-I 1 monoxide, Glutathione, -mediated decomposition, propylene 947(ab) â€œbackgroundâ€•question, 938(ab) amine oxime derivatives, ligand structure, images of beta-emitters, neural network Gene, models ofmental disease, 22N(8) 988(ab) restoration, 889(ab) General Accounting Office (GAO) Gold-199, no-carrier-added, production of, -induced Compton scatter, collimator probe details U.S. isotope troubles, 22N(9) 980(ab)

2278 The Journal of Nuclear Medicine Hippocampus

Granulation tissue, microautoradiographic study deep hypothermic cardiac surgery, choreo defect detection, restoration filters, 842(ab) ofF-18FDG,mousetumortissue,840(ab) athetoid syndrome, brain Tc-99m HMPAO emission and transmission noise propagation, Granulocytes, radiolabeled, kinetics, systemic SPECT,838(ab) non-uniform attenuation correction, vasculitis, 491 detection ofcardiovascular infections, 902(ab) Granulocyte stimulating factor, hypermetabolic radiolabeled leukocytes, 1493 reconstructions, truncated projections, bone marrow, 11-201-chloride uptake, 2014 F-18 4-fluoro-4-deoxy-n-glucose imaging agent, 831(ab) Graves' disease 983(ab) three-detector, simultaneous transmission and euthyroid, autonomously functioning thyroid functional recovery after revascularization, C-i 1 emission, 901(ab) carcinoma, 2024 acetate compared to F-18 FDG, PET, standardization ofcardiac tomographic imaging, thyroid and orbital radiolabelled somatostatin 855(ab) 1434 accumulation, 894(ab) function in neonates and children, arterial standardized imaging, actions ofthe Board of Gravity, -assisted drainage view, diuresis switch operation, PET, 977(ab) Trustees, SNM, 23N(4) renography, 1022(ab) globally denervated human and canine, static PET studies, automated three-dimensional scintigraphic assessment, MIBG uptake, analysis, 1008(ab) H 1444 11-201SPECT,Tc-99mtransmissionsource, high cardiac risk, patients referredfor vascular simultaneous acquisition of emission/ Haloperidol, SPECT imaging ofdopamine D2 surgery,adenosine thallium scintigraphy, transmission data, 2238 receptors, 1-123 IBZM SPECT, 898(ab) 952(ab) transplantation, coronary arteriopathy, SPECT Hand high count rate PET, spatially dependent 11-201 vs. sestamibi, 951(ab) reflex sympathetic dystrophy, excessive deadtime losses, 2226 transplantation rejection in primates, inflammatory response, 936(ab) imaging ofHl histamine receptors, C-il antimyosin agents, 1994 regional dose distribution, staff formulating/ pyrilamine and C-li doxepin, 885(ab) uncomplicated valvular replacement, dispensing/administering immune mechanisms in disease, Malhinckrodt significance, In-li 1 antimyosin radiopharmaceuticals, 1065(ab) Fellow, 17N(6) scintigraphy, 895 unilateral voluntary movement, regional incomplete right bundle branch block, normal volumes, delineation of myocardium, PET and cerebral uptake, Tc-99m exametazine, 1623 coronary angiogram, reversible 11-201 SPECT,933(ab) Hapten, valency, pretargeted immunoscintigraphy, perfusion defects, 1556 Hemsagloma, hepatic, diagnosis, triple-head high murine tumor uptake, 2006 intracoronary Doppler probes and PET, resolution SPECT, 9l8(ab) Head, trauma, remote history of, Tc-99m HMPAOSPECT,52 concordant quantification, flow reserve, Hematoma 836(ab) chronic subdural, cerebral blood flow, Tc-99m Head and neck cancer C-li methioninePET,691 iron, noninvasive in-vivo measurement, 1278 HMPAOSPECT,246 isolatedperfusedrat, subceliulardistribution, subdued, current role ofSPECT, 248 staging, Tc-99m monoclonal antibody 174H.64 SPECT,912(ab) Tc-99mMIBI, 1516 Hematopoletic neoplasia, soft-shell clam, 998(ab) left ventricular mass and infarct size, N-13 Hemiplegla, alternating, childhood, Tc-99m Health and Human Services (HHS) ammonia PET, explanted human hearts for HMPAOSPECT,102l(ab) CLIA-88, 24N(3) validation, 826(ab) Hemodialyzer, cellulose-acetate, comparative Medicare reimbursement, i9N(3) major upward creep, exercise 11-201 myocardial thrombogenicity, 956(ab) new physicians, 19N(3) Hemodynamlcs, captopril-mediated changes, renal nuclear medicine comments on RVUs and SPECT,chronicobstructivepulmonary interim values, l9N(3) disease, 1846 ischemia, 907(ab) Heparin outpatient hospital reimbursement, 23N(3) measurement of receptor concentration, rebundling ofCPT-4 codes, 23N(3) instrumental errors, PET, 882(ab) anticoagulant citrate dextrose and, preparation, relative value unit update committee, 19N(3) metabolic imaging in severe coronary disease, Tc-99m red blood cells with UltraTag RBC SPECTreimbursement,19N(3) 1-123 IPPA, multicrystal gamma camera, kit, 306(le) Heart 1269 anticoagulation, Tc-99m antifibrin Fab' abnormal adrenergic neuron activity, MIBG extraction fraction, first-pass analysis, localization, acute venous thrombosis, Adriamycin-induced cardiomyopathy, 716 978(ab) 1-125 MIBG, 208 MIBG imaging In-l 11 DTPA-heparin, radiolabeling, acute Adriamycin cardiotoxicity, Tc-99m patients with heart failure, 471 protamine, 1028(ab) sestamibi, chick heart cells, 864(ab) prognostic guide, heart failure, 896(ab) Hepatobiliary tract acute onset ofcardiogenic shock, normal MIBG uptake at I-year post-cardiac transplant, excretion ofTc-99m MAG3, 990(ab) coronary arteries, 1558 partial reinnervation in man, 896(ab) Fe-PDGF as MR contrast agent, 974(ab) alcohol intoxication, cocaine distribution and PET scintigraphy kinetics, 946(ab) reorientation, issues in quantitation, 1235 bile lakes, liver transplant infarcts, 997(ab) allograft rejection, detection with 1-123 anti use of linear programming, glucose hepatic transport function, 998(ab) ICAM-i imaging, rats, l000(ab) utilization, 944(ab) Hepatocytes Annual Meeting highlights, 24N(8) postoperative and long-term outcome, lack of evaluation oflocal reduced mass, Tc-99m NGA, blood-pool scintigraphy, Tc-99m liposomes, thalliumredistribution,dipyridamole chronic liver diseases, 998(ab) 984(ab) imaging, 95l(ab) In-i 11, distribution oftransplanted cells, cardiac peak power, severely impaired left radionuclide cardiac volumes, correction for 918(ab) ventricular ejection fraction, good effort Compton scatter, buildup factor, 1642 primary rat culture model, inhibition of hepatic tolerance, 938(ab) rapid radiotracer washout, single-headed gamma uptake, radiolabeled monoclonal cardiovascular training requirements, 23N(4) camera SPECT system, 1146 antibodies, 893(ab) C-il cocaine,distributionandkinetics,521 retrospective post-therapy evaluation, coronary Hevesy Nuclear Medicine Pioneer Award, Michael C-i1HEDkinetics,870(ab) arterydisease patients, PET, 885(ab) J. Welch, l6N(7) complete ischemia-reperfusion, retention of Cu serial measurements of volumes, count-based Hexadecylphosphocholine, deoxyglucose and, PTSM, i026(ab) methods, 1324 design ofcombination therapy, FDG congestive heart failure prediction simultaneous estimation, myocardial perfusion, uptake measurements, l019(ab) Adriamycin cardiomyopathy, 1-125 MIBG, chamber volume, 933(ab) Hip 935(ab) SPECT prosthesis loosening, combined roentgenological Adriamycin therapy, In-lll antimyosin attenuation scans, three-dimensional contrast/radionuclide arthrography, 950(ab) studies, 895(ab) registration, 881(ab) S-ROM prosthesis, perioperative uptake of congestive heart failure, prognosis, 477 cardiofocal collimator, 852(ab)- MDP,950(ab) coronary blood flow, tetrofosmin uptake, defect detection, cone beam geometry, Hippocampus 846(ab) 96i(ab) blood flow, diagnosis ofAlzheimer's disease,

Subject Index â€¢1992 2279 Hippuricacid

SPECT,940(ab) Hyperinsulinemla, time course ofskeletai muscle immunoglobulins, 103l(ab) temporal lobe epilepsy, decreased binding of I- glucose uptake, F-l8 2-deoxy-2-fluoro-D- Immunoglobulin G4, 1-131 chimeric B72.3, Phase I 123 IDEX, muscarmniccholinergic glucosestudy, 1523 trial, metastatic colorectal cancer, 23 receptors, 928(ab) Hyperparathyroidism Immunoglobulins Hippuric acid, ligands, Tc-99m renal function localization ofparathyroid adenoma, Tc-99m conjugation with biotin, dendrimers as linker agents, 988(ab) sestamibi, 1801 molecules, inflammation detection, 986(ab) HIrUIOg,1-123, preparation and evaluation, blood parathyroid imaging, 1807 humanized, use ofSCID mice for in vivo clot imaging, 981(ab) parathyroid scintigraphy, subtraction algorithm, testing, 985(ab) Histidine, second Tc-99m binding site in IgG, 996(ab) Tc-99m labeling, dendrimers as linker l029(ab) primary, localization ofadenomas, Tc-99m molecules, 986(ab) HIV-l:seealsoHumanimmunodeficiencyvirus sestamibi dual-phase study, 894(ab) Immunophoresis, efficacy, reduction of -infected children, seropositive mothers, FDG Hyperplasla, focal nodular, hot spots, TBIDA myeiosuppression, radioimmunotherapy, PET,976(ab) liverscan,918(ab) 863(ab) Hodgkin's disease HypertensIon Immunoscintigraphy biopsy-confirmed residual, Ga-67 SPECT, 345 localization ofpheochromocytoma, C-l 1 HED avidin-biotin, pharmacokinetics, biotin-chelate effect oftherapy on Hodgkin's lymphoma, PET,1125 conjugates, 880(ab) Ga-67scansand MRI, 9l4(ab) non-Goldblatt renovascular, distinctive colon carcinoma, monoclonal anti-CEA limitations in usefulness, gallium imaging, pathophysiology, 907(ab) antibody, Ga-67 anti-CEA 35, 1766 prediction ofrecurrences, 9l3(ab) renal functional response, captopril, diuretic colorectal carcinoma, Loch Ness monster and, primary splenic non-Hodgkin's lymphoma, therapy, 739 1756 Ga-67 scintiscan, 1183 renovascular dosimetric evaluation, In-ill monoclonal Holmium-166, neuron-activated, polymeric captopril renal scintigraphy vs. captopril test, antibody fragments, ovarian cancer, 1113 microspheres, radionuclide synovectomy, 907(ab) dual isotope SPECT, improved demarcation of 398 prognostic value, captopril renal scintigraphy, tumors, occult colorectal carcinoma, Holmlum-l66 hydroxyapatite, radiation 2040 l000(ab) synovectomy, 937(ab) triple radiopharmaceutical renal study, DTPA gamma imaging, experimental myocardial HPLC, Tc-99m monoclonal antibody, recovery renogram, 1034(ab) infarction, rabbits, 943(ab) and calibration, l030(ab) Hyperthermia, monoclonal antibody F(ab')@ human anti-mouse response, chimeric anti-CEA Human anti-mouse antibody uptake in tumor, 958(ab) monoclonal antibodies, 903(ab) novel HAMA radioimmunoassay, ovarian Hyperthyroidism, lithium carbonate therapy, immune mechanisms in heart disease, cancer patients, 852(ab) psychiatric disorders, 996(ab) Mallinckrodt Fellow, l7N(6) patient response, ImmuRAID-CEA, 1002(ab) Hyperventilation, cerebral blood flow, temporal octahedral gallium chelate, monoclonal response after immunoscintigraphy, chimeric lobeepilepsy,968(ab) antibodies, PET, 1366 anti-CEA monoclonal antibodies, 903(ab) Hypoxia ovarian carcinoma, 1-131 labeled 145-9 Human immunodefidency virus (HIV): see also cellular, sepsis, marker F-18 fluoromisonidazole, monoclonal antibody, 905(ab) HIV-i 924(ab) pretargeted, hapten valency, murine tumor dementia, qualitative approach, SPECT, chemistry ofTc-PnAO-nitroimidazole complex, uptake, 2006 l018(ab) 919(ab) technical limitations, Tc-99m anti-CEA noninvasive monitoring of targeting of drugs, 2-fluoro-2-deoxy-n-giucose uptake, human antibodies, lOOl(ab) 3'-fluoro-3'-deoxythymidine, AIDS, cancer cells, 841(ab) two-step, medullary carcinoma ofthyroid, anti 830(ab) humangliomas,F-18fluoromisonidazolePET, CEA/anti-DTPAbispecificmAband -positive patients 2133 In-i 11 DTPA dimers, 9l2(ab) acute infection detection, In-i 11 human myocardium, detection using F-i8 FMISO PET, Impotence immunoglobulin, 903(ab) 2202 paraplegics, treatment choice, nuclear Ga-67 chest X-ray patterns, 999(ab) quantification oftumor oxygenation status, penogram, 1035(ab) pulmonary complications, Tc-99m DTPA F-l8 FMISOPET,l0l0(ab) penile blood flow, tumescence, dual aerosol, Ga-67 scanning, 81 Tc-labeled imaging agent, occlusion of LAD radioisotopic technique, 41 -relatedincidents,infection-controlproblems, coronary artery, rabbit myocardium, quantitative dynamic parameters, 1723(le) nuclear medicine departments, l3N(4) 865(ab) vascular testing, 46 viable tissue, radioiodinated 2-nitroimidazole Hunter, Oscar B. Jr., In Memoriam, 631 Indium, radioindium-labeled autologous platelets, derivatives, SPECT, 891(ab) Huntington's disease, subjects with and at risk for, MIRD dose estimate No. 15, 777 Hysterosalpingography, radionuclide, Tc-99m 1-123 IBZM and Tc-99m HMPAO SPECT, Indiun@ili pertechnetate, radiation dose to ovaries, 970(ab) antisense oligonucleotide, direct method of cell 282 Hydronephrosis labeling, whole blood, 980(ab) antenatal, surgery vs. conservative management, attachment to antibody via popular chelators, impaired renal function, 873(ab) liver homogenates, 1030(ab) assessment, ureteral function, 78 4-ICE, 4-BACE and, chelating agents, 985(ab) collimator and detector interactions, 1004(ab) infantile, natural history of, diuretic renography, Immunoconjugates hepatocytes, distribution oftransplanted cells, 2098 Cu-67 and Sm-l57, tumor therapy, 942(ab) 918(ab) suspected uretero-pelvic junction obstruction, In-l 11 cyclohexl EDTA, anti-CEA F(ab')@ human immunoglobulin, acute infection postnatal assessment, volume expanded monoclonal antibody, human tumor detection, HIV-positive patients, 903(ab) diuretic renography, 2094 xenografted nude mice, 943(ab) imaging ofinflammatory abdominal aortic ureteral status in children, kidney washout, Tc Re-186, effective stabilization, 979(ab) aneurysm, 1553 99m DTPA diuresis renography, 73 simple synthesis and activation, 1,4,7,10- labeledAb-chelator,chelatorstructure,liver, â€œwelltemperedâ€•diuretic renogram, tetraazacyclododecane, 942(ab) lOOl(ab) asymptomatic neonate, 2047 Immunoglobulin G labeled human nonspecific IgG, evaluation, Hydroureteronephrosls, â€œwelltemperedâ€•diuretic localization ofinfection, streptavidin and biotin, inflammatory bowel disease, 9i9(ab) renogram, asymptomatic neonate, 2047 1810 labeled radiopharmaceuticals, quantitative Hydroxyapatite, radiolabeling ofparticies, use, polyclonal, detection ofinflammation, 103l(ab) autoradiographic study, heterogeneous radiation synovectomy agents, 980(ab) second Tc-99m binding site, relation to activity distribution, 1825 Hyperemla, adenosine-induced coronary, early histidine groups, l029(ab) macro- and microscopic biodistribution, bone thallium imaging after PTCA, 2086 transferrin and F(ab'h conjugates, preparation, marrow and testes, rats, 954(ab) Hyperglycemia, cerebral glucose uptake, l-(C-l 1) characterization, 986(ab) octreoscan-i 11, two diasteromers, cancer n-glucose, 908(ab) vs. 1gM antibodies, infection imaging, In-Ill imaging, 900(ab)

2280 The Journal of Nuclear Medicine lodine-123 fl-methyl-branched fatty acid

targeted proteins, diagnostic imaging, 394 enhanced tumor targeting, metabolizable 840(ab) whole-body retention, inflammatory bowel chemical spacer, 957(ab) second Sino-American nuclear medicine disease, 756 IVP ZCE 025, efficacy and safety, colorectal conference, 16N(4) Indium-hi anti-carclnoembryonicantigen, carcinoma, 959(ab) sternal wound, diagnosis, Tc-99m leukocyte monoclonalantibodyZCE025,safetyand preparation ofhigh specific activity, amino imaging, 59 role, colorectal carcinoma, 14 dextran and poly-lysine, 988(ab) targeted proteins, diagnostic imaging, 394 Indium-ui anti-CEA-F(ab')@fragments, radiation Indium-ill monoclonal antibody fragments, Tc-99m antigranulocyte Fab' fragments, dosimetry, tissue distribution, rats, 1654 dosimetric evaluation, scintigraphy, In-lll oxine/Tc-99m Indium-ill antimyosin immunoscintigraphy, ovarian cancer, 1113 HMPAO leukocytes, 903(ab) detection oftumor invasion of muscle layer, Indium-ill monoclonal antimyosin Fab, cardiac Inflammation 841(ab) transplantation rejection, primates, 1994 abdominal aortic aneurysm, In-l 11 imaging, myocardial damage in Adriamycin Indium-i 11 octreoscan, kit development for 1553 cardiomyopathy, 936(ab) cancer detection, 1025(ab) accumulation in inflammatory focus, Tc-99m pathologic cardiac hypertrophy, myocyte Indium-ill oxine anti-fibrin monoclonal antibody, 1181 damage, athletes, 994(ab) absorbed dose and contamination risk, 953(ab) acute focal lesions, In-lll leukocytes, Ga-67 risk ofcongestive heart failure, Adriamycin Tc-99m HMPAO leukocytes, Tc-99m polyclonal IgG, i428(le) therapy, 895(ab) antigranulocyte Fab' fragments, infectious antimyosin imaging, detection of tumor scintigraphy, significance, uncomplicated diseases, 903(ab) invasion of muscle layer, 84l(ab) valvular replacement, 895(ab) Tc-99m leukocyte imaging and, simultaneous conjugation of human immunoglobulin, uptake, chemotherapy-induced kidney disorder, imaging, community hospital, 902(ab) dendrimers as linker molecules, 986(ab) 309(le) Indium-ill pentatreotide, scintigraphy, gastro imaging uptake in acute and remote myocardial entero-pancreatic endocrine tumors, current role, labeled autologous leukocytes, infarction, comparison with pathologic 976(ab) 65 findings, 587 Indium-ill platelets, thrombocytopenia and Tc-99m dexamethasone phosphate, i027(ab) Indium-ill antimyosin Fab, myocardial hepatic sequestration, GM-CSF, 923(ab) radiolabeled polyclonal IgG, 103l(ab) distribution, nontransmural infarction, 223 Indium-ill polyclonal IgG reflex sympathetic dystrophy ofthe hand, Indium-ill antimyosin monoclonai antibody, carbohydrate modification, sites of bacterial excessive inflammatory response, 936(ab) scintigraphy, time course, myocardial infection, 1378 tumor and, one-step labeling kit, Tc-99m HIG, infarction, 1501 1-125 LDL and, uptake, experimental arterial 1028(ab) Indium-lu BAD-Lym-l, radiochemistry and wall injury, 845(ab) Inflammatory bowel disease pharmacokinetics, l030(ab) single radiopharmaceutical kit, 1024(ab) In-Ill labeled human nonspecific Indium-ill B3 monoclonal antibody, Indium-ill somatostatin analogue immunoglobulin G, 9l9(ab) biodistribution in athymic nude mice, scintigraphy, visualization, malignant In-l 11 whole-body retention, 756 human epidermoid carcinoma xenografts, lymphoma, 903(ab) quantitation of intestinal protein loss, In-l 11 842(ab) Tc-99m somatostatin analogue and, transferrin, 919(ab) Indium-ill B72.3 monoclonal antibody, preparation, preliminary evaluation, Tc-99m glucoheptonate white blood cells, pharmacokinetics in colorectal cancer, 498 85 i(ab) 998(ab) Indium-ill BrE-3 antibody, Indium-ill transferrin, quantitation of intestinal In@nemoriam radioimmunolocalization of breast cancer, protein loss, inflammatory bowel disease, Donald W. Cole, Jr., 1726 Phase I study, 912(ab) 919(ab) Oscar B. Hunter, Jr., 631 Indium-ill CilO anti-CEA monocbonalantibody, Indium-ill white blood cells Insulin CTand,metastasesdetection,colorectal chronic osteomyelitis, site of fracture or surgery, clamp, myocardial glucose utilization, F-18 carcinoma, 904(ab) lower extremity, 902(ab) FDGPET, 1255,1263 Indium-ill cyclohexyl EDTA, anti-CEA F(ab')@ necrotizing tracheobronchitis, 1704 -dependent diabetes mellitus, secondary monoclonal antibody and, human tumor Infants: see also Pediatric patients gastroparesis, 1707 xenografted nude mice, 943(ab) Tc-99m MAO3 clearance, preliminary â€œnormalâ€•Interleukin 2, tumor uptake of monoclonal Indium-ill CYT-356, preoperative identification, values, 102l(ab) antibody, 934(ab) metastatic prostate carcinoma, lOOl(ab) Infection Intestine, quantitation of protein loss, In-i 11 Indium-Ill DOCT, 1-123 TOCT somatostatin acute, In-l 11 human immunoglobulin, HIV transferrin, inflammatory bowel disease, analogues and, somatostatin receptor positive patients, 903(ab) 9l9(ab) positive neoplasms, 914(ab) AIDS and infectious disease, Annual Meeting lodides, contrast material, potential effects, Indium-ill DTPA-D-Phe-l-octreotide highlights, 24N(8) radioactive thyroid uptake, 237 handling by isolated perfused rat liver, 955(ab) assessment of infectious conditions, Iodine-l23 somatostatin receptor scintigraphy, 652 musculoskeletal system, Tc-99m HIG, 1-125 and I-I 31 labeled compounds, Indium-ill DTPA-heparln, radiolabeling and 839(ab) radiotoxicity, mouse testes, 2196 pharmacokinetics, protamine, bacterial, effects ofcarbohydrate modification, myocardial viability after infarction, exercise biodistribution,l028(ab) polycional IgG, 1378 redistribution SPECT 11-201, 906(ab) Indium-ill IgG bone, Tc-99manti-granulocyteantibodies,526 scintigraphic follow-up, differentiated thyroid infectious diabetic foot complications, 950(ab), detection in rats, Tc-99m liposome labeling carcinoma, l020(ab) 1330 procedure, i027(ab) Tc-99m and reflex sympathetic dystrophy ofthe hand, diagnosis of mycotic aneurysm, leukocyte dual radionuclide data acquisition, excessive inflammatory response, 936(ab) scintigraphy, 1486 quantitative brain SPECT, 972(ab) Indium-ill immunogiobulins, infection imaging, differentiation from malignant CNS lesions, SPECT,brain,2030 1gM vs. IgO antibodies, 103l(ab) FDG PET, AIDS, 838(ab) Iodine-i23 BMIPP Indium-ill leukocytes F-18 FDG, 925(ab) hypertrophic cardiomyopathy, l9l4(le) diffuse pulmonary uptake, drug-induced focal, radiolabeled proteins, biodistribution and TL-201 and, assessment, ischemic but viable pneumonitis, I 175 kinetics, 388 myocardium, 885(ab) Ga-67 and, acute sarcoidosis, 2027 imaging focal sites, Tc-99m hydrazino Iodine-123 UT, SPECT, monoamine transporter Ga-67 polycional IgG and, acutiJ@@al nicotinamide conjugated chemotactic sites, non-human primate brain, 945(ab) inflammatory lesions, 1428(le) peptides, 910(ab) Iodine-l23 ERC 9, potential new pancreatic infection mishaps, 27N(4) imaging in patients with streptavidin, imaging agent, 84l(ab) Indium-ill monoclonal antibody radiolabeled biotin, 924(ab) Iodine-123 fl-methyl-branched fatty add, chimeric cT84.66, radiation dose estimates, localization, role for avidin-biotin, 1816 myocardial emission computed 953(ab) orthopedic, value of bone marrow scanning, tomography, hypertrophic cardiomyopathy,

Subject Index â€¢1992 2281

orosDective validation. sinale samolÃ³lechniaue. labetedaÃ¼tologous.current roie. imaging Iodlne-123 HIDPM

6 increased lung uptake, ischemic heart disease, xenografts, 1021(ab) Iodlne-l23 HIDPM, portal systemic shunt 955(ab) intraoperative detection, pheochromocytoma, fraction quantification, liver diseases, mechanisms ofdown-regulation, idiopathic i020(ab) 997(ab) cardiomyopathy, 896(ab) uptake by serotonin transporter, 935(ab) Iodlne-l23 hirulog, preparation and evaluation, neural crest tumors, l072(ab) Iodine-l25 monoclonal antibody blood clot imaging, 98i(ab) prognosis in congestive heart failure, 477 biodistribution, hand-held NaI-CryStaIdetector, Iodlae-123 IBF, SPECF, precinical study, D2 scintigraphy, metastatic carcinoid tumors, 1121 l002(ab) dopamine receptor, 870(ab) uptake at i-year post-cardiac transplant, partial microdosimetry estimations, internalization, Iodine-l23 IBZM reinnervation in man, 896(ab) human glioma cells, 942(ab) dopamine D2 receptors, dynamic SPECT and Iodine-123 MIHA, myocardial viability, FDG Iodine-125 PAB, preparation and characterization, whole body imaging, 896(ab) PET, 953(ab) potential malignant melanoma imaging quantitation in human plasma, 87l(ab) Iodine-i23 somatostatin analog, dosimetry and radiopharmaceutical, 889(ab) SPECT biodistribution, neuroendocrine tumors, Iodine-l25 QNB, muscarinic receptor binding, differential diagnosis of Parkinsonism, 1613 pharmacokinetic sensitivity, rat brain, 9i7(ab) Iodlne-l23 SP4, imaging atherosclerosis, 845(ab) 883(ab) dopamine D2 receptors, 1964 Iodlne-i23 TISCH, dosimetry, 954(ab) Iodine-125 Tyr-3-octreotrlde, handling by isolated dopamine D2 receptors, effects of age, Iodlne-i23 TOCr perfused rat liver, 955(ab) 897(ab) In-i 11 DOCT somatostatin analogues and, Iodlne-l3l dopamine D2 receptors, haloperidol, 898(ab) somatostatin receptor-positive neoplasms, amount and tumor size, Alderson phantom, dopamine D2 receptors, Parkinson's disease, 914(ab) planar imaging, 925(ab) 9l7(ab) scintigraphy, metastatic carcinoid tumors, 1121 anti-pan B-cell antibodies, dopamine D2 receptors, Parkinson Iodlne-123 Tyr-3-octreotlde, compared to In-l 11 radioimmunotherapy, B-cell lymphoma, syndromes, 9l7(ab) DTPA-D-Phe-l-octreotide, somatostatin 863(ab) dopamine D2 receptors, unilateral receptor scintigraphy, 652 Bl andBC8antibodies,traceandtherapeutic Parkinson's disease, 1016(ab) Iodine-iN 3F9, PET, tumor dosimetry, amounts, 864(ab) dopamine D2 receptors, Wilson's disease, radioimmunotherapy in a child with camera-induced scatter, collimator penetration, 897(ab) neuroblastoma, 2020 889(ab) Parkinson's disease, multi-system atrophy and Iodlne-i24 monoclonal antibodies, PET, c-erbB-2 contamination, thyroid cancer patients, 2110 dystonia, 1018(ab) protein overexpression, breast cancer, 2154 1-123and1-125labeledcompounds, semiquantification, scatter correction, 972(ab) Iodlne-i25 radiotoxicity, mouse testes, 2196 subjectswithandat riskforHuntington's anti-P185HER2 monocional antibody, animal imaging therapeutic doses, clinical gamma disease, 970(ab) tumor model, 934(ab) camera, 771 Iodlne-123 IDEX, decreased binding to 1-123 and 1-131 labeled compounds, outpatient nuclear medicine therapy, petition muscarinic cholinergic receptors, radiotoxicity, mouse testes, 2196 would ease strictures, l3N(7) hippocampus, temporal lobe epilepsy, rat brain blood flow, plastic scintillation pan-B-cell monoclonal antibody, B-cell 928(ab) detectors, position-sensitive lymphoma,radioimmunotherapy,893(ab) Iodlne-i23 ILlS, SPECT, dopamine D2 receptors, photomultipliers,1003(ab) post-thyroid cancer therapy, radiation safety supranuclear palsy, lOl9(ab) Iodine-l25 altanserine, synthesis, potential ligand, considerations, 1402 Iodine-i23 IMP SPECT and serotonin S@receptors, QSPECT ofphantom, transfer ofCT cola, cerebral blood flow i023(ab) manual alignment, 925(ab) rotating gamma camera, 963(ab) Iodlne-l25 antimyosin, interference of myosin radioimmunotherapy ofleukemia, bone marrow Tc-99m HMPAO and, uptake in drug abuse, heavy chain fragments, myocardial radiation absorbed dose estimation, 941(ab) i015(ab) infarction, 895(ab) taste dysfunction, thyroid cancer, 996(ab) SPECT Iodlne-i25 digoxin, high myocardial therapeutic amounts, iodination of monoclonal cerebral blood flow, no arterial sampling, accumulation, 545 antibodies, 982(ab) 969(ab) Iodlne-i25 epidepride, 1-125 ioxipride and, therapy for thyroid cancer, quantitative cerebral perfusion, progressive supranuciear alternate syntheses, 982(ab) dosimetric approach, 894(ab) palsy, 704 Iodlne-l25 epidermal growth factor, handling by therapy for thyroid carcinoma, complications, dementia, 10l5(ab) isolatedperfusedratliver,955(ab) sequela and dosimetry, 2214 nondemented older patients, Down's Iodlne-125 fibrinogen, fibrin deposition, coronary -treated patients, risk to others, 2116 syndrome, 967(ab) artery injury, 845(ab) utility in well-differentiated thyroid cancer, partition coefficient, regional cerebral blood Iodine-l25 iodoacylcycloadenosin-4'-ene, synthesis chest X-rays, bone scans, 894(ab) flow,91i(ab) and metabolism, potential inhibitor, S whole-body scan, replacement with Tc-99m HMPAO and adenosyl-L-homocysteine hydrolase, thymgiobulin measurement, l72Qe) dual-isotope brain imaging, normal 980(ab) Iodlne-l3l chimeric 5723, Phase I trial, volunteers, 827(ab) Iodlne-i25 5-lodo-6-nitroqulpszlne, synthesis and metastatic colorectal cancer, 23 regional cerebral blood flow, SPECT and evaluation, presynaptic serotonin ligand, Iodine-l31 hippurate, Tc-99m MAG3 or, MEl, 10l2(ab) 890(ab) functional and anatomic evaluation, renal N-Isopropyl-Iodine-123 IMP, SPECT, regional Iodine-i25 ioxlpride, 1-125 epidepride and, transplants, l035(ab) cerebral blood flow, 965(ab), 1741 alternate syntheses, 982(ab) Iodlne-l3iliplodol,high-dosetargetedirradiation, Iodine-l23 iodosmphetamine, scintigraphy, Budd Iodlne-125 LDL liver tumors, 1020(ab) Chiari syndrome, 744 binding to parenchymal and non-parenchymal Iodlne-131 LL2 monoclonal antibody, repeated Iodlne-i23 IPPA cells, normal and estradiol-stimulated rat low-dose radioimmunotherapy, lymphoma, metabolic cardiac imaging, multicrystal gamma liver,i028(ab) 863(ab) camera, severe coronary disease, 1269 In-l 11 polyclonal IgG and, uptake, Iodine-l3l Lym-l, body and blood clearance and SPECT, myocardial involvement, systemic experimental arterial wall injury, 845(ab) marrow radiation dose, B-cell malignancies, myopathies, 995(ab) Iodlne-125 LSD, improved preparation, 982(ab) 94l(ab) Iodlne-l23 2'-ISP, SPECT, D2 dopamine Iodlne-125 MIBG Iodlne-l31 MIBG receptors, 897(ab) abnormal cardiac adrenergic neuron activity, bone scintigraphy and, detection of Iodlne-l23 [SD, improved preparation, 982(ab) Adriamycin-induced cardiomyopathy, 208 neumblastoma, 1735 Iodlne-l23 MIBG Adriamycin and congestive cardiomyopathy, brain imaging, 33N(9) cardiac imaging 215 diagnosis ofpheochromocytoma, 833(ab) prognostic guide, heart failure, 896(ab) intracellular distribution, electron microscopic scintigraphic assessment ofuptake, globally prognostic value, heart failure, 471 autoradiography, neumblastoma denervated human and canine hearts, 1444

2282 The Journal of Nuclear Medicine Leukocytes

scintigraphy Joint induced acute renal failure, 948(ab) diagnostic value, kindred with MEN-Il, inflammation renal artery stenosis, cortical residual activity, l065(ab) Tc-99m HIG, 839(ab) captopril renography, 906(ab) pitfalls, diagnosis ofneuroblastoma, 930(ab) Tc-99m HIG and bone scans, rheumatoid renal tubular transport, Tc-99m complexes, therapy for carcinoid syndrome, 834(ab) arthritis, 840(ab) 920(ab) Iodlne-13l monoclonal antibody Journal of Nuclear Medicine (JNM), seeking new suspected uretero-pelvic junction obstruction, bone marrow suppression, recombinant G-CSF, editor, 20N(7) postnatal assessment, volume expanded 933(ab) diuretic renography, 2094 CC49 K Tc-99m, ligands related to MAG3 and hippuric imaging considerations, l00l(ab) acid, 988(ab) radioimmunotherapy SPECT images, CT and Kanji-Kana reading process, analysis by PET, Tc-99m DMSA high-resolution SPECT, three advanced colorectal cancer, l002(ab) 827(ab) head rotating gamma camera, 102i(ab) immunoscintigraphy of ovarian carcinoma, Kawasaki syndrome, cardiac perfusion Tc-99m DTPA uptake-plasma volume product, 905(ab) abnormalities, long-term follow-up, 929(ab) glomerular filtration rate, 1712 radioimmunoscintigraphy, renal cell carcinoma, Kidney Tc-99m L,L-EC imaging agent, 551 913(ab) blood flow, convection-diffusion model, 949(ab) Tc-99m MAG3 Iodlne-l3i monoclonal antibody fragments, bone cancer, pre-operative sterilization, intra-arterial hepatic activity, 992(ab) marrow toxicity, 941(ab) Sm-153 microspheres, 1024(ab) simplified ERPF determination, 1034(ab) Iodlne-13l Mu-9 IgG, Re-188 and, therapeutic cationic renal tubular agent, Tc-99m DACH, Tc-99m scan, diagnosis, bleeding mycotic iliac potential, single and fractionated doses, normal human volunteers, 923(ab) aneurysm, 1548 l000(ab) chemotherapy-induced disorder, antimyosin transplantation Iodlne-i3l octreotide, dosimetry and antibody uptake, 309(le) functional and anatomic evaluation, Tc-99m biodistribution, 1-123 somatostatin analog, clearance, single-injection multisample MAO3 vs. 1-131 hippurate, 1035(ab) neuroendocrine tumors, 1613 methods, 948(ab) kinetics and chronic rejection, renal artery Iodlne-i3i OIH comparison ofTc-99m direct vs. N2S2 chelate, stenosis, 923(ab) radiation dosimetry, human biodistribution labeled NR-LU-l0 Fab', tumored nude renal artery stenosis, captopril-enhanced studies, 33 mice, 909(ab) scintigraphy, 263 single-injection multi-sample renal clearance computer-based nuclear medicine teaching file, Tc-99m mertiatide, atlas, l073(ab) methods 1073(ab) transplant hypertension, iliac artery stenosis, comparison, 948(ab) -depth correction in renal uptake rate, Tc-99m 1178 optimum sample times, 948(ab) DMSA,compartmentmodeling,l004@ab) triple radiopharmaceutical renal study, standard Iodine-13i l,2-Pal-3-IPPA, site specific/stable direct and indirect Tc-99m labeled antibody, DTPA renogram, renovascular radioiodination, pancreatic lipase, urine comparison in mice, 909(ab) hypertension, 1034(ab) analysis, 1028(ab) diuretic MAG3 renal scintigraphy, routine unexpected pressor responses, captopril renal lodocholesterol, radiation injury after interstitial protocol, congenital and acquired renal scintigraphy, 906(ab) injection, 17226e) disorders, 1035(ab) uptake ofavidin, isoelectric point, 986(ab) 5-Iododeoxyuridine, efficacy of DMSA renal scans, variability, standardized washout during Tc-99m DTPA diuresis radioimmunotherapy, human tumors rating scale, 922(ab) renography, ureteral status, children, 73 growing in nude mice, 1530 dynamic studies, quantitative analysis, factor Knee, acute ligamentous injuries, subchrondrai 3-Iodophenyliwthiocyamte, radiodinated, analysis, 949(ab) bone infractions, scintigraphy and MEl, coupling to monoclonal antibodies, effects ofdipyridamole on function, Tc-99m 516 1029(ab) DTPA, 355 Krypton-Slm lomazenil, binding to human benzodiazepine excretion of Tc-99m-labeled organic cations, anatomy ofradioisotope lung scanning, 676 receptor, dynamic SPECT, 91 l(ab) 2190 go with the flowâ€”buthow fail, 1939 Ion mass spectrometry microscopy, secondary, functional clearance, captopril, diuretic therapy, multiple-gated imaging, right ventricular Tc-99m mapping, leukocytes, 2162 739 volume determination, 932(ab) Iron imaging with Tc-99m 2GAM, 923(ab) separation of regional ventilation and volume, hepatic and cardiac, noninvasive in vivo impaired renal function, antenatal 1935 measurement, 1278 hydronephrosis, surgery vs. conservative Kupifer cells, dosimetry at cellular level, Tc-99m transferrmnand hepatic Ga-67 concentration, management,873(ab) sulphur colloid injection, 380 Ga-67 distribution, 1701 model-based quantitation, knowledge-based Kuwait, burning oil wells and air pollution, lung Irradiation factor analysis, 947(ab) imaging studies, 978(ab) high-dose targeted, primary liver tumors, 1-131 normalized diuretic renogram parameters, diagnosis, obstructive uropathy, 923(ab) lipiodol, l020(ab) L total body, toxicity, non-Hodgkin's lymphoma, parenchymal renal lesion after ESWL, Tc-99m 960(ab) DMSA, 990(ab) Iminin, platelet-binding, direct Tc-99m labeling, Ischemia PET studies, use ofabdominal aorta, arterial 103l(ab) delayed, cerebral angioplasty and vasospasm, input function determination, 613 Landau-Kleffner syndrome, regional cerebral brain SPECT, 1789 plasma flow and glomerular filtration rate, perfusion, related childhood aphasias, 1758 renal, captopril-mediated hemodynamic spinal cord injury, l035(ab) Language, analysis ofKanji-Kana reading process changes, 907(ab) post-transplanted patients, by PET, 827(ab) Isoeiectrlc focusing, chromatofocusing studies, radioangioscintigraphy, 991(ab) L4ead-203immunoconjugates, biodistribution, monoclonal Fab', 2148 potential imaging agents, Tc-99m MAG3, chelate rigidity and denticity, l030(ab) Isotec, Inc., rejection ofpetition, l4N(6) 919(ab) Leukemia, bone marrow radiation absorbed dose Isotopes potential of camera-based method, MAG3 estimation, 1-131 radioimmunotherapy, DOE's problems, 34N(lO) clearance, gamma variate fit, 99l(ab) 941(ab) medical use of, Nuclear Regulatory pre- and post-pyeloplasty, functional Leukemia, myelogenous, acute, modeling and Commission, 30N(9) assessment, diuretic renogram, 977(ab) dosimetry, anti-CD33 monoclonal antibody trouble in U.S., GAO probe, 22N(9) procedures of choice in renal nuclear medicine, Ml95,941(ab) 175(le) Leukocytes J prospective validation, single sample technique, labeledautologous,currentrole,imaging Tc-99m MAG3 clearance, 1620 inflammation, 65 Jaundice, neonatal, diagnostic criteria for biliary rapid tubular transport, structural requirements, radiolabeled, detection, cardiovascular atresia, Tc-99m EHIDA hepatobiliary Re and Tc-99m complexes, 900(ab) infections, 1493 scintigraphy, 899(ab) real time monitoring, risk of radiocontrast scintigraphy, diagnosis ofmycotic aneurysm,

Subject Index â€¢1992 2283 Uganda

1486 isolatedperfused,1-125Tyr-3-octreotide,In-i 11 enhanced V/Q mismatch sign, pulmonary Tc-99m mapping, secondary ion mass DTPA-D-Phe-l-octreotideand1-125 embolism, 1072(ab) spectrometry microscopy, 2162 epidermal growth factor, 955(ab) imaging studies of persons exposed to air Ligands lesions, Tc-99m monoclonal antibodies and pollution, burning oil wells in Kuwait, angiotensin II, distribution, imaging potential, Tc-99m colloid, image subtraction analysis, 978(ab) 900(ab) 913(ab) increased uptake ofl-123 MIBG, ischemic heart binding and animal biodistribution, no-carrier model-based quantitation, knowledge-based disease, 995(ab) added radioiodinated cocaine analogs, factor analysis, 947(ab) indeterminate probability scan, decision 981(ab) necrosis, Tc-99m medronate, Budd-Chiari analysis, l251(le) chemical family of, dopamine D2 receptors, syndrome, 1390 infection, accuracy ofearly gallium imaging, 98 l(ab) normal and estradiol-stimulated, binding of immunocompromised patients, 957(ab) diaminedithiol, labeling with Re-l86, l932(ab) Tc-99m LDL and 1-125 LDL, l028(ab) intermediate probability/indeterminate scans, flumazenil, quantification of benzodiazepine PET studies, use of abdominal aorta, arterial pulmonary angiography, 849(ab) receptors, PET, 883(ab) input function determination, 613 mean transit times of teboroxime, compared to macrocyclic, bifunctional DTPA and, serum portal systemic shunt fraction quantification, Tc-99m pertechnetate, 846(ab) stability studies with Y-88, 103l(ab) 1-123 HIDPM, 997(ab) metastases, microdistribution, monoclonal PET, cerebral dopamine D2 receptors, 847(ab) reduced accumulation, radiolabeled monoclonal antibodies, 957(ab) phosphorus-nitrogen backbone, formulation, antibodies, In-l 11 thioether-poly-L-lysine MIBG extraction fraction, first-pass analysis, new radiopharmaceuticals, 1072(ab) DTPA monoclonal antibody 716 radioiodinated high-affinity dopamine D2 TP41.2F(ab')2, 570 model-based quantitation, knowledge-based receptor, in vivo comparison, 848(ab) -spleen scan, fatty liver, masquerade as factor analysis, 947(ab) -receptor modeling, PET, multi-injection neoplasm, 258 neutrophil sequestration, intercellular adhesion approach, 943(ab) TBIDA scan hot spots, focal nodular molecules, endotoxemia, 1023(ab) relation to MAO3 and hippuric acid, Tc-99m hyperplasia, 918(ab) perfusion and ventilation scans, severe diffuse renal function agents, 988(ab) transplantation, bile extravasation, scintigraphy, obstructive airway disease, 1072(ab) structure, glutathione-mediated decomposition, 115 radioaerosol clearance, effect of molecular size, propylene amine oxime derivatives, 988(ab) transplant infarcts, bile lakes, hepatobiliary l022(ab) synthesis ofl-125 altanserine, SPECT, serotonin scintigraphy, 997(ab) radioisotope scanning, anatomy of, 676 52 receptors, l023(ab) transport function, hepatobiliary scintigraphy, radiolabeled granulocyte kinetics, systemic Tc and Re complexes, unsymmetrical BAT 998(ab) vasculitis, 491 ligand, 989(ab) volumemeasurementwith SPECT,autopsyand radiopulmonary clearance, appropriate Light, photic stimulation study, arterial partial NMRimaging,1066(ab) background subtraction, 836(ab) pressure, carbon dioxide, 827(ab) Y-90 microsphere therapy, three-dimensional scan and pulmonary arteriogram improvement, Liposomes, Tc-99m, new labeling procedure, tumor dosimetry, 735 urokinase, 849(ab) infection detection in rats, 1027(ab) Liver disease, diffuse alcoholic, emission scan interpretation, 1417, 1422 Lithium carbonate, therapy for psychiatric tomography, 1337 interobserver variation, 978(ab) disorders, hyperthyroidism, 996(ab) Liver neoplasms scintigraphy, follow-up, transplantation, 835(ab) Utbotripsy, extracorporeal shockwave, dual energy acquisition, 11-201 and Tc-99m single transplant, quantitative exercise-rest parenchymal renal lesion, Tc-99m DMSA, phytate, high-resolution three head SPECT, ventilation-perfusion imaging, 835(ab) 990(ab) 976(ab) solitary pulmonary nodule, differential Liver evaluation with F-18 FDG PET, 333 diagnosis, FDG PET, 836(ab) activity in Tc-99m MAG3 renal scans, 992(ab) high-dose targeted irradiation, 1-131 lipiodol, thallium uptake, adenosine Tl-20l scintigraphy, arteriovenous malformations, embolization, 1020(ab) 1600 hereditary hemorrhagic telangiectasia, 260 imaging by 11-201 and Tc-99m phytate, high uptake of Tc-99m sestamibi, correlation with chelator structure, In-l 11 labeled Ab-chelator, resolution three-head SPECT, 9l8(ab) LV ejection fraction, 846(ab) i00i(ab) Low-level radioactive waste (LLRW) ventilation, Tc-99m DTPA and Tc-99m chronic disease, evaluation oflocal reduced California radioactive waste site, licensing desferoxami.ne aerosols, SPECT, 835(ab) mass, Tc-99m NGA, 998(ab) decision, 40N(9) ventilation-perfusion scans cirrhosis, portal venous blood flow, pulsed disposal of, 30N(l0) computer-assisted diagnosis, pulmonary Doppler and per-jejunum scintigraphy, federal deadline, activists and politicians, embolism, 1003(ab) 997(ab) 15N(i) number ofsegmental mismatches, likelihood clearance ofTc-99m HIDA derivatives, federal policy, challenged, 25N(12) ofpulmonary embolism, 849(ab) hyperbilirubinemic states, 1551 gauging the effect ofcourt ruling, 28N(8) Lung neoplasms diagnosis ofhepatic hemangioma, triple-head repository closures, 34N(9) mediastinum, FDG PET staging, 828(ab) high-resolution SPECT, 918(ab) shouldering burden of, 20N(6) radioimmunodetection, human monoclonal diagnostic imaging, 1344 waste network, 34N(9) antibody, 958(ab) enhanced tumor targeting, metabolizable Low-Level Radioactive Waste Policy Amendments treatment planning and monitoring, F-l8 FDG chemical spacer, In-I 11 monoclonal Act (LLRWPA) PET,975(ab) antibody, 957(ab) shouldering burden, 20N(6) Lymphedema FDG uptake kinetics, impact of glucose Supreme Court to hear case, 33N(3) lymphoscintigraphy, 999(ab) ingestion, dynamic PET, 945(ab) Lung multiscintigraphic imaging approach, 874(ab) hepatic arterial-to-portal venous blood flow, blood flow, protein flux measurements, PET, Lymph nodes validation, radionuclide techniques in an 1661 mediastinal, mapping, F-18 deoxyglucose PET, animal model, 239 chronic obstructive pulmonary disease, major 828(ab) hepatic sequestration ofln-l 11 platelets, upward creep of heart, exercise 11-201 reactive, infection and, F-18 FDG, 925(ab) thrombocytopenia, GM-CSF, 923(ab) myocardial SPECT, 1846 Lymphocytes, Tc-99m HMPAO, radiotoxicity hepatobiliary scintigraphy, intrahepatic vs. complications of HIV infection, Tc-99m DTPA study, micronucleus assay, 1167 extrahepatic cholestasis, 1186 aerosol, Ga-67 scanning, 81 Lymphoma homogenates ofln-l 11 and Y-90, attachment to diffuse pulmonary uptake, In-l 11 leukocytes, F-l8 FDG PET, 532 antibody via popular chelators, l030(ab) drug-induced pneumonitis, 1175 Hodgkin's, effect oftherapy, Ga-67 scans and inhibition ofhepatic uptake, radiolabeled diseases, V/Q ratio frequency distribution, MRI, 9l4(ab) monoclonal antibody, primary rat 1023(a) malignant hepatocyte culture model, 893(ab) disposition ofgallium-67, Pneumocystis F-18FDG scintigraphy,chemotherapeutic iron, noninvasive in vivo measurement, 1278 pneumonia, 512 impact, 858(ab)

2284 TheJournalof NuclearMedicine Monoclonal antibodies

In-lll somatostatin analogue scintigraphy, microautoradiography, 984(ab) Y-90 therapy, three-dimensional tumor 903(ab) MEN-H, kindred with, diagnostic value, 1-131 dosimetry, 735 kinetics and therapeutic potential, Ga-67, MIBO scintigraphy, l065(ab) Microwave 926(ab) Meningloma, prediction ofhistological type, boiling procedure for Cardiolite vials, 468(le) proliferative activity, PET F-l8 FDC}, 325 11-201 SPECT, 97l(ab) breakage ofTc-99m sestamibi vial, 176(le) non-Hodgkin's Mental disease, genetic models, 22N(8) MIRD dose Ga-67 scintiscan, 1183 Metalodobenzylguanldine, heart and lung approach and limitations, 781 toxicity, total body irradiation, 960(ab) extraction fraction, first-pass analysis, 716 estimate No. 15, radioindium-labeled optimal imaging time for thallium, tumor agent, Metastasis autologous platelets, 777 844(ab) bone, pharmacokinetics, Re-l86 after Re-186- pamphlet No. 14, urinary bladder model, repeated low-dose radioimmunotherapy, 1-131 HEDP, 646 radiation dose calculations, 783 LL2 monoclonal antibody, 863(ab) bone cancer, escalating dose schedule, Sm-153 Misonidazole, retention after occlusion of LAD staging, role ofgallium scanning, 1588(le) EDTMP, 1451 coronary artery, regional myocardial thryoid, uptake, Tc-99m MIBI and 11-201 bone disease, multidose Sm-153 EDTMP, pain metabolism, blood flow, 993(ab) chloride, 1396 palliation, 992(ab) Mitral valve disease, Tc-99m radionucide Lymphoma, B-cell, 1-131 anti-pan B-cell bone pain, different therapeutic doses, Sr-89, angiography, thrombosis detection, left antibodies, radioimmunotherapy, 863(ab), 937(ab) atrial appendage, 365 893(ab) breast cancer Molybdenum-99 Lymphosdntigraphy clinical value, CA 15-3 plasma levels, 854(ab) DOE actions, l4N(6) diagnosis oflymphedema, 999(ab) radioimmunotherapy, 862(ab) doubts about U.S. production, 2lN(i0) internal mammary, breast cancer prognosis, carcinoid tumors, scintigraphic comparison, government plan, slow advancement, 1lN(2) 859(ab) 1-123 MIBG and 1-123 TOCT, 1121 threatened reactor worker strike, 19N(9) Tc-99m dextran, transverse rectus abdominus colon cancer, dose fractionation, radiolabeled Monoamine, transporter sites, 1-123 CIT SPECT, myocutaneous flap, autogenous breast antibodies, 1648 non-human primate brain, 945(ab) reconstruction, 859(ab) detection in colorectal carcinoma, In-lll CllO Monoclonal antibodies anti-CEA monoclonal antibody, CT, All, diagnosis, neuroendocrine tumors, 834(ab) M 904(ab) @9/A4amyloid, Alzheimer's disease, angiopathy, gastro-entero-pancreatic endocrine tumors, 2184 Magnetic resonance spectroscopy, fluorinated In-l 11 pentatreotide scintigraphy, 976(ab) Annual Meeting highlights, 13N(8) polymericmolecularprobes,non-invasive gastrointestinal cancer, radioimmunotherapy, anti-CEA/anti-DTPA bispecific, two-step assessment, pH, 974(ab) 863(ab) immunoscintigraphy, medullary carcinoma Malformations, intracranial arteriovenous, lung, microdistribution, monoclonal antibodies, ofthyroid, 9l2(ab) sequential high resolution SPECT, Tc-99m 957(ab) antiferritin, linker-conjugated F(ab'), fragments, RBC and Tc-99m HMPAO, 839(ab) prostate carcinoma, preoperative identification, 987(ab) Malignancy bonelesions,11-201uptakepattern,869(ab) In-lll CYT-356, lOOl(ab) anti-fibrin, Tc-99m labeling, accumulation in prostate carcinoma to bone, strontium-89, low inflammatory focus, 1181 genitourinary, post-treatment evaluation, FDG PET,829(ab) dose infusion cisplatin, 1437 anti-pan-carcinoma NR-LU-l0, biotin conjugates, radioimmunotherapy, 880(ab) Tc-99m sestamibi SPECT, F-l8 FDG glucose, quantitative tumor scintigraphy, dogs with osteosarcoma, 1542 attachment of monofunctional DTPA analogs, 858(ab) Malignancy, B-cell, body and blood clearance, recurrent soft-tissue sarcoma and, gallium 988(ab) marrow radiation dose, 1-131 Lym-l, imaging, 1594 BC-2, detection ofbreast tumors, 999(ab) 94l(ab) spinal, radionucide bone scan, MRI imaging, B72.3/CC49/CC83, radioiodination, Manometry, esophageal disorders and 992(ab) pharmacokinetics, 960(ab) scintigraphy, 1301 thyroid carcinoma, Tc-99m TB! scintigraphy, CEA-producing cancer, radioimmunodetection, ManpowerSurvey, 1992, 5lN(ll) 914(ab) 1750 MDP, perioperative uptake, S-ROM hip Methionine, thymidine or, location in cell, chimeric antibody chCE7, prosthesis, 950(ab) radiation-induced alterations, 841(ab) radioimmunolocalization, neuroblastoma Medlastinum Methylene, bridged phosphineoxide-phosphine, xenografts, 231 biopsy-confirmed residual Hodgkin's disease, versatile chelating agent, Re-188, 979(ab) chimeric anti-CEA, HAMA response after Ga-67 SPECT, 345 MIBI, -SPECT and stress echocardiography, immunoscintigraphy, 903(ab) FDG PET staging, lung cancer, 828(ab) choice of stress for diagnostic perfusion, chimeric cT84.66, In-lli labeling, radiation lymph node mapping, F-18 deoxyglucose PET, wall motion imaging, 825(ab) dose estimates, 953(ab) 828(ab) Microautoradiography chimeric M0v18, reactive with ovarian cancer Medical Internal Radiation Dose (MIRD), F-18FDG, granulationtissuesand phagocytes, associated antigen, 2000 radiopharmaceutical uptake, dose mouse tumor tissue, 840(ab) coupling, radioiodinated 3- heterogeneity, quantitative high accumulation of2-[F-l8]FDOPA, non-S iodophenylisocyanate, 1029(ab) autoradiography, 1833 phase melanocytes, Bl6 melanoma, Cu-64-labeled, PET imaging, 1685 Medicare 984(ab) direct and indirect Tc-99m labeled antibody, fee schedule, 34N(9) Microdosimetry, estimations ofl-125 monoclonal comparison in mice, 909(ab) SNM and ACNP response, 18N(l) antibody 425, internalization, human dose fractionation ofradiolabeled antibodies, OfficeofPaymentPolicy,36N(9) glioma cells, 942(ab) metastatic colon cancer, 1648 reform, charting the impact, 18N(2) Micrometastases ethics, 296 statement by physician payment review continuing evolution, 2180 F(ab'>@fragments, c-kit protooncogene commission, 24N(3) neuroblastoma, radioiodinated MIBG, overexpression, scintigraphic detection, volume performance standard, 24N(3) multicellular tumor spheroids, 859(ab) 893(ab) Melanoma plasmapheresis in radioimmunotherapy, F(ab'),tumoruptake,hyperthermia,958(ab) malignant mathematical model, dosimetry, 2167 F-18 antimyosin monoclonal antibody F-18 FDG PET, 975(ab) Micronucleus assay, lymphocyte labeling, Tc-99m fragments, preliminary investigations, preparation ofl-125 PAB, 889(ab) HMPAO, radiotoxicity, 1167 canine myocardial infarct model, 575 uveal, radioimmunoscintigraphy, 3-step Microspheres human/mouse chimeric, recognition ofCAl2S, monoclonal antibody pretargeting intra-arterial Sm-153, pre-operative sterilization, ovarian cancer radioimmunoimaging, technique, 959(ab) kidney cancer, 1024(ab) l001(ab) Melanoma, B16, non-S phase melanocytes, polymeric, radionuclide synovectomy, neuron 1-131 chimeric B72.3, Phase I trial, metastatic accumulation of 2-[F-18JFDOPA, activated holmium-l66, 398 colorectal cancer, 23

Subject Index â€¢1992 2285 MonteCarlo

In-li 1 B72.3, pharmacokinetics, colorectal Muscle, skeletal, time course of glucose uptake, 884(ab) carcinoma, 498 euglycemic hyperinsulinemia, F-l8 2- ECG response and perfusion images, thallium In-l 11 labeled IVP ZCE 025, efficacy and deoxy-2-fluoro-n-glucose study, 1523 stress test, l723(le) safety, colorectal carcinoma, 959(ab) Muscular dystrophy, myocardial involvement, enhanced detection after thallium reinjection, In-l I 1 thioether-poly-L-lysine-DTPA 1-123 IPPA SPECT, 995(ab) quantitative reversibility maps, visual monoclonal antibody-TP41.2F(ab'),, Musculoskeletal system, assessment of infectious analysis, 916(ab) reduced hepatic accumulation, 570 conditions, Tc-99m HIG, 839(ab) exercise-induced, first-pass radionuclide iodination, therapeutic amounts of 1-131, Myasthenia gravis, 11-201 SPECT, 1020(ab) angiography, upright bicycle ergometry, 982(ab) Mycobacteriumas'ium-inlracellulare,accuracyof 359 labeling ofwhite blood cells, 34N(5) early gallium imaging, pulmonary extent and severity, PET, predictor of prognosis labeling with F-18, N-succinimidyl 4-[F-18] infection, immunocompromised patients, following thrombolytic therapy, 837(ab) fluorobenzoate, 881(ab) 957(ab) general thallium redistribution model, 915(ab) Ml95, modeling and dosimetry, acute Myelosuppression, reduction of, efficacy of increased lung uptake in 1-123 MIBG, 955(ab) myelogenous leukemia, 941(ab) immunophoresis, radioimmunotherapy, metabolic evidence, dipyridamole stress, 866(ab) microdistribution, experimental lung 863(ab) myocardial energy balance, C-l 1 SAH PET, metastases, 957(ab) Myocardial infarction 2144 monoclonal Fab', chromatofocusing studies, acute, Tc-99m glucarate and 11-201, rats, 1988 PET ischemic segments, accelerated clearance, 2148 acute and remote, In-i 11 antimyosin uptake, C-l I acetate, 856(ab) NR-LU-iO pathologic findings, 587 regional cardiac adenosine, PET, 2138 CH2 domain deletion mutant, artifact or, gated Tc-99m sestamibi SPECT, -reperfusion, retention of Cu-PTSM, radioimmunotherapy potential, l028(ab) 927(ab) Langendorffperfused rat heart, 1026(ab) Re-186 direct vs. chelate labeling, tumored canine model, preliminary investigations, F-l8 right ventricular, inferior myocardial infarction, nude mice, 910(ab) antimyosin monoclonal antibody low-level exercise Tc-99m sestamibi octahedral gallium chelate, fragments, 575 SPECT,876(ab) immunoscintigraphy, PET, 1366 consequences of ventricular tachycardia, 11-201 defect reversibility and severity, optimizing intraperitoneal scintigraphic phase analysis, 994(ab) quantitative vs. visual analysis, 905(ab) radioimmunotherapy, 959(ab) experimental, gamma imaging, rabbits, 943(ab) Myocarditis, immune mechanisms in heart radioimmunodetection oflung cancer, 958(ab) increase in FDG uptake, prognostic indicator, disease, Malhinckrodt Fellow, l7N(6) radioimmunotherapy, MIRDOSE dosimetry 886(ab) Myocardium software protocol, 926(ab) infarct-specific tracers, transmural uptake, accumulation of radioiodinated digoxin radiolabeled perfusion tracers, 229 derivative, possible Na,K-ATPase imaging antibody-macrocyclic chelate conjugates, inferior, right ventricular ischemia, low-level agent, 545 103l(ab) exercise Tc-99m sestamibi SPECT, 876(ab) aerobic, fatty acid kinetics, 1864 chimeras, 29 instant kit method, labeling antimyosin Fab', biokinetics of Tc-99m tetrofosmin, one-day fusion ofSPECT images with CT/MRI Tc-99m, 144 imaging, 874(ab) images, 960(ab) interference in antimyosin imaging, circulating blood flow heterogeneousdistribution,bindingsite myosin heavy chain fragments, 895(ab) co-injection technique, 1152 barrier, 893(ab) interval between reinjection and imaging, expected variability, anesthetized canine, inhibition ofhepatic uptake, primary rat 11-201 image, 915(ab) 884(ab) hepatocyte culture model, 893(ab) late infarct size and ejection fraction, methods for quantification, N-13 ammonia oncogene-encoded molecules, tumor imaging thrombolytic therapy, 939(ab) PET, 881(ab) and therapy, 2160 left ventricular mass and, N-13 ammonia PET, polar map displays, cardiac PET images, 1628 radiation absorbed dose, planar scintigraphic explanted human hearts for validation, Tc-99m Q12 activity, dogs, 993(ab) views, 925(ab) 826(ab) blood flow and glucose uptake, ischemia, F-l8 second generation high-affinity anti-CEA, necessity ofthallium reinjection, 916(ab) deoxyglucose, 1346 904(ab) negatively charged-polymer-modified blood pool spillover, method for correction, 3-step pretargetingtechnique, antimyosin, 959(ab) dynamic cardiac FDG PET, 882(ab) radioimmunoscintigraphy, patients without, pharmacologic stress, extent bridging, predictive value, dipyridamole melanoma, 959(ab) and location ofCAD, 2067 thallium imaging, 1905 TNT-l and TNT-l-F(ab')2, Re-186, regional metabolic abnormality, relation to characteristics of Tc-99m tetrofosmin, coronary radioimmunotherapy, 987(ab) perfusion, wall motion, 659 heart disease, 875(ab) tumor-associated antigens, similarity and co -related arterial patency, serial tomographic clinical efficacy of tetrofosmin, 874(ab) expression, 853(ab) imaging, Tc-99m sestamibi, 2080 comparison ofdefect size, Tc-99m tetrofosmin, tumor uptake, effect of interleukin 2, 934(ab) size determination, cardiac myosin heavy chain, peak exercise, 874(ab) ZCE 025, In-l 11 anti-CEA, colorectal 853(ab) computer-aided diagnosis, coronary artery carcinoma, 14 time course, In-l 11 antimyosin monoclonal disease, artifical neural network, 272 Z2D3 antibody scintigraphy, 1501 continuous monitoring, left ventricular function imaging atherosclerotic lesions, antibody 11-201 compared to Tc-99m sestarnibi, 865(ab) during exercise, coronary jeopardy score, avidin-biotin interactions, 934(ab) viability, iodo-labeled methyl fatty acid, FDG 938(ab) localization, atherosclerotic lesions, 936(ab) PET, 953(ab) damage in Adriamycin cardiomyopathy, In-l 11 Monte Carlo, modeling techniques, radiation dose Myocardial ischemia antimyosin antibody, 936(ab) calculation, bone-to-marrow interface, 623 adenosine infusion, hemodynamic-scintigraphic defect size and severity, correlation, Tc-99m Morphine study, 952(ab) sestamibi and N-13 ammonia PET, 875(ab) -augmented cholescintigraphy assessment of viable myocardium, combined delineation of, heart volumes, PET and SPECT, false-negative, subacute gallbladder imaging, 1-123 BMIPP and 11-201, 885(ab) 933(ab) perforation, 256 blood flow and deoxyglucose uptake, myocyte diffuse necrosis, acute onset, cardiogenic shock, potential pitfalls, 898(ab) viability, 1353 1558 Moyamoya disease, SPECT/MRI/angiography, blood flow and glucose uptake, F-l8 distribution ofln-l 11 antimyosin Fab, Tc-99m before and after external-to-internal carotid deoxyglucose, 1346 sestamibi and, nontransmural infarction, arterybypass, 1692 detection by combining flow reserve with 223 Multidrug resistance, tumor, in vivo identification, metabolic assessment, coronary artery emission computed tomography, 1-123 beta tritium-3-colchicine, 1373 disease, 837(ab) methyl-branched fatty acid, hypertrophic Multiple systemic atrophy, selective metabolic early or delayed reperfusion, myocardial cardiomyopathy, 6 involvement, 10l4(ab) oxidative metabolism, mechanical function, extraction of teboroxime, interaction with

2286 The Journa@of Nuclear Medicine Neuroblastoma

blood, 94 quantification ofblood flow, l72(le) status ofcollateral flow, 856(ab) FDG PET studies, oral glucose loading or rapid synthesis ofno-carrier-added N-13 Tc-99m MIBI scintigraphy, thallous chloride insulin clamp methods, 1263 dopamine, 93l(ab) injection, 906(ab) flow reservedecline with age, higher cardiac regional metabolism and blood flow, Tc-99m sestamibi SPECT vs. F-18 FDG PET, work at rest, 836(ab) misonidazole retention, occlusion of LAD 886(ab) glucose utilization, insulin clamp, F-18 FDG coronary artery, 993(ab) 11-201 and Tc-99m sestamibi SPECT, PET,1255,1263 regional perfusion 905(ab) hibernating, irreversibleperfusion defects, Cu-62 PTSM, 837(ab) viability after infarction, exercise-redistribution Rb-82 and F-18 FDG PET, l065(ab) Cu-6l pyruvaldehyde thiosemicarbazone, SPECT11-201,906(ab) human pharmacokinetics and 884(ab) viable radiopharmacological studies, Tc-99m CPI, reinjection studies, 11-201 SPECT, chronic coronary arterydisease, 505 1949 collateralization, 915(ab) 11-201 and Tc-99m sestamibi, 815 hypoxic, detection using F-18 FMISO PET, reperfusion imaging with Tc-99m sestamibi, viable and non-viable, blood flow and flow 2202 acute chest pain, non-diagnostic EKG, reserve measurements, 856(ab) imaging, breast tissue attenuation, 96l(ab) 876(ab) Myocytes imaging regional hypoxia, Tc-99m 2- resting and exercise imaging in children, Tc damage in pathologic cardiac hypertrophy, nitroimidazole, occlusion of LAD coronary 99m MIBI SPECT, 929(ab) athletes, In-I 11 antimyosin antibody artery, 865(ab) retained Ga-68 radiopharmaceuticals, 93l(ab) studies, 994(ab) infarcted and periinfarcted, oxidative retention characteristics, 11-201, Tc-99m endothelial and fibroblast-like cells, Tc-99m metabolism, C-ll acetate PET, 953(ab) sestamibi and Tc-99m teboroxime, 865(ab) sestamibi, 11-201, 102 iodo-labeled methyl fatty acid, viability, FDG simultaneous rest Tl-201/stress Tc-99m Myopathy, systemic, myocardial involvement, PET, 953(ab) sestamibi, perfusion SPECT, 854(ab) 1-123 IPPA SPECT, 995(ab) kinetics ofCu-62 PTSM, non-human heart, 684 180' SPECT, scatter, attenuation and depth Myosin left ventricular time-activity curve, 0-15 water dependent resolution, 842(ab) antimyosin imaging, detection of tumor PET, 1669 SPECTstudywithfan-beamcollimators, invasion ofmuscle layer, 841(ab) MIBG heart and lung extraction fraction, first newborn period and early infancy, 930(ab) heavy chain, determination of infarct size, pass analysis, 716 structural characterization, Tc-99m tetrofosmin, 853(ab) misalignment between PET transmission and 850(ab) heavy chain fragments, interference in emission scans, 1209, 1214 subcellular distribution, antimyosin imaging, myocardial infarction, N-13 ammonia stress perfusion imaging in PET, bis(dithiocarbamato)nitrido TC(V), male 895(ab) objective computerized quantitative rats, 850(ab) Myotonic dystrophy, regional cerebral blood flow method, 1009(ab) sympathetic nerves, postnatal maturation, high impairment, 839(ab) oxidative metabolism, early or delayed resolution scintigraphy, 935(ab) reperfusion, mechanical function, 884(ab) sympathetic neuronal function, intravenous N perfusion cocaine injection, dogs, 994(ab) Na,K-ATPase, possible imaging agent, myocardial adenosine stress, N-13 ammonia PET, systemic myopathies, 1-123 IPPA SPECT, accumulation, radioiodinated digoxin deny 825(ab) 995(ab) ative, 545 blood flow and, Tc-99m tetrofosmin, 993(ab) Tc-99m imaging agent, kit development, National Biomedical Tracer Facility blunted response to dipyridamole, older Technecard, 850(ab) Congressional subcommittee, U.S. radioisotope adults, i425(le) Tc-99m nitrido dithiocarbamate, improved supply crisis, l6N(iO) long-term follow-up, Kawasaki syndrome, synthesis, 989(ab) Congressional support, 35N(l 1) 929(ab) Tc-99m perfusion agents, 22N(l) government relations update, 16N(3) quantification, 0-15 water and Rb-82 PET, Tc-99m PPN.l0l 1 SPECT, clinical evaluation, National Emission Standards for Hazardous Air 884(ab) 875(ab) Pollutants (NESHAP), Environmental Pro quantitative evaluation, gated or non-gated Tc-99m sestamibi, comparison, same-day tection Agency, 24N(3) Cardiolite SPECT, 927(ab) protocols, 186 National Institutes ofHealth(NIH), educating law radial slices, SPECT, 1070(ab) Tc-99m sestamibi SPECT makers, 30N(l0) Tc-99m MIBI radionuclide angiography and comparison, short and standard data Neonates: see also Pediatric patients SPECT,dipyridamole,846(ab) acquisition, 855(ab) asymptomatic, hydronephrosis or hydrouretero thallium uptake after reinjection, 915(ab) early and delayed imaging, coronary artery nephrosis, â€œwelltemperedâ€•diuretic reno tissue viability, hypoperfused regions, 857(ab) disease, 855(ab) gram, 2047 11-201 SPECT vs. Rb-82 PET, 1064(ab) same day, 876(ab) brain SPECT, extracorporeal membrane oxygen wall thickness, simultaneous estimation, Tc-99m tebo SPECT, delay of image ation,1943 933(ab) acquisition, 952(ab) cardiac function, arterial switch operation, PET, perfusion and ventricular function, teboroxime, adenosine, accuracy and optimal 977(ab) simultaneous assessment, total coronary imaging time, 854(ab) jaundice, diagnostic criteria for biliary atresia, artery occlusion, 825(ab) thickening and phase analysis, Tc-99m Tc-99m EHIDA hepatobiiary scintigraphy, perfusion and viability, 3-D SPECT, Tc-99m sestamibi multiple gated SPECT, 926(ab) 899(ab) sestamibi stress perfusion, 926(ab) tissue fraction, rapid imaging technique, 994(ab) Neoplasms: see also specific type perfusion at fatal infarction, location and size, tissue uptake, cationic technetium complexes, somatostatin receptor-positive, 1-123 TOCT and scintigraphic defects, 251 1033(ab) In-l 11 DOCT somatostatin analogues, perfusion imaging with dipyridamole or tomographic perfusion imaging, effect of patient 914(ab) adenosine, serum caffeine levels, 24-hour motion, 1566 Nerve, central cholinergic terminals, PET studies, abstention, 866(ab) uptake in dogs, side chain modifications, 101l(ab) perfusion scintigraphy, integration of wall bis(dithiocarbamato) nitrido Neural crest neoplasms, 1-123 MIBG, 1072(ab) kinetic and perfusion data, 933(ab) technetium(V), l034(ab) Neural-network, classifier, PET scans, normal and perfusion studies, blinded evaluation, planar viability Alzheimer's disease subjects, 1459 Tc-99m sestamibi, 668 chronic coronary artery disease, TL-201 Neuroblastoma perfusion with PET correction for patient SPECTvs.F-18DOPET,886(ab) 1-131 MIBG and bone scintigraphy, 1735 motion, automated region definition, delayed post-reinjection Tl-20l imaging, 1-131 MIBG approval, 33N(9) 882(ab) 1064(ab) location of, opsoclonus-myoclonus, MIBG usage, PET, region-of-interest strategy, 1243 F-18 FDG, PET and SPECT, 1064(ab) 930(ab) planar perfusion imaging, Tc-99m tebo, 11-201 radioisotopic assessment, sestamibi micrometastases, radioiodinated MIBG, multi andcoronaryangiography,1783 scintigraphy, 1925 cellular tumor spheroids, 859(ab)

Subject Index â€¢1992 2287 Neuroendocnneneoplasms

pitfalls in diagnosis, 1-131 MIBG scintigraphy, putenized quantitative method, heart, stimulated auditory cortex, 974(ab) 930(ab) l009(ab) Nuclear medicine radioimmunotherapy in a child, tumor dosime Nitrogen-i3 dopamine, no-carrier-added, rapid syn accuracy of Neuronet diagnosis, thyroid nodule, try, 1-124 3F9 PET, 2020 thesis, myocardial imaging, 93l(ab) backpropagation simulator, 954(ab) xenografts 2-Nitroimidazole, radioiodinated derivatives, viable acupuncture message transmission, 409 distribution of 1-125 MIBG, electron micro hypoxic tissue, SPECT, 89l(ab) Annual Meeting highlights, 12N(8) scopic autoradiography, 102l(ab) Nitroimidazoles, chemistry of Tc-PnAO-nitmimi artifacts in, 1068(ab) radioimmunolocalization, chimeric antibody dazole complex, localization in hypoxic tis certificate program, nuclear pharmacy training, chCE7, 231 sue, 9l9(ab) l073(ab) Neuroendocrine neoplasms Nitrous oxide, endogenous opiate system, C-I I car computer-aided instruction, l067(ab) diagnosis with Al 1 monoclonal antibody, fentanil PET, 883(ab) computer-based radiology teaching files, 834(ab) Nordion, privatization, l9N(2) l066(ab) dosimetry and biodistribution, 1-123 somato Norepinephrine, disturbed neuronal energy metab computer-based renal teaching file, 1073(ab) statin analog, 1613 olism, Adriamycin cardiomyopathy, 935(ab) computerized teaching file, l066(ab) Neurolite Nuclear energy computer system, efficient management, imaging aid in diagnosis and localization of stroke, history 16N(12) and non-imaging information, 1006(ab) 878(ab) Nuclear magnetic resonance departments, infection-control problems, blood imaging of cross cerebellar diaschisis in stroke, anatomy-oriented 3-D ROl definition system, reinfusion, 13N(4) 968(ab) l006(ab) forum, 15N(5) Neurology, second Sino-American nuclear mcdi brain functional and structural deficits, young hardcopy images, high-resolution plain-paper cine conference, l6N(4) alcoholics, l070(ab) laser printers, 947(ab) Neuroma, cranial and spinal, PET-fluorodeoxyglu brain images, rapid registration, l005(ab) imaging data, use of local area networks, intra cose,1931 cerebral blood flow and SPECT, differential di departmental distribution, 946(ab) Neurons agnosis, dementia, 10l4(ab) misadministration spurs statewide inspection, -activated holmium-l66, polymeric micro C-l 1 flumazenil, benzodiazepine receptor bind California nuclear medicine departments, spheres, radionuclide synovectomy, 398 ing, alcohol-dependent men, 10l6(ab) 32N(3) cholinergic, F-18 labeled acyclic analogues, ye chronic osteomyeitis, site of fracture or surgery, multifunctional image-containing database, samicol, 983(ab) lower extremity, 902(ab) 947(ab) monoaminengic, C-l 1 tetrabenazine PET, brain comparative study of 11-201, CT/angiography, multi-media workstation, 947(ab) biodistribution, 870(ab) bone and soft tissue sarcoma, 843(ab) one day in the routine, 463(le) myocardial sympathetic neuronal function, intra 3D PET and, image registration, simple device, outpatient therapy, petition would ease strictures, venous cocaine injection, dogs, 994(ab) l008(ab) 13N(7) Neuropsychological test, cerebral blood flow, FDG PET and, atypical dementia, Alzheimer's practice of, 14N(8) Tc-99m HMPAO SPECT, chronic subdural disease, 965(ab) regional dose distribution to hands, staff formu hematoma, 246 Fe-PDGF as hepatobiliary contrast agent, lating/dispensing/administering radiophar Neuroradiology, interventional, brain blood flow, 974(ab) maceuticals, l065(ab) SPECT, 826(ab) ferrum as a contrast agent, 973(ab) role in systematic imaging evaluation, suspected Neurotransmission, membrane trapping of C-I 1 1, fusion with SPECT images, radiolabeled mono osteomyeitis, 1063(ab) 2-diacylglycerols, phosphatidylinositol turn clonal antibojlies, 960(ab) therapeutic applications, 3lN(3) over, 413 Ga-67 scans and, effect of therapy, Hodgkin's threatenedreactorworkerstrike,l9N(9) Neutron, source, Department ofEnergy, 32N(l0) lymphoma, 914(ab) transfer ofimages, interfile file format, 1007(ab) Neutrophils, sequestration in lung, intercellular moyamoya disease, before and after external-to use of Internet, computer communications to adhesion molecules, endotoxemia, 1023(ab) internal carotid artery bypass, 1692 world community, l067(ab) Newsline MRI contrast agents, nonionic gadolinium (Ill) workstation for all digital department, 947(ab) Commentary DTPA-bisamide complexes, 974(ab) Nuclear probes functional brain scans, evidence in criminal normal and pathological gastric emptying, cardiology, 448 court, i8N(6) 956(ab) miniature cadmium telluride detector, ventricu government will respond to those who seek PET and lar function, coronary artery bypass grafting, influence, 25N(lO) accuracy of surface fit registration, brain, 441 Lines from the President, 24N(6), 38N(9), 921(ab) Nuclear Regulatory Commission (NRC) 32N(i2) fully automated and robust coordinate match â€œbelowregulatory commissionâ€•consensus fail second Sino-Amenican nuclear medicine con ing system, 1009(ab) ure, 25N(l) ference, 16N(4) primary brain tumors, 867(ab) below regulatoryconcern, l8N(3) shouldering burden of low-level radioactive primary progressive aphasia, 857(ab) compatibility, agreement states still chafing, 27N(3) waste, 20N(6) radionuclide bone scan and, detection of spinal costs ofdual regulation, 29N(l0) Forum: The Future ofNuclear Medicine, l5N(5) metastases, 992(ab) licensing fees, 30N(9) Newspapers, citations in medical journals, 27N(l) radionuclide studies and, osteomyeitis, 992(ab) medical quality management rule, l8N(3) Nicotine, tritiated, altered accumulation in brain, rapid registrationand review, brain, 1067(ab) medical use ofisotopes, 30N(9) senescence accelerated mouse, 1023(ab) scintigraphy and, bone marrow, staging of breast new commissioner, 18N(3) Nltrogen-13 ammonia cancer, 9l4(ab) nuclear physician's case against QM rule, 37N(5) logistics, flow-through trapping, 931(ab) SPECT liver volume measurement, l066(ab) override of 0MB disapproval, quality manage myocardial perfusion PET images, adenosine standardization, cardiac tomographic imaging, ment rule, 32N(lO) stress, coronary artery disease, 825(ab) 1434 probe ofMedical Uses staff, 30N(9) PET subchrondral bone infractions, acute ligamentous quality management rule, 23N(4), 34N(9) defect size and severity, 875(ab) kneeinjuries, 516 radiation protection, 33N(9) left ventricular mass and infarct size, explanted Tc-99m HMPAO and 1-123 IMP, cerebral blood sending teams to study risk, medical misadmin human hearts for validation, 826(ab) flow, SPECT, 10l2(ab) istration, 26N(4) methods for quantification, myocardial blood Tc-99m HMPAO SPECT and CT, diagnosis of userfees, l8N(3) flow, 881(ab) dementia, 972(ab) withdrawal oftraining criteria, 33N(12) regional perfusion reserve, coronary arterydis 11-201 compared to Tc-99m MIBI, recurrent ease, 826(ab) brain tumors, 867(ab) 0 regional uptake and blood flow variations, lack 11-201 SPECT and F-l8 FDG PET, recurrent ofcorrelation with other methods, 837(ab) brain tumors, 867(ab) Oak Ridge National Laboratory, calutrons, i5N(6) stress perfusion imaging in PET, objective com Nuclear magnetic resonance spectroscopy, proton, Occupational Safety and Health Administration

2288 TheJournalof NuclearMedicine Phagocytes

(OSHA), blood-borne pathogens, 26N(3) partition coefficient, regional cerebral blood Pathogens, blood-borne, 26N(3) Octreoscan, In-ll 1 labeled somatostatin analog, kit flow, 91 l(ab) Paul Aebersold Award, Mathew Thakur, 34N(5) develoment, cancer detection, 1025(ab) somatosensory stimulation, thalamic lesions, Pediatric patients: see also Infants, Neonates Octreoscan-lli, two diasteromers, cancer imaging, 858(ab) alternating hemiplegia, Tc-99m HMPAO 900(ab) Rb-82 and, myocardial perfusion, PET, 884(ab) SPECT,102i(ab) Olfactory .system, investigation with FDG-PET, Oxygen-18 water asymptomatic siblings, vesicoureteral reflux, 858(ab) purification, photochemical combustion, 982(ab) cyclic voiding cystography, 873(ab) Oncogene, -encoded molecules, radiolabeled anti simple procedural change, F-18 FDG synthesis, brain tumors, Tc-99m MIBI/Tl-201 SPECT, bodies, tumor imaging and therapy, 2160 l027(ab) 844(ab) Oncology, Annual Meeting highlights, 11N(8) target for production ofF-18, 932(ab) cardiac function in neonates and children, arte Opiates, effect of nitrous oxide, C-l 1 carfentanil rial switch operation, PET, 977(ab) PET,883(ab) P cerebral blood flow and predetermined ROIs, Orphan drug, coalition, 33N(9) Xe-133 SPECT, 977(ab) Osteoma, osteoid, radionuclide imaging, radiogra Paget's disease, bone scintigraphy, intravenous cerebral palsy, quantitative perfusion-defect in phy and computed tomography, 269 pamidronate, 1589 dexes, Tc-99m HMPAO SPECT, 977(ab) Osteomyeitis Pain changes in regional cerebral blood flow, brain cellulitis and, dual bone and WBC scan imaging, bone maturation, 696 planar and SPECT imaging, 839(ab) metastases, therapeutic doses ofSr-89, 937(ab) children and adolescents, radionuclide cystogra chronic, site of fractureor surgery, lower extrem Re-186 HEDP treatment, 859(ab) phy, vesicoureteral reflux, 1022(ab) ity, 902(ab) low back developmental cognitive disorders, F-i8 FDG comparison of MRI and radionuclide studies, 180' SPECT ofthe spine, 950(ab) PET,973(ab) zygapophyseal joint injection, SPECT and 992(ab) febrile urinary tract infections, Tc-99m DMSA planar bone scintigraphy, 868(ab) infectiousdiabetic foot complications, In-li 1hu scanning, 976(ab) lower extremity, bone scintigraphy, preschool man nonspecific immunoglobulin G, 1330 first nuclear medicine symposium, 40N(9) children, 351 suspected, role of nuclear medicine, systematic glomerular filtration rate measurement, ade palliation, multidose Sm-153 EDTMP, met imaging evaluation, 1063(ab) quacy ofone blood sample, 873(ab) astatic bone disease, 992(ab) Osteoporosis HIV-l-infected, seropositive mothers, FDG PET, Palladium-i09, chelates and their bioconjugates, better prediction, risk factor assessment, multiple 976(ab) 987(ab) regression analysis, 869(ab) newborn period and early infancy, myocardial Palsy bone mineral content and density, healthy SPECT,fan-beamcollimators,930(ab) progressive supranuclear, cerebral perfusion, 704 twelve-year-old white females, 1143 obstructive uropathy diagnosis, normalized di supranuclear, dopamine D2 receptors, 1-123 ILlS bone mineral density and spine fracture, cyclic uretic renogram parameters, 923(ab) SPECT, 1019(ab) oral phosphate, etidronate, 1 opsoclonus-myoclonus, location of neuro Pamidronate, intravenous, bone scintigraphy, Pa optimization of follow-up measurements, bone blastoma, MIBG usage, 930(ab) get'sdisease, 1589 mass, 1406 preschool children, bone scintigraphy, lower cx Pancreas, new imaging agent 1-123 ERC 9, 841(ab) Osteosarcoma Pancreatic lipase, site specific/stable radioiodina tremity pain ofunknown origin, 351 lower limb, stress fractures, 1699 tion, 1-131 l,2-Pal-3-IPPA, urine analysis, radioimmunotherapy for neuroblastoma, tumor primary, thyroid, 1399 1028(ab) dosimetry, 1-124 3F9 PET, 2020 quantitative tumor scintigraphy, time to metas Paraplegia, impotence, treatment choice, nuclear single plasma GFR, l73(le) tasis, 1542 penogram, i035(ab) skeletal screening, traumatic brain injury, Ovarian neoplasms Parathyroid 873(ab) -associated antigen, characteristics, chimeric imaging, 1807 symptomatic infants and children, radionucide monoclonal antibody MOv18, 2000 imaging with Tc-99m sestamibi, 313 evaluation, Ebstein's deformity, 930(ab) dosimetric evaluation of immunoscintigraphy, localization of enlargement, Tc-99m MIBI and ureteral status, kidney washout, Tc-99m DTPA In-l 11 monoclonal antibody fragments, Tl-201 scintigraphy, ultrasound and CT, diuresis renography, 73 1113 895(ab) urinary tract infection, 872(ab) early detection of recurrences, Tc-99m monoclo pathology, simultaneous dual-isotope SPECT, Pelvis, radioiodine uptake, rectal wall teratoma, nal antibody, CA 125, 904(ab) 131 thyroidectomy for papillary carcinoma, 1848 management with Tc-99m monocional antibod scintigraphy, subtraction algorithm, 996(ab) Penis ies, 904(ab) Parathyroidectomy, influence on bone mineral con blood flow, tumescence, dual-radioisotopic tech novel HAMA radioimmunoassay, 852(ab) tent, 869(ab) nique, 41 radioimmunoimaging, recognition ofCAl25, hu Parkinson's disease corporal venous leak, Tc-99m red blood cells, 49 man/mouse chimeric monoclonal antibody, delayed SPECT and regional cerebralblood flow, nuclear penogram, treatment choice, impotent l00l(ab) 1-123 IMP, 1015(ab) paraplegics, 1035(ab) Ovary, radiation dose, radionuclide hysterosalpin dementia and laterality of disease onset, regional Peptides gography, Tc-99m pertechnetate, 282 cerebral blood flow, 1012(ab) attachment of monofunctional DTPA analogs, Oxygen-i5 differential diagnosis by 1-123 IBZM SPECT, 988(ab) arrival delay of tracers, intravascular radioactiv 9l7(ab) imaging and therapy oftumors, 35N(5) ity, brain, 909(ab) differentiation of syndromes, dopamine D2 re molecules with messages, annual meeting high PET, intrasubject and intersubject averaging, ceptor imaging, 1-123 IBZM SPECT, lights, ION(8) 1009(ab) 9l7(ab) Percutaneous transluminal coronary angioplasty Oxygen-i5 butanol, PET, cortical areas in brain, discordant twins, PET, 1013(ab) (FFCA), early thallium imaging, tomo visual imagery in reading, 908(ab) dopamine D2 receptor imaging, 1-123 IBZM graphic evaluation, adenosine-induced cor Oxygen-iS water SPECT, 917(ab) onary hyperemia, 2086 bolus, signal-to-noise improvements, 3D PET, dopamine fiber loss, C-l 1 CFT, 946(ab) Perfusion, index of, mean transit time, 1004(ab) lOlO(ab) 1-123 IBZM SPECT, 1018(ab) Perfusion tracers, transmurai uptake, infarct-spe myocardial tissue fraction, rapid imaging tech loss of 6-[F-18]fluoro-L-dihydroxyphenylalanine cific tracers, 229 nique, 994(ab) metabolites, striatum, 916(ab) Peripheral vascular disease, functional imaging, PET MPTP-primate model, glucose metabolism, 1797 cerebral language area, 2D brain surface map, 965(ab) pH, non-invasive assessment, fluorinated polymeric 857(ab) multiple systemic atrophy, selective metabolic molecular probes, magnetic resonance spec event-related potentials, auditory cognitive involvement, 1014(ab) troscopy, 974(ab) task, 1016(ab) striato-nigral degeneration, dopamine Di and D2 Phagocytes, microautoradiographic study of F-18 left ventricular time-activity curve, 1669 receptor imaging, PET, 917(ab) FDG, mouse tumor tissue, 840(ab)

Subject Index â€¢1992 2289 Phantom

Phantom, influence ofperfusion defect size, Tl-20l radioindium-labeled autologous, MIRD dose es a-dihydrotetrabenazine, monoamine termi activity,tomographicdefectseverity, 995(ab) timate No. 15, 777 nals, 983(ab) i.-Phenylalanlne, delayed infusion, F-18 DOPA up Pt..eumocystis,pneumonia, pulmonarydisposition, C-ll thymidine, kinetic modeling, DNA synthe takeinbrain, 1383 gallium-67, 512 sis, 1009(ab) Pheochromocytoma Pseumocystis carinii L-l-C-ll tyrosine and F-18 FDG, radiation-in C-il HEDPET,1125 accuracy of early gallium imaging, pulmonary duced inhibition, tumor growth, 373 1-131 MIBG approval, 33N(9) infection, immunocompromised patients, cardiac 1-131 MIBO imaging, 833(ab) 957(ab) attenuation scans, three-dimensional registra intraoperative detection, 1-125 MIBG, 1020(ab) Tc-99m DTPA aerosol and Ga-67 scanning, 81 tion, 881(ab) Phosphate, cyclic oral, etidronate and, bone mm Pneumonitis, drug-induced, diffuse pulmonary up polar map displays, myocardial blood flow, caddensity,1 take,In-lll leukocytes, 1175 1628 Phosphatidylinositol, turnover, membrane trap Poland, radionuclide production threatened, position paper, 23N(4) ping, C-l 1 l,2-diacylglycerols, 413 20N(7) cardiac function in neonates and children, arte Phosphines, methylene bridged phosphineoxide Poly-lysine, amino-dextran and, In-i 11 labeled rial switch operation, 977(ab) phosphine, versatile chelatingagent, Re-188, monoclonal antibody, 988(ab) cardiac volumes, delineation of myocardium, 979(ab) Polyvinyl alcohol sponge, embolization of hepatic 933(ab) Phosphinimines, functionalized, small molecule arteriovenous malformations, hereditary central cholinergic nerve terminals, 101l(ab) neutral-lipophilic Tc-99m agents, 851(ab) hemorrhagic telangiectasia, 260 cerebral blood flow Phosphorus, -nitrogen backbone ligands, formula Positive expiratory pressure, effectiveness of PEP brain perfusion Tc-99m ECD SPECT, 966(ab) tion, new radiopharmaceuticals, 1072(ab) mask, Tc-99m DTPA aerosol ventilation, regional variation in statistical maps, l008(ab) Phosphorus hydrazides cystic fibrosis, 835(ab) cerebral glucose metabolism, striatal F-DOPA chelating agents, bifunctional frameworks, Positron emission tomography uptake, patients with chores, 1015(ab) Tc-99m and Re-i88, 9l0(ab) F-l8 FMISO, noninvasive detection, hypoxic cerebral metabolism multifunctional, new Tc-99m radiopharmaceu myocardium, 2202 epilepsy, effect ofdisease duration, 1018(ab) ticals, 1032(ab) myocardialbbood flow, deoxyglucose uptake, my standardized approach, controlled behavioral Photodiodes, room temperature, high-rate/high-res ocyte viability, 1353 conditions, 101l(ab) olution PET module, crystal identification, regional cardiac adenosine, 2138 clinical 862(ab) Positron emission tomography (PET) bloody future, 620 Physician Payment Review Commission (PPRC) acetazolamide Tc-99m HMPAO SPECT and, debate continues, 1587(le) access to care, 24N(3) cerebrovascular disease, 877(ab) science behind it, 1586(le) Medicarevolumeperformancestandard,24N(3) analysis ofKanji-Kana reading process, 827(ab) clinical applications in cancer, 330 report to Congress, 36N(9) anatomy-oriented 3-D ROl definition system, clinical neurological, interactive computer-based statement on Medicare, 24N(3) l006(ab) atlas, 107l(ab) Planar imaging approval ofdrug master file, 33N(9) combined with radioimmunoscintigraphy, F-18 Alderson phantom, nuclear quantitation, tumor arterial input function determination, hepatic monoclonal antibody fragments, 1535 size and 1-131 amount, 925(ab) and renal studies, use of abdominal aorta, Cu-64 antibodies, 1685 bone scintigraphy and SPECT, zygapophyseal 613 Cu-64 radiopharmaceuticals, scintillating fiber joint injection, chronic low back pain, benperidol analogs, D2 receptor-specific PET detector module, small animals, lOlO(ab) 868(ab) tracers, 848(ab) decline ofL-6-[F-l8@fluorodopa rate constant K1, dual bone and WBC scan imaging, osteomyelitis, brain, automated stereotactic transformation, vs. aging, 964(ab) cellulitis, 839(ab) 1007(ab) -defined targets for stereotaxic brain biopsy, gated, detection, coronary arterydisease, 866(ab) brain functional and structural deficits, young 868(ab) myocardial perfusion, Tc-99m, Tl-20l and cur alcoholics, 1070(ab) design features and performance, animal re onary angiography, 1783 C-l 1 acetate search, 595 scintigmphicviewsofmonoclonal antibodies, bio compared with F-18 fluorodeoxyglucose, re discordant twins with Parkinson's disease, distribution, radiation absorbed dose, covery after revascularization, 855(ab) 1013(ab) 925(ab) oxidative metabolism, infarcted and periin dopamine Dl and D2 receptor imaging, striato scintigraphy and SPECT, rotating slit collimator, farcted myocardium, 953(ab) nigral degeneration, Parkinson's disease, lOOS(ab) C-ll carazolol, evaluation in pigs, 885(ab) 917(ab) Tc-99m ECD, global cerebralblood flow, Rhesus C-li carfentanil, effect of nitrous oxide, endoge dual-labeling agents, dopamine D-2 receptors, monkeys, 979(ab) nous opiate system, 883(ab) 890(ab) thallium, areas ofreverse redistribution, viability C-li COP 12177, mechanisms of down-regula dual-tracer, lumped constant imaging, 944(ab) with PET, 886(ab) tion, idiopathic cardiomyopathy, 896(ab) dynamic, l-aminocyclobutane[C-l l]carboxylic vs.SPECT,low back pain, 868(ab) C-l 1 cocaine, distribution and kinetics, human acid, 2-compartment model, brain tumors, Plasma body, 521 922(ab) algorithm for estimating slope, PATLAK analy C-ll flumazenil dynamic studies ofthe heart, temporal sampling, sis, dynamic PET data, 944(ab) benzodiazepine receptor binding, alcohol-dc kinetic model parameters, 881(ab) concentrations, body dimensions, single-sample pendent men, 1016(ab) ECG gated, C-i 1 monoxide, â€œbackgroundâ€•ques clearance determinants, 629(le) benzodiazepine receptors, human brain ho tion, 938(ab) D-dimer concentration, suspected pulmonary mogenates, 101l(ab) enhanced fluorodeoxyglucose uptake, metabolic embolus, 978(ab) C-Il HED, localization of pheochromocytoma, design, combination therapy, 1981 extracellular fluid volume measurements and, re 1125 evaluation of neural-network classifier, normal producibility, critically ill patients, 1468 C-il labeled compounds, contribution, labeled and Alzheimer's disease subjects, 1459 human, quantitation, 1-123 IBZM, 87i(ab) carbon dioxide, 581 examination ofvisual mental imagery, 908(ab) Plasmapheresis, radioimmunotherapy of micro C-I 1 methionine, effective method, imaging of extent and severity of ischemic myocardium at metastases, mathematical modeling, dosim head and neck cancer, 691 risk, predictor ofprognosis following throm etry, 2167, 941(ab) 2-C-l 1 methyl-amino-2-methyl-3-phenyl-l-pro bolytic therapy, 837(ab) Plasminogen activator, tissue, Tc-99m inhibition, panol, serotonin uptake sites, 86l(ab) F-18, bone blood flow and influx rate, 937(ab) thrombosis scintigraphy, 1029(ab) C-ll NMSP, D2 dopamine receptor densities, F-18 antimyosin monoclonal antibody frag Platelet 848(ab) ments, preliminary investigations, canine -binding laminin peptide, direct Tc-99m labeling, C-l 1 SAH, myocardial energy balance, 2144 myocardial infarct model, 575 103i(ab) C-l 1 tetrabenazine, brain biodistribution, mon F-18 biotin, tumor localization, 1026(ab) -fibrin deposition on coronary sterns, anticoagu oaminergic neurons, 870(ab) F-l8 BMY 14802, synthesis and resolution, ba lation, minipig model, 845(ab) C-l 1tetrabenazine and C-I 1methoxy derivative, boons, 830(ab)

2290 TheJournalof NuclearMedicine Positron emission tomography (PET)

F-18 BT-SCH,synthesisand in vivoevaluation, 992(ab) model sequences, factor analysis, dynamic struc dopamine Dl ligand, 829(ab) temporal lobe metabolism, refractory epilepsy, tures, 101l(ab) F-l8 deoxyglucose, mediastinal lymph node 928(ab) MPTP-primate modelofParkinson'sdisease, glu mapping, 828(ab) treatment planning and monitoring, lung to cose metabolism, 965(ab) F-18FDG mors, 975(ab) MR brain images and, accuracy of surface fit accuracy in dementia diagnosis, 967(ab) TSH stimulation ofthyroid cancer, T4 replace registration, 92i(ab) Bayesian regression, metabolic rate of glucose ment therapy, 894(ab) MEl and utilization, 944(ab) F-18 FDOPA, nigrostiiatai function, ratio fully automated and robust coordinate match brain, registered atlas, 107l(ab) method and graphical analyses, 945(ab) ing system, 1009(ab) brain tumor therapy, 107I(ab) F-l8 fleroxacin, pharmacokinetics in rabbits, primary brain tumors, 867(ab) cerebral glucose metabolic rates, 30- and 45- 924(ab) multi-energy maximum-likelihood reconstruc minute acquisitions, 2103 F-l8 fluconazole, pharmacokinetics, humans, tion algorithms, 83l(ab) chest imaging, 975(ab) 924(ab) myocardial, region-of-interest strategy, 1243 cranial and spinal neuromas, 1931 F-l8 fluorideion, skeletalkinetics,633 myocardial perfusion, correction for patient mo decreased cerebral glucose metabolism, Cush F-l8 fluom analog oftamoxifen, estrogen recep tion, automated region definition, 882(ab) ing's disease, 834(ab) toTs, radiosynthesis, 985(ab) N-13 ammonia design ofcombination therapy, hexadecylphos F-l8 fluorocarazolol adenosine stress, myocardial perfusion images, phocholine and deoxyglucose, 1019(ab) $-adrenergic radiotracer, 984(ab) 825(ab) developmental cognitive disorders, 973(ab) ligand, @-adrenergicreceptors, 983(ab) defect size and severity, 875(ab) differential diagnosis, solitary pulmonary nod 6-F-18fluoro-L-dopakinetics,carbidopaadmin left ventricular mass and infarct size, explanted ule, 836(ab) istration, 1472 human hearts for validation, 826(ab) differentiation of infectious from malignant F-18 fluommisonidazole, hypoxia, human methods for quantification, myocardial blood CNS lesions, AIDS, 838(ab) gliomas, 2133 flow,881(ab) 3-D semiquantitative method, intractable 1cm F-18FMISO,quantification,tumor oxygenation regional perfusion reserve, coronary artery dis poral lobe epilepsy, 970(ab) status, lOlO(ab) ease, 826(ab) evaluation ofliver tumors, 333 F-18monoclonalantibodyfragments,934(ab) N-l3 ammonia stress perfusion,objectivecom fully quantitative neurological studies, without F-i8 NMSP,benzamideanalogsand, 985(ab) puterized quantitative method, heart, arterial blood sampling, 922(ab) fast maximum-likelihood reconstruction, 1710 1009(ab) glucose loading or insulin clamp methods, flumazenil as a ligand, quantification, benzodi neurological indications, approval by Blues, myocardium, 1263 azepine receptors, 883(ab) 40N(l 1) HIV-l-infected children, seropositive mothers, fluorinatedSCH 38548 derivatives, dopamineDl new generation, performance evaluation, 86i(ab) 976(ab) receptors, 829(ab) nonpeptide substance P analog, 860(ab) increased uptake as prognostic indicator, myo forum, l5N(5) 0-15, intrasubject and intersubject averaging, cardial infarction, 886(ab) functional brain scans, evidence in criminal i009(ab) insulin clamp, myocardial glucose utilization, court, 18N(6) 0-15 butanol, cortical areas in brain, visual im 1255,1263 GABAergic modulation of endogenous dope agery in reading, 908(ab) investigation ofolfactory system, 858(ab) mine, acetylcholine release, 847(ab) 0-15 water late-life depression, 1013(ab) Ga-68 platelets, 93i(ab) cerebral language area, 2D brain surface map, left premotor cortex specialization, finger heart and brain, use oflinear programming, glu 857(ab) movements, 857(ab) cose utilization and receptor binding, event-related potentials, auditory cognitive low grade and anaplastic astrocytomas, brain 944(ab) task, l016(ab) imaging, 966(ab) hepatic FDG uptake kinetics, impact of glucose left ventricular time-activity curve, 1669 lymphoma,532 ingestion, 945(ab) partition coefficient, regional cerebral blood malignant lymphoma, proliferative activity, high count rate cardiac, spatially dependent dead flow,91l(ab) 325 timelosses,2226 somatosensory stimulation, thalamic lesions, malignant melanoma, 975(ab) high-rate, high-resolution module, room temper 858(ab) mediastinum, lung cancer, 828(ab) attire photodiodes, crystal identification, octahedral gallium chelate, monoclonal antibod method for correcting myocardium to blood 862(ab) ies, immunoscintigraphy, 1366 pool spillover, 882(ab) high resolution image reconstruction, restoration, offering ofittle additional value, compared with MIHA,myocardialviability,953(ab) detector response, 872(ab) SPECT,i586(le) MEl data and, atypical dementia and Aix 1-1243F9, tumor dosimetry,radioimmunother parameter optimization programs, 1069(ab) heimer's disease, 965(ab) apy in a child with neuroblastoma, 2020 parametric Dopa-decarboxylase imaging, 879(ab) multiple systemic atrophy, selective metabolic 1-124 monoclonal antibodies, c-erbB-2 protein pathophysiological evaluation, progressive involvement, 1014(ab) overexpression, breast cancer, 2154 aphasia, 1016(ab) myocardial viability, coronary artery disease, image reconstruction, artifacts, l069(ab) PATLAK analysis, algorithm, estimation of 886(ab) image reconstruction for volume imaging, axial slope, 944(ab) parietal lobe epilepsy, lOl7(ab) extent, 87l(ab) primary progressive aphasia, 857(ab) post-treatment evaluation, genitourinary ma improved quantitation of small objects, restora probes for cocaine receptors, non-human primate lignancies, 829(ab) tion and correction algorithms, 872(ab) model,946(ab) preoperative chemotherapy, locoregionally ad inexpensive high resolution detector, photomul protein flux measurements, pulmonary blood vanced breast cancer, 828(ab) . tiplierquadrantsharing, 101 l(ab) flow,1661 pm-operative staging, colorectal carcinoma, intracomnary Doppler probes and, concordant radiolabeled cocaine analogs, receptor imaging 975(ab) quantification, flow reserve, 836(ab) agent, i025(ab) presurgical localization, epileptogenic zones, ischemic segments, accelerated clearance, C-I 1 Rb-82,vs.11-201SPECT,myocardialperfusion, 928(ab) acetate, 856(ab) 1064(ab) prognostic implications, temporallobe surgery, labeledcarbondioxide,transientmetabolite,585 Rb-82 vs. F-l8 FDG, hibernating myocardium, 929(ab) ligand, cerebral dopamine D-2 receptors, 847(ab) irreversible perfusion defects, 1065(ab) quantitation, tumor glucose metabolism, 339 ligand-receptor modeling, multi-injection ap real time-weighted integration, rapid calculation, quantitative dynamic and whole body, breast proach, 943(ab) functional images, l008(ab) cancer, 828(ab) Macintosh programs, 1069(ab) reoriented cardiac, issues in quantitation, 1235 radiation-inducedresponse, head and neck car maximum-likelihood reconstruction, clinically resolution,quantification, visual interpretation of cinorna, 829(ab) important characteristics, 1678 FDG brain tumor studies, 872(ab) recurrent brain tumors, 867(ab) measurement of receptor concentration, instru retrospective post-therapy evaluation, cardiac residual or recurrent musculoskeletal sarcoma, mental errors, heart, 882(ab) function, coronary arterydisease, 885(ab)

SubjectIndexâ€¢1992 2291 scanner gantry and bed, on-line repositioning, bowel disease, 919(ab) In-l 11 labeling, 953(ab) alignment with prior studies, 92l(ab) Proteins 1-131 QSPECT ofphantom, transfer of CT vols, sentence comprehension,grammatical and se radiolabeled, biodistribution and kinetics, focal manual alignment, 925(ab) mantic components, l012(ab) infection, 388 ovaries, radionucide hysterosalpingography, septum-less volume imaging scanner, count rate targeted, diagnostic imaging, 394 Tc-99m pertechnetate, 282 performance, 86l(ab) Proto-oncogenes Radiation dosimetry, In-I 11 anti-CEA-F(ab')@ fag sinogram noise, quantitative assessment, repro c-erbB2overexpression,1-124monoclonalanti ments, tissue distribution, rats, 1654 jection, l008(ab) bodies and PET, breast cancer, 2154 Radioactive waste spatial low frequency pattern analysis, normals c-kit, scintigraphic detection, monoclonal agreement statesstill chafing, NRC compatibility, and schizophrenics, 287 F(ab')2, 893(ab) 27N(3) SPECTand, F-18 FDG and Tl-20l, myocardial oncogene-encoded molecules, radiolabeled anti low-level: see Low-Level Radioactive Waste viability, 1064(ab) bodies, tumor imaging and therapy, 2160 monitored retrievable storage, 27N(l) staff formulating/dispensing/administering radio Psychiatry Radioactive Waste Act, hearing by Supreme Court, pharmaceuticals, regional dose distribution, functional brain SPECT, powerful clinical 37N(5) hands, 1065(ab) method, 1888 Radioactivity, intravascular, arrival delay of 0-15 standardization, cardiac tomographic imaging, lithium carbonate therapy, hyperthyroidism, tracers, brain, 909(ab) 1434 996(ab) Radioaerosols, pulmonary radioaerosol clearance, standardized tests ofperformance, 1429(le) VFCA: see Angioplasty, percutaneous transluminal appropriate background subtraction, static cardiac, automated three-dimensional coronary 836(ab) analysis, 1008(ab) Pulmonary embolism Radloangioscintigraphy,renal post-transplanted pa Tc-94m radionuclide purity requirements, phar atelectasis, infrequent chest X-ray finding, tients, 99l(ab) macokinetic studies, 850(ab) 849(ab) Radiochemistry Tc-99m sestamibi, defect size and severity, computer-assisted diagnosis, ventilation-perfu microwave fields, C-il alkylations, 1026(ab) 875(ab) sion lung scanning, 1003(ab) pharmacokinetics and, In-l I I BAD-Lym-l, temporal lobe epilepsy, mesial temporal origin, enhanced V/Q mismatch sign, i072(ab) l030(ab) 1014(ab) likelihood, number of segmental mismatches, Radiocontrast, -induced acute renal failure, real three-dimensional ventilation-perfusion lung scans, 849(ab) time monitoring, 948(ab) MRI image registration, simple device, low probability V/Q scans, routine ventilation Radiofluorination, heterogeneous nucleophilic, l008(ab) imaging, 1022(ab) thermally stable ion exchange resin, 984(ab) scanners with retractable septa, scatter correc suspected, D-dimer plasma concentration, Radiography tion, 879(ab) 978(ab) computed, dual-isotope autoradiography, signal-to-noise improvements, bolus 0-15 Putrescine, experience, value of, 1720 l005(ab) water activity, l0l0(ab) Pyeloplasty, pre- and post-, functional assessment, neuro-SPECTimaging,immature third ventricle three-dimensional functional brain images, au diuretic renogram, 977(ab) teratoma, 435 tomated method, rotational correction, 1579 Pyrrolidinyl acetamide, derivatives, labeling with osteoid osteoma, 269 T-18 labeled ligands, benzodiazepine receptor F-18, 830(ab) Radloimmunoassay, novel HAMA, ovarian cancer studies, 883(ab) patients, 852(ab) tracers, industry split over approval, 24N(9) Q Radioimmunodetection trans-C-i 1 McN-5652, serotonin uptake sites, Quality Management Rule, override of 0MB dis cancer identification, 803 860(ab) approval, NRC, 32N(l0) lung cancer, monoclonal antibody HB4C5, transmissionand emissionscans,myocardialim 958(ab) aging, 1209, 1214 R R.adioimmunoimaging transmission processing, accuracy, attenuation Radiation alkylamine conjugation chemistry, labeling of correction, 862(ab) -induced alterations, location in cell, methionine antibodies, 986(ab) triazolam and cental type benzodiazepine recep or thymidine, 841(ab) second Sino-American nuclear medicine confer tors, baboons, 973(ab) -induced inhibition of tumor growth, L-Il-@CJ ence, l6N(4) tritium-3-colchicine, in vivoidentification, tumor tyrosine and F-18 FDG, PET, 373 xadioimmunoscintigraphy multidrug resistance, 1373 -induced response, FDG PET, head and neck combined with PET, F-l8 monoclonal antibody two-dimensional restoration filter, quantitation carcinoma, 829(ab) fragments, 1535 ofamygdala, 921(ab) injury after interstitial injection, iodocholesterol, 1-131 monoclonal antibody, renal cell carcinoma, volume imaging, attenuation correction, 862(ab) i722(le) 913(ab) vs. SPECT, Annual Meeting highlights, l3N(8) local and systemic effects, bone metabolism, pretargeted immunoscintigraphy, hapten val whole-body quantitative SPECT, 1774 ency, murine tumor uptake, 2006 attenuation correction, 862(ab) perceptions ofrisk, 20N(7) three-step monoclonal antibody pretargeting methodsand performancecharacteristics, 1191 protection, 33N(9) technique, uveal melanoma, 959(ab) whole-body imaging, l069(ab) implications, nonuniformity ofdose, 384 Radloimmunotherapy Postcholecystectomy, noninvasive test, Sphincter of safety antibody pretargeting, three-step approach, Oddi dysfunction, 1216 forbeginners, 167 880(ab) Pregnancy, testing for, QM program, 30N(9) post-I-13l thyroid cancer therapy, 1402 biotin conjugates, anti-pan-carcinoma NR-LU Progestins, Tc-99m and Re-186 labeled, synthesis synovectomy 10 monoclonal antibodies, 880(ab) and receptor binding, 558 Ho-166 hydroxyapatite, 937(ab) cancer, 1110 Propylene amine oxime, derivatives, glutathione radiolabeling, hydroxyapatiteparticles, 980(ab) child with neuroblastoma, tumor dosimetry, mediated decomposition, ligand structure, Radiation dose 1-124 3F9 PET, 2020 988(ab) absorbed, Tc-99m teboroxime, humans, 88 chimeric antibody chCE7, neuroblastoma xeno Prostate-specificantigen,serial measurements,ra biodistribution and, planar scintigraphic views, grafts, 231 diotherapy, localized cancer, 853(ab) radiolabeled monoclonal antibodies, 925(ab) efficacy, 5-iododeoxyuridine, human tumors Prostatic neoplasms, F-18 androgens, potential im calculation, bone-to-marrow interface, Monte growing in nude mice, 1530 aging agents, 724 Carlomodeling,623 efficacy of immunophoresis, reduction of mye Protamine, In-l 11 DTPA-heparmn, radiolabeling, calculation at bone-to-marrow interface, 1915(le) losuppression, 863(ab) pharmacokinetics, 1028(ab) distribution in thyroid follicle, revised method, event loss estimation, 1005(ab) Protein 926(ab) 1-131, bone marrow radiation absorbed dose es flux measurements, pulmonary blood flow, PET, dynamic urinary bladder model, MIRD pam timation, leukemia, 94l(ab) 1661 phiet No. 14, 783 1-131 anti-pan B-cell antibodies, B-cell lym intestinal loss, In-I 11 transferrin, inflammatory estimates for chimeric monoclonal cT84.88, phoma, 863(ab)

2292 The Journal of Nuclear Medicine Receptors

1-131 Bl and BC8 antibodies, traceand therapeu rophenyl)-8-(3E- and 3Z-iodopropen-2- toradiography, 1833 tic amounts, 864(ab) yl)nortropanes,mappingofcocaine receptor Radiopharmacy, how magic is the bullet, what will 1-131CC49SPECT,CTand, advancedcolorectal sites, SPECT, 890(ab) it do?, 549 cancer, 1002(ab) Radlonuclides Radmosynthesis, imaging estrogen receptors with 1-131 monoclonal antibody, bone marrow arthrographyand roentgenologicalcontrast,total PET,F-18fluoroanalog,tamoxifen,985(ab) suppression, recombinant 0-CSF, 933(ab) hip prosthesis loosening, 950(ab) Radiotherapy 1-131 pan-B-cell monoclonal antibody, B-cell bone scan, MEl imaging, detection ofspinal me computersand instrumentation, SNM Mid-Win lymphoma, 893(ab) tastases, 992(ab) 1cr Meeting, 23N(l) intraperitoneal, postural effects, monoclonal an cardiac volumes, correction for Compton scatter, regional, Re-186 cell binding agent, 899(ab) tibodies, 959(ab) buildup factor, 1642 regional bone formation and, 1780 metastatic breast cancer, 862(ab) common bile duct clearance, endoscopic nasobi serial measurements, prostate-specific antigen, 1â€” metastatic gastrointestinal cancer, 863(ab) liary drainage tube, gallbladder stone, calized cancer, 853(ab) micrometastases 997(ab) Sr-89,metastaticprostaticcarcinoma, 1316 continuing evolution, 2180 cystography, vesicoureteral reflux, children and Radiotoxicity, lymphocyte labeling, Tc-99m plasmapheresis, mathematical modeling, adolescents, 1022(ab) HMPAO, micronucleus assay, 1167 941(ab) dual, Tc-99m and 1-123, quantitative brain RadiOtraCers monoclonal antibody, MIRDOSE dosimetry SPECT,972(ab) monocationic, Tc-99m N2S@,synthesis and eval software protocol, 926(ab) evaluation of Ebstein's deformity, symptomatic uation, 990(ab) plasmapheresis, micrometastases, dosimetry, infants and children, 930(ab) rapid washout from the heart, single-headed 2167 four methods, left ventricular volume determi gamma camera SPECT system, 1146 potential of CH2 domain deletion mutant, NR nation, 763 targeted proteins for diagnostic imaging, 394 LU-b, monoclonal antibody and F(ab')@, hysterosalpingography, Tc-99m pertechnetate, Reactor, -produced Sc-47, evaluation for radioim 1028 radiation dose to ovaries, 282 munotherapy, 900(ab) prospects and problems, anti-antibody, 958(ab) image quantification, scatter correction tech Readlng@visual imagery, cortical areas in brain, reactor-produced Sc-47, 900(ab) nique, 888(ab) PETstudywith0-15 butanol, 908(ab) Re-l86 monoclonal antibodies, Phase I trials, production threatened in Poland, 20N(7) Receiver operating characteristics (ROC) 1099 stress tests, efficacy, referral bias, 2074 analysis for optimizing quantitative results, repeated low-dose, 1-131 LL2 monoclonal anti studies and MEl comparison, osteomyeitis, esophageal scintigraphy, 832(ab) body, lymphoma, 863(ab) 992(ab) anatomyofROC curve, 1068(ab) Re-l86 TNT-l and TNT-l-F(ab')@ monoclonal validation of techniques in an animal model, Receptors antibodies, 987(ab) ratio, hepatic arterial-to-portal venous blood @-adrenergic second generation high-affinity anti-CEA mono flow, 239 F-18fluorocarazololPET, 984(ab) clonal antibody, 904(ab) Radiopharmaceuticals F-18 fluorocarazolol synthesis, 983(ab) toxicity oftotal body irradiation, non-Hodgkin's absorbed dose calculations, rapidly growing tu angiotensin II, ligand distribution, imaging po lymphoma, 960(ab) mors, 277 tential, 900(ab) Radiolndium, -labeled autologous platelets, MIRD bis(dithiocarbamato)nitrido Tc(V), subcellular benzodiazepine dose estimate No. 15, 777 distribution, male rats, 850(ab) activity-related plasticity, adult mouse brain, Radloiodination chromatofocusing studies, monoclonal Fab', 883(ab) B72.3/CC49/CC83 monoclonal antibodies, 2148 binding of iomazenil, dynamic SPECT, pharmacokinetics, 960(ab) development by National Lab and Biotech Firm, 91 l(ab) corticotropin-releasing factor, CRF-receptor im 44N(l 1) C-ll flumazenilbinding, chronic alcohol-dc aging, 996(ab) formulation, phosphorus-nitrogen backbone li pendent men, 10l6(ab) E2020 analogs, mapping, sigma receptors, gands, 1072(ab) C-ll flumazenilPET, human brain homoge 890(ab) Ga-68, myocardium, 93l(ab) nates, 101l(ab) ETACreagent,cross-linkingantibody Fab' fag government relations update, 15N(3) F-18labeledligands,PET, 883(ab) ments, 943(ab) Hevesy Nuclear Medicine Pioneer Award, Mi flumazenil as a ligand, PET, 883(ab) 1-131 l,2-Pal-3-IPPA, pancreatic lipase, urine chad J. Welch, 16N(7) hypometaboicparietal cortex, Alzheimer'sdis analysis, 1028(ab) incidence ofadverse reactions, 1025(ab) ease, 887(ab) 3-iodophenylisothiocyanate, coupling to mono industry seeks speedier reviews, 19N(2) interaction with traizolam, PET, 973(ab) clonal antibodies, 1029(ab) industry split over approval, PET tracers, 24N(9) occupancy, SPECT, 887(ab) new simple iodination method, 982(ab) In-i 11-labeled, quantitative autoradiographic visualization, C-i 1 RO 15-4513, 860(ab) 2-nitroimidazole derivatives, viable hypoxic tis study, heterogeneous activity distribution, cocaine sue,SPECT,891(ab) 1825 mapping with radioligands, SPECT, 890(ab) novelcandidate forSPECT imaging, sigma recep I.V. administration, prevention of contamina PET imaging probes, non-human primate tors, 981(ab) tion, 1027(ab) model,946(ab) Radioiodlne, pelvic uptake, rectal wall teratoma, kits,reconstitutionand fractionation,1915(le) radiolabeledanalogs,PET, 1025(ab) thyroidectomyforpapillarycarcinoma, 1848 preparation ofl-125 PAB, malignant melanoma, corticotropin-releasing factor, radioiodination, Radiolodine-13l, therapy for well-differentiated 889(ab) potential tracer, 996(ab) thyroid cancer, 1132 radiotoxicity, I-123/I-i25/I-l3l-labeled com dopamine Radlolsotopes pounds,mouse,2196 density measured by C-il raclopride and lung scanning, anatomy of, 676 rapid clearance, simulation, dynamic SPECT, NMSP, same living human brain, 847(ab) medical use of, NRC Medical Use Division, 1200 effects ofage, SPECT and IBZM, 897(ab) 30N(9) second Sino-American nuclear medicine confer dopamine Dl, fluorinated SCH 38548 deriva production and research, questions about future ence, l6N(4) tives, PET radiotracers,829(ab) ofDOE, l3N(6) single kit, radiolabeling human polyclonal IgG, dopamine D2 threatened reactor worker strike, l9N(9) Tc-99m or In-l 11, l024(ab) alternate syntheses, 1-125 ioxipride and 1-125 Unites States supply of, Congressional subcom staff formulating/dispensing/administering, re epidepride, 982(ab) miftee, 16N(l0) gional dose distribution to hands, 1065(ab) chemical family ofligand, 981(ab) Tc- and Re-labeled progestins, 558 density, C-l 1 NMSP PET, 848(ab) alternate syntheses, 1-125 ioxipride and 1-125 ep Tc-99m dual-labeling agents, PET and SPECT, 890(ab) idepride, 982(ab) multifunctional phosphorus hydrazides, dynamic SPECT and whole body imaging, I- C-lI NNC 722, dopamine uptake system, 1032(ab) 123 IBZM, 896(ab) 931(ab) perfusion agents, 22N(l) 1-123 IBZM SPECT, 1964 radioiodinated 2@9-carboxymethoxy-3@9-(4-ch1o- uptake and dose heterogeneity, quantitative au 1-123 IBZM SPECT, haloperidol, 898(ab)

Subject Index â€¢1992 2293 Reconstruction

1-123 IBZM SPECT, Parkinson's disease, response, 872(ab) Reperfusion, infarct-related arterial patency, serial 917(ab) image, filtered back-projection, iterative linear tomographic imaging, Tc-99m sestamibi, 1-123 IBZM SPECT, Parkinson syndromes, algorithms, 871(ab) 2080 917(ab) improved resolution, SPECT, simulation results, Resins, thermally stable ion exchange, heteroge 1-123IBZM SPECT, unilateral Parkinson's dis 85 l(ab) neous nucleophilic radiofluorination, ease, l016(ab) iterative 984(ab) 1-123 IBZM SPECT, Wilson's disease, 897(ab) algorithm, SPECT grey matter imaging, 1225 Resource Based Relative Value Scale (RBRVS), 1-123 2'-ISP SPECT, 897(ab) quantification, human basal ganglia, 878(ab) PPRCreport to Congress,36N(9) in vivo SPECT with iodine-iodolisuride,su maximum-likelihood Respiration, effect of cocaine, Tc-99m D,L pranuclear palsy, 1481 clinically important characteristics, 1678 HMPAO,rat brain slices,964(ab) PETtracers,benperidolanalogs,848(ab) improved brain SPECT, 964(ab) Restenosis, fibrin deposition, coronary artery in preclinical study, 1-123 IBF SPECT, 870(ab) PET images,artifacts, l069(ab) jury, 845(ab) preparation,F-18 NCQ616 andC-l 1FLB 457, quantitative method, single-orbit cone beam Rhenium-186 860(ab) SPECT, 892(ab) anti-P185HER2 monoclonal antibody, animal radioiodinated high-affinity ligands, 848(ab) quantitative performance of maximum likei tumor model, 934(ab) specific and non-specific binding ofC-l 1 YM hood, image wide resolution convergence, cell binding agent, regional radiotherapy, 899(ab) 0915 1-2, age dependency, 897(ab) 87l(ab) comparison of bone-seeking agents, mechanistic superior PET ligand, 847(ab) three-dimensional iterative, SPECT, 879(ab) implications, 899(ab) supranuclear palsy, 1-123 ILlS SPECT, volume-imaging PET, function of axial extent, direct vs. chelate labeled NR-LU-lO monocional 10l9(ab) 87l(ab) antibody, tumored nude mice, 910(ab) dopamine Dl and D2, striato-nigral degenera Red blood cells immunoconjugates, effective stabilization, tion, Parkinson's disease and PET, 917(ab) human, reduction of teboroxime extraction, rab 979(ab) glucose utilization and, use of linear program bit heart, 864(ab) labeling the diaminedithiol ligand system, ming, PET studies of heart and brain, serial measurements of cardiac volumes, count 1032(ab) 944(ab) based methods, 1324 pharmacokinetics after Re-186-HEDP, bone me hepatic, biochemistry, Ga-68 DF-NGA, 1160 UltraTag RBC kit, anticoagulants, reagent vol tastases, 646 histamine Hl ume, 989(ab) Tc-99m complexes and blocking drugs, distribution of C-l 1 pyrila Reflux structural requirements, rapid tubular trans mine, 968(ab) duodenogastric, significance, diagnosis of acute port, 900(ab) C-l 1 pyrilamine and C-i 1 doxepin, heart, cholecystitis, 898(ab) unsymmetrical BAT ligand, 989(ab) 885(ab) gastroesophageal, abnormal esophageal motility, TNT-l and TNT-l-F(ab'), monoclonal antibod 5-HT3, potential tracer for imaging, 830(ab) angina-like chest pain, 955(ab) irs, radioimmunotherapy, 987(ab) ligand-, PET, multi-injection approach, 943(ab) vesicoureteral Rhenium-l86 etidronate, radiochemical and chem measurement of concentration in the heart, in cyclic voiding cystography, asymptomatic sib ical stability of injection, radiolysis effects, strumental errors, PET, 882(ab) lings, 873(ab) l024(ab) muscarmnic, synthesis and biodistribution, C-il radionuclide cystography, children and adoles Rhenium-186 HEDP, treatment of bone pain, 2a-tropanyl benzilate, 423 cents, 1022(ab) 859(ab) muscarinic acetylcholine, 1-125 QNB, rat brain, Regional wall motion Rhenium-186 IgG, metabolic studies, normal and 883(ab) choice of stress for diagnostic perfusion, MIBI tumor-bearing mice, 979(ab) muscarinic cholinergic SPECT, stress echocardiography, 825(ab) Rhenium-186 monoclonal antibodies, radioimmu decreased binding of 1-123 IDEX, temporal regional metabolic abnormality, relation to per notherapy, Phase I trials, 1099 lobe epilepsy, 928(ab) fusion, myocardial infarction, 659 Rhenium-l86 progestin, Tc-99m and, synthesis and tracer kinetic analysis, C-i 1 NMPB, 882(ab) thrombolytic therapy, Tc-99m sestamibi defect receptor binding, 558 opiate kappa, synthesis, F-18 N-(2-(pyrrolidinyl)- size, 927(ab) Rhenium-188 l-phenylethyl)acetamide analog, 830(ab) Regions of interest (ROl) 1-131 Mu-9 IgO and, therapeutic potential, single serotonin, mapping, C-l 1 methylketanserin, anatomy-oriented 3-D ROI definition system, and fractionated doses, l000(ab) 1026(ab) 1006(ab) methylene bridged phosphineoxide-phosphine, serotonin S2, 1-125 altanserine SPECT, l023(ab) maximum likelihood-expectation maximization versatile chelating agent, 979(ab) sigma reconstruction, SPECT, 451 Tc-99m and, bifunctional frameworks, phospho mapping of, radioiodinated E2020 analogs, Rejection rus hydrazide chelates, 910(ab) 890(ab) cardiac allograft, 1-123 anti-ICAM-l imaging, Rhemum-lSS antibody, generation by direct label novel candidate for SPECT imaging, radioiod rats, i000(ab) ing methods, 909(ab) ination, 981(ab) cardiac transplantation, antimyosin agents, pri Rhenium-188 RC(V)-DMSA, facile synthesis, tri somatostatin mates, 1994 phenylphosphine reduction, perrhenate at room temperature, 1024(ab) 1-123 TOCT and In-l 11 DOCT somatostatin Renography Rheumatic fever analogues, neoplasms, 9l4(ab) captopril carditis, importance, scintigraphic diagnosis, scintigraphy, In-i 1l-DTPA-D-Phe-l-octreo captopril-stimulated PRA, bilateral renal artery 995(ab) tide, 652 stenosis, 907(ab) Tc-99m radionucide angiography, thrombosis Reconstruction cortical residual activity, renal artery stenosis, detection, left atrial appendage, 365 accelerated, ordered subsets, 960(ab) 906(ab) Rotor's disease, scintigraphic aspect, Tc-99m me algorithm, singular value decomposition, atten segmental branch renal artery stenosis, 266 brofenin, 1550 uation in SPECT, 831(ab) diuresis, gravity-assisted drainage view, 1022(ab) Rubidium-82 Bayesian, registered anatomical images as priors, diuretic 0-15 water and, myocardial perfusion, PET, SPECT,963(ab) functional assessment, pre- and post-pyelo 884(ab) cardiac SPECT, truncated projections, 83l(ab) plasty, 977(ab) PET cone beam, algorithm, displaced center-of-rota natural history, infantile hydronephrosis, 2098 vs. F-18 FDG, hibernating myocardium, tion, 89l(ab) DTPA, triple radiopharmaceuticalrenal study, 1065(ab) 3D ML-EM, improved signal-to-noise, 961(ab) renovascular hypertension, l034(ab) vs. 11-201 SPECT, myocardial perfusion, fan beam convolution, variable focal length col volume expanded diuretic, postnatal assessment, 1064(ab) limators, 891(ab) suspected uretero-pelvic junction obstruc fast iterative method, basis, functional regions, tion, 2094 S 831(ab) â€œwelltemperedâ€•diuretic, hydronephrosis or hy fast maximum-likelihood, 1710 droureteronephrosis, asymptomatic neo Samarium-153 high resolution PET image, restoration, detector nate, 2047 comparison of bone-seeking agents, mechanistic

2294 The Journal of Nuclear Medicine Seizures

implications, 899(ab) adrenal or juxtaadrenal masses, 996(ab) 9l4(ab) Cu-67 immunoconjugates, tumor therapy, appearance of Alzheimer's disease, Tc-99m parathyroid, subtraction algorithm, 996(ab) 942(ab) HMPAOSPECT,181 phase analysis, consequences, ventricular tachy intra-arterial microspheres, pre-operative sterili assessment ofMIBG uptake, globally denervated cardia, 994(ab) zation, kidney cancers, l024(ab) human and canine hearts, 1444 planar, SPECT and, rotating slit collimator, Samarium-l53 EDTMP bile extravasation, presence of ascites, hepatic 1005(ab) escalating dose schedule, metastatic bone cancer, transplantation, 115 planar bone 1451 biliary, grading of hyperperfusion, rim sign, SPECT,lowbackpain, 868(ab) multidose, pain palliation, metastatic bone dis 898(ab) zygapophyseal joint injection, chronic low ease, 992(ab) bolus transport and contraction parameters, mul back pain, 868(ab) Sarcoidosis tiple-swallow investigations, 1291 plastic detectors, high-resolution 1-125 imaging, acute, In-l 11leukocyte and Ga-67 imaging, 2027 bone rat brain blood flow, 1003(ab) assessment ofdisease activity, Ga-67 citrate scan 1-131 MIBG and, detection of neuroblastoma, presurgical HMPAO, patients with medically re ning, 751 1735 fractory seizures, 967(ab) uveitis, Ga-67 citrate scanning, 1851 intravenous pamidronate, Paget's disease, 1589 pulsed Doppler and per-jejunum, portal venous Sarcoma lower extremity pain of unknown origin, pre blood flow, liver cirrhosis, 997(ab) Ewing's and osteogenic, scintigraphic differentia school children, 351 quantitative tumor, time to metastasis, dogs with tion, gallium and bone scintigraphy, Tc-99m MDP abdominal uptake, continuous osteosarcoma, 1542 1063(ab) ambulatory dialysis, 2052 radiolabeled amyloid P-component, 913(ab) Kaposi's, Tc-99m DTPA aerosol, Ga-67 scan captopril-enhanced, renal artery stenosis, en-bloc renal ning, 81 pediatric renal transplant, 263 captopril, renal artery stenosis, 2045 musculoskeletal, F-l8 FDG PET, 992(ab) cardiac blood-pool, Tc-99m liposomes, 984(ab) captopril, unexpected pressor responses, soft-tissue, metastasis, gallium imaging, 1594 detection of overexpressed c-kit protooncogene, 906(ab) soft tissue and bone, 11-201 scan patterns, monoclonal F(ab')2 fragments, 893(ab) prognostic value with captopril, renovascular 843(ab) diabetes, gastric motility disturbances, 832(ab) hypertension, 2040 Scandlum-47, reactor-produced, evaluation for ra differentiation of osteogenic sarcoma, Ewing's Rotor's disease, Tc-99m mebrofenin, 1550 dioimmunotherapy, 900(ab) sarcoma, gallium and bone scintigraphy, sestamibi, radioisotopic assessment, myocardial Scatter l063(ab) viability, 1925 acceptance testing and quality assurance, WAM diuretic MAO3 renal, routine protocol, congenital somatostatin analog, carcinoid tumors, 9l4(ab) module, 1005(ab) and acquired renal disorders, l035(ab) somatostatin receptor, In-l 1i-DTPA-D-Phe-l attenuation and depth-dependent resolution, dobutamine stress thallium, usefulness and octreotide, 652 180' myocardial SPECT, 842(ab) safety, 951(ab) sphincter ofOddi dysfunction, 1223 camera-induced, collimator penetration, 1-131 esophageal subchrondral bone infractions, acute ligamentous imaging, 889(ab) achalasia and achalasia-like disorders, 590 kneeinjuries, 516 component, SPECT projections, 842(ab) reproducibility, normal ranges, 2106 Tc-99m antifibrin, acute deep venous thrombo Compton ROC-analysis, 832(ab) sis, 848(ab) deconvolution-fitting, energy and spatial regu F-l8 FDG, chemotherapeutic impact, malignant Tc-99m antigranulocyte Fab' fragments, com larization, 842(ab) lymphoma, 858(ab) pared to In-lu oxine/Tc-99m HMPAO1eu prediction process and cubic spline, SPECT, gastric emptying ofliquids, 956(ab) kocytes, infectious diseases, 903(ab) 888(ab) hemodynamic-scintigraphic study, myocardial is Tc-99m EHIDA hepatobiliary, diagnostic criteria radionuclide cardiac volumes, buildup factor, chemia, adenosine infusion, 952(ab) forbiiary atresia, neonataljaundice, 899(ab) 1642 hepatobiliary Tc-99m HMPAO cerebralcortical activity, 117 correction bile lakes, liver transplant infarcts, 997(ab) Tc-99m HMPAO cerebral perfusion, timely attenuation and, SPECT imaging, 2232 hepatic transport function, 998(ab) brain death declaration, 2209 3D PET studies, scanners with retractable intrahepatic vs. extrahepatic cholestasis, I 186 Tc-99m MAO3, captopril, renal artery stenosis, septa, 879(ab) high-resolution, postnatal maturation, myocar 990(ab) dual photopeak window, uniformity, 962(ab) dial sympathetic nerves, 935(ab) Tc-99m MIBI, myocardial viability, thallous dual-photopeak window method, 605 1-123 iodoamphetamine, Budd-Chiari syndrome, chloride injection, 906(ab) energy spectra, neural network, 963(ab) 744 Tc-99m TBI, detection of metastases, thyroid four methods, Monte Carlo-simulated source 1-123 MIBG and 1-123 TOCT, metastatic carci carcinoma, 9l4(ab) distributions, 962(ab) noid tumors, I 121 thallium radionuclide image quantification, 888(ab) 1-131 MIBO incremental diagnostic value and impact, 1727 semiquantification, 1-123 IBZM SPECT, diagnostic value, kindred with MEN-Il, incremental value, cost consciousness, 1732 972(ab) l065(ab) thrombosis, Tc-99m inhibited recombinant t-PA, spectral imaging, standard acquisition energy pitfalls, diagnosis of neuroblastoma, 930(ab) 1029(ab) window, 888(ab) importance of diagnosis, carditis in rheumatic 11-201 whole-body SPECT, 1007(ab) fever, 995(ab) localization, parathyroid enlargement, 895(ab) Sal 38548, fluorinated derivatives, PET radiotra In-i 11 antimyosin, significance, uncomplicated viable myocardium, chronic coronary artery cers, dopamine D-l receptors, 829(ab) valvular replacement, 895(ab) disease, 505 Schizophrenia In-ill antimyosin monoclonal antibody, time tomographic myocardial perfusion, integration of depression and, Tc-99m HMPAO SPECT, course, myocardial infarction, 1501 wall kinetic and perfusion data, 933(ab) 972(ab) In-i 11 labeled human nonspecific IgO, evalua torsion in triorchidism, 1854 mapping of sigma receptors, radioiodinated tion, inflammatory bowel disease, 919(ab) two-phase scrotal, classification of varioceles, E2020 analogs, 890(ab) In-i 11 pentatreotide, gastro-entero-pancreatic 1034(ab) spatial low frequency pattern analysis, positron endocrine tumors, 976(ab) ventilation-perfusion, intermediate likelihood-ra emission tomography, 287 In-l 11 somatostatin analogue, visualization, ma tio results, 849(b) Schwannoma, cranial and spinal neuroma, PET lignant lymphoma, 903(ab) white blood cell, monoclonal antibodies, septic fluorodeoxyglucose, 1931 leukocyte, diagnosis ofmycotic aneurysm, 1486 loosening ofendoprostheses, 840(ab) Scientific exhibits, prizes, 19N(2) location and size of defects, myocardial perfu Sclerosis, systemic, left ventricular diastolic func Scintigraphy sion, fatal infarction, 251 tion, 68 adenosine thallium, high cardiac risk, patients marrow changes, hormonal changes, 1427(le) Scrotum, two-phase scintigraphy, classification of referred for vascular surgery, 952(ab) MIBG, location of neuroblastoma,opsoclonus varioceles, 1034(ab) adenosine 11-201, lung thallium uptake, 1600 myoclonus. 930(ab) Seizures adrenocortical, unilateral incidentally discovered MRIand, bone marrow,stagingofbreast cancer, medically refractory, presurgical HMPAO scm

Subject Index â€¢1992 2295 Self-referral

tigraphy, 967(ab) cardiac potential added clinical value, 910(ab) simple and partial, foci localization, Tc-99m cardiofocal collimator, 852(ab) gated or non-gated Cardiolite, quantitative eval HMPAOSPECT,97l(ab) defect detection, cone beam geometry, 961(ab) uation, myocardial perfusion abnormalities, Self-referral, bans on, 36N(9) defect detection, restoration filters, 842(ab) 927(ab) Senescence, accelerated mouse, altered tritiated nic emission and transmission noise propagation, gatedTc-99msestamibi,left ventricularejection otine accumulation, l023(ab) non-uniform attenuation correction, fractions, 927(ab) Sepsis 902(ab) generalized Gibbs prior, maximum a posteriori cellular hypoxia, marker F-18 fluoromisonida reconstructions, truncated projections, 831(ab) EMSPECT reconstruction,832(ab) zole, 924(ab) volume, delineation ofmyocardium, 933(ab) grey matter imaging, compensation, iterative re loosening of endoprostheses, WBC scintigraphy cerebral blood flow and MRI, differential diag construction algorithm, 1225 with monoclonal antibodies, 840(ab) nosis, dementia, 1014(ab) high-resolution three-head, dual energy acquisi spread of infectious complications, odontogenic cerebral perfusion, relative error-estimation, re tion, livertumor imaging,976(ab) abscess, Tc-99m HMPAO-labeled WBC gional analysis, 969(ab) hippocampal blood flow, diagnosis, Alzheimer's scan, 254 cerebral perfusion abnormalities, Alzheimer's disease, 940(ab) Serotonin disease, 973(ab) 1-125 altanserine, potential ligand, serotonin S2 improved preparation, 1-123 LSD or 1-125 LSD, clinical, promotion of, 38N(9) receptors, i023(ab) 982(ab) cocaine receptor site mapping, radioligands, 1-123 CIT. monoamine transporter sites, non presynaptic, synthesis and evaluation, 1-125 5-I- 890(ab) human primate brain, 945(ab) 6-NQP,890(ab) collimation, spatially variant focusing, 89l(ab) 1-123 IBF, precinical study, D2 dopamine recep transporter, MIBO uptake, 935(ab) compared to PET, l586(le) tor, 870(ab) uptake sites comparison ofsingle/dual/triple-head, 1070(ab) 1-123 IBZM trans-C-l I McN-5652, 860(ab) Compton scatter correction method, prediction differential diagnosis ofParkinsonism, 917(ab) 2-[C-l i]methyl-amino-2-methyl-3-phenyl-l- process, cubic spline, 888(ab) dopamineD2 receptors,1964 propanolPET, 86l(ab) computer-directed coregistration, multislice dopamine D2 receptors, effects ofage, 897(ab) Shock, cardiogenic, acute onset, normal coronary functional and anatomic images, external dopamine D2 receptors, haloperidol, 898(ab) arteries, 1558 fiducials, 96l(ab) dopamine D2 receptors, Parkinson's disease, Shunt cone-beam, sampling considerations, 89l(ab) 917(ab) left-to-right, quantitation, recircuiation subtrac continuous imaging protocol, Tc-99m tebo and dopamine D2 receptors,Parkinson syndromes, tion, 1917(le) 11-201, 1304 917(ab) portal systemic, fraction quantification, 1-123 Cramer-Rao bound analysis of effects, attenua dopamine D2 receptors, Wilson's disease, HIDPM,997(ab) tion, feature size and activity estimation, 897(ab) Sincalide, continuous infusion, calculation, gall 962(ab) dopamine D2 receptors, unilateral Parkinson's bladder ejection fraction, 537 current role, imaging ofsubdural hematoma, 248 disease, 10l6(ab) Single photon emission computed tomography delayed, 1-123 IMP, dementia, 10i5(ab) Parkinson's disease, multi-system atrophy and (SPECT) diagnostic . accuracy, Alzheimer's disease, dystonia, 10l8(ab) l80, spine, patients with LBP, 950(ab) 1019(ab) semiquantification, scatter correction, 972(ab) acquisition, effects, differential tracer washout, dual bone and WBC scan imaging, osteomyeitis, 1-123 IBZM and Tc-99m HMPAO, subjects with 125l(le) cellulitis, 839(ab) and at risk for Huntington's disease, 970(ab) adrenal, without dexamethasone suppression, dual-detector, cone beam tomography, 892(ab) 1-123 ILlS, dopamine D2 receptors, supranuclear primary aldosteronism, 834(ab) dual isotope, brain, headtome set 031, 1017(ab) palsy, 10i9(ab) anatomy-oriented 3-D ROl definition system, dual isotope immunoscintigraphy, improved de 1-123 IMP l006(ab) marcation of tumors, occult colorectal car cerebral blood flow, no arterial sampling, attenuation correction cinoma, l000(ab) 969(ab) dual-energy X-ray CT, 901(ab) dual-labeling agents, dopamine D-2 receptors, cerebral perfusion, progressive supranuclear iterative methods, 962(ab) 890(ab) palsy, 704 basal ganglia uptake, monkey brain phantom, dual radionucide, feasibility with 1-123 and nondemented old patients, Down's syndrome, 963(ab) Tc-99m, 85l(ab) 967(ab) Bayesian reconstruction, registered anatomical dynamic partition coefficient, regional cerebral blood images as priors, 963(ab) detection and correction ofmotion, 911(ab) flow,91i(ab) benzodiazepine receptor occupancy, relation to iomazenil binding to human benzodiazepine 1-123 IPPA, myocardial involvement, systemic benzodiazepine medication, 887(ab) receptor, 91 i(ab) myopathies, 995(ab) blood flow in stroke, clinical prognosis, 878(ab) kinetic modeling, teboroxime, 878(ab) 1-123 2'-ISP, D-2 dopamine receptors, 897(ab) brain simulation, radiopharmaceuticals with rapid 1-131 CC49 monoclonal antibody, radioimmu attenuation effect, 96i(ab) clearance, 1200 notherapyand CT, advancedcolorectalcan blood flow, interventional neuroradiology, whole body imaging, 1-123 IBZM and dope cer, l002(ab) 826(ab) mine D2 receptors, 896(ab) imaging and quantitation, spatial factors, cerebral angioplasty, delayed ischemia due to equitable reimbursement, 36N(9) 1069(ab) vasospasm, 1789 fast maximum-likelihood reconstruction, 1710 imaging in small animals, 852(ab) dual radionucide data acquisition, Tc-99m four scatter correction methods, Monte Carlo improved colonic transit procedure, easily pre and1-123,972(ab) simulated source distributions, 962(ab) pared marker, 833(ab) extracorporeal membrane oxygenation, neo functional brain, powerful clinical method, 1888 improved reconstructed resolution, simulation nates, 1943 functional brain scans, evidence in criminal results, 851(ab) maximum-likelihood reconstruction, 964(ab) court, i8N(6) in vivoimagingofD2 receptor,iodine-iodolisur multimedia multimodality interactive com fusion with CT/MRI images, radiolabeled mono ide, supranuciear palsy, 1481 puter tutorial, 107i(ab) clonal antibodies, 960(ab) liver volume measurement, autopsy and NMR rapid registration, i005(ab) Ga-67 citrate, biopsy-confirmed residual Hodg imaging, l066(ab) transcranial Doppler, acute ischemic stroke kin's disease, mediastinum, 345 maximum likelihood-expectation maximization therapy, 968(ab) gamma camera, image truncation, cone beam reconstruction, ROC analysis, 451 brainperfusion CT, 901(ab) maximum-likelihood important characteristics, cocaine abuse, AIDS dementia complex, 1312, gated, Tc-99m sestamibi, fixed defects as infarct clinically important characteristics, 1678 887(ab) or artifact, 927(ab) MCSPECT prototype, cylindrical brain SPECT differential diagnosis, dementia, 1017(ab) gated blood-pool imaging system, 852(ab) regional cerebral blood flow, PET comparison, parametric display, 3-D biventricular function, measured attenuation map, attenuation correc 966(ab) 952(ab) tion, simple method, 843(ab)

2296 The Journal of NuclearMedicine Single photonemission computed tomography (SPECT)

MIBI, choice of stress for diagnosticperfusion, tion method, 892(ab) resting and exercise myocardial imaging, chil wall motion imaging, 825(ab) standardization, cardiac tomographic imaging, dren, 929(ab) moyamoya disease, before and after external-to 1434 stability, perfusion defect size, 876(ab) internal carotid artery bypass, 1692 Tc-99m and 1-123, validation by phantom stud Tc-99m monoclonal antibody 174H.64, staging multi-energy maximum-likelihood reconstruc ies, brain, 2030 headand neckcancer,9l2(ab) tion algorithms, 831(ab) Tc-99m CEROTEC, interictal localization, epi Tc-99m PPN.lOll, clinical evaluation, myocar multi-head camera, sensitivity, resolution and leptic foci, 966(ab) dium, 875(ab) imagequality, 1859 Tc-99m DMSA Tc-99m sestamibi multiple gated, myocardial thickening, phase three-head rotating gamma camera, renal scan, dobutamine, coronary arterydisease, 866(ab) analysis, 926(ab) 102l(ab) F-l8 FDG glucose PET, malignancy, 858(ab) myocardial triple-head imaging, urinary tract infection, myocardial viability, 886(ab) computer-aided diagnosis, coronary artery dis 99l(ab) right ventricular ischemia, inferior myocardial ease, 272 Tc-99m DTPA and Tc-99m desferoxamine aer infarction, 876(ab) fan-beam collimators, newborn period and osols, lung ventilation, 835(ab) same day, myocardium, 876(ab) early infancy, 930(ab) Tc-99m ECD, kinetic behavior, compartment spontaneous chest pain, coronary intervention, 180' myocardial, scatter, attenuation and depth analysis and dynamic SPECT, 909(ab) 875(ab) dependent resolution, 842(ab) Tc-99m exametazine, unilateral voluntary hand Tc-99m TEBO myocardial perfusion, Tc-99m MIBI radio movement, regional cerebral uptake, 1623 delay of image acquisition, myocardium, nuclide angiography, dipyridamole, 846(ab) Tc-99m HMPAO 952(ab) neuro-SPECT and radiographic imaging, imma acetazolamide, cerebrovascular disease, preprocessing masking technique, 854(ab) ture third ventricle teratoma, 435 877(ab) three-detector, simultaneous transmission and N-isopropyl[I-l23]IMP, regional cerebral blood acetazolamide, vascular response and dias emission, 901(ab) flow, 1741 chisis, 967(ab) three-dimensional N-isopropyl[I-123]p-ioodoamphetamine, re acute aphasia, 970(ab) cerebral blood flow, obsessive-compulsive dis gional cerebral blood flow, 965(ab) alternating hemiplegia, childhood, 102l(ab) order, 838(ab) perfusion imaging, autopsy-diagnosed dementia, Barre-Liou syndrome, cervical manipulation, iterative reconstruction, 879(ab) 939(ab) 972(ab) myocardial perfusion, Tc-99m sestamibi stress PET and, F-18 FDG and 11-201, myocardial bilateral and symmetrical anomalies, brain, perfusion, 926(ab) viability, 1064(ab) 485 three-headed, transmission data acquisition, planar bone scintigraphy and, zygapophyseal brain, 1875 901(ab) joint injection, chronic low back pain, carbon dioxide reactivity, cerebrum and cere 11-201 868(ab) bellum, 1014(ab) attenuation correction, 1574 planar scintigraphy and, rotating slit collimator, cerebral blood flow, brain tumors and strokes, brain tumor recurrence, 867(ab) l005(ab) 97 l(ab) distinction, high-grade from low-grade projections based on analytical scatter functions, cerebral blood flow, chronic subdural hema gliomas, 868(ab) estimate, scatter component, 842(ab) toma, 246 effect ofpatient motion, 1566 project underway, 44N(l 1) cerebral blood flow, choreo-athetoid syn exercise-redistribution, myocardial viability prototype emission-transmission CT imaging sys drome, 838(ab) after infarction, 906(ab) tem, 1881 cerebrovascular reserve capacity, carotid artery F-l8 FDG PET and MRI, recurrent brain tu qualitative approach to HIV dementia, 1018(ab) stenosis, 971(ab) mors, 867(ab) quantification, attenuation and scatter correc compared to MR/CT, diagnosis of dementia, influence of perfusion defect size, tomographic tion, cardiac imaging, 2232 972(ab) defect severity, 995(ab) quantitative crossed cerebellar diaschisis, cerebral infarc meningioma, prediction of histological type, 1-131, transfer ofCT vols, 925(ab) tion, 877(ab) 971(ab) local and systemic effects of radiation, bone 3-D semiquantitative method, intractable tem myasthenia gravis, 1020(ab) metabolism, 1774 poral lobe epilepsy, 970(ab) myocardial viability, coronary artery disease, quantitative stress-redistribution 11-201, prone feasibility, cortical activation study, 1015(ab) 886(ab) imaging, validation, 1509 independent aura/ictal/interictal cerebral per of theoretical derivations, empirical evidence, quantitative vs. visual analysis, 11-201 defect re fusion, 438 1578 versibility and severity, 905(ab) kinetic behavior, brain, 135 recurrent primary brain tumors, 107l(ab) radial slices, myocardial perfusion studies, linearization algorithm, cerebral blood flow, re-evaluation for brain tumor, 844(ab) 1070(ab) 9l2(ab) reinjection studies, collateralization, 915(ab) radioiodinated high-affinity dopamine D2 recep localization, epileptic foci, 971(ab) sensitivity to patient motion, 1571 tor ligands, in vivo comparison, 848(ab) neurofocal imaging, brain, 1070(ab) teboroxime resting washout, coronary disease, radioiodinated 2-nitroimidazole derivatives, via perfusion change after thrombolytic therapy, 876(ab) ble hypoxic tissue, 89l(ab) ischemic stroke, 877(ab) vs.Rb-82PET,myocardialperfusion,1064(ab) radioiodination ofsigma receptors, 981(ab) presurgical evaluation, temporal lobe epilepsy, 11-201 and Tc-99m phytate, livertumor imaging, rapidly cleared tracers, 1206 929(ab) high-resolution three-head imaging, 918(ab) rapid registration and review, brain, i067(ab) quantitative perfusion-defect indexes, children 11-201 and Tc-99m sestamibi reimbursement, 19N(3) with cerebral palsy, 977(ab) heart transplantation, coronary arteriopathy, sequential high resolution, intracranial arterio regional cerebral blood flow, Down's syn 951(ab) venous malformations, Tc-99m RBC and drome, 1013(ab) myocardial viability, 905(ab) Tc-99m HMPAO, 839(ab) regional cerebral blood flow, Wisconsin card 11-201 myocardial, major upward creep of heart, simultaneous acquisitions, ICBF and glucose me sorting test, 967(ab) COPD, 1846 tabolism, 965(ab) schizophrenia and depression, 972(ab) triple-headed DMSA, comparison with ultraso simultaneous dual-isotope, parathyroid pathol scintigraphic appearance, Alzheimer's disease, nography, 922(ab) ogy, 131 181, 312 triple-head high-resolution simultaneous emission/transmission, scanning sensitivity and specificity, dementia, l013(ab) diagnosis, femoral head avascular necrosis, line source, attenuation correction, 90l(ab) status epilepticus, 928(ab) 936(ab) simultaneous rest 11-201/stress Tc-99m seats Tc-99m HMPAO and 1-123 IMP, cerebral blood diagnosis, hepatic hemangioma, 918(ab) mibi, myocardial perfusion, 854(ab) flow, 1012(ab) vs. PET, Annual Meeting highlights, l3N(8) single-headed gamma camera system, rapid ra Tc-99m HMPAO and Tc-99m ECD, kinetics, vs. planar bone scintigraphy, low back pain, diotracer washout, heart, 1146 brain tumors, 969(ab) 868(ab) single-orbit cone beam, quantitative reconstruc Tc-99m MIBI whole-body, method for scatter correction,

Subject Index â€¢1992 2297 Skeleton

1007(ab) carotid artery, cerebrovascular reserve capacity, Synovectomy Xe-133 thrombendarteriectomy, 97l(ab) radiation cerebral blood flow and predetermined ROIs, coronary, adenosine, 11-201 compared to Ho-l66 hydroxyapatite, 937(ab) children, 977(ab) Tc-99m teboroxime, 864(ab) radiolabeling, hydroxyapetiteparticies, 980(ab) surgical outcome, temporal lobe epilepsy, iliac artery, renal transplant hypertension, 1178 radionucide, polymeric microspheres, neuron lOi8(ab) renal artery activated holmium-166, 398 Skeleton captopril-stimulated PRA, 907(ab) axial, bone mineral density, acromegaly, 1608 chronic rejection, renal kinetics in transplants, T bone mineraldensity,dual-energyX-rayabsorp 923(ab) tiometry, 1137 cortical residual activity, captopril renography, Tamoxifen, F-l8 fluoro analog, radiosynthesis, es kinetics,evaluation,F-l8 fluorideion PET,633 906(ab) trogen receptors and PET, 985(ab) nonvisualization, bone scan, secondary to intra Tc-99m MAG3scintigraphy, captopril, 990(ab) Taste,dysfunction, thymidcancer, 1-131treatment, venousetidronatetherapy,748 Stents, coronary, platelet-fibrin deposition, antico 996(ab) screening in children, traumatic brain injury, agulation, 845(ab) Teboroxime 873(ab) Stereotaxy, automated, transformation, functional extraction in rabbit heart, reduction by incuba Sn(II) complexes,macromolecular,direct Tc-99m brain PET images, 1007(ab) tion with human RBC, 864(ab) labelingwithantibody, 1029(ab) Stomach kinetic modeling, dynamic SPECT imaging, Sn(II)-DPEDO kit, Tc-99m labeled brain scanning, antral processing ofsolid meal, acute and chronic 878(ab) elimination of chiral centers, coordination alcohol, 832(ab) myocardial perfusion imaging, adenosine, accu sphere,920(ab) applications ofamplitude images, interpretation, racy and optimal imaging time, 854(ab) Sn-ll7m, comparison of bone-seeking agents, gastric bleed studies, l006(ab) preprocessing masking technique, SPECT, mechanistic implications, 899(ab) Fourierapproachto gastricmotility,956(ab) 854(ab) resting washout and stress thallium SPECT, cur Society of Nuclear Medicine (SNM) gastric uptake ofGa-67 in AIDS, 643 onary disease, 876(ab) ACNP and, medicare fee schedule, 18N(l) Streptavidin Technetium-94m, radionucide purity require actions ofthe Board ofTrustees, 23N(4) biotin and, localization ofinfection, 1810 ments, pharmacokinetic studies, PET, Annual Meeting highlights, molecules with mes imaging infection/inflammation, radiolabeled 850(ab) sages, lON(8) biotin, 924(ab) Technetiwn-96,companson ofbone-seekingagents, Annual Meeting preview, 33N(5) labeledbiotin and, tumor localization,substitute mechanistic implications, 899(ab) budget testimony, l3N(6) for antibody,934(ab) Technetium-96 sestamlbl, myocardial blood flow, court upheld nuclear quality management rule, Striati, variation ofaxial recovery, tilt, solution of, co-injection technique, 1152 19N(7) 921(ab) Technetium-99m government relations update, 30N(9), 14N(12) Striatum, loss of 6-[F-l8]fluoro-L-dihydroxyphen alkyl-hydroxyamamide complexes, 1033(ab) identifying nuclear medicine's practitioners, ylalanine metabolites, 916(ab) anatomy ofradioisotope lung scanning, 676 26N(4) Stroke brain scanning agent, elimination of chiral cen licensing decision, California radioactive waste acute ischemic, transcranial Doppler, brain tess, coordination where, 920(ab) SPECT,968(ab) site,40N(9) cationic complexes, myocardial tissue uptake, Mid-WinterMeeting,computersand instrumen blood flow, clinical prognosis, SPECT, 878(ab) 1033(ab) tation, 23N(l) brain tumors and, cerebral blood flow, HMPAO cellbindingagent,920(ab) new way to order medicine books, 33N(3) SPECTand MRI technique,971(ab) compared to N2S2 chelate labeled NR-LU-l0 Nuclear Medicine Week goes international, cross cerebellar diaschisis, neurolite imaging, Fab', tumored nude mice,909(ab) 33N(3) 968(ab) complexesand Re,structuralrequirements,rapid standardization, cardiac tomographic imaging, functional brain SPECT, powerful clinical tabular transport, 900(ab) 1434 method, 1888 direct labeling, platelet-binding laminin peptide, trustees favor central office move to nation's ischemic, perfusion change after thrombolytic 103l(ab) capitol, 27N(8) therapy, Tc-99m HMPAO SPECT, 877(ab) direct labeling of antibody, macromolecular Somatostatin, radiolabeled, thyroid and orbital ac neurolite as an aid in diagnosis and localization, Sn(II) complexes, 1029(ab) cumulation, Graves' disease, 894(ab) 878(ab) dual-radioisotopictechnique,tumescence,penile Somatostatin analogue, Tc-99m and In-lil, prep Strontium-89 blood flow, 41 aration, preliminary evaluation, 851(ab) different therapeutic doses, metastatic bone pain, equilibrium imaging, Kr-81m, right ventricular Spasm, infantile, regional cerebral blood flow, 937(ab) determination, 932(ab) 1018(ab) low-dose infusion cisplatin and, hormone refrac evaluation of 12 biotin derivatives, 920(ab) Species differences, interspecies variation in biodis tory prostatecarcinomametastaticto bone, gated blood-pool imaging, ECG gated PET C-il tribution, Tc-99m CPI, 1357 1437 monoxide, â€œbackgroundâ€•question, 938(ab) Spherolds, multicellular tumor, radioiodinated radiotherapy, metastatic prostatic carcinoma, human immunoglobulin, dendrimers as linker MIBG, neuroblastoma micrometastases, 1316 molecules,986(ab) 859(ab) Substance P analog, nonpeptide, synthesis of, PET hypodermically injected, study on radioactive Sphincter of Oddi studies, 860(ab) pathways, 403 dysfunction N-Succlnlmldyl 4-(F-I8lfluorobenzoate, labeling of 1-123and noninvasive test, postcholecystectomy, 1216 monoclonalantibodieswith F-l8, 881(ab) dual radionucide data acquisition, quantita scintigraphic evaluation, 1223 Sudden death, thaffium scan, court litigation, 120 tive brain SPECT, 972(ab) Spinal cord, injury, renal plasma flow, glomerular Supranuclear palsy, in vivo SPECT with iodine feasibility, dual radionucide SPECT imaging, filtration rate, 1035(ab) iodolisuride,D2 receptor, 1481 851(ab) Spine Supreme Court, case against radioactive waste pol SPECT,brain, 2030 fracture, bone mineral density, cyclic oral phos icy amendments act, 33N(3) ImmunRAID-CEA, patient response, human phate and etidronate, 1 Surgery, vs. conservative management, antenatal anti-mouse antibody, 1002(ab) neuroma, PET-fluorodeoxyglucose, 1931 hydronephrosis, impaired renal function, inhibited recombinant tissue plasminogen acti Spleen 873(ab) vator, thrombosis scintigraphy, 1029(ab) -liver scan, fatty liver, masquerade as neoplasm, Sympathetic nervous system -labeled organic cations, synthesis, renal excre 258 localization of pheochromocytoma, C-i 1 HED tion, 2190 radiolabeledgranulocytekinetics, systemicyes PET, 1125 labelingofantimyosin Fab', instant kit method, culitis, 491 MIBG heart and lung extraction fraction, first myocardial infarct model, 144 Starling effect, reduced exercise capacity, cardiac pass analysis, 716 mapping ofleukocytes, secondary ion mass spec transplantation, 939(ab) myocardial, postnatal maturation, high-resolu trometry microscopy, 2162 Stenosla tion scintigraphy, 935(ab) myocardial imaging agent, kit development,

2298 The Journal of Nudear Medicine Technetium-99m HMPAO

Technecard,850(ab) Technetium-99m DACH, potential new cationic healthy human subjects, 480 new radiopharmaceuticals, multifunctional phos renal tubular agent, normal human volun Technetium-99m EHIDA, hepatobiliary scintigra phorus hydrazides, l032(ab) teers, 923(ab) phy, diagnostic criteria for biiary atresia, radionuclide angiography, thrombosis detection, Technetium-99m desferoxainine, Tc-99m DTPA neonatal jaundice, 899(ab) left atrial appendage, 365 aerosols and, SPECT lung ventilation, Technetium-99m erythrocytes, modification of in Re-188 and, bifunctional frameworks, phospho 835(ab) beling technique, effectiveness, 2222 rus hydrazide chelates, 910(ab) Technetium-99m dexamethasone phosphate, imag Technetlum-99mexametazine, regional cerebral up Re complexesand, unsymmetricalBAT ligand, ing ofinflammatory lesions, 1027(ab) take, unilateral voluntary hand movement, 989(ab) Technetium-99m dextran, lymphoscintigraphy, 1623 renal scan, diagnosis, bleedingmycotic iliac aneu transverse rectus abdominus myocutaneous Technetium-99m fragment E,, thrombus imaging, rysm, 1548 flap, autogenous breast reconstruction, preparation, preliminary evaluation, 710 second binding site in IgG, relation to histidine 859(ab) Technetium-99m 2GAM, renal imaging, evaluation groups, 1029(ab) Technetium-99m DISIDA, utility of cholescintig in humans, 923(ab) serial measurements of cardiac volumes, count raphy, laparoscopic cholecystectomy, Technetium-99m glucarate, 11-201 and, acute myo based methods, 1324 898(ab) cardial infarction, rats, 1988 side chain modifications, bis(dithiocarbamato) Technetium-99m DMSA Technetium-99m glucoheptonate white blood cells, nitrido technetium(V), myocardial uptake, elimination ofbackground and kidney-depth cor inflammatory bowel disease, 998(ab) l034(ab) rection, compartment modeling, renal up Technetium-99m HDP, incidence of adverse mac small molecule neutral-lipophiuic agents, func take rate, 1004(ab) tions, 1025(ab) tionalized phosphinimines, 851(ab) febrile urinary tract infections, 976(ab) Technetium-99m HIDA, hepatic clearance of deriv targeted proteins, diagnostic imaging, 394 parenchymal renal lesion after ESWL, 990(ab) atives, hyperbilirubinemic states, 1551 Tl-20l and, dual-isotope autoradiography, corn pentavalent, small coordination complexes, tu Technetium-99m HIG puted tomography, l005(ab) mor imaging, 469(le) assessment of infectious conditions, musculo transmission source, 11-201 cardiac SPECT, si renal scans, variability, standardized rating scale, skeletal system, 839(ab) multaneous acquisition of emission/trans 922(ab) bone scans and, joint inflammation, rheumatoid mission data, 2238 replacement with Tc-99m MAG3, exclusion, fo arthritis, 840(ab) two new myocardial perfusion agents, 22N(l) cal renal defect, 2090 detection of bone and joint inflammation, Xe-l33 and, dual isotope imaging, energy SPECT 839(ab) weighted acquisition, 889(ab) three-head rotating gamma camera, renal scan, one-step labeling kit, imaging of inflammation Technetium-99m D,L-HMPAO, uptake mechanism 102l(ab) and tumors, l028(ab) in cell cultures, dissociated postnatal rat cer triple-head imaging, urinary tract infection, Technetium-99m HMPAO ebellum, 108 991(ab) angiography ofthe brain, quantitative approach, Technetium-99m antibody triple-headed SPECT, comparison with ultraso 877(ab) direct and indirect, comparison in mice, 909(ab) nography, 922(ab) brain perfusion SPECT, acute aphasia, 970(ab) pharmacokinetic modeling, 958(ab) Technetium-99m DTPA brain scans, high-resolution SPECT, neurofocal Technetium-99m anti-CEA antibodies, techni aerosol, MIRD dose estimate Report No. 16, imaging, 1070(ab) cal limitations of immunoscintigraphy, 1717 brain SPECT l00l(ab) aerosol and gallium-67 scanning, pulmonary bilateral and symmetrical anomalies, 485 Technetium-99m antifibrin, scintigraphy, acute complications, HIV infection, 81 cerebral angioplasty, delayed ischernia due to deep venous thrombosis, 848(ab) aerosol clearance, effect of molecular size, vasospasm, 1789 Technetium-99m antiflbrin Fab', localization or 1022(ab) cerebral blood flow, choreo-athetoid syn pharmacokinetics, anticoagulation by hepa bifunctional, macrocyclic ligands, serum stability drome, 838(ab) rim,acute venous thrombosis, 978(ab) studies with Y-88, 103l(ab) r-CBF variability, 826(ab) Technetium-99m anti-fibrin monoclonal antibody, diuresis renography, ureteral status, children, 72 regional cerebral blood flow, Down's syn accumulation in inflammatory focus, I 181 effects ofdipyridamole, renal function, 355 drome, l013(ab) Technetium-99m antigranulocyte antibody incidence ofadverse reactions, 1025(ab) cerebral cortical activity, scintigraphy, 117 clinical usefulness, differential diagnosis, intra monofunctional analogs, attachment to peptides cerebral perfusion, internal carotid artery occlu cranial abscess, 957(ab) and antibodies, 988(ab) sion, 969(ab) suspected bone infections, 526 radiation dosimetry, human biodistribution stud cerebral perfusion scintigraphy, timely brain Technetium-99m antigranulocyte Fab' fragments, ies, 33 death declaration, 2209 scintigraphy, compared to In-i 11 oxine/Tc renal uptake-plasma volume product, glomerular comparative study of TCGH and TcHMPAO, 99m HMPAO leukocytes, infectious dis filtration rate, 1712 diagnosis ofbrain death, l016(ab) eases, 903(ab) single-injection multi-sample renal clearance compartment analysis and dynamic SPECT, ki Technetium-99m antigranulocyte monoclonal anti methods, optimum sample times, 948(ab) netic behavior, Tc-99m ECD, 909(ab) body, fever of unknown origin, 902(ab) Tc-99m desferoxamine aerosols and, SPECT differential diagnosis ofdementia, 939(ab) Technetium-99m antimyosin Fab', instant kit lung ventilation, 835(ab) 1-123 IMP and method, myocardial infarct model, 144 ventilation, effectiveness of PEP mask, cystic fi dual-isotope brain imaging, normal volunteers, Technetium-99m avidin, kidney uptake, isoelectric brosis, 835(ab) 827(ab) point, 986(ab) Technetium-99m DTPA-HSA, cerebrovascular re regional cerebral blood flow, drug abuse, Technetium-99m bicisate: see Technetium-99m sponse to acetazolamide, new method for 10l5(ab) ECD monitoring, 969(ab) regional cerebral blood flow, SPECT and MRI, Technetium-99m Cerotec Technetium-99m ECD 1012(ab) brain scan, assessment, brain death, 970(ab) brain perfusion SPECT, cerebral blood flow, independent aura/ictal/interictal cerebral perfu SPECT, interictal localization, epileptic foci, PET,966(ab) sion, 438 966(ab) brain retention, effect ofradiolabeled impurities, intraarterial carotid artery injection, recurrent Technetium-99m colloid, Tc-99m monoclonal an dosimetry, 989(ab) glioma, 966(ab) tibodies and, image subtraction analysis, kinetic behavior in human brain, compartment isomers D,L and effect of cocaine, uptake and liver lesions, 9l3(ab) analysis and dynamic SPECT, compared to respiration, rat brain slices, 964(ab) Technetium-99m complexes, properties that facili Tc-99m HMPAO, 909(ab) isomers D and i@,biological evaluation, l032(ab) tate renal tubular transport, 920(ab) planar imaging, global cerebral blood flow, mon kinetic behavior in human brain, cerebral blood Technetium-99m CPI keys, 979(ab) flow, dynamic SPECT, 135 human pharmacokinetics and radiopharmacol SPECT,kinetics,brain tumors, 969(ab) -labeledWBCscan, spreadof infectiouscompli ogical studies, 1949 synthesis ofisomers, brain, monkeys, 979(ab) cations, odontogenic abscess, 254 interspecies variation in biodistribution, 1357 Tc-99m HMPAO and, intrasubject comparison, lymphocyte labeling, radiotoxicity study, micron

Subject Index â€¢1992 2299 Technetium-99m HMPAOleukocytes

ucleusassay, 1167 clinical experience with Tc-99m nanocolloid, dren, 929(ab) presurgical scintigraphy, patients with medically 999(ab) stability, perfusion defect size, 876(ab) refractory seizures, 967(ab) diagnosis ofsternal wound infection, 59 subcellulardistribution and analysis, perfused rat SPECT In-I 11 oxine and, simultaneous imaging, corn hearts, 1516 acetazolamide, cerebrovascular disease, munity hospital, 902(ab) 11-201 877(ab) Technetium-99m liposomes follow-up, differentiated thyroid carcinoma, acefazolamide effect, vascular response and cardiac blood-pool scintigraphy, 984(ab) 844(ab) diaschisis, 967(ab) newly developed labeling procedure, successful and MRI, recurrentbrain tumors, 867(ab) alternating hemiplegia, childhood, 102l(ab) infection detection, rats, 1027(ab) 11-201 chloride and, uptake, primary thyroid attenuation correction, brain, 1875 Technetium-99m MAG3 lymphoma,1396 Barre-Liou syndrome, cervical manipulation, clearance 11-201 scintigraphy and, localization, parathy 972(ab) camera-based method, gamma variate fit, mid enlargement, 895(ab) brain blood flow, interventional neuroradiol 991(ab) 11-201 SPECT and, childhood brain tumors, ogy, 826(ab) optimized camera based method, 948(ab) 844(ab) carbon dioxide reactivity, cerebrum and cere preliminary â€œnormalâ€•values, infants, 102l(ab) uptake in benign and malignant bone lesions, bellum, 10l4(ab) prospective validation, single sample tech compared to Tc-99m MDP, 319 cerebral blood flow, brain tumors and strokes, nique, 1620 use in peripheral vascular disease, 629(ie) 97 l(ab) diuretic renal scintigraphy, routine protocol, con Technetiuin-99m monoclonal antibody cerebral blood flow, chronic subdural hema genital and acquired renal disorders, CA 125, early detection, ovarian cancer recur toma, 246 1035(ab) rences, 904(ab) cerebrovascular reserve capacity, carotid artery evaluation of new ligands, renal function agents, F023C5 anti-CEA IgG1, gastrointestinal tumor stenosis, 97 l(ab) 988(ab) targeting, role ofCEA content, 892(ab) cocaine abuse, AIDS dementia complex, 1312 hepatobiliary excretion, 990(ab) 174H.64, SPECT, staging of head and neck can crossed cerebellar diaschisis, cerebral infarc kits, prolonging useful life, 991(ab) cer, 912(ab) tion, 877(ab) modified amide bonds, 1032(ab) HPLC,recoveryand calibration, l030(ab) 3-D semiquantitative method, intractable tern potential renal imaging agents, 919(ab) management of colorectal and ovarian cancer, poral lobe epilepsy, 970(ab) radiation dosimetry, human biodistribution stud 904(ab) feasibility of cortical activation study, subtrac ies, 33 Tc-99m colloid imagesubtraction analysisand, tion method, 1015(ab) renal scans, hepatic activity, 992(ab) liver lesions, 913(ab) @ kinetics, brain tumors, 969(ab) replacement of Tc-99m DMSA, exclusion, focal Technetium-99m monocationic radiotracers, linearization algorithm, cerebral blood flow, renal defect, 2090 synthesis and evaluation, 990(ab) 9l2(ab) scintigraphy, captopril, renal artery stenosis, Technetium-99m nanocolloid, clinical experience, localization, epileptic foci, 971(ab) 990(ab) 999(ab) perfusion change after thrombolytic therapy, simplified ERPF determination, 1034(ab) Technetium-99m NGA, evaluation oflocal reduced ischemic stroke, 877(ab) single-injection multi-sample renal clearance mass, functioning hepatocytes, chronic liver presurgical evaluation, temporal lobe epilepsy, methods diseases, 998(ab) 929(ab) comparison, 948(ab) Technetium-99m nitrido dithincarkmate@ myocar quantitative perfusion-defect indexes, children optimum sample times, 948(ab) dial imaging agents, improved synthesis, with cerebral palsy, 977(ab) technescan,labelingconditionsand QC, 1033(ab) 989(ab) regional cerebral blood flow, Wisconsin card vs. 1-131 hippurate, functional and anatomic Technetium-99m 2-nitroimidazole, imaging re sorting test, 967(ab) evaluation, renal transplants, 1035(ab) gional hypoxia, occlusion of LAD coronary remote history, traumatic brain injury, 52 Technetium-99m MDP artery, rabbit myocardium, 865(ab) schizophrenia and depression, 972(ab) accumulation of F-18 FDG, bone fracture, Technetium-99m P53, myocardial imaging agent, scintigraphic appearance, Alzheimer's disease, 869(ab) structural characterization, 850(ab) 181, 312 compared to Tc-99m MIBI uptake, benign and Technetlum-99m pertechnetate sensitivity and specificity, dementia, 1013(ab) malignant bone lesions, 319 pulmonary mean transit times, teboroxime, status epilepticus, 928(ab) diffuse abdominal uptake, continuous ambula 846(ab) subjects with and at risk for Huntington's dis tory dialysis, bone scintigraphy, 2052 radionuclide hysterosalpingography, radiation ease, 970(ab) extraosseous uptake, pathophysiologic approach, dose to ovaries, 282 SPECT compared to MR/CT, diagnosisof de 1063(ab) thyroid scanning, 1722(le) mentia, 972(ab) gallium and, scintigraphic differentiation, osteo Technetium-99m phytate Tc-99m ECD and, intrasubject comparison, genic and Ewing's sarcoma, l063(ab) high-resolution three-head SPECT, dual energy healthy human subjects, 480 1-131 MIBG and bone scintigraphy, detection of acquisition, liver tumor imaging, 976(ab) Tc-99m RBC and, sequential high resolution neuroblastoma, 1735 11-201 and, liver tumor imaging, high-resolution SPECT, intracranial arteriovenous malfor skeletal nonvisualization, bone scan, intravenous three-head SPECT, 918(ab) mations, 839(ab) etidronate therapy, 748 Technetium-99m phytate sucralfate, new proce Technetium-99m HMPAO leukocytes, Tc-99m an Technetium-99m mebrofenin, scintigraphic aspect, dure, advanced ulcer avid agent, 1033(ab) tigranulocyte Fab' fragments, scintigraphy, Rotor's disease, 1550 Technetlum-99m polyclonal IgG 903(ab) Technetium-99m medronate, uptake in hepatic ne carbohydrate modification, sites of bacterial in Technetium-99m HMPAO lymphocytes, fast diag crosis, Budd-Chiari syndrome, 1390 fection, 1378 nosis ofabdominal infections, 1253(le) Technetium-99m mertiatide, atlas of renal trans single radiopharmaceutical kit, 1024(ab) Technetium-99m hydrazino nicotinamide, conju plant imagingstudies, l073(ab) Technetium-99m PPN.lOll, SPECT, clinical eval gated chemotactic peptides, imaging focal Technetium-99m MIBI uation, myocardium, 875(ab) sitesofinfection, 910(ab) compared to 11-201 scintigraphy with reinjec Technetium-99m progestin, Re-186 and, synthesis Technetium-99m hydroxyamic acids, tumor imag tion, viable myocardium, chronic coronary and receptorbinding,558 ing agents, 988(ab) artery disease, 505 Technetlum-99m Q12, myocardial blood flow in Technetium-99m IDA, quantitative cholescintigra radionuclide angiography, SPECT myocardial canine heart, 993(ab) phy, differentiation, congenital gallbladder perfusion, dipyridamole, 846(ab) Technetium-99m red blood cells abnormality, 431 rest-redistribution 11-201, chronic coronary ar gastrointestinal bleeding studies, early negative Technetium-99m L,L-E@ renal imaging agent, 551 terydisease,905(ab) images, 202 Technetium-99m LDL, binding to parenchymal scintigraphy, myocardial viability, thallous chlo penile corporal venous leak, 49 and non-parenchymal cells, normal and es. ride injection, 906(ab) preparation with UltraTag RBC kit, evaluation, tradiol-stimulated rat liver, 1028(ab) SPECT heparmn and anticoagulant citrate dextrose, Technetlum-99m leukocytes resting and exercise myocardial imaging, chil 306(le)

2300 The Journalof NuclearMedicine Thallium-201

Tc-99mHMPAOand, sequentialhighresolution roid, 1393 Thalllum-201 SPECT, intracranial arteriovenous malfor vial breakage with microwave oven, l76(le) accumulation by epidermoid inclusion cyst, 1857 mations, 839(ab) Technetium-99m somatostatin analogue, In-i 11 so adenosinescintigraphy, high cardiac risk, patients Technetium-99m sestamibi matostatin analogue and, preparation, pm referred for vascular surgery, 952(ab) acute Adriamycin cardiotoxicity, chick heart liminary evaluation, 85l(ab) afterbrain surgeryand irradiation, quantification cells, 864(ab) Technetlum-99m sulphur colloid, dosimetry, cellu using an animal model, 964(ab) cardiac perfusion abnormalities, Kawasaki syn lar level, Kupffer cells, 380 brain SPECT, re-evaluation for brain tumor, drome, 929(ab) Technetium-99m T691, preclinical studies, regional 844(ab) comparison ofrest-redistribution 11-201 uptake, cerebral perfusion, 1836 cardiac SPECT imaging, Tc-99m transmission coronary artery disease, 905(ab) Technetium-99m TBI, scintigraphy, detection of source, simultaneous acquisition of emis defect size, thrombolytic therapy, regional wall metastases, thyroid carcinoma, 914(ab) sion/transmission data, 2238 motion, 927(ab) Technetium-99m ThIDA, hot spots on liver scan, -chlorideuptake, hypermetabolicbone marrow, detection ofcoronary artery disease, 1091 focal nodular hyperplasia, 918(ab) granulocyte stimulating factor, 2014 dobutamine and exercise, coronary artery dis Technetium-99m teboroxime comparison of digital and analog film display, ease, 951(ab) absorbed radiation dose to humans, 88 l003(ab) gated SPECT, characterization of fixed defects, detection ofcoronary artery disease, 1091 CT/MRI/angiography in bone and soft tissue infarct or artifact, 927(ab) myocardial blood flow, co-injection technique, sarcoma, 843(ab) localization ofparathyroid adenoma 1152 defect reversibility and severity, quantitative vs. hyperparathyroidism, 1801 myocardial extraction, interaction with blood, 94 visual analysis, 905(ab) primary hyperparathyroidism, 894(ab) myocardial SPECT imaging, delay of image ac delayed post-reinjection, detection ofviable myo lung uptake, correlation with LV ejection frac quisition, exercise-induced perfusion defects, cardiurn, 1064(ab) tion, 846(ab) 952(ab) dipyridamole multiple gated SPECT, myocardial thickening, planar myocardial perfusion imaging, 11-201 and improvement of image quality, walking exer phase analysis, 926(ab) coronary angiography, 1783 cise, 2061 myocardial distribution, nontransmural infarc retention characteristics, canine myocardium, predictive value, myocardial bridging, 1905 tion, 223 865(ab) dipyridamole imaging, dose comparisons, coro myocardial imaging, comparison, same-day pro 11-201 and nary artery disease, 866(ab) tocols, 186 continuous SPECT imaging protocol, 1304 dobutamine, scintigraphy, usefulness and safety, myocardial reperfusion imaging, acute chest pain, coronary stenosis, vasodilation with adenosine, 951(ab) non-diagnostic EKG, 876(ab) 864(ab) early imaging after PTCA, 866(ab) myocardial SPECT imaging Technetium-99m tetrofosmin tomographic evaluation, adenosine-induced comparison, short and standard data acquisi biokinetics, myocardial perfusion, one-day im coronary hyperemia, 2086 tion, 855(ab) aging, 874(ab) exercise myocardial SPECT, major upward creep early and delayed imaging, 855(ab) clinical efficacy, myocardial imaging agent, ofheart, COPD, 1846 parathyroid imaging, 313 874(ab) exercise-redistribution SPECT, myocardial via perfusion and regional contraction, peak left yen comparison ofdefect size, peak exercise, 874(ab) biity after infarction, 906(ab) tricularejection fraction, coronary artery dis effect of coronary blood flow on uptake, rabbit exercise whole-body thallium perfusion imaging, ease, 847(ab) heart, 846(ab) peripheral vascular disease, 1797 PET,defectsizeand severity,875(ab) myocardial imaging high-resolution three-head SPECT, dual energy planar, blinded evaluation, myocardial perfusion coronary heart disease, 875(ab) acquisition, liver tumor imaging, 976(ab) studies, 668 perfusion and blood flow, 993(ab) 1-123 branched fatty acid analogue and, assess retention characteristics, canine myocardium, structural characterization, myocardial imaging ment, ischemic but viable myocardium, 865(ab) agent, 850(ab) 885(ab) same-day acquisition protocol, 468(le) Technetium-99m(V)-DMSA, facile synthesis of Re importance ofdelayed scanning, 463(le) scintigraphy, radioisotopic assessment, myocar 188-labeled RC(V)-DMSA, triphenylphos influence of perfusion defect size, tomographic dial viability, 1925 phine reduction, perrhenate at room tern defectseverity,995(ab) serial tomographic imaging, infarct-related arte perature, l024(ab) injection, myocardial viability, Tc-99m scintig rial patency, reperfusion therapy, 2080 Technetium-99m (V)-thiocyanate, gastric empyting raphy, 906(ab) SPECT and intragastricdistribution, oil, presence of lack of redistribution, dipyridamole imaging, dobutamine, coronary artery disease, 866(ab) liquid or solid meal, 1283 postoperative and long-term outcome, F-18FDG glucosePET, malignancy,858(ab) Technetium-PnAO-nitroimidazoie complex, chern 95 l(ab) rnyocardial viability, 886(ab) istry of, localization in hypoxic tissue, myocardial blood flow, co-injection technique, right ventricular ischemia, inferior myocardial 9l9(ab) 1152 infarction, 876(ab) Technology, coming reform of health care system, optimal imaging time as a tumor agent, lym same day, myocardium, 876(ab) 24N(4) phoma, 844(ab) spontaneous chest pain, coronary intervention, Telangiectasla, hereditary hemorrhagic, emboliza planar myocardial perfusion imaging 875(ab) tion, hepatic arteriovenous malformations, detection, coronary artery disease, 1091 11-201 and, myocardial viability, 905(ab) 260 Tc-99mtebo,1783 stress perfusion, myocardial function and viabil Tenascin, detection ofbreast tumors, labeled BC-2 quantitative stress-redistribution SPECT, prone ity, 3-D SPECT, 926(ab) monoclonal antibody, 999(ab) imaging, validation, 1509 stress/rest 11-201 SPECT, rnyocardial perfusion, Teratoma redistribution, FDG PET, increased FDG uptake 854(ab) immature third ventricle, radiographic and after myocardial infarction, 886(ab) 11-201 and neuro-SPECT imaging, 435 redistribution model, 9i5(ab) heart transplantation, coronary arteriopathy, rectal wall, pelvic radioiodine uptake, thyroidec reinjection 95l(ab) tomy for papillary carcinoma, 1848 enhanced detection of ischemia, quantitative imaging, myocardial infarction, 865(ab) Testes reversibility maps, 916(ab) quantitative dual isotope autoradiography, up macro-and microscopicbiodistribution,In-ill, interval between reinjection and imaging, post take in rabbits, 993(ab) rats, 954(ab) MI patients,915(ab) rest/exercise imaging, defect reversibility, radiotoxicity, I-123/I-125/I-131-labeled corn patients without previous myocardialinfarc 855(ab) pounds, mouse, 2196 tion, 9i6(ab) uptake kinetics, rat heart endothelial and fibro l,4,7,lO-Tetraazacyclododecane, simple synthesis rest-redistribution blast-like cells, 102 and activation, immunoconjugation, chronic coronary artery disease, relation to viablemyocardium,815 942(ab) Tc-99m MIBI, 905(ab) uptake by recurrent Hurthle cell carcinoma, thy Thakur, Mathew, Aebersold Award, 34N(5) resting sestamibi uptake, coronary artery dis

Subject Index â€¢1992 2301 Thallium-201chloride

ease, 905(ab) tomography, pharmacologic stress and, extent Tomography, cone beam, dual-detector SPECT sys rest/stress Tc-99m sestamibi SPECT, myocardial and location ofCAD, 2067 tern, 892(ab) perfusion, 854(ab) transient exercise vs. dipyridamole-induced left Tracers, new developments, 16N(8) retention characteristics, canine myocardium, ventricular cavitary dilatation, 95i(ab) Tracheobronchitis, necrotizing, In-li 1 white blood 865(ab) uptake after reinjection, regional ventricular cell scan, 1704 reversible perfusion defects, incomplete right function, myocardial perfusion, 9i5(ab) Transferrin bundle branch block, normal coronary an uptake pattern in bone lesions, differentiation, hepatic Ga-67 concentration and, Ga-67 distri giogram, 1556 benign from malignant processes, 869(ab) bution, 1701 scan Thallium-201 chloride, Tc-99m MIBI and, uptake, IgG and F(ab')@conjugates, preparation, charac contribution, differentiated thyroid carcinoma, primary thyroid lymphoma, 1396 terization, 986(ab) 955(ab) Thrombendarteriectomy, carotid artery stenosis, Transplantation interpretation, court litigation, 120 cerebrovascular reserve capacity, 971(ab) cardiac, reduced exercise capacity, Starling effect, patterns, bone and soft tissue sarcoma, 843(ab) Thrombocytopenia, hepatic sequestration ofln-l 11 939(ab) scintigraphy platelets, GM-CSF, 923(ab) distribution in cells of In-ill hepatocytes, adenosine, lung thallium uptake, 1600 Thrombogenicity, comparative, cellulose-acetate 918(ab) incremental diagnostic value and impact, 1727 hemodialyzer, 956(ab) lung, scintigraphy in follow-up, 835(ab) incremental value, cost consciousness, 1732 Thrombolytic therapy renal localization, parathyroid enlargement, 895(ab) late infarct size and ejection fraction, acute myo atlas of imaging studies, Tc-99m mertiatide, scintigraphy with reinjection, viable myocar cardial infarction, 939(ab) l073(ab) dium, chronic coronary artery disease, 505 perfusion change, ischemic stroke, Tc-99m functional and anatomic evaluation, Tc-99m SPECT HMPAOSPECT,877(ab) MAG3vs.1-131hippurate, 1035(ab) attenuation correction, 1574 predictor of prognosis, PET, ischemic myocar hypertension, iliac artery stenosis, 1178 brain tumor recurrence, 867(ab) dium at risk, 837(ab) renal kinetics, chronic rejection, renal artery ste distinction, high-grade from low-grade Thrombosis nosis, 923(ab) gliomas, 868(ab) acute deep venous, Tc-99m antifibrin scintigra single lung, quantitative exercise-rest ventilation heart transplantation, coronary arteriopathy, phy, 848(ab) perfusion imaging, 835(ab) 951(ab) acute venous, anticoagulation by heparin, TrI*ZOIam, interaction with central type benzodi meningioma, prediction of histological type, Tc-99m antifibrin Fab' localization, 978(ab) azepine receptors, PET, baboons, 973(ab) 971(ab) detection in left atrial appendage, Tc-99m radio Trionix, lawsuit of ADAC Laboratories, gamma myasthenia gravis, 1020(ab) nuclide angiography, 365 camera technology, 18N(2) myocardial viability, coronary artery disease, imaging, Tc-99m frament E1, preliminary evalu Triorchidism, scintigraphy oftorsion, 1854 886(ab) ation, 710 Tritium-3-colchicine, tumor multidrug resistance, of theoretical derivations, empirical evidence, scintigraphy, Tc-99m inhibited recombinant t in vivoidentification,1373 1578 PA, 1029(ab) Tuberculosis, extrapuimonary, Ga-67 scan, corn recurrent primary brain tumors, 107l(ab) thallium scan, court litigation, 120 puted tomography, 2118 reinjection studies, collateralization, 915(ab) Thymidine, methionine or, location in cell, radia Tumescence, evaluation ofpenile blood flow, dual sensitivity to patient motion, 1571 tion-induced alterations, 84l(ab) radioisotopic technique, 41 teboroxime resting washout, coronary disease, Thyroglobulin, measurement, 1-131 whole-body Tumor-associated antigens, similarity and co 876(ab) scan, thyroid carcinoma, l72(le) expression, recognition, different monoclo vs.Rb-82PET,myocardialperfusion,1064(ab) Thyroid nal antibodies, 853(ab) SPECT and F-18 FDG PET, MRI, recurrent autonomous nodule, treatment, percutaneous Tumors supratentorial and infratentorial brain tu ethanol injection, 954(ab) quantitative scintigraphy and time to metastasis, mors, 867(ab) follicle, radiation dose distribution, revised dogs with osteosarcorna, 1542 stress test, ECG response and perfusion images, method, 926(ab) rapidly growing, absorbed dose calculations, 277 1723(le) nodule, accuracy of neuronet diagnosis, backpro solid Tc-99m and, dual-isotope autoradiography,corn pagation simulator, 954(ab) 5-iododeoxyuridine, efficacy of radioimmu puted tomography, l005(ab) orbital radiolabeled somatostatin accumulation, notherapy, 1530 Tc-99m glucarate and, acute myocardial infarc Graves' disease, Graves' ophthalmopathy, localization with streptavidin and labeled bio tion, rats, 1988 894(ab) tin, substitute for antibody, 934(ab) Tc-99m MIBI and post-I-13 1 cancer therapy, radiation safety con radiolabeled monoclonal antibody heteroge follow-up, differentiated thyroid carcinoma, siderations, 1402 neous distribution, binding site barrier, 844(ab) primary osteosarcoma, 1399 893(ab) MRI, recurrentbrain tumors, 867(ab) radioactive uptake, potential effects, contrast ma Tyramine cellobiose, radioiodinated monomeric Tc-99m MIBI SPECT and, childhood brain tu terial iodides, 237 antibody P-67, improved tumor retention, mors, 844(ab) scanning with Tc-99m pertechnetate, 1722(le) 987(ab) Tc-99m phytate and, liver tumor imaging, high uptake neck phantoms, 304(le) resolution three-head SPECT, 918(ab) well-differentiated neoplasms, radioiodine-131 U Tc-99m sestamibi and therapy, 1132 Ulcer, avid agent, new procedure, l033(ab) imaging, myocardial infarction, 865(ab) Thyroidectomy, papillary carcinoma, pelvic radioi Ultrasonography quantitative dual isotope autoradiography, up odine uptake, rectal wall teratoma, 1848 cerebrovascular reserve capacity, carotid artery take in rabbits, 993(ab) Thyroid neoplasms stenosis, thrombendarteriectomy, 971(ab) rest/exercise imaging, defect reversibility, differentiated, clinical meaning, circulating anti compared to triple-headed DMSA SPECT, 855(ab) thyrogiobulin antibodies, 1478 922(ab) uptake kinetics, ratheart endotheial and fibro 1-131 contamination, 2110 intracoronary probes and PET, concordant quan blast-like cells, 102 1-131 therapy, quantitative dosimetric approach, tification, flow reserve, 836(ab) viable myocardiurn, 815 894(ab) Tc-99m MIBI and 11-201 scintigraphy, localiza Tc-99m sestamibi SPECT and, myocardial via surprise findings, Chernobyl, 23N(l 1) tion, parathyroid enlargement, 895(ab) bility, 905(ab) taste dysfunction, 1-131 treatment, 996(ab) transcranial, brain SPECT, acute ischemic stroke Tc-99m teboroxime and TSH stimulation, sequential FDG PET studies, therapy, 968(ab) continuous SPECT imaging protocol, 1304 before and after T4 thyroid replacement Ureter coronary stenosis, vasodilation with adenosine, therapy, 894(ab) function, assessment of hydronephrosis, 78 864(ab) well-differentiated, chest X-rays and bone scans, kidney washout, Tc-99m DTPA diuresis renog tornographic perfusion imaging, effect of patient 1-131 scans, 894(ab) raphy, children, 73 motion, 1566 Title VII, appropriations, 26N(3) Uretero-pelvic junction

2302 The Journal of Nuclear Medicine Yttrium-SO

natural history of infantile hydronephrosis, di biventricular, parametric display, gated blood Wilson's disease, dopamine D2 receptors, 1-123 uretic renography, 2098 pool SPECT, 952(ab) IBZM, 897(ab) suspicion of obstruction, postnatal assessment, left Wound healiag, hematopoietic neoplasia, soft-shell volumeexpandeddiureticrenography,2094 count-based ratio method and volume, first clam, 998(ab) Urinary bladder, dynamic model for radiation dose poseradionucideangiography,2124 calculation, MIRD pamphlet No. 14, 783 diastole, systemic sclerosis, 68 x Urinary tract during exercise, coronary jeopardy score, febrile infections, Tc-99m DMSA scanning, chil 938(ab) human epidermoid carcinoma, biodistribution, dren, 976(ab) ejection fraction, gated Tc-99m sestamibi In-i 11 B3 monoclonal antibody, 842(ab) infection, triple-head imaging, Tc-99m DMSA SPECT,927(ab) neuroblastoma SPECT,991(ab) perfusion and performance, single radiophar distribution of 1-125 MIBG, electron micro infection in childhood, 872(ab) maceutical and one camera, 1411 scopic autoradiography, 102l(ab) Uroklaase, lung scan, pulmonary arteriogram im regions of interest, simulated annealing, radioimmunolocalization, chimeiic antibody provement, 849(ab) 932(ab) chCE7, 231 US.CosrtofAppeals, upheld nuclearquality man severely impaired ejection fraction, cardiac scintigraphic detection, overexpressed c-kit pro agement rule, l9N(7) peak power, 938(ab) tooncogene, monoclonal F(ab'>@fragments, Uveltis, sarcoid, Ga-67 citrate scanning, 1851 time-activity curve, 0-15 water PET, 1669 volumedetermination,radionucide methods, 893(ab) Xenon, duai-radioisotopic technique, tumescence, V 763 penile blood flow, 41 miniature cadmium telluride detector, coronary Varloceles, classification by two-phase scrotal scm Xenon-127, economic advantages over Xe-l33, artery bypass grafting, 441 tigraphy, 1034(ab) 305(k) myocardial perfusion and, simultaneous assess Vascular disease, Peripheral, use ofTc-99m MIBI, Xenon-133 629(le) ment, total coronary artery occlusion, method to evaluate PE, low probability V/Q Vasculitis, systemic, radiolabeled granulocyte ki 825(ab) scans, routine ventilation scans, l022(ab) netics, 491 nuclear probes in cardiology, 448 right, volume determination, Kr-8im multiple single-breath, severe diffuse obstructive airway Vasospasm, delayed ischemia, cerebral angioplasty, disease, l072(ab) gated imaging and Tc-99m equilibrium im brain SPECT, 1789 SPECT aging, 932(ab) Ventilation cerebral blood flow and predetermined ROIs, enhanced V/Q mismatch sign, pulmonary em thallium uptakeafterreinjection, myocardial per children, 977(ab) fusion, 9l5(ab) bolism, i072(ab) surgical outcome, temporal lobe epilepsy, Ventriculography, radlonuclide, rest and exercise, go withthe flowâ€”buthowfar'?,1939 lOl8(ab) lung, Tc-99m DTPA and Tc-99m desferoxamine active acromegaly, 834(ab) Tc-99rn and, dual isotope imaging, energy Vesamicol, F-l8 labeled acycicanalogues, potential aerosols, SPECT, 835(ab) weighted acquisition, 889(ab) cholinergic neuron markers, 983(ab) necrotizingtracheobronchitis, In-i 11white blood X-ray VEST, continuous, miniature cadmium telluride cellscan, 1704 chest detector, coronary artery bypass grafting, perfusion scans, severe diffuse obstructive airway atekctasis, pulmonary embolism, 849(ab) disease, single-breath Xe-l33, l072(ab) 19l4(le) bone and 1-131 scans, well-differentiated thy regional, volume and, separation by Kr-81m, mid cancer, 894(ab) 1935 W routine imaging, PE evaluation, low probability WAM module, acceptance testing and quality as Y V/Q scans, 1022(ab) surance, l005(ab) V/Q frequency distribution, pulmonary diseases, Water, contraction/relaxation of actomyosin, T2 YoimglavestigatorsSymposlum,Computerand In 1023(ab) relaxation behavior, 974(ab) strumentation Council as sponsor, 32N(l0) Ventilation-perfusion Welch, Michael J., Hevesy Nuclear Medicine Pi Yttriuai-88, bifunctional DTPA and macrocycic exercise-rest, single lung transplant, 835(ab) oneer Award, 16N(7) ligands,serumstabilitystudies, 103l(ab) lung scanning, computer-assisted diagnosis, pal Whim bleed cells Yttrium-88 lmmuaoconjugates, biodistribution, monary embolism, 1003(ab) dual bone and WBC scan imaging, osteomyeitis cheiate rigidity and denticity, l030(ab) lung scans, number of segmental mismatches, and cellulitis,planar and SPECT imaging, Yttrluni-90 likelihood ofpulmonary embolism, 849(ab) 839(ab) attachment to antibody via popular chelators, scintigraphy, intermediate likelihood-ratio re monoclonal antibodies, 34N(5) liver homogenates, 1030(ab) suIts, 849(ab) scintigraphy with monoclonal antibodies, septic microsphere therapy, three-dimensionaltumor Ventricular function loosening, endoprostheses, 840(ab) dosimetry, 735

Subject Index â€¢1992 2303 TheJournal is testinga newmethodto enableyouto get informationon a moretimely basisfromouradvertisers. Listedbelowarethecompaniesthathaveadvertisedin this issue,aswell asthosethat have been mentioned in the New Products section. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this form JNM to The Society of Nuclear Medicine, MarketingDept., 136Madison Ave., New York, NY 10016.FAX: 212/545-0221. We will forwardthis informationto the advertiser(s). DIRECTRESPONSE Deadline for response is: March 15, 1993.

Mvertisers: 1 AmericanCollegeofNuclear5 DataSpectrum 9 EncoreMedicalSystems 13 PickerInternational Physicians ChapelHill, NC Palantine,IL Bedford, OH Washington, DC (919) 732-6300 (R@8)359-4400 (216)475-1111 (202) 857-1135 Page 24A Pages 39A Page56A-InsideBack Pages 9A 6 DiversifiedDiagnosticProducts.10 Elscint,Inc. Cover 2 BiodexMedicalSystems Inc. Hackensack, NJ 14 QuintonSalesDept. Shirley, NY Houston, TX (800) 228-7226 Seattle.WA (516)924-9000 (713) 955-5323 Pages 11A-13A.36A-37A (800)426-0337 Page 38A Page53A 11 MedimaticDiv.ofM.I.D..Inc. Page 38A 3 Capintec,Inc. 7 EG&GORTEC New York. NY 15 SiemensMedicalSystems. Ramsey, NJ Oak Ridge, TN (212) 688-5620 Inc. (800) 631-3826 (615)482-4411 Back Cover Hoffman Estates. IL Page 2A Page 38A (708) 304-7252 12 OlympusCorp. Inside Front Cover-IA 4 CMEVideo 8 DuPOntCompany Lake Success, NY Cherry Hill, NJ No. Billerica, MA (800) 446-5967 16 SNMMeetings (800) 284-8433 (800) 225-1572 Page38A Pages 14A, 464, SM Page 38A Pages 17A-23A 17 SNMMembership Information

From: Your Name: Title:

Institution: Dept:

Address:

City: State: Zin: Phone: ____ FAX:

Primary Specialty: Secondary Specialty:

Circle One Answer In Each Category:

Employer Purchase Authority SNM Member 1. Hospital: 1. Recommend 1. Yes a. 500 patients plus 2. Specify 2. No b. 300-499 patients 3. Purchase c. 200-299 patients SNMSubscriber d. 100-199patients Reason for Inquiry 1. Yes 2. Private Clinic 1. Immediate Purchase 2. No 3. R&D Commercial 2. GeneralInformation 4. University 3. Budgeting Information 5. Government 6. Other ______

Index to Advertisers